Effect of food matrix interaction between dietary fibre and polyphenols on their metabolism by colonic bacteria by Mansoorian, Bahareh
  
 
 
 
 
 
Mansoorian, Bahareh (2014) Effect of food matrix interaction between 
dietary fibre and polyphenols on their metabolism by colonic 
bacteria. PhD thesis. 
 
 
 
 
http://theses.gla.ac.uk/6136/  
 
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten:Theses 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
  
 
 
 
 
 
Effect of food matrix interaction between 
dietary fibre and polyphenols on their 
metabolism by colonic bacteria 
 
 
 
 
 
Bahareh Mansoorian 
 
 
 
 
© (B.Mansoorian) year 2014 
 
 
 ii 
Effect of food matrix interaction between dietary fibre and polyphenols on their 
metabolism by colonic bacteria 
 
 
 
 
 
Bahareh Mansoorian 
M.Sc 
 
 
 
 
A Thesis submitted for the degree of Doctor of Philosophy to 
 
The School of Medicine, University of Glasgow (December 2013) 
 
 
 
 
 
From research conducted in the 
 
Section of Human Nutrition 
School of Medicine 
University of Glasgow 
New Lister Building 
Glasgow G13 2ER 
United Kingdom 
  iii 
AUTHOR’S DECLARATION 
 
I declare that the work contained within this thesis is original and is the work of the author Bahareh 
Mansoorian. I have been solely responsible for the organisation and day to day running of this study as 
well as laboratory measurements and data processing, unless otherwise referenced.  
 
 
 
 
 
 
Bahareh Mansoorian 
 
 iv 
 
ABSTRACT 
Background: The consumption of plant based foods has demonstrated an inverse association with 
disease prevalence.  Among the components of plant based foods, polyphenol and fibre are two of the 
main contenders for many health benefits. 
The majority of polyphenols and fibre pass through the small intestine unabsorbed, reaching the colon 
where they are subjected to the action of the colonic microbiota; resulting in the production of the 
potentially bioactive metabolites: phenolic acids and SCFA. These metabolites are potentially 
responsible for many of the health benefits exerted by polyphenols rich foods and fibre.  
Given the recent advances in understanding the role of colonic microbiota in metabolic and immune 
responses, factors, which may positively or negatively modify the composition of the colonic bacteria 
have also received much attention. Foods rich in dietary fibre and polyphenols have the potential to 
modify colonic bacteria through prebiotic and antibiotic action. The potential bacterial inhibition by 
polyphenolics and the stimulation of bacterial growth by fibre and polyphenols means potential for 
both sets of compounds to influence metabolite production from each other.  
Polyphenols and fibre are most often present in the same foods and may be found together in plant cell 
walls. Thus they most often enter the colon together. We aimed to explore how the presence of these 
two components in the diet may impact on the metabolite production from the other by the colonic 
microbiota.  
Methods: The food matrix interaction of fibres and polyphenols was assessed using the fibres: 
raftiline, pectin and ispaghula, having different physio-chemical properties (rate of fermentation and 
viscosity) and the polyphenols: rutin and catechin, epicatechin and other polyphenols present in cocoa 
in vitro models of phenolic acid and short chain fatty acid (SCFA) production. The impact of ispaghula 
on urinary phenolic acids after cocoa ingestion was then investigated in an acute human study. 
In Chapter-3 the impact of the fermentable fibres on phenolic acid production from isolated parent 
compound: rutin in-vitro using 24 hour batch cultures using human faecal samples from volunteers 
(n=10) after being on a 3-day low polyphenol diet was investigated. Using the same model the impact 
of rutin, quercetin and their metabolites on SCFA production from raftiline, ispaghula and pectin was 
then investigate. The SCFA were measured by GC-FID and phenolic acids by GCMS. pH and gas were 
also measured.  
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Using the same methodology the matrix interaction between raftiline, ispaghula and pectin separately 
on phenolic acid production from their parent compounds within their food matrix was investigated 
using cocoa as a rich source of polyphenols, as well as the impact of cocoa polyphenols and their 
metabolites on SCFA production from the fermentable fibres (Chapter-4) 
In Chapter-5, 24-hour urinary polyphenolic acids were measured in 5 batches (0, 0-2, 2-5, 5-8, 8-24 
hour) in 12 human volunteers after ingestion of 1g paracetamol with 20g cocoa (extra brute Cocoa-
Cacao Barry, Barry Callebaut, Hardricourt, France) with water, 15g of ispaghula with water or the 
combination of the two. Urine samples were also used for total phenol and antioxidant capacity 
measurement. Plasma was collected over six hours (every half hour for 4 hours and at 6
th
 hour) and 
used for the measurement of total phenols as well as paracetamol concentrations for the estimation of 
gastric emptying rate. Breath hydrogen was used for estimation of small bowel transit time and visual 
analogue scales (VAS) were used for the estimation of subjective appetite response to meals.  
Results: The faecal fermentation of rutin resulted in the production of the following phenolic acids: 
PAA, 4-HBA, 3-HPAA, 4-HPAA, 3,4-DHPAA, 3-HPPA and 4-HPPA. All of these phenolic acids 
were significantly reduced by at least one of the three fibres, with the exception of 3-HPPA and 4-
HPPA. The extent of inhibition of total sum of phenolic acids from raftiline and pectin was similar (p < 
0.01) and ispaghula demonstrated the least inhibitory effect (p=0.03). Rutin and quercetin had no 
impact on the SCFA production from the fermentable fibres. 
The phenolic acids identified from cocoa faecal incubations consisted of: of PAA, 3-HPAA, 4-HPAA, 
3,4-DHPAA, 3-HPPA, 4-HPPA, 3,4-DHPPA, 4-HBA, 3,4-DHBA, hippuric acid and vanillic acid. 
Unlike the rutin study where majority of phenolic acids were significantly reduced, in this study only 
four of eleven phenolic acids were affected (PAA, 3-HPAA, 4-HPAA, 4-HBA: also inhibited in the 
rutin study).The extent of phenolic acid reduction was the highest for pectin (p < 0.01), followed by 
raftiline (p < 0.01) and ispaghula (p=0.03). These phenolic acids or their parent compounds had no 
impact on SCFA production from the fermentable fibres. 
The consumption of cocoa resulted in the urinary excretion of the following phenolic acids: 3-HPAA, 
4-HPAA, 3,4-DHPAA, Hippuric, 4-HPA, 4-HBA, 3,4-DHBA, Vanillic, 4-HVA, Mandelic and 4-
HMA. All of which, with the exception of vanillic acid and 3,4-DHPAA, were reduced by ispaghula 
(Table-I). Ispaghula accelerated gastric emptying rate but had no impact on small bowel transit time.  
The analysis of total phenol (TP assay) concentration (plasma and urine) and antioxidant capacity 
(urine) did not demonstrate any difference between cocoa and ispaghula, which were both high. 
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However when they were ingested together there was a signification reduction in both total phenol and 
antioxidant capacity (p < 0.01). 
Given that urinary and plasma concentration of total phenols was no different for ispaghula and cocoa 
we analysed the free phenolic and bound phenolics in both ispaghula and cocoa, showing that cocoa 
has significantly higher free phenolics than ispaghula, whereas bound phenolics were higher in 
ispaghula. The sum of bound and free total phenols was higher in cocoa than ispaghula (approximately 
10 fold). Urinary, faecal SCFA were not measured as they are not validated to represent in-vivo 
production.  
 
Conclusion: there is a strong inhibition of phenolic acid production from polyphenol by the 
fermentable fibres and their metabolites. This inhibition is stronger in-vivo than in-vitro for ispaghula, 
which may reflect the longer interaction time in the colon and potential small bowel interaction. The 
production of SCFA from fermentable fibres was not inhibited by the polyphenols or their metabolites. 
These interactions need to be considered when assessing the bioavailability of phenolic acid production 
and their potential health benefits.  
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1.1 Plant based foods and health 
 
Diet is one of the most important modifiable life style factors influencing health and prevention of 
chronic diseases (Eyre et al., 2004). One element of the diet with the highest consensus for possible 
health benefits are plant based foods. The prospective cohort study of women from the Nurse‘s Health 
study (n=84,521) and men from the Health professional study (n=42, 148) demonstrated an inverse 
association between the intake of fruits and vegetables with the risk of coronary heart disease as 
determined by nonfatal myocardial infarction or fatal coronary disease (Joshipura et al., 2001). This 
was later supported in a review of studies recommending only increase in fruit and vegetable intake 
with clinical CVD events (mortality, myocardial infarction, coronary bypass grafting etc.) as the end 
point, as a method of cardiovascular disease (CVD) prevention (Hartley et al., 2013). 
Fruit and vegetables contain many possible bioactive constituents, including vitamins, minerals, 
sterols, but the studies in this thesis relate to dietary fibres and polyphenols, which are two of the main 
contenders for many health benefits and are present together in fruits and vegetables. There has been 
considerable interest in the potential health effects such as reduced risk of CVD and cancer, of plant 
based polyphenolics such as epi/catechins and quercetin, with stronger evidence for catechin/ 
epicatechin in regard to CVD risk, as they have been associated with a reduction in the inflammatory 
markers of CVD (Khan et al., 2014) and quercetin and rutin in regard to reduced risk of colon cancer 
through anti-proliferative properties and increasing apoptosis (Delgado et al., 2014, Chen et al., 2013). 
These effects may be related to their potential antioxidant and anti–inflammatory effects (the latter 
having more emphasis in recent years) and most studies have considered only the effects of the parent 
compounds, which may never reach the target tissues (evidence summarised in Table 3-1 and Table 
4-1). 
The majority of polyphenols pass through the human small intestine unabsorbed, reaching the colon 
where they are subjected to metabolism by the colonic microbiota. This results in their conversion to 
phenolic acids which are absorbed but for which there is little evidence on bioactivity.  Dietary fibre 
often consumed in the same foods as polyphenols will impact on the gut microbiota and many 
polyphenolics have also been reported to have both pre and antibiotic properties (Parkar et al., 2008, 
Tzounis et al., 2008a, Lee et al., 2006) and thus it is important to consider the possible colonic 
interactions of these two significant components in plant based foods.   
In addition, the proposed health benefits of polyphenolic compounds and fibre such as prevention of 
cancer (Gonzalez-Vallinas et al., 2013, Aune et al., 2011), cardiovascular disease (Fuentes and Palomo, 
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2013, Threapleton et al., 2013b), diabetes (Munir et al., 2013, Hall and Flinkman, 2012) and obesity 
(Trigueros et al., 2013) has led to potential health claims by the food industry for food products 
containing one or both of these compounds. Many of these food products such as breakfast cereals and 
nutrition bars, claiming health benefits contain both of these compounds.  
Moreover, there has been considerable level of interest in the role of the gut bacteria in health after the 
characterisation of the human gut microbiome (Qin et al., 2010) and its association with a range of 
chronic diseases and conditions such as CVD (Howitt and Garrett, 2012), obesity (Zhao, 2013), IBD 
(Mazmanian et al., 2008), allergy (Hanski et al., 2012) and auto immune disease (Tlaskalová-
Hogenová et al., 2011) and even autism (Theoharides and Doyle, 2008). Thus it is very important to 
consider how dietary factors, which influence the microbiota interact and affect bioactive molecule 
production. 
 
1.2 Carbohydrates 
 
Carbohydrates are a major component of plant based foods and they can be divided into digestible 
carbohydrates such as starch and sucrose or non-digestible carbohydrates which mostly make up the 
plant cell walls (pectin, cellulose, etc.), or have specific roles such as ispaghula which is present in the 
seed husk of Plantago ovata and due to its great water holding capacity expands greatly when it rains 
allowing the seed to germinate.  Other non-digestible carbohydrates may act as storage molecules such 
as inulin, which consists of polysaccharides (greater than 8 sugar units) and oligosaccharides (greater 
than 3 and less than 8 sugar units) such as raftilose in the roots of chicory and other plants. Non-
digestible carbohydrates often co-exist alongside plant polyphenolics in these locations. 
1.2.1 Digestible carbohydrates  
The human digestive enzymes can break only certain carbohydrate bonds such as the α (1-4) and α (1-
6) glycosidic bonds. Carbohydrates containing other bonds such as β (1-4) are not digested by the 
human digestive enzymes. Some carbohydrates made of α- linkage bonds are either directly absorbed 
by the epithelial cells such as monomers or easily broken down into their constituent monomers by the 
human digestive enzymes, such as sucrose and starch. The ingested galactose and fructose are mostly 
converted to glucose by the intestinal epithelial cells and liver, resulting in glucose being the main 
circulating monomer in the body (Whitney et al., 1998).  
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However, not all starch is digestible. The main components of starch are amylose (14-27%) and 
amylopectin (73-86%). Amylopectin is made of over 10,000 α (1-4) and α (1-6) linked glucose 
moieties in a branched manner. Amylose is smaller in size and is made of α (1-4) links in a helical 
manner, making it less accessible to α-amylase action as compared to the open and branched 
amylopectin (Cummings et al., 1996). Hence, based on digestibility, starch can be classified into 3 
groups (Goñi et al., 1996): rapidly digestible starch (RDS), slowly digestible starch (SDS) and resistant 
starch (RS).  
RDS can be found in freshly cooked foods such as potato and bread and is rapidly digested in the 
human small intestine. SDS is present in partially milled seeds and in denser textured foods such as 
pasta, these type of starch are completely digested in the human small intestine, however at a much 
slower rate than RDS. Unlike the other two types of starch, RS is not digested in the human small 
intestine and is instead subjected to colonic microbiota action in the colon (discussed in more detail in 
section 1.2.2.1 Resistant starch). 
1.2.2 Non-digestible carbohydrates  
These carbohydrates resist digestion in the human small intestine and reach the colon where they are 
fermented by the gut microbiota to different extents. It is estimated that 10 - 60g of non-digestible 
carbohydrates enter the colon daily and are used as a substrate for colonic bacteria (Cummings and 
Macfarlane, 1991). 
Some simple carbohydrates can act as non-digestible carbohydrates conditionally. This is mostly 
dependent on genetic background of individuals and disorders of the gastrointestinal tract. An example 
of this is the simple sugar lactose. In a case of lactose intolerance caused either by insufficient lactase 
production or lack of genetic expression of lactase, lactose is subjected to fermentation by colonic 
microbiota (Wiggins, 1984). Fructose may be poorly absorbed as it is not associated with active 
transport and the facilitated carrier can be overloaded. 
Oligosaccharides such as raftilose, raffinose, fructo and galacto-oligosaccharides are also non-
digestible.  They are present in foods such as artichoke, asparagus, chicory roots, onion, garlic, leeks 
and banana (Campbell et al., 1997).  This group consists of mainly fructosyl-fructose glycosidic bonds 
of either β-2,1 linked inulins or β-2,6 linked levans. Due to their low sweetness (0.3- 0.6 that of 
sucrose) and due to their higher molecular weight, they are used as bulking agents in the food industry 
(Voragen, 1998). These non-digestible oligosaccharides received much attention due to their ability to 
alter the microbial population of the colon promoting the growth of lactic acid bacteria such as 
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lactobacilli and particularly bifidobacteria (Tokunaga et al., 1993, Gibson et al., 2004). When they are 
fermented they tend to produce more of the short chain fatty acid (SCFA) butyrate (Roberfroid and 
Delzenne, 1998, Roberfroid, 2005) which has many possible health benefits detailed in section 
1.2.6.1.3 (page 25). They were termed prebiotics defined as ―a food ingredient that is composed of 
oligosaccharides that are not digestible by the host and that has a beneficial effect on host health 
through selective stimulation of the growth and/or activity of specific members of the gut microbiota‖ 
(Gibson et al., 2004).  It has been proposed that any type of dietary food that can promote the growth 
of probiotics and consequently promote health and homeostasis in the gut can be considered a prebiotic 
(Vieira et al., 2013). 
Non-digestible polysaccharides are mostly comprised of the two classes, resistant starch, contributing 
towards 8-40g of non-digestible carbohydrates reaching the colon and non-starch polysaccharides 
contributing 8-18 grams of non-digestible carbohydrates reaching the colon daily (Cummings and 
Macfarlane, 1991).  
1.2.2.1 Resistant starch 
Starch is the main form of energy storage for most plants and also one of the main contributors to the 
amount of carbohydrates reaching the colon. The partially crystalline form of starch gives rise to the 
discrete x-ray diffraction patterns A, B and C that can be used for the classification of starch into 
groups having similar properties (Gallant et al., 1992).  
Group-A starch is mostly found in cereals, group-B starch is mostly found in potatoes, bananas and 
other tubers and Groups-C starch is found in legumes. Out of these three groups, B and C are more 
resistant to pancreatic and salivary α-amylase making them more resistant to digestion in the human 
small intestine, thus available as substrates for colonic microbiota.  This is due to the three dimensional 
structure of the starch which makes it harder for amylase to penetrate as well as differences in the 
surface area to volume ration of the starch granules. 
The method of starch preparation also impacts its digestibility. Gelatinisation of starches occur during 
the process of cooking, making them more accessible to α-amylase, those with type B and C structures 
tend to re-crystallise upon cooling by forming hydrogen bonds between the polymers (retrogradation) 
most often in the form of the more resistant B-group eg. potato starch.  
Hence, resistant starch is defined as ―the sum of starch and starch degradation products that pass into 
the large intestine‖(Asp and Björck, 1992). Resistant starch can hence be further classified into:  
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(RS-1): encased starch, referring to starch granules that are physically entrapped in the food matrix. 
(RS-2): resistant starches, referring to type-B starch that resists gelatinisation during cooking and    
(RS-3): retrograded starches, referring to re-crystallised starch after cooling (Englyst et al., 1992). 
(RS-4): chemically modified resistant starch, not present in nature.  
1.2.2.2 Non-starch polysaccharide / Dietary fibre 
The definition of dietary fibre, especially in relation to its classification is highly debated, usually 
based on analytical methods rather than physiological effects and has been under review for decades 
(DeVries et al., 1999, Howlett et al., 2010), with various definitions being proposed over the years. The 
lack of an accurate and universal definition, as well as classification of dietary fibre is problematic in 
the context of food health claims by the food industry and epidemiological interpretation of health 
benefits from fibre. 
The original definition of fibre known as ―crude fibre‖ was based on its resistance to hydrolysis by acid 
and alkaline. The term dietary fibre was first used by Hipsley (1953) in reference to the components of 
cell walls that resisted digestion in the human small intestine. A supporting definition was later 
proposed in 1974 by (Trowell, 1974) as: ―plant cell wall polysaccharides and lignin‖. This was later 
developed as the non-starch polysaccharides in the UK (Trowell et al., 1978). This definition excluded 
resistant / modified starch and non-digestible oligosaccharides as dietary fibre. Later, the definition of 
dietary fibre in the UK was stated by the Department of Health (1991) as: ―dietary fibre should be 
defined as non-starch polysaccharides (NSP) where this refers to non-alpha-glucans as measured by 
the technique of Englyst and Cummings or other comparable techniques.‖ This was then followed by 
the proposed definition by the American association of Cereal Chemist in 2000:  
―Dietary fibre is the edible parts of plants or analogous carbohydrates that are resistant to digestion 
and absorption in the human small intestine with complete or partial fermentation in the large 
intestine. Dietary fibre includes polysaccharides, oligosaccharides, lignin, and associated plants 
substances. Dietary fibres promote beneficial physiological effects including laxation, and/or blood 
cholesterol attenuation, and/or blood glucose attenuation.‖ 
This definition remains the most widely used and emphasises the physiological health benefits of 
dietary fibre. However these health benefits are dependent on the type of dietary fibre. There have 
since been various proposed sub classifications of fibre to differentiate plant cell wall associated fibre 
from those added as food ingredients. The Institute of Medicine (IOM) of the National Academies 
(2001) proposed the following classification: (i)-endogenous to a food (dietary fibre) and (ii)-fibre 
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extracted and/or synthesized (functional fibre). The sum of these two make up the total dietary fibre 
content of food. A similar classification was proposed by the Codex Alimentarius Commission (2009) 
as: (i)- naturally occurring in the food as consumed, (ii)- obtained from food raw material by physical, 
enzymatic or chemical means and (iii)- synthetic carbohydrate polymers. In this regard category (ii) 
and (iii) must display a physiological property inducing health benefits. The main difference between 
the two classifications is that in the latter classification, synthesised fibre is also considered as dietary 
fibre as opposed to functional fibre. 
Classification of dietary fibres with different properties is also subject to debate, the most useful 
clinically and most relevant for the purpose of this PhD is based on their solubility and their 
fermentability. Based on this, the two main subclasses are: insoluble and soluble fibre. These 
subclasses are expected to exert different health benefits due to their different physical and chemical 
properties. Some of the factors that play a role in this classification are spatial arrangement and 
intermolecular bonds of these complex carbohydrates. Some carbohydrates such as pectin are 
composed of charged groups which act as repellents to similar charged groups, resulting in expansion 
and ultimately destabilisation of the molecule, favouring solubility. 
1.2.2.3 Health benefits of dietary fibre  
The interest in the health benefits of dietary fibre began after observations in Africa, by Burkitt, 
Trowell and Walker, linking the lack of fibre intake to prominent disorders in western and developed 
countries such as: constipation, diverticulitis, colon cancer, risk of obesity, type 2 diabetes and CVD 
(Champ et al., 2003). This was attributed to the high consumption of refined and meat based diets. 
Dietary fibre has been associated with modification of key risk factors in the development of CHD 
such as hypertension, hyperlipidemia and insulin resistance (Threapleton et al., 2013a). Additionally 
viscous fibre has demonstrated a reduction in the rate of cholesterol absorption from the small intestine 
resulting in the regulation of blood cholesterol levels (James et al., 2003). 
Fibre has also been associated with decreased risk of cancer based on systematic reviews from nine 
independent academic centres, assessed in the second WCRF expert report (Wiseman, 2008). The 
EPIC cohort study by Bingham et al. (2002) analysed the association between colorectal cancer and 
dietary fibre consumption in individuals aged 25-70 years (n=519, 978). They found an inverse 
association between the consumption of dietary fibre in food with large bowel cancer adjusted relative 
risk (0·75 [95% CI 0·59–0·95] for the highest versus lowest quintile of intake). They also found that 
the protective effect was the greatest for the left side of the colon where most dietary fibre is fermented 
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and least for the rectum. This could be attributed to fewer fermentation products reaching the right side 
of the colon and rectum. In this regard, the type of fibre and its rate of fermentation play an important 
role.  
Fibre can induce its health benefits through various mechanisms related to its viscosity (regulation of 
plasma cholesterol and glucose), fermentation (actions of SCFA and low pH) modification of gut 
transit time and stool weight (reducing exposure to carcinogens). These will be discussed later. 
1.2.3 Insoluble fibre  
Insoluble fibres, such as cellulose, pass through the human small intestine intact and it is believed that 
they undergo very little fermentation compared with soluble fibres.  However this may vary depending 
on method of investigation (in-vitro vs. in-vivo) and level of crystallisation (Edwards and Rowland, 
1992).  
They act mostly by speeding colonic transit and increasing faecal bulk (Delargy et al., 1997, Dikeman 
and Fahey, 2006) and exhibit most of their health benefits through a ‗mop and sponge‘ effect (Shomik 
Sengupta MB et al., 2001). The ‗sponge‘ binding of bile acids and carcinogens, as well as increasing 
stool bulk and the ‗mop‘ sweeping material along and out of the gut. Insoluble fibres include bran and 
cellulose and are predominant in cereal grains and vegetables (Englyst et al., 1989, Dikeman and 
Fahey, 2006). 
1.2.4 Soluble fibre 
Soluble fibres can be further divided into viscous and non-viscous. Soluble fibres exert their health 
benefits through water holding capacity, viscosity and fermentability. These properties can vary 
depending on the type of fibre. 
Through their viscosity they have shown to reduce cholesterol levels by decreasing the re-absorption of 
bile salts from the small intestine, thus increasing excretion of bile acids through faeces. Consequently 
7α-hydroxylase is activated to rapidly catabolise cholesterol and replenish the bile acid pool (Chawla 
and Patil, 2010). A review by Brown et al. (1999) has shown that 2-10 g/ day consumption of soluble 
fibre can lead to 0.57 mmol/l reduction in LDL-C per gram of viscous fibre. Fat absorption may also be 
reduced (Ganji and Kies, 1994). Another role of viscous soluble fibre is reducing glycaemic response 
by altering gastric emptying/ mouth-caecum transit time (MCTT), slowing down the transport and 
mixing of digestive enzymes, resulting in a slow or reduced absorption of glucose and other 
macronutrients consequently resulting in a reduction of insulin levels (Bourdon et al., 1999). As insulin 
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has shown to play a role in the activation of 3-Hydroxy 3-methylglutaryl- coenzyme A reductase 
(HMG-Co-AR) which in turn is involved in cholesterol synthesis, the lower insulin levels could also 
contribute to lower blood cholesterol levels (Lakshmanan et al., 1973).  
Through their fermentation, soluble fibres (and some insoluble fibres) produce short chain fatty acids, 
mainly acetic, propionic and butyric acids, which have many putative health effects. For example, it 
has been proposed that propionic acid is involved in gluconeogensis (Nishina and Freedland, 1990, 
Rémésy et al., 1992) and aids in the reduction of LDL-C by inhibiting hepatic cholesterol metabolism 
through mechanism such as reduction of HMG-Co-AR activity and inhibition of Acetyl- coenzyme A 
reductase (Acetyl-Co-AR), which is responsible for catalysing the synthesis of acetyl-CoA from 
acetate (Levrat et al., 1994, Wright et al., 1990b).  
The fermentation of different carbohydrates produces different amounts of the individual SCFA (Table 
1-1), which in turn may determine the health benefits they induce.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
 
 
Table 1-1 SCFA production from various carbohydrate sources 
Author 
(Year) 
Method  Carbohydrate choice acetate  propionate butyrate 
(Edwards et al., 1992) In-vivo 
(rats) 
 
 10%Bran 
 5%Ispaghula 
% 60.3 
% 64.4 
% 15.5 
% 22.2 
% 24 
% 13.2  
(Bindelle et al., 2007) In-vitro 
fermentation 
  
 Potato 
 Sugar-beet pulp 
 Wheat bran 
 Starch 
 Raftiline 
 Cellulose 
 Xylan  
 Citrus pectin 
% 48 
% 65.9 
% 60 
% 50 
% 46.9 
% 44 
% 62.9 
% 80.9 
% 22 
% 30.9 
% 30.9 
% 45 
% 46.9 
% 54.9 
% 31.0 
% 17.9 
% 30 
% 0.29 
% 0.39 
% 4.9 
% 4.9 
% 0.9 
% 4.9 
% 0.9 
(Le Gall et al., 2009) In-vivo  
(pigs) 
 
 
Breads with:  
 Wheat flour  
 Whole wheat grain  
 wheataleurone flour 
 Rye aleurone flour 
 
% 70.1  
% 65.5 
% 61.8 
% 66 
 
% 23 
% 24.5 
% 25 
% 24.2 
 
% 4.6 
% 8.4 
% 11.6 
% 9.0 
(Timm et al., 2010) In-vitro 
fermentation 
 
 Wheat dextrin 
 Raftiline 
 Ispaghula 
% 46.4 
% 42 
% 39.9 
% 27.2 
% 42.8 
% 48.4 
% 27.1 
% 16.0 
% 11.4 
(Chen et al., 2010) In-vivo 
(mice) 
 
 No fibre 
 Cellulose 
 Pectin 
 Konjac Glucomannan 
 raftiline 
% 65.2 
% 75.1 
% 74.4 
% 75.5 
% 59.5 
% 12.4 
% 8.4 
% 9.5 
% 9.8 
% 13.6 
% 16.5 
% 15.0 
% 15.2 
% 17.6 
% 25.5 
(Paturi et al., 2012) In-vivo 
(rats)  
 Cellulose 
 Potato fibre 
 Potato- RS 
% 58.0 
% 59.2 
% 56 
% 12.9 
% 9.5 
% 12.8 
% 9.6 
% 12.2 
% 8.8 
(Van den Abbeele et 
al., 2013) 
In-vitro 
fermentation 
 
 Raftiline 
 Arabinoxylan (long 
chain) 
% 65.9 
% 41.6 
% 6.05 
% 49.8 
 
% 27.9 
% 8.4 
 
In the studies in this thesis several soluble fibres were chosen for their different fermentation 
characteristics, physical chemical properties and potential health benefits.  These are explored below. 
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1.2.4.1 Ispaghula 
Ispaghula is a highly branched acidic arabinoxylan with the backbone containing β (1-4) and β (1-3) 
bonds and D-galactose, D-rhamnose, D-galacturonic acid, 4-O-methyl-D-glucuronic acid and 2-O- (2-
D-galactopyranosyluronic acid)-L-rhamnose (Chan and Wypyszyk, 1988, Edwards et al., 1992).  
Ispaghula, also known as isapgul and psyllium, is derived from seeds of the Plantago ovata plant 
native to Asia and the Mediterranean (Bernstein et al., 2013). The name is derived from the sanskrit 
words asp and ghol meaning horse flower, after the shape of the seeds. India produces 85% of 
ispaghula with the United States being the biggest importer of the product. Ispaghula has been used as 
a bowel regulator and its primary use is as a bulk laxative for the treatment of constipation (Chawla 
and Patil, 2010). This may be due to its high water holding capacity and speeding the flow of contents 
in the colon (Edwards et al., 1992, Edwards and Eastwood, 1992). One gram of ispaghula husk can 
increase faecal weight by 5.9g,  compared with 4.9-5.4g for wheat bran and 3.4-4.5g for oat bran (Chen 
et al., 1998, Cummings, 2001, Chawla and Patil, 2010). 
In four different meta-analyses (Brown et al., 1999, Anderson et al., 2000, Olson et al., 1997, Jenkins 
et al., 2000b) an average consumption of ispaghula husk (9g/day) resulted in 6-7% decrease in LDL-C 
concentrations. Additionally all studies demonstrated a mean 0.7 mmol/l reduction in LDL-C per gram 
of ispaghula husk regardless of using different studies in the meta-analysis with different methods of 
ispaghula consumption (Jenkins et al., 2000b). In the study by Everson et al. (1992), volunteers with 
moderate hypercholesterolemia (n=20) were fed 15g of ispaghula/day or placebo  (cellulose) for 40 
days. This study reported that bile acid synthesis was increased in volunteers showing an LDL 
reduction of 10% or more. This study also investigated the MCTT by measuring breath hydrogen for 
five hours after ispaghula / cellulose consumption. No definite peak of breath hydrogen was shown for 
one volunteer in the ispaghula arm and four volunteers in the placebo arm of the study. While 
ispaghula did not change MCTT, cellulose consumption reduced the MCTT (p< 0.01).  
The Food and Drug Administration (FDA) has allowed health claims of foods containing oat, oat 
products and ispaghula husk in regard to cholesterol reduction. The FDA has since recommended the 
addition of 3g/day of b-glucan or 7g/day of soluble fibre from ispaghula husk along with low 
cholesterol diets (Gunness and Gidley, 2010, Bernstein et al., 2013). EFSA also allow claims for 
cholesterol reduction for ispaghula (EFSA- ID2508-2007). This effect on cholesterol could be due to 
the effects of viscosity in the small intestine or fermentation or transit times in the colon (Chapter 5). 
Ispaghula is slowly and incompletely fermented (Wolever et al., 1994) producing higher proportions of 
popionic acid (Table 1-1). Unlike rapidly fermented fibres, which are fermented mostly in the proximal 
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colon, the benefits of slowly fermented fibres such as ispaghula can be extended to the distal colon. It 
is more likely for all of the colon epithelium to be exposed to fermentation products when a slowly 
fermented fibre is used (Timm et al., 2010). 
Ispaghula feeding studies (Marteau et al., 1994, Marlett and Fischer, 2003) have recovered a gel in the 
excreted stool sample of volunteers (n=14) consuming ispaghula husk (8.8g in the form of 15g 
Metamucil for 7 days) and suggested that this was the fraction responsible for the laxative and 
cholesterol reducing impact of ispaghula. Ispaghula was divided into 3 fractions: alkali insoluble 
material (fraction A), gel forming fraction (fraction B) and a viscous but not gel forming fraction 
(fraction C).  The gel forming fraction constituted over 50% of ispaghula composition.  
The fermentability of each fraction was tested using an in-vitro fermentation model.  Fraction-A was < 
5% over 48 h, fraction-B 25% over 72h and fraction-C was the highest fermented > 80% of its sugars 
disappearing by 24 h. 
Viscous fibres that have a higher molar ratio of acetate production through microbiota fermentation are 
not desirable for reduction of LDL-C as they could either have no impact or potentially even increase 
LDL-C concentrations, whereas viscous fibres that produce higher ratios of propionate to acetate are 
more desirable in this aspect (Table 1-1). Ispaghula husk is one of these viscous fibres (Jenkins et al., 
2000a). The high viscosity of ispaghula, which is maintained throughout the colon plays a key role in 
its health impacts. A study (Davidson et al., 1998a) investigating the impact of low viscosity soluble 
fibres: pectin and gum arabic at doses of 5, 9 and 15 g/day on LDL-C concentrations, did not show any 
impact on cholesterol levels whereas another study using lower doses of 3.4, 6.8 and 10.23 g/day of 
ispaghula husk over 24 days demonstrated a 5.3% reduction  in LDL-C concentration (Davidson et al., 
1998b).  
Some studies have suggested that the method of ispaghula administration might have a great impact on 
its ability to impart health benefits. Wolever et al. (1994) demonstrated that the consumption of 7.3 g 
of ispaghula in the form of an enriched breakfast cereal reduced serum total cholesterol, LDL and HDL 
(p< 0.02) but not when ispaghula was consumed separately from the breakfast cereal, 1-1.5 hours 
before meals. This was attributed to the reduced absorption of carbohydrates when ispaghula was 
mixed with the meal.  
Another influencing factor in the health impact of ispaghula could be gender and hormonal status of 
the individual. A study by (Vega-López et al., 2001) demonstrated that while 15g/ day consumption of 
ispaghula for 4 weeks reduced (p<0.01) LDL-C for men (n=24), pre-menopausal women (n=23) and 
postmenopausal women (n=21) by 7-9%; TAG was reduced only for the men by 17% (p< 0.01) while 
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it increased in post-menopausal women by 16% (p<0.01) and had no impact on pre-menopausal 
women. It is interesting to see an impact of ispaghula on TAG only for men, as no other study stated in 
this section has demonstrated an impact of ispaghula on plasma TAG concentrations. However it is 
important to note that unlike total cholesterol, LDL and HDL, plasma TAG concentrations are greatly 
influenced by the diet, which is not mentioned in their discussion. The gender/hormonal status in 
relation to TAG reduction in this study could be explained by the variation in polyunsaturated fatty 
acid consumption between the different groups. The post-menopausal women had the highest 
consumption of polyunsaturated fatty acid. The observations made may be due to the sample size 
rather than the role of hormonal status and gender.  
 
1.2.4.2 Pectin 
 Pectin is largely found in plant primary cell walls. Henri Braconnot discovered the gel forming 
complex polysaccharide in 1825 and named it pectic acid (Leclere et al., 2013b). Pectin is made of a 
group of complex polysaccharides that contain D-Galactosyluronic acid residues, bond by α (1-4) 
bonds (Leclere et al., 2013b, Ridley et al., 2001). Three main polysaccharides have been identified 
within the pectic group of galacturonic acids.  Homogalacturonan, accounts for 65% of the pectin 
molecule which is a chain of D-galactopyranosyluronic acid (GalpA) linked by α (1-4) bonds forming 
a linear chain. The carboxyl groups of the chain can be methyl-esterified or in some cases acetylated 
(Ishii, 1995, Leclere et al., 2013a). Rhamnogalacturonan-I contributes 20–35% of the molecule and is 
made of galacturonic acid and rhamnosyl disaccharides repetition bond by [→4)-α-D-GalpA-(1→2)-α-
L-Rhap-(1→] with the possible O-acetylation of the GalpA back bone on C2 and/or C3  (O'NEILL et 
al., 1990, Ridley et al., 2001, Mohnen, 2008). Substituted galacturonans are the third constituent of 
pectin, made of various groups of polysaccharides with a linear chain of D-GalpA bound by α-1-4 
bonds. An example of this is Rhamnogalacturonan-II made of a Homogalacturonan chain and different 
from Rhamnogalacturonan-I structurally. RG-II has been identified in all higher plant cell walls to date 
(O'NEILL et al., 1990, Mohnen, 2008).  
 
Citrus fruits can contain 0.5 – 3.5% pectin, largely present in the peel. Hence, pectin is mostly 
extracted from the peels of citrus fruits and apple (Lattimer and Haub, 2010). Within plants pectin 
plays an important role in the growth and development of plants, morphology and defence. In the food 
industry this viscous fibre is used as a stabilising and gelling agent (Mohnen, 2008). Apart from its 
functional properties in the food industry, pectin has also been associated with reducing the risk of 
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colon cancer and cardiovascular disease (Leclere et al., 2013a). Rats fed pectin from citrus and apple 
origin and exposed to azoxymethane had lower carcinogen levels and fewer tumours. Rats exposed to 
apple pectin additionally demonstrated decreased activity of β-glucuronidase produced from colonic 
bacteria and known to be associated with the development of colon cancer (Ohkami et al., 1995). 
Hence, it is possible that the impact of pectin administered is dependent on source of the pectin. 
However other studies demonstrated an increase in β-glucuronidase activity or no change in activity in 
the presence of different kinds of pectin (Bauer et al., 1981). Borisenkov et al. (2011), demonstrated 
that cabbage pectins increased the activity of this enzyme while sweet pepper pectins had no impact, 
again demonstrating a variation in impact depending on source of pectin. While both sources of pectin 
increased the adhesion of β-glucuronidase, increasing its excretion, cabbage pectins had a greater 
impact. In another study, 5% low methoxylated or high methoxylated pectin had no impact on the 
activity of β-glucuronidase (Bauer et al., 1981). The use of various sources of pectin makes it difficult 
to associate function and structural properties of pectin, as pectin extraction methods, size of generated 
fragments and degree of esterefication and nature of monomers play an important role in the health 
benefits pectin can induce (Leclere et al., 2013b). 
 However, pectins, which are viscous, in general have the functional ability to thicken solutions and 
this may include intestinal contents. Many of the health benefits exhibited by pectin such as prevention 
of diabetes and cardiovascular disease are attributed to this property (Lattimer and Haub, 2010). Pectin 
maintains its viscosity throughout the small intestine and hence it can enhance bile acid excretion and 
prevent its re-absorption (Leclere et al., 2013b). Additionally colonic fermentation of pectin results in 
high concentrations of SCFA production especially higher molar ratios of acetate and butyrate than 
some other fibres (Table 1-1). These properties of pectin and its complex structure have demonstrated 
many health benefits such as reduced risk of CVD and colon cancer (Leclere et al., 2013b).  
Considering acetate is particularly increased by pectin fermentation, it is speculated that the presence 
of this SCFA in the peripheral circulation could be the mechanism behind the impact of pectin on 
fibrin (Lattimer and Haub, 2010). However other studies such as Miettinen and Tarpila (1977) 
investigating the impact of 40–50 g/day pectin for two weeks administered to 9 normolipidemic and 
hyperlipidemic patients, have attributed the impact of pectin on CVD prevention to reduced blood 
cholesterol through increased faecal excretion of bile acids. This study did not demonstrate any change 
in TAG concentrations but a significant decrease in total cholesterol levels (p < 0.05) especially in 
hyperlipidemic patients. These results are similar to that seen for ispaghula trials. It is possible that 
pectin reduces the risk of CVD in more than one way. The mechanism behind CVD prevention by 
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pectin could be through increasing fibrin permeability and decreasing its tensile strength which was 
demonstrated in hyperlipidaemic men in a study by Veldman et al. (1999).  
In regard to pectin‘s potential role in prevention of colorectal cancer, there is increasing research in 
various forms of modified pectin, such as pH and/or heat modified pectin and its use as a colon cancer 
preventive compound (Maxwell et al., 2012, Leclere et al., 2013b). These reviews have demonstrated a 
promising dose-dependent role of modified citrus pectin in the prevention of cancer. A postulated 
mechanism for this cancer preventive property of modified citrus pectin was proposed to be the 
impairment of the interaction between cells as it is a rich source of galactosides and thus may compete 
with endogenous ligands of galactoside binding proteins, such as galectin-3 (Platt and Raz, 1992, 
Inohara and Raz, 1994) Further exploration of possible mechanism of action for modified citrus pectin 
in regard to cancer prevention is beyond the scope of this PhD.  
Pectin has also shown to have some prebiotic properties. Olano‐Martin et al. (2002) selectively 
stimulated the growth of certain strains of Bifidobacteria and Lactobacillus and reduced potentially 
harmful bacteria in an in-vitro batch culture study with controlled pH (6.8). It was also shown that the 
partial hydrolysis of this soluble fibre improved its prebiotic potential. This study may explain the 
outcomes of a study by Rabbani et al. (2001) showing that 4 g/kg pectin consumption in 5–12 month 
old children (n=19) with intestinal infection reduced both acute intestinal infection and diarrhoea. This 
was speculated to be due to a decrease in pathogenic bacteria such as Salmonella, Enterobacter and 
Shigella. However studies have demonstrated that the Bifidogenic impact of pectin is dependent on its 
degree of methylation and that the partial hydrolysis of this compound, converting it to pectic-
oligosaccharides can enhance its Bifidogenic properties (Olano‐Martin et al., 2002). However it is 
important to note that this may also impact other health benefits induced by pectin. Considering that 
pectin is not the first choice as a prebiotic, the hydrolysis of its structure, impacting its other health 
benefits induced through viscosity and molecular weight (Diaz et al., 2007), may be undesirable. 
 
1.2.4.3 Inulin (Raftiline)  
Raftiline, Orafti‘s inulin product was used in this thesis. Inulin, is a polymer of fructose monomers, 
containing up to 60 fructose units (Clark et al., 2012) and is naturally found in foods such as chicory, 
leek, onions, garlic, bananas, artichokes and wheat. The average consumption of inulin through the diet 
in the West is estimated around 2-12 g/day (Roberfroid, 1993). This estimation does not take into 
consideration the supplemented form of raftiline. This soluble fibre is commercially available as a 
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white powder supplement extracted from chicory roots (Sokiic et al., 2009). Inulin is more rapidly 
fermented than ispaghula and pectin which may result in more gas production causing discomfort. 
However 20g/ day of inulin was consumed without adverse gastro intestinal effects (Flamm et al., 
2001). The consumption of inulin increased stool weight and frequency and lowered pH thus relieving 
constipation (Sokiic et al., 2009).  
 In the food industry, raftiline is used as a functional food and as a prebiotic. Due to its ability to 
enhance the taste and mouth feel of food products, it is used to replace fat and sugars. (Mortensen et 
al., 2002, Lattimer and Haub, 2010, Tungland and Meyer, 2002). 
Due to the β-bonds constituting raftiline and only traces of glucose present, less than 10% of this fibre 
is digested in the small intestine, the rest is subjected to colonic bacterial fermentation (Lattimer and 
Haub, 2010) which favours higher molar ratio production of butyrate than fermentation of ispaghula 
and pectin. Stewart et al. (2008) in an in-vitro batch model for 24 hours found that the highest chain 
raftiline had the least production of butyrate, indicating that the degree of polymerization is an 
important factor in the production of SCFA from raftiline fermentation. 
As seen for ispaghula and pectin, raftiline has also demonstrated the potential to prevent CVD through 
reduced blood cholesterol levels. Mortensen et al. (2002) investigated the impact of 0 or 10% raftiline 
supplementation to an isocaloric balanced fat diet of 40 LDLR
-/-
 male mice for 16 weeks. 10% raftiline 
supplementation lowered body weight and total cholesterol, LDL, IDL and VLD, with no impact on 
HDL or TAG. However no impact was seen on plasma cholesterol in 8 healthy individuals after 3 
weeks of raftiline (10g) and a high carbohydrate/low fat diet (Letexier et al. (2003). However there was 
a significantly lower concentration of plasma TAG. The lack of effect in cholesterol levels may be 
because healthy individuals were used. It has been shown in many studies that reducing levels from 
normal is not easily achievable and it is better to use hyperlipidaemic individuals. The change in TAG 
concentrations caused by raftiline supplementation can be explained by elevated TAG concentration 
caused by the high carbohydrate diet consumption (Jeppesen et al., 1997).  
There are not sufficient studies investigating the impact of raftiline on blood cholesterol levels. A 
review by Williams and Jackson (2002) contained 9 human studies (normo- or hyperlipidaemic 
individuals) investigating the impact of raftiline on plasma cholesterol.  Four out of nine studies 
demonstrated a mild reduction in total and LDL levels with raftiline supplementation, three studies 
demonstrated a reduction in TAG and the remaining three did not demonstrate any impact of raftiline 
on plasma cholesterol. Unlike ispaghula and pectin, raftiline is not viscous. Raftiline is a prebiotic 
selectively stimulating growth of bifidobacteria (Clark et al., 2012). Hence, it can be speculated that its 
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cholesterol lowering ability is through its fermentation products and its prebiotic nature. Animal 
studies have suggested that the mechanism of action for TAG reducing effect of raftiline is through 
inhibition of hepatic fatty acid synthesis, this pathway is of importance only when a high carbohydrate 
diet is consumed, else it is relatively inactive (Parks, 2002).  
The high production of butyrate through raftiline fermentation has attracted much research in regards 
to colorectal cancer prevention potential of raftiline. The mechanisms of butyrate action in regard to 
colorectal cancer prevention are discussed in 1.2.6.1.3 Butyrate. 
 
1.2.5 Microbiota 
The human colon has a diverse colony of metabolically active microbiota, with an approximate 1000 
different species of bacteria ranging from anaerobic to aerobic and beneficial to pathogenic. The 
population of the microbiota in the colon can reach up to 10
11–1012 cfu/g of colonic content (Slavin, 
2013) accounting for 35-40% of the volume of colonic contents (Tappenden and Deutsch, 2007). 
In recent years the colonic bacteria have shown major influences on the body‘s metabolic and immune 
function and this has led to exciting scientific research to the extent that there has been an accelerating 
number of publications (10,592 publications since 1956) with 261 published between January 2014 to 
March 2014, ranging from the role of microbiota in health, obesity (Turnbaugh et al., 2006); Crohn‘s 
disease (Hofer, 2014), cancer (Schwabe and Jobin, 2013, Greenhill, 2014) and  CVD (Howitt and 
Garrett, 2012, Wang et al., 2011) to its impact on brain function and human behaviour (Cryan and 
Dinan, 2012).  
The gastrointestinal tract is colonised by bacteria at birth and its composition is highly dependent on 
birth method, environment, breast / formula feeding, genetics, diet, medication, disease (Tappenden 
and Deutsch, 2007, Scott et al., 2013) and gastrointestinal factors (Figure 1-1); leading to great inter- 
individual variation in microbial profile (Turnbaugh et al., 2007) . The individual specific microbiota 
profile is often compared to a finger print.  
The role of diet in microbiota composition begins early in life. Breast fed infants have shown to have a 
composition dominated by Bifidobacteria (Roger and McCartney, 2010, Fallani et al., 2010) compared 
to formula fed infants having a more diverse microbiota composition (Edwards and Parrett, 2002, 
Rinne et al., 2005).  After initiation of weaning healthy adult like composition is formed (Yatsunenko 
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et al., 2012).  Due to these factors high inter-individual variability can be seen in bacterial composition 
resulting in different molar ratios of SCFA production (Edwards et al., 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
Despite this great inter-individual diversity in the microbiota profile, four phyla have been identified to 
contribute most (98%) to the composition of the colony; Firmicutes (64%), followed by Bacteroidetes 
(23%), Proteobacteria (8%) and Actnobacteria (3%). The remaining 2% of the bacterial divisions are 
highly diverse and include Clostridium, Prevotella, Eubacterium, Ruminococcus, Fusobacterium, 
Peptococcus, Bifidobacterium, Escherichia and Lactobacillus (Matsuki et al., 2004, Zhu et al., 2010, 
Etxeberria et al., 2013). 
The microbiota can exhibit both beneficial and pathogenic effects; depending on their metabolic 
activities and metabolites produced as a result. Some of the health benefits associated with the 
microbiota and the products of their activity include inhibition of pathogenic growth, prevention of 
colonic cancer, reducing risk of CVD, vitamin synthesis and immune-stimulation. Their harmful 
effects are due to the production of carcinogens, intestinal infection and diarrhoea (Saulnier et al., 
2009).  There has been much debate on the consequences, such as obesity and diabetes resulting from 
an imbalance between the two prominent bacterial phyla present in the gut; Bacteroidetes and 
Firmicutes (Burcelin et al., 2009, Cani and Delzenne, 2009). This has stimulated much interest in 
Figure 1-1 Regional differences in the human large bowel 
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dietary interventions to modify gut microbiota composition, increasing the ratio of beneficial to 
pathogenic bacteria. 
In this regard, prebiotics have received much attention due to their low digestibility and bioavailability 
in the human upper gut, resulting in their availability for fermentation by selective commensal bacteria, 
leading to an improvement in bacterial composition and gut health (Gibson and Fuller, 2000). 
However, these prebiotics are mostly studied for their ability to promote beneficial bacteria and not 
their inhibitory impact on pathogenic bacteria. A study of flavanols in cocoa (Tzounis et al., 2011) 
demonstrated an increase in the growth of beneficial bacteria such as lactobacilli and Bifidobacteria 
both in-vivo and in-vitro (p < 0.01), as well as a reduction in the growth of pathogenic bacteria such as 
C. histolyticum. This opens grounds for research combining the well-known prebiotics such as fructo-
oligosaccharides and some soluble fibres with flavanols to obtain greater bifidogenic effects. 
Increased fibre consumption results in higher fermentation activity in the proximal colon, resulting in 
SCFA production and thus a drop in the pH to between 6.5 and 5.5 depending on type of fibre. This 
change in pH can greatly influence bacterial composition (Etxeberria et al., 2013) as demonstrated in a 
study by Duncan et al. (2009) where 33 bacterial species were incubated as a representation of colonic 
bacteria in an anaerobic continuous flow fermentor at pH 5.5, 6.2 and 6.7. They demonstrated a 
suppression of Bacteroides species at pH 5.5 with a promotion of gram positive bacteria favouring 
butyrate production.  
The fate of both soluble fibres and polyphenols is greatly dependent on these gut microbiota, and the 
composition of the colony can determine the extent of impact fibre and polyphenols can have on 
human health.  
The gut microbiota metabolism of polyphenols is essential for their absorption as well as production of 
more biologically active metabolites in the body. The majority of polyphenols reach the colon intact 
where they are hydrolysed to phenolic acids. However the metabolites of polyphenol are highly 
dependent on diet and vary amongst individuals (Hanhineva et al., 2010).  
The microbiota can modify the phenolic skeletons through chemical reactions, making it possible for 
lower weight metabolites to be absorbed. This is made possible by the microbial enzymes that have the 
ability to cleave rings, hydrolyse glycosides, sulphates, glucoronides, lactones, amides and esters. 
These enzymes are also key to the reduction, dehydroxylation, demethylation and decarboxylation 
reactions (Aura, 2008).  
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Similarly soluble fibres escape digestion in the small intestine, reaching the colon where they can be 
partially or completely fermented.  
Given the important role the gut microbiota play in the metabolism of carbohydrates and polyphenols, 
it is important to maintain the correct balance of host-microbiota and beneficial-pathogenic bacteria for 
human health.  
 
1.2.6 Fermentation 
The carbohydrates that have resisted digestion in the small intestine are the main source of carbon and 
energy for the colonic microbiota and are subjected to anaerobic degradation by these colonic 
organisms through which SCFA and gases are produced. This process is known as fermentation. The 
process of fermentation and production of SCFA allows for the salvage of energy from non-digestible 
substrates which would be wasted through excretion otherwise (Cummings and Macfarlane, 1991). 
(Tabernero et al., 2011, Macfarlane et al., 1992). The ileal content enters the caecum and proximal 
colon, staying there for 6-12 hours where the bacterial polysaccharidases and glycosidases are used to 
degrade the complex polysaccharides to oligomers and sugars, which are then used for fermentation by 
the anaerobic bacteria. Carbohydrate fermentation decreases as the material moves to the transverse 
colon and distal colon where they are stored until excretion (Macfarlane and Macfarlane, 2003, 
Cummings and Macfarlane, 1991). While the colonic content of nitrogen is approximately 6% of dry 
matter throughout the colon, the carbohydrate content is reduced from 20% at the proximal colon to 
11% in the distal colon due to fermentation. Lower substrate availability in the distal colon results in 
lower SCFA production in this region (Cummings and Macfarlane, 1991). However, the type of 
carbohydrate is a determining factor as some carbohydrates are very fermentable, some less so or not 
fermentable at all, passing through the colon intact.  Thus poorly fermented fibres may promote higher 
SCFA in more distal colon. 
1.2.6.1 SCFA:  
The major end products of polysaccharide, oligosaccharide, amino acids, proteins, peptides and 
glycoprotein metabolism by the gut microbiota are SCFA. Even though these metabolites can be 
produced through different substrate breakdown, polysaccharides are the biggest contributors to total 
SCFA production (Cummings and Macfarlane, 1991). The daily production of SCFA in humans 
amounts to 300mmol from which only 10 mmol/ day is excreted (Hoverstad, 1986). 
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The principal SCFA produced from all substrate fermentations, accounting for 85-95% of total SCFA 
produced are acetate, propionate and butyrate along with lesser produced formate, valerate, caproate, 
enanthate, caprylate, isobutyrate, isovalerate and isocaproate. Some of these branched SCFA such as 
isobutyrate and isovalerate can also be produced from the catabolism of branched chain amino acids 
such as valine, leucine and isoleucine (Macfarlane and Macfarlane, 2003, Flint et al., 2012).  
As mentioned previously the production of these SCFA is highest in the proximal colon reducing 
towards the distal colon (Figure 1-1). However it was found that the molar ratio of these SCFA 
remains the same throughout the length of the colon (Cummings et al., 1987). This ratio depends on the 
type of carbohydrate/carbohydrates being fermented as different carbohydrates produce different molar 
rations of SCFA making the molar ratios, carbohydrate specific (Table 1-1). 
After absorption, the colon the SCFA is removed at different rates by different tissues. Cummings et al. 
(1987) observed in sudden death victims that in the colon the molar ratio of acetate: propionate : 
butyrate was 57: 22 : 21. Most of the butyrate produced was absorbed through the colonic epithelium 
resulting in only 8% of butyrate in the portal blood. The concentration of propionate fell from 22% to 
12% after transport to the liver, indicating the uptake of propionate by the liver. Acetate remained to be 
the only SCFA present in measurable quantities in the peripheral blood. Hence it is evident that the site 
of action and health benefit exhibit of each SCFA varies.  
It is said that SCFA act mostly as an energy source; however they are also signalling molecules. The 
endogenous receptors of SCFA have been identified as G-protein coupled receptor free fatty acid 
receptor-2 (FFAR2, GPR43) as well as FFAR3 (GPR41). The receptor affinity for acetate is FFAR2, 
propionate FFAR2 and FFAR3 and butyrate FFAR3 (Le Poul et al., 2003). It was suggested that all 
three SCFA play a role in energy homeostasis by signalling through these receptors which can result in 
the modulation of gut transit time, adiposity and synthesis of glucagon like peptide-1 in the 
enteroendocrine cells, thus protecting against diet induced adiposity (Tolhurst et al., 2012, Samuel et 
al., 2008). This was not supported in a study by Lin et al. (2012) investigating the impact of these 
SCFA in FFAR3 deficient mice. It was shown that acetate and butyrate prevent weight gain 
independent from food intake, whereas propionate exhibited its impact by lowering food intake (Gao et 
al., 2009, Arora et al., 2011).   
Knowing the molar ratio of the SCFA produced from a specific fibre, the site and health benefit of 
each SCFA, it may be possible to design diets for specific health effects.  The role of SCFA in energy 
regulation may be of greater importance in regions where meeting daily energy requirements is a 
struggle.  
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1.2.6.1.1 Acetate 
Acetate is the major SCFA produced through fermentation, mainly through the oxidative 
decarboxylation of pyruvate (Cummings, 1981) contributing ≈ 60% of total SCFA production and the 
only SCFA reaching the peripheral blood in any great amount (Scheppach et al., 1991, Cummings et 
al., 1987). Within the colonic environment, acetate stimulates cell turnover and heals damaged mucosal 
tissue (Sakata, 1987). Once it has entered the circulatory system it can be utilised by the hepatic 
tissues, indicated by significantly higher concentrations in portal blood than peripheral blood 
(Cummings et al., 1987). Mostly acetate is taken up by the peripheral tissues as a source of energy 
(Cummings and Macfarlane, 1991, Pomare et al., 1985) making it the primary method of energy 
salvation from non-digestible carbohydrates. Acetate is also the primary substrate used during 
cholesterol synthesis (Hijova and Chmelarova, 2007). Acetate produced from the colonic fermentation 
is not a major source of energy, but perhaps its role is of greater importance in regions of poverty 
where carbohydrates are the main source of energy. 
Apart from the exogenous production of acetate by the colonic microflora, it is also produced 
endogenously. The actions of alcohol dehydrogenase (ADH) and cytochrome P450 2E1 (CYP2E1) 
metabolise ethanol into acetaldehyde which is then oxidised to acetate by acetaldehyde dehydrogenase 
(Shimazu et al., 2010).  Acetate levels can rise during ethanol metabolism about 20 fold as well as 
during fatty acid oxidation as seen during long periods of starvation (Lundquist et al., 1962, Seufert et 
al., 1974, Pomare et al., 1985). It was shown by Pomare et al. (1985) that individuals (n=14) in a 
fasting state had significantly higher arterial concentrations of acetate (125.6 ± 13.5 umol/l) than in 
venous blood (61.1 ± 6.9 umol/l).  Other endogenous sources of acetate are through its release in the 
nucleus and cytoplasm after the removal of acetyl groups by class I and class II histone deacetylases as 
well as after the release of acetylcholine in cholinergic nerve terminals by acetylcholine esterase 
(Tomaszewicz et al., 2003, Schweigert et al., 2004). The endogenous source of acetate is the more 
prominent source when compared to exogenous acetate production (Pomare et al., 1985).  
The sum of exogenous and endogenous acetate can be converted to Acetyl-Co-A and used in various 
metabolic pathways. This process is facilitated by the two Acetyl-Co-A synthase enzymes. The 
AceCS1 enzyme is present in high concentrations in the kidney and liver where it facilitates the 
conversion of acetate, ATP and CoA to Acetyl-Co-A, which in turn is utilised in fatty acid and lipid 
synthesis. The sterol regulatory element-binding proteins regulate the expression of AceCS1genes and 
are insulin sensitive. Under fasting and starvation modes insulin levels decrease, resulting in lower 
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regulatory element-binding proteins and thus lower fatty acid synthesis (Luong et al., 2000, Fujino et 
al., 2001, Ikeda et al., 2001).  
AceCS2 is present in high concentrations in the kidneys and cardiac muscles. The mitochondrial 
synthesis of Acetyl-Co-A in fed conditions is facilitated by Pyruvate dehydrogenase and generated 
from pyruvate. However under fasting conditions the Acetyl-Co-A produced from the liver cannot be 
completely oxidised and some of this Acetyl-Co-A is hydrolysed by acetyl-CoA hydrolases to yield 
acetate, which will enter peripheral circulation. This free acetate combined with ATP can be used by 
AceCS1 to generate acetyl-CoA (Luong et al., 2000, Yamashita et al., 2001). 
In a study by Wolever et al. (1991) 180 mmol of rectally infused acetate increased blood acetate, 
cholesterol and glucagon  levels and reduced free fatty acids as compared to the saline control. This fall 
in free fatty acids was considered to aid in the reduction of blood glucose, as free fatty acids and 
glucose compete for uptake by insulin sensitive tissues (Ferrannini et al., 1983, Wolever et al., 1989).  
1.2.6.1.2 Propionate 
Propionate is often the second most produced short chain fatty acid after acetate. The production of 
propionate can either be through the dicarboxylic acid pathway by the fixation of CO2 forming 
succinate followed by decarboxylation or through the acrylate pathway produced from lactate and 
acrylate or even through propandiol pathway by processing deoxy sugars such as fructose (Cummings, 
1981, Reichardt et al., 2014).  
Propionate may contribute towards gluconeogenesis in humans (Sakata, 1989, Anderson and Bridges, 
1984). As hepatic glucose production is a contributing factor to insulin resistance, there has been 
debate on the beneficial impact of propionate on health. It is important to note that the above two 
studies considering propionate as a gluconeogenic substrate were conducted previous to the 
identification of the intestine as a gluconeogenic organ (De Vadder et al., 2014, Mithieux et al., 2004a).  
It is now hypothesised that propionate is a substrate of intestinal gluconeogenesis as it is produced in 
the gut lumen and its metabolites enter the gluconeogenic pathway through Krebs cycle (Mithieux et 
al., 2004b, Croset et al., 2001). The release of glucose through intestinal gluconeogenesis is detected 
by a glucose sensor of the portal vein, which in turn sends a signal to the brain through the peripheral 
nervous system, promoting beneficial effects on glucose metabolism and food intake (De Vadder et al., 
2014, Delaere et al., 2012). 
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Propionate has also shown an impact on reducing food intake, however the mechanism behind this is 
not very clear and the available information is highly inconsistent. As explained previously, a 
hypothesised mechanism was through the FFAR-3. However substantial evidence on this mechanism is 
lacking. Human studies have demonstrated that the intake of sodium propionate in bread reduced the 
food intake in 6 participating individuals. Additionally insulin sensitivity was improved with lower 
glucose response after the consumption of the bread containing sodium propionate compared to control 
bread. In the same study in-vitro digestion of bread by saliva containing propionate demonstrated 
reduced digestibility (Todesco et al., 1991). This enzyme inhibiting property of propionate could be the 
contributing factor to lower glucose response and improved insulin sensitivity. These results were 
replicated in another study using various kinds of bread: whole meal bread, sourdough bread, whole 
meal bread with lactic acid, Calcium lactate or sodium propionate (62 or 185 g). Breads containing 
higher dose of sodium propionate resulted in higher satiety, improved insulin sensitivity and lower 
glucose levels. However in this study it was suggested that propionate reduces glucose response 
independent of starch digestibility as the amylolytic activity was only significantly reduced with 
Calcium lactate (Liljeberg et al., 1995). The same study was replicated with the addition of 
paracetamol as a measure of gastric emptying. It was found that breads containing sodium propionate 
slowed gastric emptying rate and hence this was proposed as the mechanism of action for propionate 
satiety properties. The same results were seen in rats fed propionate or lactate but not sodium 
propionate (Liljeberg and Björk, 1996). The addition of ultrasonography to a similar study model 
confirmed the above results, with sodium propionate induced delay of gastric emptying rate and 
reduced glucose response (Darwiche et al., 2001). 
Similarly the mechanism of cholesterol lowering effect of propionate observed in animal and human 
studies has not been clearly understood. One of the suggested mechanisms is the change in propionate 
to acetate ratio. This was observed when rectally infused acetate (180 mmol) increased plasma 
cholesterol and decreased free fatty acids, whereas the same volume of propionate had no impact on 
cholesterol levels, but increased glucose, glucagon and delayed the fall in free fatty acids. When the 
two were combined no change was observed in cholesterol levels indicating the inhibitory impact of 
propionate on cholesterol synthesis from acetate (Wolever et al., 1991). However it is important to note 
that this study used equimolar ratios of acetate: propionate. Although the concentration of acetate is 
similar to physiological concentrations (57% of total 300mmol) this concentration is much higher than 
physiological concentration of propionate (≈12.5 mmol). The metabolism of propionate by the liver 
opposes that of acetate as propionate can reduce the oxaloacetate availability required for citrate 
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formation by using it for gluconeogenesis, thus inhibiting the oxidation of acetate in the hepatic tissues. 
This in turn influences carbohydrate and lipid metabolism (Wolever et al., 1991).  
Hence the ratio of propionate to acetate may be critical in the physiological role of the SCFA in the 
body. Thus the selection of fibre type based on its molar ratio production of short chain fatty acids is of 
great importance. Slowly fermented viscous fibres producing higher relative propionate such as 
ispaghula may be preferred over rapidly fermented, high acetate producing fibres such as pectin for the 
purpose of reducing cholesterol synthesis.  
There are many studies demonstrating the cholesterol lowering effect of propionate, however the 
mechanism proposed by the studies are numerous, such as: down regulation of the genes related to 
intestinal cholesterol biosynthesis pathway (Alvaro et al., 2008b), inhibition of 3-hydroxy 3-
methylglutaryl CoA reductase a cholesterol synthesizing enzyme (Wright et al., 1990a), redistribution 
of cholesterol from plasma to liver (Illman et al., 1988), enhancement of bile acids synthesis and 
secretion and cholesterol 7α-hydroxylase activity via elevation of the mitochondrial succinyl-CoA 
(Imaizumi et al., 1992). However it is important to note that most of these studies are carried out in 
animal models. This might not necessarily be translatable to mechanism of action of propionate in 
humans. Studies have shown that rat hepatocytes can be affected by low concentration of propionate 
(0.1 mmol/L) while to see the same degree of inhibitions in humans a much higher concentration of 10-
20 mmol/l propionate was required (Lin et al., 1995). Propionate in the colon may also stimulate cell 
turnover in the gut (Sakata, 1987). 
1.2.6.1.3 Butyrate  
Butyrate is usually the least abundant SCFA ranging from 5-20% of total SCFA production 
(Aschenbach et al., 2011). Butyrate is produced by the reduction of acetoacetate (Cummings, 1981) 
and it is the preferred source of energy for the colonocytes (Bergman, 1990, Arora et al., 2011). This 
was identified by Roediger (1980) in an in-vitro study demonstrating clear intra-colonic regional 
differences for butyrate uptake, the highest being in the distal lumen. This could be due to the lower pH 
in this part of the gut which promotes butyrate-producing bacteria to compete against gram-negative 
carbohydrate-utilizing bacteria, such as Bacteroides sp (Louis and Flint, 2009).  
The higher concentration of butyrate in the colon than the portal veins suggested that most butyrate is 
utilised by the colonocytes after which it is metabolised by the hepatic tissues (Cummings et al., 1987). 
70 – 90 % of Butyrate is metabolised by the colonocytes, it enters the mitochondria to undergo β-
oxidation to Acetyl-coA, which enters the TCA cycle and results in ATP (Moco et al., 2012).  Butyrate 
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may play an important role in increasing energy expenditure (Donohoe et al., 2011, Gao et al., 2009). 
This was displayed when a 5 week treatment of butyrate resulted in 10.2% of original body weight loss 
in obese mice, along with 30% reduction in fasting glucose and 50% reduction in insulin resistance 
(Gao et al., 2009).  This is in contrast to the proposed association of butyrate production and obesity 
which has been attributed to the high energy salvage by the butyrate producing Firmicutes and 
Bacteroidetes (Turnbaugh et al., 2006), however other studies comparing the colonic composition of 
lean and obese individuals have found no association between body weight and butyrate producing 
bacteria (Duncan et al., 2008).  
Apart from being the main source of energy for the colonocytes, butyrate plays an important role in 
colonic health as it can increase cell proliferation in normal intestinal cells (Kripke et al., 1989, Sakata 
and Engelhardt, 1983) and reduce proliferation in cancer cells (Canani et al., 2011, Clarke et al., 2012, 
GIBSON et al., 1992) as well as inducing apoptosis (Scharlau et al., 2009b, Hague et al., 1995). The 
butyrate paradox termed after the contradictory patterns of butyrate action are observed as butyrate 
stimulates the physiological pattern of proliferation in the colon basal crypt, simultaneously reducing 
the earliest detectable neoplastic lesions by reducing the number and the size of aberrant crypt focus in 
the colon (Alrawi et al., 2006, Comalada et al., 2006). Butyrate has shown to promote the induction of 
differentiation of colonic epithelial cells, improvement of tight junction barrier function, suppression of 
epithelial proliferation and tumorogenesis (James et al., 2003, Zoran et al., 1997, Basson et al., 2000).  
Sodium butyrate can act as an antiproliferative on many cell types, demonstrating prevention of colon 
cancer and adenoma development (Bornet et al., 2002). Butyrate can also modify gene expression at a 
molecular level via the phosphorylation and acylation of histone proteins (Archer and Hodint, 1999). 
The passage of toxic and pro-inflammatory molecules into the sub-mucosa and systemic circulation is 
prevented by the barrier forming epithelial cells. The tight junction between these epithelial cells forms 
a barrier which can be disturbed by signalling from inflammatory cytokines that cause a change in tight 
junction proteins (Turner, 2006, Plöger et al., 2012). In this regard butyrate has demonstrated a 
modulatory impact on the expression of these tight junction proteins and the up-regulation of the 
dominant colonic mucin-2 in in-vitro models, thus improving the intestinal barrier (Plöger et al., 2012).  
An imbalance of histone acetylation can lead to the deregulation in transcriptional genes involved in 
the cell cycle progression, differentiation and apoptosis; potentially contributing to the development of 
cancer. In this regard butyrate inhibits histone deacetylase causing hyperacetylation of histones 
(Scharlau et al., 2009a, Davie, 2003). 
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Butyrate induces its anti-inflammatory properties mostly by inhibiting nuclear factor κB (NF-κB) 
activation in inflammatory cells of the colon (Inan et al., 2000). NF-κB is often dysregulated in 
individuals with colon cancer, inflammatory bowel diseases, Crohn‘s disease or ulcerative colitis. NF-
κB plays a key role in the regulation of cellular genes involved in early immune inflammatory 
responses, such as IL-6, IL-8 and TNF-α (Shao et al., 2000, Lind et al., 2001). 
Additionally butyrate may be involved in colonic motility as demonstrated by Soret et al. (2010). In 
this study the proportion of choline acetyltransferase but not nitric oxide synthase, immunoreactive 
myenteric neurons was increased by butyrate in-vitro and in-vivo. An increase in the cholinergic-
mediated colonic circular muscle contractile response in-vitro was also seen. 
Most of the butyrate related health benefits are induced within the colonic environment. However some 
studies have suggested that butyrate may induce health benefits outside the colon. This includes 
increase in energy expenditure as previously mentioned as well as down regulation of nine genes 
involved in intestinal cholesterol biosynthesis which is seen in hypercholesterolemia, when the 
intestine becomes the major site of cholesterol biosynthesis, due to this process being inhibited in the 
other organs by fasting (Alvaro et al., 2008a).  
1.2.6.2 pH 
With the proximal colon being the site of extensive carbohydrate fermentation, a large amount of 
SCFA is produced causing a low pH environment. The absorption of these SCFA accompanied by the 
production of bicarbonate keeps the caecum pH at approximately 5.6 but it can go as low as 4.5 
(Cummings et al., 1987). The pH increases gradually towards the distal colon (approximately 6.6) with 
less SCFA being present (Cummings et al., 1987). This lower luminal pH can inhibit the growth of 
pathogenic pH sensitive bacteria while promoting the growth of beneficial bacteria such as 
bifidobacteria and lactobacilli (James et al., 2003, Kiely et al., 2001). This was demonstrated in a 
continuous anaerobic culture where a number of bacteroides species survived a range of pH from 5-7, 
whereas lactobacilli and bifidobacteria surviving at pH 5 disappeared with increasing pH from 5 to 6 
and then pH 7 (Edwards et al., 1985). In a study by Duncan et al. (2009) 19 out of 23 gram-positive 
anaerobes demonstrated growth by reducing pH from 6.7 to 5.5. These butyrate producing bacteria 
comprised 50% of population at pH 5.5 whereas they were not detectable at pH 6.7. The 8 bacteroides 
representative species although present at pH 5.5, were 27% of population as compared to 86% at pH 
6.7. This indicates that the bacteriodes species can survive a range of pH but favour higher colonic pH.  
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Higher faecal pH has been identified and reviewed as a risk factor of colon cancer by many studies 
(Thornton, 1981, Walker et al., 1986, Kato et al., 2013, Van Dokkum et al., 1983). One of the proposed 
mechanisms behind this is less solubility of bile acids at lower pH resulting in less degradation of bile 
acid into co-carcinogens through the action of 7α-dehydroxylase (Thornton, 1981). Another proposed 
mechanism is that lower pH allows ammonia from urea degradation to remain in its ionised form 
(NH4
+
) which is less absorbed from the colon as compared to NH3 (Newmark and Lupton, 1990).  
Changes in colonic pH can also lead to a change in metabolic pathways of microbiota independent of 
numeric values of species. Lower pH may result in the promotion of propionate and butyrate 
production instead of acetate (Louis and Flint, 2009, Edwards et al., 1985). The lower pH may also 
enhance the absorption of minerals such as calcium and magnesium up to 6 fold as seen in a study by 
Younes et al. (1996).  
Hence SCFA may exhibit some of their health benefits indirectly by lowering the pH in the colonic 
environment. Slowly fermentable fibres may be preferable as they can regulate the colonic pH over a 
longer period of time and this beneficial impact may be extended to the distal colon and not limited to 
the proximal colon. This is of great importance as many of the colonic diseases are associated with the 
distal colon. 
1.2.6.3 Gases 
Along with other products of fermentation, the gases hydrogen, carbon dioxide and methane are 
produced. Due to the activity of hydrogen utilising species (methanogenic, acetogenic and sulphate 
reducing species) hydrogen is normally kept at low levels in the colon. Non-methanogenic individuals 
lack the ability to produce methane and poses large numbers of sulphate reducing bacteria which use 
sulphate during oxidative reactions as an electron acceptor. Examples of these are desulfovibrio, 
desulfobacte and desulfomonas (Moco et al., 2012).  
The composition of gas produced from microbiota is greatly varied and dependent on the diet. 
However individuals on the same diet have demonstrated great inter-individual variation in 
composition of gas produced, indication that gas production is influenced by diet and composition and 
metabolic activity of colonic microbiota (Manichanh et al., 2013). The absence of polysaccharides 
from the diet results in low production of hydrogen and methane (less than 50 ml/ day). When 
fermentable material is available to the microbiota the production of hydrogen and methane increases, 
the produced gas can be eliminated either as flatus or from the lungs. Hence breath hydrogen can be a 
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good measure of fermentation as 65% of gas produced at rates of 200 ml/day is excreted through 
breath (Cummings and Macfarlane, 1991).  
Hydrogen is produced as a means of reducing power disposal generated during fermentation and can 
be produced from the oxidation of pyruvate, formate or reduced pyridine nucleotide. However 
pyruvate is thermodynamically more favourable to form hydrogen and can produce hydrogen through 
being cleaved by pyruvate-formate lyase in Enterobacteria or via ferredoxin by Saccharolytic 
Clostridia (Cummings and Macfarlane, 1991). 
Highly fermentable fibres consequently result in higher gas production which leads to abdominal 
discomfort and pain in individuals (Manichanh et al., 2013). This may lead to non-compliance to 
intervention in long-term studies. Hence to incorporate soluble fibres in diet and life style of 
individuals slower fermented fibres such as ispaghula are preferred as rapidly fermented fibres can 
result in a high volume of gas produced rapidly.  
 
 
 
1.3 Polyphenols 
 
Polyphenols are one of the most common groups of bioactive compounds derived from plants. They 
greatly contribute to the colour and taste of fruits and vegetables (Duda-Chodak, 2012).  
Chemically they are characterised by the hydroxylated phenyl moieties and are naturally occurring as 
their glycosylated forms (Moco et al., 2012). Dietary intake of polyphenols has been estimated to range 
on average between 0.15 and 1 g/day and represents approximately two-thirds of the total daily 
phenolic intake, with approximately one third as phenolic acids (Lee et al., 2006). 
Polyphenols are only partially absorbed in the small intestine. The glycosidic form of these compounds 
undergo de-conjugation by hydrolases, β-glucosidases, β-glucoronidases and α-rhamnosidases (Selma 
et al., 2009). Upon reaching the colon, the gut microbiota are able to metabolise polyphenols by the 
following means: fermentation of the flavonoid backbone, deglucoronidation of flavonoids as well as 
O- and C-deglycosilation, ester and amide hydrolysis. The aromatic moieties of aglycones can undergo 
dehydroxylation, demethoxylation and demethylation, as well as ring rupture, hydrogenation, α and β-
oxidation of the substituted aliphatic groups (Williamson and Clifford, 2010). 
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The backbone rupture of the flavonoids produce hydroxylated forms of phenyl acetate or phenyl 
propionate derived from the B-ring and phloroglucinol from the A-ring. The simple phenolic acids 
produced as a result of this backbone rupture of flavonoids can be metabolised to non-aromatic 
compounds, including SCFA, lactate, gases (CO2 and H2), ethanol and oxaloacetate (Moco et al., 
2012). These phenolic acids undergo phase I and phase II metabolism in the liver, where they are 
converted to less toxic compounds through glycine-conjugation, sulphation, glucoronidation and 
methylation.  
The microbial catabolism of polyphenols has been associated with the production of benzoic acid 
which is glycine-conjugated in the liver and converted to hippuric acid, which can be easily detected in 
urine (Lord and Bralley, 2008, Bazzocco et al., 2008) but naturally this hepatic metabolite will not be 
detected in in-vitro fermentation models (Bazzocco et al., 2008). 
 
1.3.1 Health implications of polyphenols 
Most of the health claims for polyphenols in humans are obtained from epidemiological studies 
investigating the impact of fruit and vegetable consumption (Riboli and Norat, 2003). This is through 
the hypothesis that fruits and vegetables are enriched with flavonoids which have a beneficiary impact 
on health, independent from other known micronutrients (Arts and Hollman, 2005). These 
epidemiological studies have investigated the relationship between food consumption with risk of 
disease. However due to the lack of an accurate food composition data only few foods were assessed 
for flavonoid content and their association with risk of disease. In these studies it cannot be said with 
certainty which compound in the food was responsible for the observed association, as increased intake 
of fruits and vegetables results in an increased consumption of fibre and plant sterols as well. 
Furthermore, causation cannot be claimed by epidemiological studies, only an association. 
Additionally increased intake does not necessarily increase bioavailability considering some factors 
such as food matrix interaction may reduce the bioavailability, thus further complicating the 
implications for cause-effect. Even though there is a poor understanding of their mechanism of action, 
in the field of nutrition, foods rich in polyphenols are considered to be healthy in-vitro. 
While epidemiological studies have linked the consumption of plant based foods with reduced risk of 
diseases such as CVD, based on a reduction in blood pressure and improved microvascular function 
(Woodside et al., 2013, Dauchet et al., 2009b), further studies have attempted at identifying various 
components of plant based foods as a source of these health benefits. There are conflicting opinions on 
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the impact of polyphenols as a component of plant based foods on health, with some studies 
demonstrating a protective effect of these compounds against chronic diseases.  
The Hertog et al. (1993b) study was one of the first studies to demonstrate a reduced incidence of CVD 
linked mortality to flavonoid intake. While a review of epidemiological and intervention studies by 
Tangney and Rasmussen (2013) has attributed the vasodilatory effect of polyphenols to its prevention 
of CHD risk. Other studies such as the seven countries study (Hertog et al., 1995) have shown that 
foods such as tea, red wine, onions and apples are the biggest contributors to this observed health 
benefit of polyphenols.  
While a recent meta-analysis (184 intervention trials) has demonstrated a vasodilatory and blood 
pressure lowering impact of the six flavonoid subgroups combined (Kay et al., 2012); other studies 
have focused on specific polyphenols and their health benefits. Studies investigating individual 
polyphenols may be more valid than a meta-analysis on the 6 subgroups combined; given that different 
polyphenols (discussed below) have demonstrated different outcomes and impact on health. Some of 
such studies looking at individual polyphenols are the combination of The Nurses‘ Health study I, II 
and the Health Professional study follow up; indicating a reduction of 8% for hypertension through 
high anthocyanin consumption (Cassidy et al., 2011). Similarly the high consumption of flavan-3-ols 
was linked to a reduction in atherosclerosis in middle aged men (Dauchet et al., 2009a) and the 
consumption of proanthocyanidins to reduced risk of coronary artery disease in postmenopausal 
women (Mink et al., 2007). 
Some of the mechanisms associated with this health benefit of polyphenols has been suggested to be 
prevention of platelet adhesion, secretion and aggregation through anti-inflammatory properties (El 
Haouari and Rosado, 2011), reduction of oxidative stress and cholesterol ester accumulation in 
macrophages through up-regulation of antioxidant enzymes and reduction of oxidative stress 
(Mulvihill and Huff, 2010).  
Similar to the evidence for CVD prevention, the evidence on polyphenol consumption linked to 
reduced risk of cancer is modest. Epidemiological studies have demonstrated chemo-preventive 
properties for polyphenols (knekt et al., 2002). These chemo-preventive properties are dependent on 
type of polyphenol and food source. In a review by Thomasset et al. (2007), it was shown that while 
the evidence on the chemo-preventive properties of tea polyphenols qualify them for advancement in 
phase III clinical trials, the same may not be applied for the evidence on curcumin or soya isoflavones, 
and further investigation in pre-malignancies studies is required. In addition to type of polyphenol and 
food source, the impact of polyphenols may vary dependent on the site of cancer occurrence. As seen 
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in the seven countries study, while a strong correlation was found between the flavonoid intake and 
stomach cancer, there was no evidence for the same link to lung cancer. Contrary to this study, The 
Iowa women‘s study (Cutler et al., 2008) demonstrated that women with higher flavanone and 
proanthocyanidin intake had a lower incidence of lung cancer (32% and 25% respectively). There has 
also been an increased interest in the role of polyohenols in the prevention of colorectal cancer. A 
Meta-analysis of seven case-controlled studies has demonstrated an inverse association between 
flavonol and procyanidin intake and the development of colorectal cancer (White et al., 2014).  
As previously mentioned the evidence on the health benefits of polyphenols is contradicting. They 
have shown both pro-oxidant and antioxidant effects in-vitro (Halliwell, 2007, Halliwell, 2008, Skibola 
and Smith, 2000). The pro-oxidant properties of polyphenols may be due to their oxidation in cell 
culture media of in-vitro studies or their presence in hot beverages resulting in the production of 
hydrogen peroxide as demonstrated for green tea (Forester and Lambert, 2011). However it has been 
suggested that this pro-oxidant property of polyphenols may contribute to their chemo-preventive 
properties as hydrogen peroxide may induce cytotoxicity and induce apoptosis in malignant cells 
(Nakazato et al., 2005). Low levels of pro-oxidant activity may even raise xenobiotic-metabolizing and 
antioxidant defence enzymes (Li et al., 2010). The anti / pro- oxidant properties of polyphenols may be 
dependent on the concentration used. This was demonstrated by Hong et al. (2002) by incubating 10 
uM [3H] epigallocatechin 3-gallate (ECGC) with human colon adenocarcinoma cells. The further 
addition of 50 uM of ECGC to the plates resulted in the production of hydrogen peroxide and further 
uptake of the compound by the cells indicating a passive diffusion process.  
Additionally these health implications induced by polyphenols are highly dependent on the 
polyphenols reaching the site of action. Studies investigating accumulation and distribution of 
polyphenols using radiolabelled compounds have been discussed in 1.3.3Tissue uptake of polyphenolic 
compounds. Studies have demonstrated that polyphenols such as quercetin-3-O-glucuronide 
accumulate in macrophage derived foam cells, where they may be de-conjugated to the aglycones 
quercetin (Kawai et al., 2008a). In the same study quercetin-3-O-glucuronide supressed the formation 
of foam cells by supressing the expression of mRNA class-A scavenger receptor and CD36. Similar 
evidence has been shown for (-)-epicatechin-3-O-gallate (Kawai et al., 2008b). 
However, as demonstrated in a study by Mullen et al. (2002) Majority of the polyphenols are 
metabolised in the intestine with only 7.2% of ingested polyphenols found in blood and tissues such as 
0.0017% ingested radioactivity found in the brain. Thus it is important to investigate the health impacts 
of the polyphenol metabolites from their colonic metabolism by the microbiota. However, there is very 
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limited evidence on the bioactivity of phenolic acids (discussed in 1.3.5.3Bioactivity of phenolic 
acids:). They are considered anti-oxidant agents due to their ability to stabilise unpaired electrons 
which is dependent on the number and position of the hydroxyl groups (Goufo and Trindade, 2014). 
1.3.2 Bioavailability, absorption and metabolism 
1.3.2.1 Bioavailability 
The bioavailability of polyphenols can be greatly modified by factors such as food matrix interaction, 
gastric emptying, MCTT and method of administration (Erlund, 2004).  
As the majority of polyphenols escape digestion and absorption in the small intestine, they are 
catabolised by the colonic microflora to phenolic acids, through which they may exhibit some of their 
health benefits, however information on the health benefits of phenolic acids is very limited. 
Polyphenol catabolism and carbohydrate fermentation both take place in the colon. Hence, food matrix 
interaction not only in the upper digestive system, but the interaction of food metabolites and 
catabolites in the colon can be a key factor in the bioavailability of phenolic acids from polyphenol 
breakdown. 
The term bioavailability was first coined by the pharmacology industry and defined by the FDA as the 
―rate and extent to which a drug reaches its site of action‖. However the accurate quantification of a 
compound in its site of action is not possible and hence the definition was modified to allow for the 
fraction of an oral dose of a substance or its metabolites that reach the systemic circulation (Stahl et al., 
2002).  
Based on this definition bioavailability can be measured by the peak blood concentration of the 
substance (Cmax), the time taken to reach the peak concentration (Tmax) and the area under the curve 
(AUC).   
However the majority of polyphenols are not directly absorbed but reach the colon where they are 
broken down into smaller fragments known as phenolic acids. Thus bioavailability of polyphenols in 
the blood is not an accurate representation as it is more a representation of intestinal absorption, 
hydrolysis, uptake by tissue and release from body stores (Yeum and Russell, 2002). Additionally a 
large dose of polyphenol consumption, above that of daily intake is required to detect an increase over 
plasma baseline levels due to their low signal to noise ratio (Déprez and Scalbert, 1999, Yeum and 
Russell, 2002, Heaney, 2001). Another method of assessing bioavailability of polyphenols is the 
balance method, using the difference between known ingested concentration of compound and the 
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concentration of the compound excreted (Heaney, 2001). Although this method might not be accurate 
for the bioavailability of polyphenols it is a useful estimation of phenolic acid production from a 
known concentration of polyphenols. Similarly the urine increment method can be used for estimation 
of the compound bioavailability, assuming that the urinary excretion of the compound is proportionate 
to their plasma concentrations (Heaney, 2001). 
The most accurate method for assessing bioavailability of phenolic compounds is the use of radioactive 
isotopes. Using this method the distribution of labelled compounds as well as possible metabolites of 
compounds can be traced through their absorption. However the positioning and the number of the 
radiolabelled atoms in the compound is crucial in determining the strength of the signal as well as 
identification of potential metabolites and catabolites of the compound (Heaney 2001). 
1.3.2.2 Absorption 
For polyphenols to exhibit any health impact it is essential for them to be absorbed, either as the parent 
compound or as their metabolites. There are several factors that influence the absorption of 
polyphenols such as their molecular size and inter molecular linkage, solubility and lipophilicity 
(Spencer et al., 2001a). 
The majority of polyphenols present in the diet are in the form of polymers, glycosides and esters. 
These compounds cannot be readily absorbed and require hydrolysis by the intestinal enzymes or by 
the glycosidases of colonic microbiota (Manach et al., 2004). Polyphenols present as aglycones and 
few glucosides may be absorbed from the small intestine, whereas glycosides composed of more 
complex moieties such as rhamnose may only be absorbed after hydrolysis in the colon. This was 
demonstrated in an acute bioavailability study (Graefe et al., 2001) where no difference was found 
between the peak plasma concentrations of quercetin after ingestion in the form of onion or quercetin-
4-glucoside (Cmax = 2.31 ± 1.46 vs. 2.12 ± 1.63 ug/ml and Tmax 0.68 ± 0.22 vs. 0.70 ± 0.31  h after 
ingestion). Whereas Tmax was delayed to 6.98 ± 2.94 hours after ingestion of rutin, suggesting its 
absorption from the colon rather than the small intestine and the Cmax was reduced to 1.0 – 2.0 uM. The 
reduction in Cmax could be explained by the production of phenolic acids from released quercetin in the 
colon as well as less surface area for absorption as compared to the small intestine.  
The rate of absorption of 18 polyphenols was reviewed by Manach et al. (2005) using Cmax and AUC as 
an indication. There was a large variation in plasma Cmax after consumption of 50mg aglycone 
equivalents from 0.4-4 uM. gallic acid and isoflavones were found to be the most readily absorbed, 
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followed by catechins, flavanones and quercetin glucosides. The least absorbed polyphenols were 
found to be proanthocyanidins, tea galloylated catechins and anthocyanins.  
The oral absorption of flavanols has displayed large variability, ranging from 1-50% of ingested 
flavanols (Baba et al., 2000, Rein et al., 2000, Hollman et al., 2001). Some of this variation has been 
attributed to the complex in-vivo system such as gastric pH, the type and activity of microbiota. 
However, in a study (Schramm et al., 2003) investigating the impact of the antibiotic Famotidine on 
oral absorption of cocoa flavanols, changes in gastric pH failed to demonstrate any impact on the oral 
absorption (Cmax or AUC) of flavanols. The absorption and metabolism of polyphenols has been 
illustrated in Figure 1-2, with the use of Flavan-3-ols as an example. 
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Adapted using information from Monagas et al. (2010) and Moco et al. (2012) and with the use of flavan-3-ols as an example.  
 
Figure 1-2 absorption and metabolism of polyphenols 
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1.3.2.2.1 Mechanism of absorption 
Human ileostomy studies, use of human Caco-2 cells cultures and the use of rat intestinal perfusion 
(Walle, 2004) are some of the possible methods available for the understanding of polyphenol 
absorption: 
Most polyphenols present in the diet are hydrophilic, thus their penetration of the gut through passive 
diffusion in unlikely. The active transport mechanism proposed is the Na+ dependent saturable 
transport. According to this method glucosides can be transported into the enterocytes by SGLT1. 
However intact flavanol glucosides such as quercetin glucosides were not present in plasma samples 
after ingestion (Day et al., 2001, Mullen et al., 2004). This was further supported in a study by 
(Walgren et al., 2000b), when the absorbed quercetin glucosides by SGLT1 were efluxed by the 
proposed MRP2 transporter. Since then studies using rat intestinal perfusion and ileostomy patients 
have suggested that quercetin glucosides are hydrolysed allowing for the absorption of quercetin from 
the intestine (Walle et al., 2000, Sesink et al., 2003). 
1.3.2.2.2 Factors affecting absorption: 
 Glycosylation 
Glycosylation of a compound can affect both site and extent of absorption. As shown by 
Graefe et al. (2001) no differences were found between quercetin and quercetin-4-glucoside 
Cmax or Tmax. However when consumed in the form of quercetin-3-rutinoside the Cmax was 
significantly reduced and Tmax was delayed. These results were replicated in more recent 
studies by Jaganath et al. (2006b) and Mullen et al. (2006). However it is important to note 
that this lower absorption does not necessarily translate into lower bioavailability. As the 
glycosidic compounds enter the colon, where they are hydrolysed by the gut microbiota and 
made available in the form of phenolic acids.  
 Structure 
The structure of the compound can also be a key factor influencing its absorption as 
reviewed by Manach et al. (2005), 50 mg of aglycone equivalents have resulted in a range of 
0-4 uM in plasma.  This was also demonstrated for compounds containing a glycoside 
moiety where absorption takes place from the colon. (Jaganath et al., 2006a, Mullen et al., 
2008a) The Cmax/dose values for hesperetin-7-O-rutinoside appeared to be significantly 
higher (16.5 Nm/Umol) as compared to that of quercetin-3-O-rutinoside (0.09 Nm/Umol). 
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 Food matrix 
Polyphenols are not consumed in isolation from other food components. Polyphenols present 
in the diet are present in fruits and vegetables along with macronutrients, fibre, plant sterols, 
minerals etc. It is hence important to assess the impact of food matrix interactions on the 
bioavailability of polyphenol compounds. The food matrix interaction of foods commonly 
consumed alongside have been previously investigated and summarised in the relevant 
section (1.4 Food matrix interaction, page:74). These combinations may include cocoa and 
milk, strawberry and cream, orange juice and yoghurt or carbohydrates and polyphenols. We 
aimed to further investigate the food matrix interaction between two functional food groups; 
fibre and polyphenols that are present together in plant foods. 
1.3.2.3 Metabolism  
Following absorption of the phenolic compounds they are metabolised and conjugated. This can take 
place in the gastrointestinal lumen, intestinal cells or in the liver. The metabolism of these compounds 
can play a key role in the impact they exhibit in the body and their ability to enter cells (Kroon et al., 
2004).  
The phase I and phase II metabolising enzymes involved in the metabolism of polyphenolic 
compounds are the enzymes responsible for catalysing detoxification reactions as part of the primary 
defence mechanism against xenobiotic and toxic compounds (Sanchez et al., 2001). 
Once absorbed the polyphenolic compounds can be metabolised by the phase II metabolising enzymes 
(Manach et al., 2004): the uridine-5-diphosphate glucuronosyl transferase (UGTs), cytosolic phenol-
sulfotransferase (SULTs) and catechol-O-methyltransferase (COMTs). The result of phase II 
metabolism is glucuronide and sulphate conjugates with or without methylation across the catechol 
functional group with the possibility of multiple conjugates. Phase II enzymes are distributed among 
tissues such as intestines, liver and kidney. The intestinal conjugated metabolites can be taken up by 
the liver and partially secreted in bile. The detection of these metabolites in the bile suggests that they 
undergo eneterohepatic recycling after which they are secreted back into the intestinal lumen (Crespy 
et al., 1999, Crespy et al., 2003). 
1.3.2.4 Colonic metabolism  
Polyphenol compounds that have escaped absorption in the small intestine (80-90%), or have been 
returned to the colon through enterohepatic recycling will be subjected to gut microbiota metabolism 
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(Spencer et al., 2000). The range of catabolites produced, known as phenolic acids is specific to type of 
polyphenol compound and their physio-chemical properties. Many studies have tried to identify 
phenolic acids produced by the action of the colonic microbiota, either by ex-vivo faecal fermentations 
or analysis of urinary excreted phenolic acids after the consumption of polyphenol rich foods (Olthof et 
al., 2003, Aura et al., 2002, Rechner et al., 2004, Labib et al., 2004, Bravo et al., 1994). 
The mechanism of action for the catalytic and hydrolytic microbiota is suggested to be the splitting of 
the polyphenol nucleus through ring fission, as well as hydrolysis, dehydroxylation, demethylation, 
decarboxylation and deconjugation (Scheline, 1999). 
The concentration of phenolic acids in the colon is much higher (~15- 410 uM) than that of flavonoids 
(~7uM), suggesting that these phenolic acids may have direct protective effects in the colon through 
scavenging of nitrogen and oxygen species before entering circulation (Halliwell, 2007, Halliwell et 
al., 2005).  
As most of the polyphenol compounds are catabolised to phenolic acids, and as it has been shown that 
the plasma concentration of these phenolic acids is higher than conjugated metabolites (Gonthier et al., 
2003, Rechner et al., 2002), it is important to further investigate the factors that can potentially modify 
the production of these phenolic acids in the colon. 
1.3.3 Tissue uptake of polyphenolic compounds 
Polyphenols and their metabolites must reach their target tissue in order to exhibit any beneficial 
effect; hence their actual bioavailability should be assessed when they reach their site of action. 
Despite the importance of their site of accumulation and action, the information in this regard is 
limited. One way to assess this information is by using radio labelled compounds.  
Most of such studies are feeding studies in animal models, such as the ingestion of [2-
14
C]-quercetin-4-
O-glucoside in rats which resulted in high accumulation of the metabolite in the liver and kidneys, 
indicating that these organs are the main site of metabolism and excretion (Graf et al., 2005). In 
another study, rats were fed a supplemented diet of blueberry extract containing anthocyanins for 10 
weeks, this resulted in the detection of trace levels of anthocyanins in the brain (Andres-Lacueva et al., 
2005). A study by Abd El Mohsen et al. (2002) demonstrated that the consumption of epicatehin (100 
mg/kg body weight) in male wistar rats resulted in the appearance of the two metabolites epicatechin 
glucoronide and 3-O-methyl epicatechin glucuronide in the brain tissue. The presence of epicatechin in 
the brain tissue was suggested to protect against neuronal cell death induced by oxidative stress. The 
same authors detected 0.2 nmol/g unmetabolised anthocyanidin in the brain tissue of rats 18 hours after 
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feeding with 184 umol/kg of pelargonidin (El Mohsen et al., 2006). Similarly the supplementation of 
rats with 50 mg/kg and 200 mg/kg quercetin resulted in the accumulation of trace amounts of quercetin 
in the brain (Ishisaka et al., 2011). Such radioactivity in the brain was also detected after the 
consumption of 
14
C labelled grape polyphenols (Janle et al., 2010). 
In contrast, Suganuma et al. (1998) detected radioactivity in organs such as the brain, liver, lungs, 
kidney, uterus, ovary and testes after the administration of [
3
H](-)-epigallocatechin gallate into the 
stomach of male and female mice. Similar results were found for the accumulation of anthocyanins in 
plasma, liver, kidney, testes and the lungs of rats after a bilberry extract diet for two weeks (Sakakibara 
et al., 2009). 
 However, a study using 
14
C labelled quercetin-4-glucosides detected only 6.4 % of the ingested dose 
outside the gastrointestinal tract 60 minutes after administration (Mullen et al., 2002). These results 
were supported by a later study from the same authors (Mullen et al., 2008c) when rats were 
supplemented with 4 mg/kg body weight [2-
14
C] quercetin-4-glucosides. Majority of the radioactivity 
was found in the caecum and colon, after which it was degraded to phenolic acids and excreted through 
urine over 72 hours without any tissue accumulation. Similarly the supplementation of rats by gavage 
with 2.8ml of raspberry juice did not result in any anthocyanin accumulation in the brain (Borges et al., 
2007). 
Similarly, These tissue accumulation results were not replicated in a human study (n=6) where flavan-
3-ol metabolites were only detected in plasma and not in the cerebrospinal fluid after the ingestion of 
green tea (Zini et al., 2006). However there is some evidence for the accumulation of flavan-3-ols in 
prostate biopsy tissue after the consumption of 1.42 L of green / black tea (Henning et al., 2004).  
Similarly, Daidzein, genistein and their metabolites were found in prostate tissue after isoflavone 
ingestion, and in breast tissue after 300 umol of daidzein ingestion (Crozier et al., 2009).  
1.3.4 Elimination of polyphenolic compounds 
Phenolic acids can be excreted through three different pathways, bile, urine and faeces. The highly 
conjugated and large metabolites are mostly excreted through bile whereas smaller conjugates are most 
likely to be excreted through urine (Manach et al., 2004).  
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1.3.5 Phenolic acids 
Phenolic acids even though present in the diet (see below) are not very abundant. Most of the phenolic 
acids available for tissue uptake are derived from the metabolic action of the gut microbiota on larger 
polyphenolic compounds such as the flavanoids.  Phenolic acids are present as two main classes:   
1.3.5.1 Hydroxy benzoic acid derivatives 
This group of phenolic acids are mostly present as conjugates but may be found in the free form after 
the processing of fruits. The main hydroxy benzoic acid derivative is gallic acid, found in tea. The 
dimer of gallic acids known as ellagic acid is an important component of the berry variety fruits such 
as strawberries, raspberries and blackberries (Tomás‐Barberán and Clifford, 2000). The esterification 
of these hydroxybenzoic acid derivatives forms hydrolysable tannins; gallotannins (present in 
mangoes) and ellagitannins (present in strawberries, raspberries and pomegranates) which can be 
hydrolysed in the presence of acids or bases (Tomás‐Barberán and Clifford, 2000, Manach et al., 
2004).  
1.3.5.2  Hydroxycinnamic acid derivative 
This group of phenolic acids are only found in the free form if they have undergone processing, 
fermentation, sterilisation or freezing. They are mostly present as the esters of quinic acids, shikimic 
acid and tartaric acid. The most common hydroxycinnamic acids are: caffeic acid (3,4-
dihydroxycinnamic acid),  p-coumaric (4-hydroxy) and ferulic acid  (3-methoxy, 4-hydroxy) (Clifford, 
2000). Esters formed between certain trans-cinnamic acids and quinic acid (1L-1 (OH),3,4/5-
tetrahydroxycyclohexane carboxylic acid) are known as chlorogenic acids. The trans isomers of 
chlorogenic acid may be converted to cis-isomers during processing. 5-O-caffeoylquinic acid is the 
most common of the chlorogenic acid family (Clifford, 2000). 
 
1.3.5.3 Bioactivity of phenolic acids: 
Phenolic acids are mostly produced as the result of the colonic degradation of polyphenols by the 
microbiota and contribute greatly to the bioavailability of polyphenols, as it is more likely that these 
lower weight metabolites would get absorbed than their more complex parent compounds. However 
there is a large gap in the literature on the catabolic pathway of polyphenols resulting in phenolic acid 
production, the fate of the phenolic acids once absorbed and their bioactivity.  
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There has been some investigation on the antioxidant activity of these phenolic acids, which may 
suggest their potential impact on health. Franck et al. (2013) investigated the antioxidant potential of 
several phenolic acids in-vitro including benzoic acid, 3,4-DHBA, 2,6-DHBA, gallic acid, etc. The 
antioxidant potential was determined by their potential to scavenge reactive oxygen species (ROS) and 
the radiacal cation ABTS [2,2-azinobis (3-ethylbenzothiazoline-6-sulphonic acid)], which were 
produced from stimulated neutrophils (equine). The phenolic acids demonstrated a strong antioxidant 
potential which was found to be inversely correlated with their redox potential. Phenolic acids which 
were more easily oxidised such as gallic acid (redox potential 0.29 v) and 3,4-DHBA (redox potential 
0.46 v) had a higher antioxidant potential than benzoic acid, which is not easily oxidised (redox 
potential 1.1 v). It was also found that the efficiency of the phenolic acid to scavenge ATBS/ROS was 
enhanced when three hydroxyl groups were present on the aromatic ring. This property of the phenolic 
acids was shown to be dose dependent. Li et al. (2011) also investigated the antioxidant capacity of 
protocatechuic acid, 3,4-DHPAA, hydro caffeic acid, caffeic acid, gallic acid, 3,4,5-
trihydroxyphenylacetic acid and 3-(3,4,5-trihydroxy-phenyl) propanoic acid determined by their 
hydroxyl and superoxide scavenging potential and metal chelation. 3,4,5-trihydroxyphenylacetic acid 
was shown to have the highest antioxidant potential. 
The above studies were conducted in-vitro using pure phenolic compounds. A similar study (Henning 
et al., 2013) was conducted by treating colon cancer cells in-vitro with phenolic acids (at 
concentrations of 10
-4
, 10
-5,
  10
-6 
M) that had significantly increased after the consumption of green tea 
and black tea. The consumption of green tea resulted in increased urinary excretion of 4-HPAA, 3-
HPAA and polyhydroxy-ɣ-valerolactone. Whereas the consumption of black tea resulted in increased 
urinary excretion of 3-O-methylgallic acid. They also investigated the increase in serum phenolic acid, 
which was 3,4-DHPAA and 4-HPAA after green tea and 3,4-DHPAA after black tea consumption. The 
anti-proliferative effect of 3,4-DHPAA and 3-O-methylgallic acid was found to be additive. 
Similar studies undertaking the determination and comparison of antioxidant capacity of various 
phenolic acids have been summarised in Table 1-2. It is however difficult to draw conclusion from the 
results of such studies due to use of different phenolic acids with differing structure, various analytical 
methods and end-point determinants.  
As mentioned above, it has been proposed that the structural modification of the phenolic acids may 
lead to higher antioxidant properties. Phenolic acids with more hydroxyl groups (eg. Trihydroxy) have 
been shown to have higher antioxidant properties than those with fewer hydroxyl groups (eg. 
Dihydroxy or monohydroxy) (Wu et al., 2007, Dziedzic and Hudson, 1984, Siquet et al., 2006, Zhu et 
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al., 2006, Castelluccio et al., 1995). However this may not always be valid as seen in lipid peroxidation 
assays where lipophilicity plays an important role. In these assays, phenolic acids with fewer number 
of hydroxyl group, having higher lipophilicity may be more potent antioxidant agents (Siquet et al., 
2006, Wu et al., 2007). Additionally the presence of ortho-dihydroxy groups or 4-hydroxy 3-methoxy 
may contribute to higher antioxidant properties (Cheng et al., 2007).  
However, lipophilicity may not necessarily predict the bioactivity of the phenolic acids. Castelluccio et 
al. (1996)  investigated the distribution of ferulic acid in plasma using 
14
C-radiolabelled ferulic acid 
and compared the antioxidant potential of cinnamic acid and ferulic acid to the more hydrophilic 
ascorbic acid against lipid oxidation. Ferulic acid was primarily bound to the albumin fraction of the 
plasma. The remaining radiolabelled ferulic acid was partitioned between the LDL fraction and the 
aqueous fraction of the plasma. Interestingly ferulic acid was not found associated with the lipid 
fraction of LDL, thus suggesting that it exhibits most of its antioxidant potential through the aqueous 
layer. Despite this observations, ferulic acid exhibited higher antioxidant potential than the more 
hydrophilic ascorbic acid, with cinammic acid displaying the least potential.  
It has also been shown that the ester derivatives of phenolic acids may be stronger antioxidant agents 
than the parent compound (Chigorimbo-Murefu et al., 2009, MeRkl et al., 2010, Garrido et al., 2012), 
however some other studies have shown that esterification may not have any impact (Menezes et al., 
2011) or may even reduce the antioxidant properties (Gaspar et al., 2010). Interestingly the two studies 
demonstrating a higher impact of the ester derivatives have investigated lipid peroxidation (Stamatis et 
al., 2001) and antioxidant properties of sunflower oil (MeRkl et al., 2010) which may be linked to 
higher lipophilicity of these derivatives (Gaspar et al., 2010, Kikuzaki et al., 2002).  
Similar to their parent compounds (1.3.1 Health implications of polyphenols), phenolic acids may also 
act as pro-oxidant agents (Maurya and Devasagayam, 2010). This may depend on various factors such 
as pH (Medina et al., 2012), chelating capacity (Maurya and Devasagayam, 2010), presence of redox 
active metals (Sakihama et al., 2002, Zheng et al., 2008) and the concentration of the compounds; as 
lower concentrations of phenolic acids act as antioxidant agents; the higher concentration of the same 
compounds have shown to be pro-oxidants (Yen et al., 2002, Maurya and Devasagayam, 2010). 
In addition to these antioxidant properties, it has been shown that phenolic acids such as 3,4-DHPAA 
and 4-HPAA are more effective in anti-platelet aggregation activity than their parent compounds rutin 
and quercetin (Kim et al., 1998). Additionally these phenolic acids may prove to have stronger chemo-
preventive properties as has been shown by Kampa et al. (2004) for 3,4-DHPAA and 3,4- DHBA 
through anti-proliferative and apoptotic potential as seen on T47D human breast cancer cells. A study 
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by Scazzocchio et al. (2011) has also shown that phenolic acids may have an insulin like effect. In this 
study, both cyaniding-3-O-β-glucoside and protocatechuic acid increased adipocyte glucose uptake, 
GLUT4 membrane translocation, adiponectin and GLUT4 expressions and nuclear PPARγ activity.   
Even though these findings appear promising regarding the role of phenolic acids in health, the results 
of in-vitro studies, especially in regard to the actions of phenolics must take into consideration the 
amount of polyphenol consumption required to produce sufficient phenolic acids in circulation to exert 
any health impact.  
 
  
Table 1-2 Antioxidant potential of phenolic acids 
Author 
year 
Study method  Measurements Findings (phenolic acid production)  Comments 
Franck et al 
2013 
In-vitro  
benzoic acid, 3,4-DHBA, 2,6-DHBA, gallic 
acid, salicylic acid, caffeic acid, syringic acid, 
ferulic acid, propyl gallate 
Antioxidant potential determined by 
ROS and the radiacal cation ABTS 
scavenging capacity produced from 
produced from stimulated equine 
neutrophils.   
Antioxidant potential of phenolic acids related to their redox 
potential  
 
Number of hydroxyl groups and their position were related to 
their efficacy as antioxidant agents 
 
Scavenging activity towards radical cation ABTS: Gallic acid > 
propyl gallate> 3,4 –DHBA ~ ferulic acid, syringic acid > 
caffeic acid ~ 2,6-DHBA < salicylic acid > benzoic acid  
 
Scavenging activity towards ROS: propyl gallate> Gallic acid > 
caffeic acid > 3,4 –DHBA > syringic acid > Ferulic acid > 2,6-
DHBA > salicylic acid > benzoic acid 
 
 
(Li et al., 
2011) 
 In-Vitro 
Protocatechuic acid 
Positive controls:  
3,4-dihydroxyphenylacetic acid, hydrocaffeic 
acid, caffeic acid,  
gallic acid, 3,4,5-trihydroxyphenylacetic acid,  
and 3-(3,4,5-trihydroxy-phenyl) propanoic 
acid  
 
1,1-diphenyl-2-picryl-hydrazyl 
(DPPH•), ABTS+, superoxide 
anion radicals (O2−•) and hydroxyl 
radical (•OH) scavenging activity,  
ferric ions (Fe3+) and cupric ions 
(Cu2+) reducing power, ferrous 
ions (Fe2+), and cupric ions (Cu2+) 
chelating activity, compared with 
the positive controls Trolox or BHT 
3, 4, 5-trihydroxy-phenylacetic acid was the most potent radical 
scavenger generated by AAPH in liposomes 
3, 4-dihydroxyphenylacetic acid was most effective in the lipid 
peroxidation assay  
 
Protocatechuic acid showed dose-dependently antioxidant 
ability 
 
 
(Medina et In-vitro  Antioxidant potential (FRAP) and Reducing capacity: Caffeic acid > ferulic acid > galocatechin  
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al., 2007) Phenolic acids: Caffeic acid, chlorogenic 
acid, o-coumaric acid, and ferulic acid 
Polyphenols: catechin, gallocatechin, catechin 
gallate, and gallocatechin gallate 
chelating capacity (Kolayli et al. 
method) 
gallate  >  catechin gallate  > gallocatechin > catechin > 
chlorogenic acid > o-coumaric acid 
Chelating capacity:  galocatechin gallate  > catechin gallate  >  
Caffeic acid > chlorogenic acid > gallocatechin > catechin >  
ferulic  acid > o-coumaric acid 
 
Chelating capacity is dependent on number of hydroxillic 
groups in ortho position 
 
(Cheng et 
al., 2007) 
In-vitro  
caffeic acid, chlorogenic acid, sinapic acid, 
ferulic acid and p-coumaric acid  
 
Human LDL peroxidation model 
induced by 2, 2′-azobis(2-
amidinopropane hydrochloride 
(AAPH) or cupric ion (Cu2) using 
TBARS assay 
Antioxidant capacity against AAPH induced LDL 
peroxidation: caffeic acid ~ chlorogenic acid > sinapic acid > 
ferulic acid > p-coumaric acid 
 
Antioxidant capacity against Cu2 induced LDL peroxidation:  
caffeic acid ~ chlorogenic acid >  sinapic acid ~ ferulic acid ~ 
p-coumaric acid 
ortho-
dihydroxyl and 
4-hydroxy-3-
methoxyl 
groups 
increased 
antioxidant  
properties 
(Yeh and 
Yen, 2003) 
In-vitro 
Gentisic acid, chlorogenic acid, syringic acid, 
protocatechuic acid, p-hydroxybenzoic acid, 
vanillic acid, ferulic acid, gallic acid, caffeic 
acid, sinapic acid, o-coumaric acid, p-
coumaric acid, m-coumaric acid (6.7 μM) 
Mesurement of 
phenolsulfotransferase-phenols 
(PST-P) and 
phenolsulfotransferase-monoamines 
(PST-M) activity by Folds and 
Meek method.  
Antioxidant potential by ORAC, 
TEAC method. 
↓ PST-P and PST-M activity (21-30%) by chlorogenic acid, 
syringic acid, protocatechuic acid, vanillic acid, sinapic acid, 
and caffeic acid significantly (p < 0.05) 
↑ PST-P activity by p-hydroxybenzoic acid, gallic acid, gentisic 
acid, o-coumaric acid, p-coumaric acid, and m-coumaric acid 
↑ PST-M activity by gentisic acid, gallic acid, p-
hydroxybenzoic acid, and ferulic acid.  
↑ antioxidant capacity by all phenolic acids, higher for gallic 
acid, p-hydroxybenzoic acid, gentisic acid, and coumaric acid 
impact of phenolic acids on PST-P and PST-M activity related 
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to antioxidant activity for ORAC  (r = 0.71, p < 0.01; and r = 
0.66, p < 0.01) 
 
(Chen and 
Ho, 1997) 
In-vitro 
caffeic acid (CA), caffeic acid phenethyl ester 
(CAPE), ferulic acid (FA), ferulic acid 
phenethyl ester (FAPE), rosmarinic acid 
(RA), and chlorogenic acid (CHA) 
lipid oxidation inhibition activity 
using Metrohm 679 Rancimat 
instrument, Scavenging effect on 
DPPH radicals, Antioxidant activity 
in oil-water imulsion 
 
↑  induction time of lipid oxidation in lard CA > CAPE  RA > 
CHA > FA  FAPE 
↑  induction time of lipid oxidation in corn oil  RA > 
CA  CAPE  CHA  
↑ The 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) 
scavenging activity: RA  CAPE > CA > CHA > FA > FAPE  
↓ oil-in-water emulsion oxidation was CA > CAPE > RA > FA 
> CHA > FAPE 
 
(Castellucci
o et al., 
1996) 
In-vitro 
Cinnamic acid, ferulic acid, ascorbic acid  
LDL oxidation induced by 
hydroperoxide dpendent oxidative 
stress  
Distribution of ferulic acid in 
plasma tested with 14C-labelled 
ferulic acid 
Antioxidant capacity: ferulic acid > ascorbic acid> cinnamic 
acid  
Majority of radiolabelled ferulic acid found bound to albumin 
rich fraction of plasma, other fraction found partitioned 
between LDL fraction and aqueous fraction.  
 
Ferulic acid 
does not bind to 
lipid fraction of 
LDL  
(Laranjinha 
et al., 1994) 
 In-vitro  
Chlorogenic acid, caffeic acids, ellagic acid 
and protocatechuic  
Control : trolox 
Human LDL oxidation induced by 
hydrophilic azo initiator.  
Oxygen consumption and the 
fluorescence quenching of cis-
parinaric acid measured 
Antioxidant capacity :  
Chlorogenic acid > caffeic acid > trolox > ellagic acid. 
Protocatechuic 
acid excluded 
due to non-ideal 
oxidation 
inhibition 
  
 
1.3.6 Flavanoids:  
Flavonoids are one of the largest groups of natural products identified; widely distributed in plants and 
contribute greatly to their pigmentation. Over 5000 different naturally occurring flavonoids have 
already been identified and the list is still growing. The pigmentation of flavonoids is associated with 
their biological selectivity. Apart from energy capture these pigments may play a role in attracting 
suitable pollinators and selective activation of light sensitive genes.  Flavonoids are only exogenously 
provided to man as it is only plants that are capable of their synthesis (Havsteen, 2002, Kirby and 
Styles, 1970). The initial interest in flavonoids began in 1930s with an observation that flavonoids 
present in citrus fruits displayed strong antioxidant capacity and were able to decrease capillary 
permeability (Bentsath et al., 1936). With the increase in CHD prevalence in the 1990s more research 
was dedicated to flavonoids after an inverse association was observed between flavanol / flavone 
consumption and mortality from incidence of myocardial infarction in 805 individuals. The major 
sources of flavonoid consumption were identified to be tea, onions and apples (Hertog et al., 1993a). It 
is important to note that the increased consumption in flavanoids could also be associated with 
increased fruit and vegetable intake, thus increased fibre consumption. 
Flavonoids have a polycyclic structure with a C6-C3-C6 skeleton. The two phenyl rings (A and B) are 
connected by the 3 carbon bridge (ring C). It is possible for the heterocyclic ring-C to be replaced by a 
5-carbon ring such as chalcones or to be present in the isomeric open form. Flavonoids are present in 
plants mostly as their glycosidic conjugated form. Conjugation with hydroxyl, methoxyl, methyl and/or 
glycosyl substitute groups may occur in plants with occasional conjugation with aromatic/ aliphatic 
acids, sulphate prenyl, isoprenyl and methylenedioxyl groups. Sugar or hydroxyl groups present in the 
rings increase the solubility of flavonoids whereas presence of methyl groups increases lipophilicity. 
There have been 4000 compounds so far classified as flavonoids (Iwashina, 2000).  
Flavonoids can be classified into six main subcategories (Figure 1-3) Flavones, Isoflavones, Flavan-3-
ols, Flavanone, Anthocyanins and Flavonols.  This is based on cyclisation and degree of unsaturation / 
oxidation of the three carbon segments.  
The flavonols and flavan-3-ol groups have been discussed in more detail below as the compounds of 
interest for this PhD belong to these sub-groups, which are found in abundance in the diet.  
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1.3.6.1 Flavones  
This subcategory of flavonoids is not widely distributed, thus their intake through diet is not 
significant. They are mostly consumed through cereals, celery, parsley and sweet red pepper. They are 
very similar in structure to flavonols only lacking the hydroxylation at the third position of the C-ring. 
The main flavones are luteolin and apigenin (Crozier, 2003). 
1.3.6.2 Flavanones  
This subcategory of flavonoids is mostly present in citrus fruits contributing to the citrus flavour 
mostly in the form of hesperitin-7-O-rutinoside (hesperidin). They are also present in tomatoes and 
tomato products in the form of naringinin, or naringinin chalcone present in tomato peel. In tomato 
products such as ketchup naringinin chalcones are converted to naringin (Krause and Galensa, 1992). 
Flavanone structure lacks the Δ2, 3 double bond and instead has a chiral centre at the C-2 position. This 
structure is greatly reactive allowing hydroxylation, glycosylation and O-methylation (Iwashina, 2000, 
Crozier, 2003). 
 
 
Figure 1-3 Flavonoid sub-classes structure 
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Figure 1-4 Quercetin 
 
1.3.6.3 Anthocyanidins 
Nineteen types of anthocyanidins have been identified with the most common being pelargonidin, 
cyanidin, malvidin, peonidin, delphinidin and petunidin (Iwashina, 2000).  
These flavonoids are mostly present in higher plants in their glycosidic form known as anthocyanins. 
The glycosidic form of anthocyanidins are water soluble and contribute greatly to the pigmentation of 
fruits, flowers and leaves; hence playing a key role in the selection of pollinators (Clifford, 2000, 
Crozier, 2003). They also contribute to the violet / blue / red pigmentation in some commonly 
consumed fruits such as plums, berries and grapes; increasing as the fruit ripens (Peterson and Dwyer, 
1998). 
1.3.6.4 Isoflavones 
Similar to flavones, this subcategory of flavonoids is not widely distributed and is mostly consumed in 
the diet from legume sources. The most common isoflavones identified are: genistein, daidzein and 
glycitein present mostly in soy beans, black beans and split peas (Dixon and Steele, 1999, Graham, 
1991, Barnes, 2004). The estrogenic property of isoflavones created great interested in their role 
towards breast cancer prevention (Barnes, 2004). 
The B-ring of isoflavones is attached to the C-ring by C-3 rather than C-2 and in this way it differs 
from the general structure of flavonoids. The possible polymerisation, methylation and hydroxylation 
of isoflavones give rise to various subcategories such as isoflavans, isoflavanols and isoflavanones.  
1.3.6.5 Flavonols  
Flavonols are ubiquitous in plants. The most common 
flavonol in the diet is quercetin (onions) followed by 
kaempferol (broccoli), isorhamnetin (pears /onions) and 
myricetin (maize/ berries).  
Quercetin can be found in various fruits and vegetable but 
the most important dietary source of quercetin is onions 
followed by capers (Hertog, 1992). The quercetin present in onions can be found in the form of 
quercetin-4-glucoside or quercetin-3,4-diglucoside. The most common glycoside of quercetin is 
quercetin-3-glucosyl-rhamnoside also known as rutin; mostly present in tomatoes, buckweed and 
asparagus.  Quercetin can also be found in apples in the form of quercetin galactosides and in berries as 
quercetin arabinosides (Peterson and Dwyer, 1998). 
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1.3.6.5.1 Rutin and Quercetin  
Quercetin, usually conjugated to glucose, is of interest due to its ubiquitous nature in the diet especially 
in onion, pepper, kale and tea. Quercetin can also be found in its glycosidic form rutin, in foods such as 
buckwheat, dark berries, green pepper, citrus fruits and apricots. Rutin is also known as quercetin-3-
rutinoside. The disaccharide moiety of rutin is made of rhamnose (6-deoxy-Lmannose) and glucose 
(Jaganath et al., 2009). Rutin is pale yellow in colour, slightly yet more soluble in water than its 
aglycone, quercetin.  
Normal plasma quercetin concentration is the lower nM range, and supplementation with quercetin 
pushes the concentration to the higher nM or lower uM range (Hollman et al., 1996). The half-life of 
quercetin and its metabolites in plasma are relatively high, ranging from 11-28 hours (Hollman et al., 
1997a, Manach et al., 2005). Other studies have reported even longer half lives of quercetin 
metabolites ranging from 20-72 hours (Day et al., 2001). Hence continuous supplementation with 
quercetin may raise plasma concentrations of this compound substantially. The tissue distribution of 
quercetin and its metabolites were shown to be the highest in the lungs, liver and kidneys.  
Quercetin has displayed strong antioxidant property due to its ability to scavenge oxygen free radicals, 
chelate metals and prevent oxidation of LDL in-vitro (Kandaswami and Middleton Jr, 1994, Bors et al., 
1990, Navab et al., 1996). The oxidation of LDL is a risk factor in the development of atherosclerosis, 
hence quercetin may also play a role in the prevention of CVD (Navab et al., 1996, Steinberg et al., 
1989).  
However some of these properties of quercetin may be affected by the presence of the rutinose 
disaccharide in rutin. In a recent study it was demonstrated that this disaccharide moiety reduces the 
anti-inflammatory properties of quercetin in-vitro. Both quercetin and rutin demonstrated strong anti-
inflammatory action, however this was found to be higher in quercetin than rutin (Cai et al., 2014). 
Quercetin has also demonstrated anti-cancer properties in-vivo and in-vitro by induction of apoptosis 
and inhibition of growth of pancreatic cancer cells (Angst et al., 2013). In another animal model study 
a 20 week quercetin diet (0.02% wt/wt) delayed the incidence of skin tumour by 2 weeks in mice with 
over expression of IGF-1 in the skin, known to be a risk factor of tumour incidence and progression.  
Mice fed quercetin also had lower tumour multiplicity by 35% (Jung et al., 2013). However these 
studies lack information on required dose in human for impact, and possible toxicity of high doses of 
quercetin consumption as pharmaceutical supplements (Harwood et al., 2007).  
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These observations made in-vitro and in animal studies have been met with doubt in their translation to 
health benefits in humans due to the low solubility, absorption and thus bioavailability of these 
compounds.  
1.3.6.5.1.1 Absorption and bioavailability of rutin and quercetin  
The absorption of quercetin is greatly influenced by the sugar moiety attached. The sugar-flavanol 
bond is a β- glycoside bond, which is mostly resistant to hydrolysis by the pancreatic enzymes 
(Hollman et al., 1997b, Day et al., 2000). The deglycosylation step involves β-glucosidases that 
releases the aglycone for passive diffusion. The intestinal lactase phlorizin hydrolase (LPH) has 
demonstrated a specific activity in the deglycosilation of flavonoids and in particular quercetin, as 
shown in an in situ rat small intestine perfusion model. The carrier mediated transport of quercetin 
glycosides may involve the sodium dependent glucose transporter-1 (Arts et al., 2002) and / or the 
multi-drug resistance protein 2 (Walgren et al., 2000a, Walgren et al., 2000b). Hydrolysis by the β-
glucosidases follows after the carrier mediated transport (Németh et al., 2003). 
Once absorbed, quercetin is metabolised in the small intestine, liver and kidney through phase II 
metabolism or it is subjected to ring fission by the colon microbiota, resulting in the formation of 
phenolic acids (Hollman and Katan, 1998, Day et al., 2000). Rutin on the other hand, escapes 
absorption in the small intestine and is subjected to hydrolysis by the colonic microbiota.  
In a study (Hollman et al., 1995) with ileostomy patients (n=9), quercetin glucosides provided in the 
form of fried onions had the highest absorption (52 ± 15% of ingested) compared with pure quercetin 
aglycones (24 ± 9 % of ingested) and pure quercetin-rutinosides (17±15% of ingested). While in this 
study glucosides seem to increase absorption of quercetin, the opposite is seen for glycosides.  
However it is important to note that in this study quercetin glucoside was provided in the form of fried 
onions compared to pure aglycone or glycoside form. More recent studies have demonstrated that fried 
and baked onions have 7-25% increase in quercetin, and boiled onions have a loss of 18% in quercetin 
concentration (Lombard et al., 2005). This may have influenced the results of this study. 
The study was repeated again (Hollman et al., 1997b) to investigate the absorption of quercetin-
glucosides from onion ingestion, quercetin-glycosides from apple or pure quercetin-rutinoside. They 
found similar bioavailability of quercetin from apples and rutin as 30% relative to onions. Tmax was 
also delayed for plasma quercetin after ingestion of apples (2.5h) and rutin (9h) as compared to 0.7h 
after ingestion of onions. 
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The increased absorption of quercetin in the presence of the glucoside could be due either to the 
facilitation of glycoside absorption by deglycosylation (Day et al., 2000, Németh et al., 2003) or carrier 
mediated transport (Gee et al., 2000, Walgren et al., 2000a). 
The presence of rutinose not only impacts extent of absorption but also site of absorption. While 
quercetin can be absorbed from the small intestine, the fate of rutin is determined by the colonic 
bacteria. This has been indicated by delayed Tmax after consumption of rutin compared to quercetin, 
suggesting the colon as the site of absorption (Graefe et al., 2001, Jaganath et al., 2006b). 
Hence, rutin escapes absorption in the small intestine and is subjected to colonic microbiota action, 
where it is hydrolysed to phenolic acids. Based on this observation, it may not be correct to state that 
the disaccharide moiety of rutin reduced the bioavailability of quercetin, but rather it made quercetin 
available in the form of phenolic acids. 
1.3.6.5.1.2 Phenolic acid production from rutin and quercetin 
The phenolic acid production from rutin and quercetin has been analysed in plasma, urine and faecal 
incubations. For the scope of this PhD we are interested in the phenolic acid production from rutin in 
faecal incubations. As rutin escapes absorption in the small intestine it enters the colon where it is 
hydrolysed to quercetin. The released quercetin is then catabolised to phenolic acids.  
There are various factors that can influence the type and concentration of phenolic acids produced from 
rutin in the colon. Higher doses of rutin were shown to deglycolise less easily to quercetin as compared 
to lower doses of rutin (Rechner et al., 2004). Hence administration of high doses of rutin may not 
necessarily translate into higher production of phenolic acids from this compound.  
The presence of glucose (as a model of fermentable carbohydrate) was also found to alter the 
metabolites produced as well as increase deglycosylation of rutin and hence phenolic acid production 
(Jaganath et al., 2009). In the absence of glucose 3,4-DHBA was converted into 4-HBA, whereas this 
pathway was directed towards the production of HPAA derivatives in the presence of glucose.  Thus 
stimulating the growth/metabolism of the colonic bacteria may influence the metabolites seen in the 
colon.  
Despite the differences in methodology and concentration of compounds used in the studies summarised 
in Table 1-3, they all identified 3,4-DHPAA as the major metabolite from quercetin breakdown. This 
phenolic acid was produced early in the fermentation and declined between 6-8 hours after incubation, 
concomitantly the production of 3-HPAA was observed. The phenolic acids produced were: 3,4-
DHPAA, 3-DHPPA, 3,4-DHBA, 4-HBA, 3-HPPA, 3,4-Dihydroxy toluene, 3,4-Dihydroxy 
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Benzaldehyde, phloroglucinol and 3,4-dihydroxytoluene. These studies demonstrated a high donor 
dependent variation in metabolite production. The speculated catabolic pathway of rutin has been 
illustrated in Figure 1-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 Speculated catabolic pathway of rutin by colonic microbiota - Adapted from Jaganath et al. (2010) 
 
  
 
Author 
 ( year) 
Study method   Measurements of 
 phenolic acids 
Results Comments 
(Justesen 
et al., 
2000) 
in-vitro fermentation  
N=3 
(i)-12.5 mg/ml rutin  (ii)-12.5 mg/ml quercetin  
LCMS  Phenolic acids:  3,4-DHPAA > 3 or 4- HPAA, 3 or 4-
HPPA, 3,4-Dihydroxy toluene, 3,4-Dihydroxy 
Benzaldehyde 
  
Rutin and quercetin were 
added as 100mg to 8ml of 
fermentation buffer 
directly =12.5 mg/ml 
(Aura et 
al., 2002) 
in-vitro  fermentation 
N=4 
(i)-1 umol rutin  (ii)-1 umol isoquercitrin or (iii) 0.20 
umol mixture of quercetin glucoronides 
 
HPLC-MS  Phenolic acids:  3,4-DHPAA >  3-HPAA, 3,4-DHPPA 3,4-DHPAA appeared in 
2h  
3-HPAA appeared at 8h 
(Rechner 
et al., 
2004) 
in-vitro fermentation 
N=4 
(i)-180 mg/l rutin (ii)-350 mg/l rutin 
LCMS and GCMS  Phenolic acids:  3,4-DHPAA >  3-HPAA, 3-HPPA  Faster deglycosylation of 
rutin to quercetin at lower 
concentrations of rutin 
(Labib et 
al., 2004) 
in-vitro Pig caecum model  
N=3  
(i)-250 mM  quercetin 
 
HPLC-DAD Phenolic acids:   phloroglucinol, 3,4-
dihydroxyphenylacetic acid, and 3,4-dihydroxytoluene 
 
3,4-DHPAA highest up to 
6h.  
 
(Jaganath 
et al., 
2006a) 
in-vitro fermentation  
N=3 
(i)-28 umol rutin  (ii)-55 umol quercetin or (iii) 
18×106 dpm of [4-14C]quercetin + / - 0.5g  glucose  
HPLC-PDA-MS2  Phenolic acids:  3,4-DHPAA >  3-HPAA, 3,4-DHBA, 4-
HBA, 3-HPPA 
-presence of glucose enhanced deglycosilation of rutin 
-presence of glucose increased phenolic acid production 
  
3,4-DHPAA appeared in 
2h  
3-HPAA appeared at 24h 
Table 1-3 phenolic acid production from rutin and quercetin 
  
1.3.6.6 Flavan-3-ols 
Flavan-3-ols are ubiquitous in the plant kingdom and can be found in high concentrations in cocoa, 
blackberries, sour cherries, apricots and grapes; contributing to the astringent taste of some foods such 
as tea and wine. They are present in nature either in monomeric forms such as (+)-catechin (Figure 1-
7) and (-)-epicatechin (Figure 1-6) or in the oligomer and polymer formations such as 
proanthocyanidins / condensed tannin (Porter, 1988). 
Additionally esterification with gallic acid gives rise to 
compounds such as catechin gallates and gallocatechin 
through hydroxylation; present highly in green tea in the 
forms (-)-epigallocatechin gallate and (-)-epigallocatechin 
(Stewart et al., 2005).  
It is estimated that the flavn-3-ol intake from the diet varies 
within a range of 100- 550 mg (Auger et al., 2004, 
Hammerstone et al., 2000). The reported estimation of daily 
intake varies and is most often based on average wine consumption. Auger et al. (2004) reported an 
average of 100.4 mg flavanol units based on moderate wine consumption (180 ml/ day). Whereas 
Hammerstone et al. (2000) reported an estimated range of 147.1- 164.7 mg per daily serving of food.  
According to Guyton and Hall (2010) the amount of chyme reaching the caecum from the ileum 
averages 1500ml daily. Hence the concentration of flavan 3-ols present in the caecum would on 
average range between 60-360 ug/ml. 
 
 
 
 
 
 
 
 
Figure 1-7 Epicatechin 
 
 
Figure 1-6 Epicatechin 
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Once in the colon, the first step in the catabolism of flavan-3-ols has been suggested as the production 
of hydroxyphenyl valerolactones and valeric acids. This takes place through the decarboxylation, 
dehydroxylation, lactonization and oxidation reactions following the opening of procyanidin C-ring 
(Selma et al., 2009). The production of these metabolites from monomeric flavan-3-ols is thought to be 
through the cleavage of the monomers by microbial esterases, the opening of the C-ring results in the 
production of diphenylpropan-2-ol which is then converted to 5-(3,4-DHP)- γ-valerolactone in the case 
of epi/catechins (Roowi et al., 2009, Groenewoud and Hundt, 1986). The breaking of the valerolactone 
ring eventually gives rise to 5-(3,4-DHP)-valeric acid and/or 4-H -5-(3,4-DHP)-valeric acid (Monagas 
et al., 2010). The β-oxidation of the side chains of these metabolites subsequently results in the 
formation of HPPAs and HBAs (Meselhy et al., 1997). Studies have shown that procyanidin dimers 
may also initially be depolymerised into monomeric units prior to further degradation (Stoupi et al., 
2010b, Appeldoorn et al., 2009), however this is seen as less than 10% in the case of B2 procyanidins 
(Stoupi.,2010). 
The catabolic pathway of 3,4-DHPAA has been greatly debated. It was initially proposed that this 
metabolite was mainly produced through the breakdown of procyanidins, with the cleavage of the 
upper unit of procyanidin dimers, with the lower unit giving rise to above described production of 
valerolactones. However it is now debated that 3,4-DHPAA may also be produced through the α-
oxidation of 3,4- DHPPA produced through the catabolism of the monomeric compounds. The further 
preferential dehydroxylation of 3,4-DHPAA at C-3 and C-4 in the case of epi/catechins gives rise to 4-
HPAA and 3-HPAA respectively (Gonthier et al., 2003, Stoupi et al., 2010a). It has been suggested 
that the production of 3-HPAA may also be formed through the α-oxidation of 3-HPPA and 3,4-DHBA 
may be produced through the rapid degradation of 3,4-DHPAA (Stoupi et al., 2010a, Fogliano et al., 
2011). 
The understanding of the catabolic pathway of these flavan-3-ol metabolites is limited due to the use of 
different analytical methods and as previously demonstrated, great variations in faecal microbiota 
composition. Depending on the catabolic capacity of these microbiota it is possible that different 
pathways exist, with some more predominant than others. 
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1.3.6.6.1 Cocoa 
Cocoa tree originated in the South African tropical regions. There are a few subspecies of the cocoa 
tree. The main cultivated subspecies accounting for 90% of the worlds usage is Theobroma cacao var. 
Forastero, this subspecies was developed in the Amazon basin (Tomás‐Barbéran et al., 2012).  
The use of cocoa for treatment of ailments can be traced back to the Maya and Aztecs; where cocoa 
was claimed to relieve fever and diarrhoea, sooth stomach and intestinal ache and promote strength in 
the ―weak and fainthearted‖. In later years the use of cocoa for its medicinal value was extended to 
prolonging longevity. The medicinal use of cocoa in Europe is traced back to 1500s and has been 
recorded ever since the 17
th
 century (Dillinger et al., 2000). 
Cocoa is now widely consumed in the form of confectionary/ chocolate products and beverages. The 
annual consumption of cocoa in the European Union ranged from 1.3 kg per head in Portugal to 8.8 kg 
per head in Germany (Wollgast and Anklam, 2000) and in 2010 the world wide consumption was 
estimated at over 3.5 million tons in 2010 (FAO, 2010). The high concentration of polyphenols in 
cocoa beans results in a bitter taste making them unpalatable in their natural state. Hence they are 
processed to produce more palatable products.  
During this process the cacao pods are broken open and covered by large leaves, allowing the pulp to 
ferment for 6-8 days: during which invertase converts sucrose to fructose and glucose. The glucose 
released is taken up during the fermentation process. The ethanol yield is converted into acetic acid 
during this process. The proteins are converted to peptides and amino acids while phenolic compounds 
are converted to quinines, which through polymerisation yield highly insoluble compounds responsible 
for the brown pigmentation of cocoa. The seeds are then dried to reduce moisture from 55% to 7.5%.  
During cocoa powder manufacturing the cocoa beans are roasted at 150 °C, followed by the 
mechanical separation of shell (hull) from the meat (nib). The nib containing 55% cocoa powder are 
ground while hot to produce the liquor, which is then pressed to produce the cocoa butter used in 
chocolate manufacturing. The cocoa powder is produced by pulverising the residual cake (Bixler and 
Morgan, 1999).  
Cocoa products have displayed a variety of health benefits but they are mainly studied due to the 
antioxidant and anti-inflammatory properties of their polyphenols. Consumption of cocoa has been 
associated with increased levels of plasma antioxidants, thus preventing LDL oxidation (Kurosawa et 
al., 2005). Additionally cocoa flavanols have demonstrated the ability to increase nitric oxide 
synthesis, suppress platelet activation, positively modulate eicosanoid synthesis, inhibit the production 
of certain pro-inflammatory cytokines and stimulate the production of anti-inflammatory cytokines 
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(Zhu et al., 2002, Schramm et al., 2001, Karim et al., 2000, Andújar et al., 2012, Rein et al., 2000). 
Short term consumption (15 day) of dark chocolate has also increased insulin sensitivity and reduced 
blood pressure (Grassi et al., 2005). Cocoa procyanidins with a higher degree of polymerisation 
(pemtomers) selectively inhibited proliferation of breast cancer cells without affecting normal cell 
proliferation (Ramljak et al., 2005).    
All of these potent biological properties of cocoa polyphenols contribute towards their health benefits 
such as protective mechanism in heart disease and anti-carcinogenic properties. However this is highly 
dependent on concentration of polyphenols required to exhibit these effects and the relative 
bioavailability of these polyphenols.  
The impact of a cocoa drink on gut microbiota was investigated in a study by Tzounis et al. (2011).  In 
this study 22 volunteers were supplemented with either a high cocoa flavonol drink (494mg total cocoa 
flavanols) or a low cocoa flavonol drink (29mg total cocoa flavanols). Cocoa was consumed mixed in 
150ml of water for a period of 4 weeks, allowing 4 weeks of wash out between the two arms of the 
study. Faecal samples were collected before and after each intervention. This study demonstrated that 
while consumption of high cocoa flavanol drink increased certain bacterial species such as 
bifidobacteria (p<0.01) and lactobacilli (p<0.01), other bacterial species were decreased such as 
clostridia (p<0.01). This study also demonstrated a reduction in plasma  TAG and C-reactive protein 
(CRP) (p<0.05) as well as a correlation between changes in the lactobacilli to a decrease in CRP levels 
(p<0.05, R
2
= 0.33).  
1.3.6.6.2 Polyphenols in cocoa  
Cocoa is a great source of polyphenols and contains flavanols mostly in the form of monomers (+)-
catechin, (-)-epicatechin and the polymers proanthocyanidins as well as anthocyanins, flavonol 
glycosides, phenylethylamine, N-oleoyl, N-linoleoylethanolamine, clovamide and theobromine (Rios 
et al., 2003). It is estimated that cocoa contributes towards 20% of total catechin consumption in the 
West (Arts et al., 1999). Cocoa has shown to have a higher concentration of polyphenols per dose of 
consumption than tea or red wine (Lee et al., 2003) and higher procyanidin content than that of 
cranberries and blue berries on a dry weight basis (Gu et al., 2002).   
The bitter taste resulting from high concentrations of polyphenols in cocoa makes them unpalatable in 
their natural form. They are processed in order to make them palatable. The process of fermentation / 
dutching and chocolate manufacturing results in the reduction of polyphenol content of cocoa from 
100% to approximately 10% (Andújar et al., 2012, Miller et al., 2008, Rusconi and Conti, 2010).  
 60 
 
Cocoa polyphenols are comprised of the monomers (+)-catechin and (-)-epicatechin, the combination 
of the two form proanthocyanidins, which is present in dark cocoa in high concentrations. 100 g dark 
chocolate contains, on average, 42 mg (−) -epicatechin and 12 mg (+)-catechin (Tzounis et al., 2008a). 
Catechin and epicatechin have high solubility in water relative to most other flavonoids (Schramm et 
al., 2003). Procyanidins represent 50% of the approximate 1g of daily polyphenol consumption 
(Gonthier et al., 2003). The procyanidins are mainly present as B1 – B5, C1 and D procyanidins made 
up of dimers, trimers and oligomers of the flavan-3,4-diols linked through 4 6 and 4 8 bonds. 
Whereas, the anthocyanidins are present in the 2 forms of cyanidin-3-α-L-arabinoside and cyanidin-3-
D-galactoside. Some traces of dimeric epicatechin glycosides such as 3-O-arabinoside and 3-O-
galactoside conjugates of (+)-epicatechin-(2α7, 4α8)-(+)-epicatechin have also been reported. The 
proportion of polyphenol content in cocoa is displayed in the image (Figure 1-8) below (Andújar et al., 
2012, Gu et al., 2006). 
 
 
 
 
Recent studies have demonstrated that unlike previously thought, the (-)-catechin enantiomer is the 
most abundant form of catechin found in chocolate products (Donovan et al., 2006). While (-)-catechin 
is found to be more abundant in the cocoa products, (+)-catechin is most abundant in the natural state 
of the cocoa (Gotti et al., 2006). This could be a result of processing and the epimerisation at the 2 
positions of (-)-epicatechin. However, regardless of its abundance, (+)-catechin remains to be the most 
bioavailable form of catechin enantiomers in cocoa products. Donovan et al. (2006) analysed the 
bioavailability of 10, 30 or 50 umol/l of (-)-catechin and (+)-catechin in male wistar rats (n=15). The 
plasma concentration of (-)-catechin was found to be 2-8 fold lower than that of (+)-catechin (p<0.005) 
for all concentrations. Similar results were seen for intestinal absorption (p<0.01). (-)-catechin 
Figure 1-8 Polyphenol composition of cocoa 
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constitutes 89% of total catechins according to other studies (Neilson et al., 2009). Cocoa also contains 
phenolic acid derivatives in the form of N-caffeoyl-3-O -hydroxytyrosine also known as clovamide and 
N-p-coumaroyl-tyrosine (deoxyclovamide). 
The total polyphenol content of cocoa beans is estimated to be 6-8% of dry weight (Zumbé, 1998). Due 
to the variation in cocoa products and analytical methods, there is a great variation in reported 
concentrations of polyphenols quantified in cocoa. An example of this is seen in Table 1-4 as mg/g dry 
weight of de-fatted cocoa.  
Table 1-4 cocoa polyphenol concentration 
Author  
(year) 
Measurement Dark  
chocolate 
Milk 
chocolate 
Cocoa 
 powder  
Method 
(Waterhouse et al., 
1996) 
Total Phenol 8.4 5.0 20.0 Folin-ciocalteau, 
Gallic acid eqv. 
(Vinson et al., 1999) Total Phenol 36.5±5 15±5.8 65±19 Folin-ciocalteau, 
Catechin eqv. 
(Adamson et 
al.,1999) 
Procyanidins 1.7±0.08 0.7±0.17 - NP-HPLC 
(Adamson et al., 
1999) 
Catechins+epicatechins  0.8±0.08 0.2±0.05 - NP-HPLC 
(Arts et al., 1999) Catechins+epicatechins 0.5 0.16 - RP-HPLC 
 
1.3.6.6.3 Bioavailability of cocoa polyphenols 
The health benefits derived from cocoa have been associated with its flavan-3-ol content especially 
circulating (-)-epicatechin in relation to prevention of CVD (Schroeter et al., 2006, Rasmussen et al., 
2005). These health benefits are thus dependent on the bioavailability of these polyphenolic 
compounds from cocoa.  
The fate of flavan-3-ols post consumption is very much the same as the fate of flavanols described 
above. Ingested (-)-epicatechins are absorbed from the small intestine and appear in circulation 30 
minutes after ingestion mostly in the form of sulphate, glucuronide and methylated substances due to 
the action of sulphotransferases, uridine-5-diphosphate glucuronosyltransferases and catechin-O-
methyltransferases as they are transported to the portal vein. These compounds may then undergo 
phase II metabolism after which they may be transported to the colon through bile. Most studies on 
bioavailability of the flavan-3-ols, catechin and epicatechin use green tea as a source of these 
compounds. Typically volunteers follow a low polyphenol diet for a period of 24-48 hours, baseline 
blood and urine samples are collected after an overnight fast, after which volunteers ingest dietary 
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source of the compound with repeated measures of blood and urine taken over the following 24-48 
hours while volunteers remain on the low polyphenol diet. Bioavailability measurement of compounds 
can also take place using animal models (Baba et al., 2001). Baba et al demonstrated that (-)-
epicatechin was more bioavailable in rats than (+)-catechin, which was shown to be more bioavailable 
than (-)-catechin (Donovan et al., 2006). 
The events that occur pre-absorption are of importance in determining the compounds and 
concentration available for absorption (Spencer et al., 2001a). Saliva has displayed little to no impact 
on catechin and procyanidin modification (Tsuchiya et al., 1997). Epicatechin was found to be stable 
under stimulated gastric conditions as well (Auger et al., 2008). There is however on-going debate on 
the stability of cocoa procyanidins in the stomach and small intestine and whether or not they are 
cleaved to produce epicatechin before reaching the colon. The stability of these compounds is highly 
dependent on the surrounding pH. Procyanidins were shown to be unstable at a pH of 2.0 when they 
were incubated in acid and simulated gastric juice; 60-80% of the oligomers were decomposed to 
monomeric and dimeric units of epicatechin during the first 90 minutes and were almost completely 
decomposed by 3.5h (Spencer et al., 2000, Spencer et al., 2001b). It was also demonstrated that higher 
polymerised index of monomers were more readily cleaved. Similar results were seen in a study by 
zhou et al. (2002) demonstrating instability of dimers in simulated gastric juice. However they also 
demonstrated a higher stability for the monomers (+)-catechin and (-)-epicatechin in simulated gastric 
juice as well as an inverse relationship between pH levels and stability of monomeric and dimeric 
units. Monomeric compounds were found to be relatively stable at a pH of 5.0 with increasing 
instability as the pH was increased to 9.0 in the following order of relative stability (+)-catechin > (-)-
epicatechin > Dimers.  
However Rios et al. (2002) demonstrated that proanthocyanidins were stable in the stomach of healthy 
volunteers (n=6) fed 500 ml of a cocoa beverage containing 733 mg procyanidin polymers and 351 mg 
structurally related flavanol monomers using a nasal-gastric tube. The contents of the stomach were 
collected every 10 minutes for the quantification of flavanols and procyanidins. It is important to note 
that in such studies, the composition of cocoa may have a buffering effect on the gastric pH and affect 
observations. 
The degree of polyphenol absorption from the small intestine can be studied in ileostomy patients. 
Such studies have found that 20% of ingested catechin, epicatechin and metabolites in the form of tea 
extract (polyphenol E) are found in the ileal fluid (Auger et al., 2008). In similar studies the ingestion 
of apple juice in 11 ileostomy patients demonstrated 90% recovery of ingested procyanidins in 
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ileostomy bags, even though they were present at a lower degree of polymerisation (Kahle et al., 2007). 
The absorption of flavanols has displayed large variability, ranging from 1-50% of ingested flavanols 
(Baba et al., 2000, Rein et al., 2000, Schramm et al., 2003, Hollman et al., 2001). Some of this 
variation has been attributed to the complex in-vivo system such as gastric pH, the type and activity of 
microbiota. However, in a study by Schramm et al (2003) investigating the impact of the Famotidine 
on oral absorption of cocoa flavanols, changes in gastric pH failed to demonstrate any impact on the 
absorption (Cmax and AUC) of flavanols. Another factor influencing the variation in bioavailability and 
metabolites produced is the composition of the cocoa product and the degree of processing. As 
discussed previously, processing may result in higher concentrations of the less bioavailable (-)-
catechin than (+)-catechin. In commercially available cocoa products, taste and palatability of the 
product are key factors and hence, these products may be subjected to higher degrees of processing 
such as dutching, subsequently making their phenolic content less available. An example of this is seen 
in the study by Mullen et al. (2009) where commercially available Green & Blacks cocoa was used, 
displaying higher concentrations of (-)-catechin compared to (+)-catechin. Some of the studies 
Investigating Bioavailability of cocoa polyphenols are summarised in Table 1-4. 
  
 
Author Study method   Measurements Results Comments 
(Richelle et 
al., 1999) 
 
Acute in-vivo  (n=8)  
(i)-40g  black chocolate (Nestle noir)  
having 282 umol (-)-epicatechin 
 (ii)-80g black chocolate (Nestle noir) 
HPLC  
(plasma 
epicatechin)  
Plasma concentration of epicatechin ↑significantly with 40g of 
chocolate, Cmax= 355 nmol/L  and Tmax= 2.0 h 
80g of chocolate  ↑ epicatechin significantly, Cmax= 676 nmol/L  
and Tmax= 2.6 h 
Delay in Tmax due to ad 
libitum consumption of 
bread  
Bitter taste of high dose 
cocoa may result in changes 
of gastric emptying. 
(Baba et al., 
2000) 
Acute in-vivo  (n=5) 
(i)-35g chocolate containing 760umol (-)-
epicatechin and 240umol of catechin 
(ii)-35g cocoa containing 760umol (-)-
epicatechin and 240umol of catechin 
HPLC and 
LCMS  
(plasma & 
urineepicatechin) 
Cmax of (-)-epicatechin after 2 hours of chocolate consumption = 
4.77 ± 0.94 umol/L 
Cmax of (-)-epicatechin after 2 hours of cocoa  consumption = 
4.94 ± 0.94 umol/l 
- 
(Wang et al., 
2000) 
Acute in-vivo parallel (n=20) 
Chocolate = 5.3mg total procyanidin/g [1.3 
mg/g= (-)-epicatechin] +40g bread 
 (i)-0g chocolate (ii)-27g (iii)-53g (iv)-80g 
HPLC  
(plasma 
epicatechin) 
↑ (-)-epicatechin respectively : 
0g chocolate= 19 ± 14, 27g chocolate=133 ± 27 
53g chocolate=258 ± 29, 53g chocolate=355 ± 49 
Was not determined if 
catechin content was (+)-
catechin or  (-)-catechin  
(Holt et al., 
2002) 
 Acute in-vivo (n=20) 
 (i)- 0.375 g cocoa/kg body weight +300ml 
water 
1g cocoa = 12.2 mg monomers, 9.7 mg 
dimmers and 28.2mg polymers 
HPLC  
(plasma 
monomers and 
polymers) 
 
Procyanidin dimer, (−)-epicatechin, and (+)-catechin detected in 
the plasma at  0.5 h (16 ± 5 nmol/L, 2.61 ± 0.46 μmol/L, and 
0.13 ± 0.03 μmol/L, respectively).  
And by 2 h it reached (41 ± 4 nmol/L, 5.92 ± 0.60 μmol/L, and 
0.16 ± 0.03 μmol/L, respectively). 
 
(Mullen et al., 
2009a) 
Acute in-vivo  (n=9) 
Cocoa drink=10g cocoa powder +   Hot 
water 
cocoa= 22.3 umol (-)-catechin mostly          
23 umol (-)-epicatechin and 70mg 
procyanidins 
HPLC-PDA-
MS2  
(plasma and 
urine 
metabolites) 
24 hour urine excretion of (epi)catechin metabolites= 7.32  ± 
0.82 umol = 16.3  ±1.8% of ingested  
2 metabolites in plasma and 4 in urine  
Urine: (epi)catechin-O-sulphate (RT 15.5 min),                               
(-)-epicatechin-O-glucuronide 
Urine and plasma : (epi)catechin-O-sulphate (RT 18.6  min), O-
methyl-(epi)catechin-o-sulphate  
Majority of catechins were 
the (-) isomer which are less 
bioavailable 
Table 1-5 Bioavailability of cocoa polyphenols 
  
1.3.6.6.3.1 Phenolic acid production from cocoa 
As previously discussed, 20% of catechins and 90% of procyanidins reach the colon; where they are 
subjected to colonic microbiota degradation. Moreover, the very low amounts of different flavan-3-ols 
monomers, proanthocyanidin dimers and trimmers detected in human plasma as glucuronidated, 
sulphated and methylated conjugates as well as sulphate metabolites in rat urine after the consumption 
of red wine or cocoa is an indication that most of these compounds reach the colon intact where they 
are subjected to microbial degradation and converted to phenolic acids (Holt et al., 2002, Sano et al., 
2003). 
Considering that procyanidins make up the largest concentration of polyphenols in cocoa, it could be 
postulated that cocoa exhibits most of its health benefits through the colonic metabolites of its 
polyphenols. However, the bioactivity of phenolic acids and how they are metabolised by colonic 
bacteria has not been thoroughly studied. Studies on  colonic production of phenolic acids include  
Colonic production of phenolic acids has been studied in various forms:  
 In-vivo measurement of metabolites excreted through urine and plasma after ingestion of foods 
containing polyphenols of interest: for this method volunteers typically follow a low 
polyphenol diet ranging from 24-72 hours, followed by an overnight fast, collection of 
baseline urine / plasma samples. They are then given the food source of interest followed by 
the collection of blood and urine samples. Urine samples are typically collected in batches 
over 24-48 hours post ingestion or as 24 hour urine samples. Blood is typically taken 
through canulation over 6 hours after food ingestion. Volunteers remain on a low polyphenol 
diet throughout the sample collection period. Although this is a good method of phenolic 
acid measurement, there is the possibility of non-compliance to low polyphenol diet, or 
consumption of different diet on different arms of the study (in the case of cross over 
models), resulting in phenolic acid production from food sources other than that of 
investigation. 
 Animal study models: This model is typically used for the incorporation of native compound in 
the diet of animals such as rats/mice and pigs. This is later corrected for the amount of food 
consumed, however the distribution of compounds in the diet are not even and hence 
percentage of ingestion will not be precise. Secondly some animals might have more 
potential for hydrolysing and degrading native compounds than possible in the human 
caecum.  
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 In-vitro faecal fermentations (ex-vivo): In this model fresh faecal sample from human 
volunteers is used as a source of colonic microbiota in a simulation model of the colon. 
Faecal samples are either used for individual fermentations or pooled as a diverse source of 
microbiota. In this model native source of the phenolics or the food source as a whole matrix 
can be incubated with the faecal inocula. Samples are taken typically at baseline and every 2 
hours for 6 hours and at 24 and 48 hours post incubation. Ensuring anaerobic conditions in 
this model is key. This model is ideal for understanding pathways of production and 
conversion of phenolic acids. However as absorption and eneterohepatic circulation is not 
modelled this limits the representativeness of the model. 
 
A number of studies using the above models have been summarised in Table 1-6. In An in-vitro study 
by Roowi et al. (2010), colonic metabolites of (-)-epicatechin (50 umol) were found to be mostly 
transitory: 3-HPPA, 3,4-DHP-γ-valerolactone and 3,4-DHP-γ-valeric acid. Lower concentrations of 4-
HPAA and 3-HPAA were also identified. However high concentrations of 3-HPAA were present in the 
faecal slurry alone with no added substrate incubations (control), suggesting that this phenolic acid is 
derived mostly from the background diet. Presence of transitory traces of (2,4,6-trihydroxy)-propan-2-
ol in this study suggested its production as a first catabolite from (-)-epicatechin degradation, and its 
later conversion to 3,4-DHP-γ-valerolactone  3,4-DHP-γ-valeric acid  3-HPPA 4-HPAA. The 
method used for the identification and quantification of these phenolic acids is key. Some phase II 
metabolites such as the glucuronides and sulphates of 3,4-DHP-γ-valerolactone can go undetected by 
the GCMS (Llorach et al., 2009).  
The findings of Roowi et al. (2009) was supported by a similar study incubating (-)-epicatechin and 
(+)-catechin at concentrations of 150 mg/L and 1000 mg/L. This study in addition demonstrated that 
the degradation of (+)-catechin required its conversion to (+)-epicatechin before the production of 3,4-
DHPAA (Tzounis et al., 2008a). The rate of (+)-catechin degradation was found to be significantly 
higher than that of (-)-epicatechin at 4 and 8 hours for the lower concentration and at 8, 10 and 17h for 
the higher concentration. However both monomers produced the same final catabolites regardless of 
different steps in the pathway.  
The majority of ingested procyanidins reach the colon intact. Very few studies have detected 
procyanidins in plasma samples. Holt et al. (2002) identified dimers B2 but not B5 present in the 
purified cocoa standard in plasma as early as 0.5 hours after cocoa ingestions in humans. A significant 
increase from baseline values for catechins and epicatechins was also observed within 0.5h after 
ingestion of cocoa, demonstrating much higher concentrations of catechin (2.61 ± 0.46 μmol/L 
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compared to 0.08 ± 0.46 μmo/L baseline) than epicatechin (0.13 ± 0.03μmo/L compared to 0.00 μmo/L 
baseline). Other studies have failed to demonstrate the presence of procyanidins in plasma. Although 
Tmax appeared the same for monomers and dimer B2, the Cmax for dimer B2 was 100 fold lower than 
that of the monomers. Unlike Holts‘s observation, procyanidin dimers, trimers, tetramers and 
pentamers were identified in the plasma of rat fed procyanidins (Shoji et al., 2006). The dose 
administered was of a much higher range (1g/kg body weight), considering total polyphenol 
consumption in humans is estimated as 1g. Additionally administration through gavage might have had 
an impact on the observed results. It was suggested by shoji et al. (2006) that the extraction method 
using 8 μmol/L of urea as compared to the more common extraction method of using methanol / 
acetonitrile prevented the irreversible binding of plasma proteins to procyanidins. While these animal 
and human studies suggest the absorption of procyanidins other studies have not replicated these 
results. 
Unlike the controversy around the absorption of intact procyanidins, the fate of the procyanidins 
reaching the colon is clearer. Recent studies have demonstrated extensive degradation of procyanidins 
by colonic microbiota. Procyanidins are known to be metabolised into hydroxyl benzoic acids, phenyl 
acetic acids (PAA), mono/ di-phenyl acetic acids and mono/ di-phenyl propionic acids (PPA) (Rios et 
al., 2003).  
Gonthier et al. (2003), fed rats a diet containing catechin. The abundant excreted urinary compounds 
comprised of catechin and its 3′-O-methylated derivative, when rats were fed a dimer B3 or trimer C2 
diet, neither intact catechin nor its methylated forms were detected. 
The oral dosing of rats with [
14
C] procyanidin B2 resulted in 60% urinary excretion in 96 hours of 
radioactivity greatly varying from the intact compound consumed. This is further supported by in-vitro 
faecal fermentation of [
14
C] procyanidin B2 in studies that have identified the following as the main 
phenolic acids produced from this compounds in-vitro: 3,4-DHPAA, 3,4-DHPVA, 3,4-DHP-γ-
valerolactone,  3-HPAA, 4-HPAA, 3-HPPA, PVA, 3,4-DHPPA,  
Monohydroxylated-phenylvalerolactone and 1-(3,4-dihydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)-
propan-2-ol, 1-(HP)-3-(2,4,6-THP)-propan-2-ol (Stoupi et al., 2010b, Appeldoorn et al., 2009).  
While conjugated forms resulting from phase II metabolism are absent in faecal fermentation results, 
there is on-going debate on the urinary excretion of (-)-epicatechin metabolites in free or conjugated 
forms. While majority of studies have suggested the former, other studies such as (Llorach et al., 2009) 
have identified glucuronide and sulphate conjugates of valerolactone in urinary excretion.  
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It is clear from above studies that more research is needed on the in-vivo fate of cocoa polyphenols and 
their colonic catabolites. The speculated catabolic pathway of cocoa polyphenol catabolism by colonic 
microbiota has been illustrated in Figure 1-9. The majority of studies investigating phenolic acid 
production from cocoa have utilised the parent compounds (catechin/ epicatechin/ procyanidins) in the 
fermentation model. It is however more important to investigate the production of these phenolic acids 
from cocoa as a whole matrix as this can greatly impact the production of phenolic acids. Moreover, 
these compounds are not consumed as independent nutrients but as part of a food source. Such studies 
have demonstrated 3-HPAA, 3-HPPA and 3,4-DHBA as the main metabolites of cocoa in-vitro 
fermentation (Fogliano et al., 2011).  
  
 
 
Figure 1-9 Speculated catabolic pathway of cocoa polyphenols by colonic microbiota - Adapted from Monagas et al. (2010) 
 
  
Table 1-6 Phenolic acid production from cocoa polyphenols 
Author 
year 
Study method  Measurements Findings (phenolic acid production)  comments 
Holt et al  
(2002) 
n=5  
Age: 23-34 yrs, average b.d.w  = 70.5 ± 4.6 
Cocoa 0.374 g/kg b.d.w + 300ml water + white bread 
1g cocoa = 12.2mg monomers, 9.7mg dimers and 28.2 
mg polymers  
LCMS  Procyanidins B2 and B5 identified in purified cocoa standards. 
Significant increase in Dimer B2 concentration at 0.5, 2 and 6h 
(p<0.05). B5 not detected in plasma samples. 
Significant increase from baseline in catechin (2.61 ± 0.46 μmol/L 
compared to 0.08 ± 0.46 μmo/L) and epicatechin (0.13 ± 0.03μmo/L,  
0.00 μmo/L)  concentrations within 0.5 hours of consumption p <0.05  
 
Average 
consumption: 
26.4 g cocoa, = 
323 mg 
monomers and 
256 mg dimers 
(Rios et al., 
2003) 
n=11  
2 day polyphenol-free diet  
80g of chocolate (439 mg proanthocyanidins and 147 mg 
catechin). 
Urine collected for 24h, at 0, 3, 6, 9, 24 and 48h. 
GCMS 3-HPAA, Ferulic, 3,4-DHPAA, 3-HPPA 
VanilliC. 3-HBA 
 
Mullen et al 
2009 
n=9 cross over 
Age: 20-43, BMI:24.7  
1g paracetamol + 5g lactulose +  
250ml of a cocoa drink with hot water or hot milk (250ml 
+10g green and blacks cocoa).  
Cocoa = 45 umol (-)epicatechin and (-)catechin 
HPLC-MS  3,4-DHPPA,  3,4-DHPAA, 3-Methoxy-4-HPAA, 3,HPAA, PAA, 
protocatechuic, 4-HBA, 3-HBA, 4-HPA, Hippuric, Vanillic, Caffeic, 
Ferulic, p-coumaric, m-coumaric  
 
Sarda et al 
 2009  
n=42 cross over Long term study 
Age: 69.7 ± 11.5 At  risk of CVD 
20g cocoa *2 day +250ml skimmed milk 4 weeks 
 
 LCMS-MS  Vanillic, 3,4-DHPAA, 3-HPAA, 5-(3,4-DDHP)-γ – valerolactone, 3,4-
DHPPA,  3-HPPA, HVA, PAA, m-coumaric, p-coumaric, caffeic, 
ferulic, protocatechuic, Vanillic, 4-HBA, 3-HBA, 4-HHA, 3-HHA 
 
Llorach et 
al  
(2009) 
Acute- in-vivo randomised control crossover  
n=10  
Age: 18-50 yrs BMI: 21.6 2.1 
Cocoa: 0.71 ± 0.09 mg/g (−)-epicatechin, 0.21 ± 0.01 
mg/g (+)-catechin, 0.64 ± 0.06 mg/g of procyanidin B2. 
(i)-40g cocoa +250ml milk   (ii)-40g cocoa +250ml water 
(iii)- 250ml milk  
LCMS  5-(3,4-dihydroxyphenyl)- γ-Valerolactone  sulphate,  5-(3,4-
dihydroxyphenyl)- γ-Valerolactone  glucuronide, O-Methylepicatechin, 
Epicatechin-O-Sulphate,   
3-Methoxy-4-hydroxyphenylvalerolactone,   
3-Methoxy-4-hydroxyphenylvalerolactone glucuronide,  4-hydroxy-5-
(3,4-dihydroxyphenyl)-valeric acid, Vanillic acid 
Milk did not 
affect cocoa 
polyphenol 
bioavailability 
(Tzounis et 
al., 2011) 
In-vivo n=22   
Age: 30.2 ± 11yr, BMI 23.2 ± 2.5) 
LCMS - with 
fluorescent 
No flavanols present in the non-inoculated Faecal sample 
↑ Plasma epicatechin after HFC from 24.7 ± 6.6 to 72.9 ± 12.7 mmol/L 
Drinks matched 
for fibre 
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Faecal samples collected before and after a 
High cocoa flavanol diet (494 mg cocoa flavanols/d) or 
Low cocoa flavanol diet (23 mg  cocoa flavanols/d) 
4 weeks + 4 weeks washout period 
detector ( p<0.01) but not for catechin 3- and 4- O- methyl- epicatechin 
Epicatechin and 3- and 4- O- methyl- epicatechin detectable in 24 urine 
sample for HFC. 
 
(Tzounis et 
al., 2011) 
In-vivo n=22  
Age: 30.2 ± 11yr, BMI: 23.2 ± 2.5) 
Faecal samples collected before and after a 
High cocoa flavanol diet (494 mg cocoa flavanols/d) or 
Low cocoa flavanol diet (23 mg cocoa flavanols/d) 
4 weeks + 4 weeks washout peri 
Reverse phase 
HPLC 
 ↓ monomers, dimmers and oligomers after 6h of incubation  
 
↑transient increase of trimers at 6h 
 
↓time dependent, epicatechin, catechin and dimer B2  
 
↑ 5-(3,4-dihydroxyphenyly)-γ-valerolactone 
Batch culture 
fermentation 
with 10g Faeces 
(with 10ml 
phosphate 
buffer. 
     
Gonthier et 
al  
(2003) 
Animal model-Male wistar rats (n=25) /Parallel /5 days 
Weight= 228 ± 3 g 
(i) - semipurified diet (20g/d) 
(ii)-semipurified diet (20g/d) + 1% (w/w) catechin 
(iii)-semipurified diet (20g/d) + 1% (w/w) procyanidin B3 
(iv)-semipurified diet (20g/d) + 1% (w/w) procyanidin C2 
(v) semipurified diet (20g/d) + 1% (w/w) polymers 
HPLC-MS  metabolites from catechin diet only:  catechin, 3-O-methyl catechin, 
3,4-DHVA, ferulic acid 
Metabolites from catechin and dimer: 3,4-DHPPA, 3-HBA, 3-HHA 
Metabolites from catechin, dimer, trimer diet: 3-HVA,  
Metabolites from catechin, dimer, trimer, polymer diet: 3-HPPA,     m-
coumaric, p-coumaric, 3,4-DHPAA, 3-HPAA, protocatechuic, 4-HBA, 
vanillic, 4-HPPA, HA 
 
Stoupi et al  
2010 
Animal model, wistar rats (n=5) 
Weight =200-250g 
(i)-Intravenous (~150ul/animal) adjusted to 21 mg/kg b.d.w 
(ii)-oral (~500ul/animal) adjusted to 21 mg/kg b.d.w 
(iii)- to 10.5 mg/kg b.d.w 
Urine and faeces collected @ 0, 24, 48, 72, and 96 h after 
dosing 
Blood collected (0.1 ml) @ 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 15, 
18, 20, 22, and 24 h 
 24h  urine: 69% excreted for intravenous group, 58% for oral groups 
Total urinary excretion 76%  for intravenous group, 62%  and 63% for 
oral groups 
 
24h  faeces: 25% excreted for intravenous group, 39% and 40%  for 
oral groups 
Total urinary excretion 28%  for intravenous group, 41% for oral 
groups 
Excretion of 
radioactivity 
higher in urine 
than faeces 
 
     
(Déprez et 
al., 2000) 
n=1 
In-vitro fermentation (48h) with procyanidin 
150 ul of  100 mmol/L expressed 
as catechin unit equivalents, i.e., 29 g/L) 
final concentration of  5 mmol/L 
GCMS 4-HPAA, 3-HPAA, 3-HP-valeric, PPA, 4-HPPA and 3-HPPA  both labelled 
and non-
labelled 
procyanidins 
 
(Bazzocco 
et al., 2008) 
 Digestion followed by in-vitro fermentation 
Marie-mernard apples – short PA chains 
Avrolle apples- long PA chains 
Phenolic acids 
SCFA 
production 
Marie mernard apples more microbial metabolites than avrolle 
Phenolics produced = 3,4-DHPPA, 3-HPPA, 3-PPA, BA, 3,4-DHPAA, 
3-HPAA.  
Ciders had the 
lowest average 
degree of 
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 Primary metabolite =3,4-DHPPA 
Followed by :  3-HPPA, 3-PPA, BA, PAA 
 
↑BA from pre-digested apples than non-digested 
↑ PAA from non-digested than digested 
 
Cider with the shortest PA had the highest profile of PPA, PA 
BA for cider was lower than that of digested apple 
 
Cider had the most extent of conversion (44% for avrolle cider and 
62% for marie.m cider) 
 
Maximal extent was reached much later (6-8h) with the marie.m apples 
than the extracts (2h) 
Delay in time needed for maximal extent of conversion when avrolle.p  
fermented alone (4h) than fermented with cell wall preparation (8h)  
polymerisation. 
 
3,4-DHPPA 
from ring-
fission of 
catechins 
Rest from 
dehydroxylation 
of 3,4-DHPPA 
 
No phenolic 
acid produced 
from cell wall 
preparations. 
 
Tzounis et 
al  
(2008)  
In-vitro fermentation   (pH controlled stirred batch-culture) 
n=3 
(i)-[FS + (+)-catechin (150mg/L or 1000 mg/L)] ± 1% 
(w/v) sucrose or FOS  
(ii)-[FS + (-)-epicatechin (150mg/L or 1000 mg/L)] ± 1% 
(w/v) sucrose or FOS  
 
 
 Phenolic acids from (-)-epicatechin: 
5-(3,4-DHP)—valerolactone,  PPA 
5-phenyl—valerolactone 
Phenolic acids from (+)-catechin: 
(+)-epicatechin  
5-(3,4-DHP)—valerolactone   
5-phenyl—valerolactone 
 
Rate of (+)-catechin metabolism much more than (-)-epicatechin at 4 
and 8 hours for 150mg/L and at 8, 10 and 17h for 1000 mg/L 
concentration (p<0.001) 
 
(-)-epicatechin bacterial metabolism was higher in the presence of both 
sucrose and FOS at 8 and 10h (p<0.01). 
(+)-catechin bacterial metabolism was higher in the presence of both 
sucrose and FOS at  4 (p<0.01), 8 and 10h (p<0.001). 
 
-volunteers 
were not put on 
low polyphenol 
diet 
Appeldoorn 
et al (2009) 
In-vitro fermentation (n=4 pooled) 
Mixture of dimmers (5umol) incubated as : 
(i)- FS + 1% (w/v) suspension of procyanidins 
(ii)-FS +5 % (w/v) suspension of procyanidins 
(iii)-FS 
HPLC 
analysis of 
phenolics 
Phenolic acids produced:  
Main phenolics: 3,4-DHPAA, 3,4-DHPVA,  
Other phenolics: 3-HPAA, 4-HPAA, 3-HPPA, PVA,  
Monohydroxylated phenylvalerolactone and 1-(3,4-dihydroxyphenyl)-
3-(2,4,6-trihydroxyphenyl)propan-2-ol 
Volunteers were 
not on a low 
polyphenol diet  
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Roowi et al  
2009 
In-vitro fermentation  N=3 (2male, 1 female) 
(i)- FS + 1ml of epicatechin  [50umol (-)-epicatechin] + 
50g glucose (ii)-FS alone  
 
GCMS 
analysis of 
phenolic acids 
in faecal 
slurries 
Phenolic acids produced :  
4-HPAA, 3-HPAA, 3-HPPA (54%) , 5-(3,4-dihydroxyphenyl)-γ-
Valerolactone  (38%) , 5-(3,4-dihydroxyphenyl)-valeric acid (32%). 
4-HPAA very 
small amounts 
Stoupi et al 
(2010) 
In-vitro fermentation (N=1) 
(i)-FS + 5mM (-)-epicatechin 
(ii)-FS + 5mM Dimer B2 
LCMS 
analysis of 
phenolics 
Phenolic acid production from (-)-epicatechin and procyanidin B2@6h: 
 
1-(3,4-DHP)-3-(2,4,6-THP)- propan-2-ol,  1-(HP)-3-(2,4,6-THP)-
propan-2-ol,   5-(3,4-DHP)-γ-valerolactone,  3-HPPA 
 
Phenolic acid production from (-)-epicatechin only @12h: 
5-(3-HP)-γ-valerolactone,  5-(4-hydroxy)-(3′,4′-DH)PVA, 3-HPPA,   3-
HPAA,  3,4-DHPPA 
 
Phenolic acid production from procyanidin B2 only @24h: 
5-(3-HP)-γ-valerolactone,  5-(4-hydroxy)-(3′,4′-DH)PVA, 3-HPPA,   3-
HPAA,  3,4-DHPPA 
 
Phenolic acid production from (-)-epicatechin and procyanidin B2 
@24h: 
  5-(3,4-DHP)VA,  5-(3′-HP) VA 
 
Only 1 
volunteer used  
(Fogliano et 
al., 2011) 
In-vitro fermentation (n=1) 
Continuous fermentation model after digestion  
Insoluble-fraction of cocoa  
20g of cocoa in 120ml of water digested, followed by 
dialysis and freeze drying 
A concentration of 1% w/v used.  
LC/MS/MS 3-HPAA 
3-HPPA 
3,4-DHBA 
-and an unknown compound with MRM  fragmentation peak of m/z 
289245  
 
Dall‘Asta et 
al (2012) 
In-vitro fermentation (n=3) 
(i)- FS+ 9%  chocolate extract (90% chocolate) 
LCMS 
analysis of 
polyphenols 
and phenolic 
acids 
Phenolic precursors: epicatechin, catechin, procyanidin dimmers-B, 
procyanidin trimers-B, procyanidin tetramers-B 
 
Phenolic acids: 5-(3,4-DHP)- γ-valerolactone, 3,4-DHPAA, 
protocatechuic, HBA, salicylic 
Concentration 
not given 
  
 
1.4 Food matrix  
 
The food matrix is defined by the USDA as ―The nutrient and non-nutrient components of foods and 
their molecular relationships, i.e. chemical bonds, to each other‖.  Food matrix interaction therefore 
refers to when components of such matrices possess the physio-chemical properties to influence the 
metabolism of another component in the food matrix.  This may lead to the enhancement or inhibition 
of the absorption and or metabolism of one or both of the components.  Food matrix interactions may 
be the result of direct chemical interaction such as the mineral-oxalate binding which may reduce 
mineral absorption (eg. Spinach oxalate and calcium) or indirect, such as the influence of polyphenol 
or fibre on the colonic microbiota resulting in the potential modification of each other‘s metabolism by 
the bacteria. 
As discussed in various sections above, the majority of polyphenolic compounds enter the colon either 
as the native compounds present in food or as the metabolites of small intestinal hydrolysis and/or 
conjugates of phase II metabolism. It is becoming increasingly evident that most of the absorption 
occurs via lower molecular weight catabolites produced through colonic microbiota action but the 
bioactivity of these in human tissues and their role in disease prevention is not certain, although there 
have been studies (summarised in Table 1-2) demonstrating antioxidant properties in-vitro (Rice-Evans 
et al., 1996), protection from in-vitro lipid peroxidation (Sroka and Cisowski, 2003) and chemo-
protective effects in cancer cell lines (Henning et al., 2013). The same bacterial ecosystem is 
responsible for some of the health benefits induced by dietary soluble fibre, by fermentation and 
production of bioactive compounds: SCFA. Nutrients present in the diet can alter gut physiology and 
hence impact the metabolite production from the microbiota. Alteration of GI physiology can include 
effect on gastric emptying time, intestinal motility, acid, bile and enzyme secretion, blood and lymph 
flow as well as changes in the function of the endocrine and nervous system, depending on type of 
food and matrix in which it is ingested (Schramm et al., 2003). 
Most studies have focused on the fermentation end products of non-digestible carbohydrates, proteins 
and their health benefits, studies on the active metabolites of polyphenol degradation by these 
microbiota are more scarce.  
Studies investigating the metabolite production from these food components have demonstrated a high 
inter-individual variation in metabolites produced from colonic microbiota action. These variations can 
be attributed to genetics, age, body weight, gastrointestinal disease, ethnicity and diet. There has been 
extensive research on how diet can modify colonic microbiota by selectively stimulating growth of 
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specific bacterial strains as seen for prebiotics or by selectively inhibiting growth of certain bacterial 
strains as seen by some phenolic compounds. Changes in bacterial composition should subsequently 
affect metabolite production from these food components. Dietary compounds can also influence the 
metabolite production by altering small intestinal absorption. This is seen in the case of viscous fibres.  
These two food components: polyphenols and fibre not only have the ability to alter the composition of 
colonic microbiota, but are both present in the same foods. Most studies have investigated the health 
benefits exhibited by each of these food components separately; however, their food matrix interaction 
is key to their ability to induce a beneficial health impact. Hence it is of great importance to determine 
if this food matrix interaction results in a synergistic combination of health benefits from fibre and 
polyphenols or if there is any inhibitory impact.  
Polyphenols in plants can be found either in the free form (extractable) or bound (non-extractable) to 
the protein and /or fibre components of the plants. The free polyphenols, which are easily extracted are 
usually low molecular weight phenolics while the high molecular weight polyphenols that are non-
extractable can be found both in the free and in the bound forms (Bravo et al., 1994, Saura-Calixto et 
al., 1991, Terrill et al., 1992). The importance of considering the amount of bound phenolics in food is 
not well known, thus most studies have not taken into consideration the presence of these polyphenols 
and their contribution to health in-vivo. In plant based foods these bound phenolics may be associated 
with dietary fibre and, similar to the fibre, they pass through the digestive system and reach the colon 
intact where they are subjected to microbial action (Perez-Jimenez et al., 2013). An example is longer 
chain proanthocyanidins that have shown a binding affinity towards plant cell walls which contain the 
dietary fibre pectin (Bazzocco et al., 2008, Le Bourvellec et al., 2007). The concentration of these 
bound polyphenolics can range from 26 mg/100g as measured in whole grain (Hatcher and Kruger, 
1997) to 1240 mg/100g in acai fruit (Rufino et al., 2011).  These would normally not be included in 
studies on health risks.   
Thus dietary fibres and polyphenols are not only consumed together in a diet as a result of 
simultaneous ingestion of a mixture of foods but they can also be found in a bound form in plant based 
foods, ensuring they both reach the colon. Once in the colon the bound polyphenols can be released 
from their food matrix (Perez-Jimenez et al., 2013) and can impart prebiotic or antibiotic properties on 
the colonic microbiota, which would subsequently impact the metabolism of other components of the 
food matrix which rely on the colonic bacteria for their metabolism.  
The chemical structure of carbohydrates makes a range of physiochemical properties possible, 
resulting in matrix interactions with other carbohydrates, fats, proteins and minerals. Carbohydrate rich 
 76 
 
foods, especially major dietary fibre sources, may contain anti-nutrient components such as phytic acid 
and tannins. Phytic acid has been shown to reduce the absorption of trace element such as zinc and 
copper by forming insoluble complexes through divalent cations (Gibson, 1994). Turnlund et al. (1984) 
demonstrated that the absorption of zinc was reduced from  34%  to 17.5% when 2.34 g of phytate was 
added. Furthermore when foods containing oxalate, such as cocoa or spinach are present with phytic 
acid and minerals, they form a fibre- nutrient-oxalate matrix, which is more difficult to breakdown than 
the fibre-nutrient or oxalate-nutrient bond alone. This was demonstrated in a 4 week study by Kelsay 
and Prather (1983) when volunteers were fed a high fibre -high oxalate diet (fruits/vegetable + 
spinach), low fibre-high oxalate diet (spinach) or high fibre-low oxalate diet (fruits/veg+ cauliflower). 
A negative apparent balance of Ca, Mg and zinc was reported when high fibre foods were added to 
high oxalate diets (p<0.05).   
Food matrix interactions involving polyphenols have been reported typically involving protein-
polyphenol binding and investigation of the impact of milk based products on bioavailability of 
polyphenols from food sources. Milk commonly consumed with cocoa in the form of cocoa beverage 
or milk chocolate on cocoa polyphenol bioavailability has shown controversial effects. 
Interest in the impact of milk on cocoa polyphenol bioavailability was initiated when Serafini et al. 
(2003) demonstrated that the increased plasma antioxidant levels [from 100± 3.5% to 118.4 ± 3.5% 
(p<0.01)] brought about by the consumption of 100g of dark chocolate was no longer observed when 
the cocoa was consumed along with 200ml of milk or as milk chocolate. Furthermore, the consumption 
of milk and milk chocolate also reduced the absorption of (-)–epicatechin (p<0.01). The antioxidant 
analysis of defatted dark cocoa and milk cocoa demonstrated that twice the quantity of milk chocolate 
needs to be consumed to match dark chocolate antioxidant levels.  
However, other studies such as Roura et al (2007) investigated the impact of milk on flavan-3-ol 
metabolites from 40g of cocoa (128umol flavan-3-ol monomers) consumed with milk or water in a 
crossover model (n=21) and found no significant effect on urinary excretion of metabolites. Similarly  
Keogh et al. (2007) investigated the impact of milk proteins on cocoa in the form of polyphenol 
extracts in a cross over study (n=24). They did not find a difference in average plasma polyphenols 
between no-milk cocoa beverage [2.7g polyphenols + 7g non-dairy creamer+7g sugar (33.4g powder) 
+ 200ml water] and milk cocoa beverage [2.7g polyphenols+ 7g skimmed milk powder (35% pr, 54% 
lactose), 2.5g cocoa butter and 4.5g sugar +200ml water]. The cocoa in this study contained 293 mg/g 
total flavanols, 50.8g of which were catechin+epicatechin (1:7). 
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Following the controversy created by these studies, Mullen et al (2009) investigated the impact of 10g 
of cocoa [45 umol (-)-epicatechin + (-)-catechin] consumed with hot milk vs. hot water for 9 volunteers 
in a cross over model. Four metabolites were detected in urine peak-1: (epi)catechin-O-sulphate (Rt 
15.5), peak-2: (-)-epicatechin-O-glucoronide (Rt 17.4), peak-3: this peak shared the same mass 
spectrum as peak-1 and thus it was identified as (epi)catechin-O-sulphate, however it eluted with a 
delay (Rt 18.6), peak-4: O-methyl-(epi)catechin-o-sulphate (Rt 22.1), and the two main metabolites 
identified in urine were also detected in plasma peak-3: (epi)catechin-O-sulphate (Rt 18.6) and peak-4: 
O-methyl-(epi)catechin-o-sulphate (Rt 22.1). When cocoa was consumed with water the combined 
urinary excretion of the metabolites for the 0–2-h (3938 ± 538 nmol vs. 2115 ± 323 nmol, p<0.01) and 
2–5-h (2690 ± 470 nmol vs. 1914 ± 322 nmol, P<0.05) was significantly higher for the cocoa-water 
beverage compared to the cocoa-milk beverage. However the impact of milk on plasma pharmokinetics 
was more modest compared to its impact on urine pharmokinetics. Milk extended the t1/2 of plasma 
(epi)catechin-O-sulphate from 1.5 ± 0.1 to 2.0 ± 0.2 h (P<0.05) and reduced AUC for plasma 
(epi)catechin-O-sulphate from 173 ± 27 to 135 ± 16 nmol· h/L. 
Studies using high concentrations of cocoa polyphenols reported no inhibitory impact of milk on the 
bioavailability of these phenolics, whereas studies using concentrations of polyphenols present in 
commercially available cocoa demonstrated an inhibitory impact.  Thus the impact of milk appears to 
be saturatable suggesting some sort of binding. 
Impact of milk- based foods have been seen for other polyphenol rich foods. The impact of milk on the 
bioavailability of tea polyphenols which are similar to those found in cocoa has also been a topic of 
interest. Reddy et al. (2005) demonstrated that the consumption of black tea (7g tea leaves in 350ml 
boiling water+ sugar with or without milk) resulted in significantly higher plasma catechin levels, the 
addition of milk to the tea reduced the catechin AUC (p<0.05). However the antioxidant capacity of tea 
did not change when milk was added, interestingly a correlation was found between plasma catechin 
levels and antioxidant potential only when tea was consumed without milk (p<0.01).  
Some studies have suggested that the brewing method of black tea may be of importance when 
considering the impact of milk on bioavailability of black tea. Kyle et al. (2007) tested the impact of 
infusion time of six different tea brands (3g tea leaves in 300ml boiling water with or without milk) 
with different infusion time: 3, 5, 7 and 10 minutes. The antioxidant capacity, total phenolics and 
catechin levels of plasma increased with infusion time and none of these results were affected by the 
addition of milk. Van der Burg-Koorevaar et al. (2011) also investigated the impact of brewing 
methods such as amount  of  milk and sugar on the catechin concentrations from 1 tea bag (Indian tea 
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and English tea in 170ml boiling water)  in an in-vitro simulation of digestion. 5.6% of milk resulted in 
a 59% recovery of total catechins whereas higher amounts of milk (15-40%) resulted in the 40% 
recovery. When sugar was added to 25% milk with English tea the impact of milk was no longer seen. 
The authors suggested that sucrose had a stabilising impact on the milk protein and catechin 
interaction.  However Keogh et al. (2007) did not demonstrate any impact of  2.45g of milk proteins on 
the bioavailability of catechins after the consumption of 2g of chocolate polyphenols, sugar and cocoa 
butter (in 200ml water). 
Most of the above studies have investigated the impact of milk on black tea which has a 3-fold lower 
concentration of catechins than green tea (van het Hof et al., 1998). The impact of milk on green and 
black tea was investigated by Leenen et al. (2000). Green tea increased plasma antioxidant capacity 
significantly more than black tea, however milk had no impact on the antioxidant capacity of either. 
Plasma catechins were not measured in this study. It may be that the plasma catechins were reduced 
but there was no impact on antioxidant capacity as seen by Reddy et al. (2005). 
Mullen et al. (2008) investigated the impact of cream on polyphenol bioavailability from strawberries. 
In this study cream delayed gastric emptying and small bowel transit time resulting in more than one 
hour delay in Tmax for pelargonidin-3-O-glucuronide but did not affect total absorption of this 
compound and its urinary excretion. If anything there was a trend for increased absorption probably 
due to the greater time in the small intestine.   
In a study on yoghurt and orange polyphenolics, there was no impact on plasma polyphenol levels or 
gastric emptying and mouth-caecum transit time (Mullen et al 2008) but the yoghurt appeared to delay 
the appearance of polyphenols in the first 5 hours after ingestion and reduced the amount of phenolic 
acids (sum of 5 phenolic acids identified as colonic metabolites) in urine tenfold (6.7 umol vs 62  
umol) (Roowi et al 2009).  The mechanism for this effect is unclear. 
 
  
Table 1-7 food matrix interactions 
Author year Study method  Measurements Findings comments 
(Serafini et 
al., 2003) 
Cross over study (n=12)- Milk on cocoa   
Dark chocolate and milk chocolate – defatted twice  
age 32.2 ±1.0 yrs,  weight of 65.8 ± 3.1 
BMI  21.9 ± 0.4 
100g dark chocolate with or without 200ml full fat milk, or 
200g milk chocolate (40ml milk) 
FRAP one 
hour after 
cocoa 
consumption 
Cocoa FRAP: 
Dark chocolate  147±4.5 , Milk chocolate 78.3 ± 3.4 
Plasma FRAP :  
Dark chocolate from 100 ± 3.5% to 118.4 ± 3.5% (p <0.01). returning to 
baseline after 4h 
No sig increase with milk or milk chocolate 
(-)-Epicatechin measurement  
Absorption was much less if cocoa was consumed with milk or as milk 
chocolate (p<0.001) 
 
(Roura et 
al., 2007) 
cross over – 1 week wash out (n=21) 
40g cocoa  [(–)-Ec 70.5 mg/100 g, procyanidin B 2 
63.75 mg/100 g, catechin 21 mg/100 g, and 5 mg/100 g of 
flavonols, 
including isoquercitrin, quercetin, quercetin-3-glucoside, 
and quercetin-3-arabinoside] +250ml water / milk  
LCMS-MS 
2 hours after 
cocoa 
consumption 
 
(–)-Ec-glucuronide was the only (–)-Ec metabolite detected, showing a 
mean (SD) plasma concentration of 330.44 nmol/l (156.1) and 273.7 
nmol/l (138.42) for CC-W and CC-M, respectively (p<0.01) 
 
(Keogh et 
al., 2007) 
N=24  
Age 50 – 65 yrs. BMI  18 – 30  
(i)-Milk- free beverage = 2.7g polyphenols + 7g non-dairy 
creamer +7g sugar  (33.4g powder) + 200ml water 
(ii)-Milk beverage: 2.7g polyphenols+ 7g skimmed milk 
powder (35% pr, 54% lactose), 2.5g cocoa butter and 4.5g 
sugar +200ml water 
Cocoa : total flavanols=293 mg/g catechin+epicatechin = 
50.8g (1:7~)  
HPLC-MS No impact of milk protein on average plasma polyphenol 
 
Milk protein significantly reduced Tmax  for epicatechin  with differences 
at 1 and 2 h (p<0.01) and marginally sig at 4h and 5h (p<0.05) 
Low polyphenol meal provided 4h after dosing  
 
Catechin was sig lower at 4h with milk powder (p<0.01) 
Skimmed 
milk used 
 
 
(Mullen et., 
al 2009 ) 
Cross over- Milk on cocoa (n=9) 
Age 20-43 yrs, Bmi 24.7 2.7  
1g paracetamol  
5g lactulose  
 
250ml cocoa drink with hot water or hot milk (250ml +10g 
green and blacks cocoa).  
Cocoa ( 45 umol (-)epicatechin and (-)catechin 
 
 
HPLC-MS  Gastric emptying and transit time not affected by milk  
2 metabolites in plasma and 4 in urine  
Minor effects on plasma pharmokinetics of (epi)catechin-o-sulphate and 
no effects on o-methyl-(epi)catechin-o-sulphate 
 
However milk sig decreased the excretion of 4 urinary metabolites from 
18.3% to 10.5% of ingested dose  
 
Urine: (epi)catechin-o-sulphate 
              (-)-epicatechin-o-glucoronide 
              (epi)catechin-o-sulphate 
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              o-methyl-(epi)catechin-o-sulphate 
plasma : (epi)catechin-o-sulphate 
              o-methyl-(epi)catechin-o-sulphate  
Plasma: significant effect on the Cmax for (epi)catechin-O-sulphate. 
significantly extend the t1/2 of (epi)catechin-O-sulphate from 1.5 ± 0.1 to 
2.0 ± 0.2 h (P = 0.02). Milk also significantly reduced the AUC for 
(epi)catechin-O-sulphate from 173 ± 27 to 135 ± 16 nmol · h/L 
Urine: the combined urinary excretion of the metabolites for the 0–2-h 
and 2–5-h samples was significantly higher for the cocoa-water drink 
than for the cocoa-milk beverage. These values were 3938 ± 538 nmol 
compared with 2115 ± 323 nmol for the 0–2-h samples (P< 0.01) and 
2690 ± 470 nmol compared with 1914 ± 322 nmol for the 2–5-h samples 
(P = 0.04) 
(Mullen et 
al.,2008)  
Acute in-vivo (n=8). 
Age:  23-48yrs and BMI= 23.7 ± 1.2  
5g lactulose+1g paracetamol +  
(i)-200g strawberries (222 µmol of pelargonidin-3-O-
glucoside)  or  
(ii)-200g strawberries + 100ml double cream 
HPLC-PDA-
MS2 analysis 
(urine and 
plasma) 
strawberry alone: Cmax of pelargonidin-3-O-glucoside  = 274 ± 24 
nmol/L and Tmax = 1.1 ± 0.4 h 
when strawberry+cream Cmax=  227 ± 35 nmol/L  and Tmax =  2.4 ± 0.5 h 
tmax significantly lower for the combination than strawberry alone 
(p<0.01) 
Cmax only significantly lower between 0-2 hours and only for hydroxyl 
cinnamis acid 
 
(Roowi et., 
al 2009) 
Acute in-vivo cross over (n=5) 
Age: 21 – 50 years, average BMI: 23.1  
orange juice fortified with 131 lmol of hesperetin-7-O-
rutinoside 
(i)- 250 ml orange juice (ii)250ml orange juice +150 ml full 
fat yoghurt (3.8%) (iii)- water  
Control group: (N=5)  
Age: 31 – 38 years of age, average BMI 30.9 ( 24.2 – 46.9) 
GCMS  
(urine) 
Phenolic acids produced:  3-HPAA, 3-hydroxyphenylhydracrylic acid, 
dihydroferulic acid, 3-methoxy-4-hydroxyphenylhydracrylic acid and 3-
HHA 
Total pheolic acid production from orange juice= 62 ± 18 μmol orange 
juice + yoghurt= 9.3 ± 4.4 , water=6.7 ± 1.8 μmol 
Yoghurt reduced total phenolic acid produced from orange juice (p<0.05 
 
No change in gastric emptying- mouth-caecum transit time 
Volunteers 
consuming 
water not 
same as other 
2 arms 
 
  
1.4.1 Impact of carbohydrates on polyphenol bioavailability 
The impact of carbohydrates on polyphenolic bioavailability depends not only on their physio-
chemical properties but also on the location in the gut of the interaction with other compounds 
(upper/lower digestive system). Previous studies have investigated the impact of simple carbohydrates 
such as sugars on the bioavailability of polyphenols. However sugars are mostly absorbed in the small 
intestine. The food matrix interaction between soluble fibres and polyphenols is more likely as soluble 
fibres retain their structure in the upper gut and they enter the colon together where they are subjected 
to degradation by the colonic microbiota. The possible impacts of fibre on the digestive system have 
been adapted from Edwards et al. (2012) and elucidated below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viscous soluble fibres such as ispaghula may impact polyphenol metabolism and phenolic acid 
production before and after these polyphenols reach the colon. The matrix formed by the viscous fibre 
may entrap the polyphenols in the upper gut making them less accessible for absorption. Hence greater 
 
 Reduced of intestinal 
mixing:  
-Slower absorption of 
nutrients 
-possible reduction in 
rate/extent  of absorption of 
non-nutrients, and nutrients   
-Reduced fat absorption 
-Reduced reabsorption of 
bile  
 Modification of Mouth-
caecum           transit time 
 
 
 SCFA production:  
-Increased cell proliferation 
-Stimulation of apoptosis  
-Increased absorption of water 
-Supply of energy for colonocytes  
-Promotion of gut health and gut 
healing 
-Reduced colonic pH:  
-Inhibition of 7α-dehydroxylase 
-Inhibition of production and 
absorption of ammonia 
-improved absorption of minerals 
such as calcium and magnesium 
Decreased cell proliferation 
 Reduced transit time: 
-Reduced exposure to toxins and 
carcinogens 
 Dilution of colonic contents 
-Dilution of toxins and carcinogens/ less 
exposure 
  
 
 
 Increased viscosity:  
-Modification of  gastric 
emptying  
-increased satiety 
 
Figure 1-10 Potential impact of fibre on the digestive system- Adapted from Edwards et al., (2012) 
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amounts of these polyphenols are transferred to the colon and excreted. Once in the colon, the impact 
will depend on the fermentability of the fibre.  Those mostly or completely fermented, such as pectin, 
may interact by altering bacterial activity (Scott et al., 2013) and changing pH whereas less 
fermentable fibres such as ispaghula dilute colonic content and decrease transit time (Edwards et al., 
2012). The latter may result in increased faecal excretion of phenolic and polyphenolic acids.  
1.4.1.1 The evidence:  
Few studies have investigated the impact of carbohydrates on bioavailability of cocoa polyphenols.  
Schramm et al (2003) investigated the effect of carbohydrates in the form of table sugar (0, 8.75, 17.5 
kj/kg body weight) and bread on the bioavailability of catechin and epicatechin of a flavanol rich, 
sugar free cocoa (0.125 g/kg body) mixed with water (2ml water /kg body weight).  Sugar increased 
Cmax and AUC of flavanols (p<0.05), also resulting in a faster rate of flavanol elimination (p<0.05). 
When cocoa was consumed with bread, the absorption AUC of flavanols increased from 3.3% to 4.4% 
resulting in an increased flavanol Cmax (p<0.05). The impact of whole milk and butter was also 
investigated, not displaying any interaction with flavanol bioavailability. Tmax was not affected by any 
food group.  
A similar study was conducted by Neilson et al (2009) investigating the impact of different matrices in 
the form of beverage and confectionary on epicatechin bioavailability in a 6h crossover model. These 
included dark chocolate (CDK), high sucrose (CHS), high milk protein (CMP) confections and sucrose 
milk protein (BSMP), non-nutritive sweetener milk protein (BNMP) cocoa beverages. All matrices 
contained 94 umol (-)-epicatechin and 32 umol catechin. There were no differences in AUC, Cmax or 
Tmax within the confectionary group or the beverage group. However, the beverage group had higher 
Cmax compared to the confectionary group (45 ± 4.3 BSMP, 41.6± 2.1 BNMP, 31.6± 2.8 CDK, 24.7 ± 
1.9 nM CMP) but not different from CHS (34 ± 3.3) as well as lower Tmax (0.9, 1.1 hours for beverage 
and 2.3, 1.8 and 2.3 for confections respectively); suggesting that the physical form of the cocoa could 
have an impact on the bioavailability of epicatechin (p<0.05). 
Renouf et al. (2010) demonstrated that the addition of non-dairy creamer and sugar or milk to coffee 
did not impact total absorption of metabolites as AUC did not differ between the 3 different arms of the 
study. However the addition of non-dairy creamer (containing vegetable fat but no lactose) did reduce 
the Cmax of hydroxycinnamic acid (p=0.039) and increase the Tmax of ferulic (p=0.009) and isoferulic 
acid (p=0.014). It is difficult to attribute this effect to the creamer or sugar content of the non-dairy 
creamer. The delay in Tmax may be due to the vegetable fat content of the creamer.  
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There are several hypotheses explaining the increased polyphenolic absorption aided by simple 
carbohydrates such as sugar in-vivo. Some of these include controlled cellular flavanol absorption by 
SGLT1 transporters and lactase phlorizin hydrolase enzymes (Gee et al., 2000). This was further 
demonstrated when specific quercetin glycosides were absorbed at a higher rate than their aglycones or 
diglycosides (Gee et al., 2000).  
In the colon, carbohydrates may impact on polyphenol metabolism by altering colonic bacterial 
activity. Jaganath et al. (2006) measured the colonic metabolism of 28 umol rutin or 55 umol quercetin 
or 18×10
6
 dpm of [4-
14
C]quercetin  with or without 0.5g of glucose. In this study the addition of 
glucose to faecal incubation vessels increased the extent of rutin deglycosilation and subsequent 
phenolic acid production. Interestingly this study demonstrated that the presence of glucose can alter 
the decomposition pathway and metabolite production. Glucose influenced the catabolic pathway by 
directing the conversion of 3,4-DHBA towards HPAA derivative production instead of 4-HBA 
production seen in the absence of glucose. Glucose was used to mimic the presence of fibre, most often 
present in the gut along with the polyphenol. Glucose is a common constituent of cellulose, beta glucan 
and other dietary fibres.  However, simple carbohydrates lack the physio-chemical properties of fibre 
such as viscosity and slower fermentation rates for less rapidly fermented soluble fibres such as  
ispaghula.  
Tzounis et al (2008) conducted a continuous in-vitro fermentation model incubating 150 mg/L or 1000 
mg/L of (+)-catechin and (-)-epicatechin in the presence or absence of sucrose and / or fructo-
oligosaccharides. Both catechin and epicatechin had a higher rate and total production of colonic 
bacterial metabolites in the presence of both sucrose and fructo-oligosaccharides. This was seen at 9 
and 10 hours after incubation for (-)-epicatechin (p<0.01) and at 4 (p<0.01), 8 and 10 hours (p<0.01) 
for catechin. 
Unfortunately there is not much evidence on the impact of soluble fibre on the bioavailability of 
polyphenols and phenolic acid production from these compounds. In a study by Bazzocco et al. (2008) 
two different apple varieties were used: Marie-mernard apples contain short chain proanthocyanidins 
and avrolle apples containing long chain procyanidins. The freeze-dried apples were digested and 
incubated in a faecal fermentation model, additionally the respective cider and proanthocyanidin 
extracts of the relevant apples were incubated separately. The proanthocyanidn extract of avrolle 
apples was also incubated along with 100mg of cell wall preparation containing pectin. The prominent 
phenolic acids produced from these apple proanthocyanidins were found to be 3,4-DHPPA followed by 
HPPA, 3-PPA, BA, 3,4-DHPAA and 3-HPAA. There was no phenolic acid production from cell wall 
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preparations alone. When cell wall preparations were added to proanthocyanidin extract incubation the 
maximal extent of conversion was delayed from 4 hours to 8hours post incubation. However, there was 
no difference in the total concentration of phenolic acid production. Additionally the maximum extent 
of conversion for marie-mernard apples was much later (6hours) as compared to their 
proanthocyanidin extracts (2hours). This study also demonstrated that the maximum conversion and 
proanthocyanidins occurred in cider samples having the shortest proanthocyanidin chains.  
While simple sugars and prebiotics can enhance the deglycosilation of parent compounds reaching the 
colon and increase phenolic acid production, there is not enough evidence on the impact of more 
complex carbohydrates such as soluble fibres on phenolic acid production from polyphenols.  
 
 
 
  
 
Table 1-8 Impact of carbohydrates on polyphenol bioavailability 
Author 
year 
Study method  Measurements Findings comments 
(Schramm 
et al., 2003) 
 cross over study- in-vivo (n=6) 
Study-1 :  effect of table sugar 
sugar (0, 8.75, 17.5 kj/kg body weight) + 0.125 sugar free 
flavanol rich cocoa (in 2ml water /kg body weight) 
 
Study-2:  effect of nutrient rich foods 
Better, bread, steak  and water ( 8.75, 17.5 and 8 ml/kg 
body weight) + 0.125 sugar free flavanol rich cocoa (in 2ml 
water /kg body weight) 
 
Study-3: effect of miscellaneous foods 
Water, bread, grapefruit juice, whole milk ( 8.75, 17.5 and 
8 ml/kg body weight) + 0.125 sugar free flavanol rich 
cocoa (in 2ml water /kg body weight) 
 
Study-4: effect of Famotidine 
(a) Water and cocoa  
(b) Water, cocoa and 20mg famotidine (1h before 
water and cocoa) 
HPLC of non-
(plasma) 
 
Plasma 
antioxidant 
capacity 
Study-1:  
Sugar ↑ plasma Cmax (8.75 kj/kg) and ↑  plasma AUC (8.75 and 17.5 
kj/kg) As well as faster rate of flavanol elimination (E1/2: 8.75 and 17.5 
KJ/KG)  P <0.05 
 
Study-2 CHO rich foods increased flavanol absorption 
% of flavanol absorption 
Cocoa alone 3.3% 
+bread 4.4%  ↑ AUC and ↑Cmax p<0.05 
+steak 3.1%  ↑ E1/2 p<0.05 
+butter 3.7%  
 
Study-3 
Cocoa alone  
+bread  ↑ AUC and ↑Cmax ↑ E1/2 p<0.05 
+milk - 
+grape juice  ↑ AUC ↑ E1/2 p<0.05 
 
Study-4 
No effects on flavanols  
No correlation between ability of foods to buffer pH and flavanols 
Correlation between CHO content of foods and flavanol absorption  
r=0.83 p<0.02 
No changes in 
Tmax 
However their 
data points 
were limited 
which could 
have lost 
sensitivity to 
Tmax 
 
Displayed 
very large 
STDEV 
(Neilson et 
al., 2009) 
Study-1  
In-vivo N=6 (3male, 3 female) cross over  
7 day wash out  
Mean age: 23.8 ± 1.7 
Mean BMI: 25.5 ± 0.7 
40g Confections: -dark chocolate – high sucrose – high 
milk protein 
250 ml Beverage: -sucrose milk protein – non-nutritive 
sweetener milk protein (solid ingredients dissolved in 
HPLC 
(plasma) 
 
Higher bioavailability from cocoa beverages than chocolates  
High sucrose slightly increased epicat AUC but not significantly and 
milk proteins slightly reduced epicat AUC but not significantly 
 
NO difference in bioavailability within groups but the state in which the 
cocoa was consumed resulted in a difference in epicat bioavailability 
(p<0.05) 
Tmax lower for beverage than confections but not significant 
 
Limited time 
points  
Milk protein 
limits 
bioavailability 
while sucrose 
increases 
based on 
cmax this was 
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water and consumed) 
 
Cocoa = 36mg cat+epicat 
 
Study-2 
In-vitro 
digestion 
No difference in Tmax between groups 
 
Cmax sig higher for beverages p<0.05 than confections (45 ± 4.3 BSMP , 
41.6± 2.1 BNMP 31.6± 2.8 CDK 24.7 ± 1.9 nM CMP  but not different 
from CHS ( 34 ± 3.3 )    
Sucrose slightly increased Cmax  
CHS higher Cmax than CMP 
seen in the 
confections 
but not 
beverages 
Renouf et al 
(2010) 
Acute in-vivo cross over (n=9)  
Age 21-50 yrs 
(i)-4g soluble instant coffee+400ml water 
(ii)- 4g soluble instant coffee+360ml water+40ml whole 
milk 
(iii)- 30.5 g premixed instant coffee with sugar and non-
dairy creamer =4 g of instant coffee 
4g coffee =335 mg (900 μmol) of total chlorogenic acid 
ingested  
LCMS 
(plasma) 
No difference in AUC for coffee ± milk or NDC/sugar 
No impact of milk on Cmax and Tmax 
Non-dairy creamer reduced Cmax of Hydroxycinnamic acid (p<0.01) and  
isoferulic acid (p= 0.02).  
Non-dairy creamer reduced Increase Tmax for ferulic (p<0.01) and 
isoferulic (P=0.01). 
 
     
Jaganath 
(2006) 
In-vitro fermentation  
N=3 
(i) 28 umol rutin  (ii) 55 umol quercetin or (iii) 18×106 
dpm of [4-14C]quercetin + / - 0.5g  glucose  
HPLC-PDA-
MS2 analysis 
of phenolic 
acids 
Phenolic acids:  3,4-DHPAA >  3-HPAA, 3,4-DHBA, 4-HBA, 3-HPPA 
-presence of glucose enhanced deglycosilation of rutin 
-presence of glucose increased phenolic acid production 
  
3,4-DHPAA 
appeared @ 
2h  
3-HPAA @ 
24h 
(Bazzocco 
et al., 2008) 
 Digestion followed by in-vitro fermentation 
Experiment-1  (n=4) 
(i)-100mg Marie-mernard apples – short PA chains 
(ii)-25mg of Proanthocyanidin extract from Marie-mernard 
apples 
(iii)-100mg cider 
(iv)- 100mg of Cell wall preparation containing pectin 
 
Experiment-2 
 (i)-100mg Avrolle apples- long PA chains 25mg or 100mg 
(ii)-25mg proanthocyanidin extract  
Phenolic acids 
SCFA 
production 
Marie mernard apples more microbial metabolites than avrolle 
Phenolics produced = 3,4-DHPPA > 3-HPPA, 3-PPA, BA, 3,4-DHPAA, 
3-HPAA.   Primary metabolite =3,4-DHPPA 
↑BA from pre digested apples than non-digested 
↑ phenyl acetic acid from non-digested than digested 
 
Cider with the shortest PA had the highest profile of PPr, PA 
BA for cider was lower than that of digested apple 
Cider had the most extent of conversion (44% for avrolle cider and 62% 
for marie.m cider) 
 
Differences 
between 
benzoic acid 
and phenyl 
acetic acid 
between 
digested and 
non-digested 
apples. 
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(iii)-25m 25mg proanthocyanidin extract + 100mg cell wall 
preparation 
(iv)-100mg cider 
(v)-100mg of Cell wall preparation containing pectin 
 
Maximal extent was reached much later (6-8h) with the marie.m apples 
than the extracts (2h) 
when PA from avrolle.p was fermented with cell wall preparation the 
maximal extent was much later (8h) compared to when they were 
fermented alone (4h) 
No phenolic acid produced from cell wall preparations. 
Tzounis et 
al  
(2008)  
In-vitro fermentation   (pH controlled stirred batch-culture) 
(N=3) 
(i)-[FS + (+)-catechin (150mg/L or 1000 mg/L)] ± 1% 
(w/v) sucrose or FOS  
(ii)-[FS + (-)-epicatechin (150mg/L or 1000 mg/L)]± 1% 
(w/v) sucrose or FOS  
 (-)-epicatechin bacterial metabolism was much higher in the presence of 
both sucrose and FOS at 8 and 10h (p<0.01). 
(+)-catechin bacterial metabolism was much higher in the presence of 
both sucrose and FOS at 4 (p<0.01), 8 and 10h (p<0.01). 
 
volunteers 
were not put 
on low 
polyphenol 
diet 
Neilson et 
al., 2009) 
Study-2 
In-vitro followed by digestion 
 
Matrices were diluted to provide equivalent of one serving 
as the in-vivo study 
Confections were melted at 50 C for 15 mins to mimic the 
melting and chewing process. 
 Influence of product matrix on flavan-3-ol bioavailability was modest 
 
Sig differences seen between relative rate of absorption (Tmax) and Cmax 
of epicatechin seen between beverages and confections  
 
No differences in EC recovery from beverages or confections but C had 
sig higher recovery from beverages than from confections.  
 
Recovery for 
EC similar in 
all forms but 
different for C  
Hence the 
physical form 
might not 
have an 
impact on EC 
but might 
affect C  
 
  
1.4.2 Impact of polyphenols on fibre  
The composition and activity of the microbiota is the main influencing factor in the health benefits 
induced by fibre and polyphenols reaching the colon; as the microbiota‘s capacity to ferment and 
metabolise compounds determines the final metabolite products, their bioavailability and their impact 
on human health. 
In addition to all other health benefits induced by polyphenols they have also demonstrated 
antibacterial activity. This property of polyphenols may indirectly impact their own bioavailability as 
well as the bioavailability of active metabolites from compounds such as soluble fibre. However most 
evidence of this property of polyphenols has been obtained from studies conducted on specific 
pathogenic bacteria in-vitro rather than complex ecosystems such as that in the colon a clear 
understanding of their ability to impact the complex gut microbiota and the mechanism behind this 
antimicrobial property is needed (Duda-Chodak, 2012). 
1.4.2.1 Mechanism of action 
There have been many hypotheses on the mechanisms of the antimicrobial actions of polyphenols. The 
lack of consistency in the proposed mechanisms is due to the large family of polyphenols and the 
structural minor structural differences among them, resulting in different mechanisms of action. Most 
studies have investigated the impact of 1-2 compounds of a certain polyphenol sub-group. 
A general hypothesis that could be applicable to most polyphenolic compounds is that polyphenols 
bind to bacterial cell membranes, thus disrupting membrane function and inhibiting cell growth (Sirk et 
al., 2009). It has also been suggested that the antimicrobial property may be attributed to the ability of 
polyphenols to form strong bonds with heavy metals. As bacteria contain metalloenzymes it is possible 
that this interaction of polyphenols with heavy metals causes inhibition of enzymes, and impairment of 
ion channels. The deficiency in available iron in the gut may affect certain sensitive bacterial species. 
The mechanisms of action proposed from 1987-2004 have been reviewed by Cushnie and Lamb 
(2005), summarising three possible mechanism of action:  
 Damage of cytoplasmic membrane caused by perforation and/ or reduction in the fluidity of 
the membrane (Ikigai et al., 1993, Tsuchiya and Iinuma, 2000). 
 Nucleic acid synthesis inhibition caused by the inhibition of topoisomerase  (Mori et al., 1987, 
Bernard et al., 1997, Plaper et al., 2003). 
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 Energy metabolism inhibition caused by the inhibition of NADH-cytochrome c reductase 
(Haraguchi et al., 1998). 
Since 2005 more studies have been presented supporting the mechanisms summarised by Cushnie and 
Lamb. (2005). These include damage of cytoplasmic membrane by the flavan-3-ols, flavonol and 
flavonal, inhibition of nucleic acids by flavan-3-ols and isoflavones as well as inhibition of energy 
metabolism by the flavan-3-ol and flavanol group.  In addition inhibition of cell wall synthesis and the 
inhibition of cell membrane synthesis have also been proposed (Cushnie and Lamb, 2011). Some 
compound specific mechanisms of action have also been proposed such as enzyme inhibition and 
reactive oxygen generation for epigallocatechin gallate and the inhibition of DNA gyrase by quercetin 
have been proposed (Cushnie and Lamb, 2005). 
The evidence provided could suggest that polyophenolic compounds either have several methods of 
action or that the method of action is dependent on the structure of the compound.  
1.4.2.2 Impact of compound structure  
Duda Chodak. (2012) demonstrated that the aglycone quercetin had a strong antimicrobial impact, 
while the aglycone catechin did not demonstrate much antimicrobial ability. This was attributed to the 
double bond between C2-C3 and presence of a carbonyl group in quercetin. However, the flavanones 
hesperetin and naringenin having a saturated C-ring also exhibited antimicrobial activity, these 
flavanones also contain a carbonyl group. Hence, it can be postulated that the carbonyl group is 
responsible for the antimicrobial activity of these compounds. Interestingly it has been shown that the 
presence of a carboxyl group on C4 of the A-ring of chalcones increases their aqueous solubility by 60 
folds without affecting their antimicrobial activity, additionally the hydroxylation at position 2 of their 
A-ring is a determining factor in their antimicrobial properties, however these have been attributed to 
their increased structural stability (Nielsen et al., 2004, Ávila et al., 2008). Batovska et al. (2009) 
demonstrated that even though the presence of a hydroxyl group on the C-4 of the B-ring could be 
important, it is not sufficient for the antimicrobial action and the presence of this hydroxyl group on the 
A ring is the determining factor. Other studies have demonstrated that in the case of flavones the 
presence of O-acyl or O-alkylamino chain on the C-7, and hydroxylation at C-5 of the A-ring enhance 
the antimicrobial activity (Li et al., 2009, Suresh Babu et al., 2006). The same was seen for the 
presence of O-acyl or O-alkylamino chain on the C-3 of the C-ring for flavan-3-ols and flavonols (Park 
and Cho, 2010, Ávila et al., 2008, Otsuka et al., 2008). It was also found that the antimicrobial activity 
of flavones can be improved by replacing the oxygen atom at C-4 with nitrogen or sulphur (Ullah 
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Mughal et al., 2006). These structure-related enhancements in antimicrobial activity have lead many 
researchers to modify the structure of polyphenols in order to use them as strong antimicrobial agents. 
However the discussion of these modifications and their implications are beyond the scope of this PhD. 
The use of natural compounds such as polyphenols as antibiotics is becoming increasingly important in 
the light of antibiotic resistance of many bacterial species.  
1.4.2.3 The evidence:  
The antimicrobial properties discussed above cannot be generalised to all polyphenol categories. Duda 
Chodak et al. (2005) investigated the impact of various polyphenols on in-vitro cultures of individual 
bacteria representing the gut microbiota (Table 1-9). While the aglycones inhibited bacterial growth, 
this was not true for their glycosidic forms.  Rutin had no effect but quercetin inhibited growth of all 
bacterial species tested at concentrations as low as 20 ug/ml. The authors stated then that the 
glycosidated polyphenol would have no effect but of course in the colon, rutin is first degraded to 
quercetin which would have antibacterial effects even though its presence may be short lived. It is 
unlikely however that many polyphenol aglycones are present in the gut as they are ingested mainly in 
conjugated forms. While the glycosides demonstrated an inhibitory impact on certain strains of 
bacteria, this was seen at MIC ≥ 250 ug/ml. Only compounds demonstrating MIC ≤ 100 are 
considered noteworthy and those demonstrating MIC ≤ 10 are of great interest (Rios and Recio, 2005).  
In a study (Tzounis et al., 2008a) the impact of catechin and epicatechin at concentrations of 150 mg/L 
and 1000 mg/L were investigated in an in-vitro fermentation model with or without the addition of 1% 
(w/v) sucrose / FOS. Even though there were no differences in the total bacterial count it was found 
that (-)-epicatechin increased the number of Eubacterium rectale-C at 150 mg/L only, while (+)-
catechin increased the growth of Lactobacillus spp. and Bifidobacterium spp. at 150 mg/L and 
coccoides-Eubacterium rectale at both150 and 1000 mg/L. (+)-catechin was also found to inhibit the 
growth of C. histolyticum group at 1000 mg/L. Although authors have stated that these polyphenolics 
may have a prebiotic impact, the increase in bacterial species was seen only at lower concentrations of 
150 mg/l. and a possible explanation for this could be that the inhibition of other bacterial species 
allowed the these species to grow more, as the total number of bacteria remained constant. 
Additionally higher concentrations demonstrated an inhibitory and not prebiotic impact on the bacterial 
growth.  
The same authors (2011) carried out an in-vivo study comparing the impact of a high polyphenol cocoa 
supplementation (494 mg cocoa flavanols/day) to a low polyphenol cocoa supplementation (23 mg 
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cocoa flavanols/day) for four weeks, collecting faecal samples before and after interventions and 
measuring bacterial growth. Supporting their previous study, they found no change in total bacterial 
count while the high polyphenol cocoa diet resulted in the increase of selective bacterial species: 
lactobacillus and Enteroccocus (p<0.01) for both diets, Bifidobacteria (p<0.01) only for the high 
flavanol cocoa diet and a reduction in C. histolyticum counts (p<0.001). Furthermore this study found a 
reduction in TAG and CRP levels after cocoa supplementation. Interestingly the reduction in CRP 
values was inversely related to the Lactobacillus spp. count (p<0.05, R
2
= -0.33). This study suggests 
that the long-term consumption of cocoa can have a prebiotic impact on the gut microflora. However it 
is important to note that cocoa products contain relatively high fibre content and it is difficult to 
separate the polyphenol or fibre content of the cocoa as being responsible for these observations. These 
results were supported in a study by Parkar et al. (2008) investigating the impact of various 
polyphenolics at a concentration of 62.5-1000 ug/m on 4 different bacterial strains: Escherichia coli, 
Staphylococcus aureus , Salmonella typhimurium, Lactobacillus rhamnosus. This study did not 
demonstrate any antibacterial impact of the glycosides rutin or phloridzin, while quercetin and 
naringenin had the lowest MIC for all bacterial strains. Catechin and epicatechin demonstrated the 
same MIC for all bacterial strains except for L.rhamnosus, with catechin having an MIC of ≤ 250 
ug/ml and epicatechin requiring a higher concentration of 500 ug/ml. The MIC of the polyphenols was 
compared to that of Gentamicin.   L. rhamnosus demonstrated less sensitivity to the polyphenol and 
Gentamicin, requiring higher MIC. Thus it is possible that this probiotic may be less affected by 
polyphenols in the gut. The lowest antimicrobial impact was seen for isoflavones, flavonols and 
glycosides while phenolic acids had an intermediate impact. Unlike the previous study, this study did 
not find any structural association with antimicrobial activity, with the exception of glycosilation, 
which is not of relevance in in-vivo studies as discussed before. The lack of structure–growth inhibition  
association was also demonstrated in a study by Lee et al. (2006) investigating the impact of tea 
polyphenols and their colonic phenolic acid derivatives (epicatechin, catechin, 3-O-methyl gallic acid, 
gallic acid and caffeic acid, 3-PPA,  4-HPAA, 4-HPPA) on 28 colonic microbiota species. The results 
of this study supported previous studies demonstrating a general inhibition of pathogenic bacteria 
(Clostridium perfrigens, Clostridium difficile and Bacteroides. spp) especially by the phenolic acid 
derivatives and a small to no impact on the commensal and probiotic bacteria (as Clostridium spp, 
Bifidobacterium spp and Lactobacillus spp).  
Most of the above studies have investigated the impact of polyphenolic compounds in-vitro and very 
little is known on their impact after long-term consumption. Interestingly a study by Smith and Mackie 
(2004) demonstrated that long term (3.5 weeks) consumption of 0.7% and 2% proanthocyanidins in 
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rats significantly increased the number of tannin resistant bacteria from 0.3% ±5.5% to 25.3%± 8.3% 
and from 0.3% ±5.5% to 47.2%± 5.1% respectively (p<0.05), while gram-positive bacteria decreased 
in the presence of the proanthocyanidins. The post-proanthocyanidin diet analysis of faecal bacteria 
demonstrated a return of tannin resistant bacteria to pre-treatment numbers.  
Even though polyphenols demonstrated an anti-bacterial impact, they are mostly consumed as food 
components and not as independent compounds. In a study investigating the impact of (10% w/w) 
cocoa on faecal microbiota of wistar rats, a reduction in Bacteroides, Clostridium and Staphylococcus 
(p<0.05), without the total bacterial count being affected, was observed. In addition the cocoa diet 
resulted in a lower body weight (p<0.01), which was correlated to the reduction of Clostridium species. 
There was no difference in food consumption between the two groups (Massot-Cladera et al., 2012).  
None of the above studies have investigated the impact of this antimicrobial activity on metabolite 
production from the colonic bacteria. Kemperman et al. (2013) investigated the impact of 1000 mg/day 
of tea extract polyphenols on the growth of gut microbiota and their metabolite production for 2 weeks 
in a Simulator of Human Intestinal Microbial Ecosystem (SHIME). In addition to the antimicrobial 
activity seen by tea extract, a reduction in butyrate concentration was demonstrated, which was 
attributed to the inhibition of butyrate producing bacteria. This was accompanied by an initial increase 
in acetate concentration. Towards the end of the study a drastic reduction in total SCFA and acetate 
concentration was demonstrated. This reduction in SCFA production corresponded to reduction in 
bacterial numbers observed.  Even though this in-vitro model is ideal for studying the longer-term 
impact of polyphenols on gut bacteria in-vitro, there is still a lack of other factors such as host-bacteria 
interrelationship and presence of other influencing food matrix interactions.  
Etxeberria et al. (2013) extensively reviewed the previous evidence (in-vitro and in-vivo) on the impact 
of various food sources and food extracts, as well as pure compounds on bacterial populations which is 
not the core of this PhD. They elucidated the variation in antibacterial properties of different 
polyphenolic compounds as well as the variation in sensitivity to polyphenolic compounds by the 
bacterial populations. Polyphenolic compounds demonstrated an antimicrobial impact especially 
towards pathogenic bacteria both in-vitro and in-vivo, with less impact on the commensal bacteria. 
However, the authors concluded that the implications of these changes as well as the interaction of 
these polyphenolic compounds with other compounds in-vivo or in-vitro have not been sufficiently 
investigated and understood. 
. 
  
Table 1-9 Antibacterial activity of polyphenolics 
Author year Study method  Measurements Findings comments 
(Arima et 
al., 2002) 
In-vitro 
Incubated Bacillus cereus and Salmonella enteritidis with 
or without Quercetin, Quercitrin, Rutin, Kaempherol, 
Morin, Thymidine and Uridine 
Growth of 
bacteria 
measured by 
paper disk 
method  
Quercetin and morin inhibited growth at 100 ug/disk and  
Rutin no inhibitory impact even at 400 ug/disk or at concentration 1000 
ug/ml 
 
MIC of quercetin on S. enteritidis and B.cereus alone = 250 ug/ml and 
350 mg/ml 
 
MIC of quercetin+ Rutin on S. enteritidis and B.cereus alone = 100 
ug/ml and 200 mg/ml 
 
MIC of morin or kaempherol on S. enteritidis and B.cereus alone = (150 
and 400 ug/ml) and (300 and 800) mg/ml 
 
MIC of morin or kaempherol + Rutin on S. enteritidis and B.cereus alone 
= (50 and 150 ug/ml) and (100 and 400) mg/ml 
 
 
(Smith and 
Mackie, 
2004) 
In-vivo long term  
Adult wistar rats (n=18) 
Proanthocyanidins extracted from A.angustissima added to 
the diet at concentrations of 0.7% And 2% for 3.5 weeks 
 
Faecal samples collected weekly. 
DNA 
fingerprinting 
of bacterial 
populations 
Increase in both total bacterial count and  tannin-resistant bacterial count 
 
0.7% proanthocyanidin diet: increase in tannin resistant bacteria from 
0.3% ±5.5% to 25.3%± 8.3% p<0.05) 
 
2% proanthocyanidin diet: increase in tannin resistant bacteria from 0.3% 
±5.5% to 47.2%± 5.1%  (p<0.05) 
 
 
 
(Vaquero et 
al., 2007) 
In-vitro 
Bacteria obtained from human source: Escherichia coli, 
Proteus mirabilis, Serratia marcescens, Flavobacterium sp. 
and Klebsiella pneumonia  
Incubated along with 5, 10, 25, 50, 100, 200, 500 and 1000 
ug/ml of Gallic, Vanillic, Protocatechuic, caffeic acids, 
Rutin, Quercetin, Catechin.  
Agar diffusion 
test 
-Rutin: weak impact on S.marcescens with  MIC > 10 ug/ml and 
moderate impact on E.coli with MIC > 25 
 
-Quercetin: strong impact on S.marcescens, P.mirabilis, E.coli and 
K.pneaumoniae at MIC> 2, 10 and 25 respectively  
 
-Catechin: moderate impact on S.marcescens and E.coli with  MIC > 100 
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(+)-control: Chloramphenicol and (-)-control:ethanol and 50 ug/ml respectively. Strong impact on P.mirabilis MIC > 500 
 
The phenolic acids only had a weak to moderate impact on E.coli (MIC> 
25-50) and a moderate to strong impact on K.pneumoniae (Gallic and 
Vanillic acid only) with MIC> 10 ug/ml 
(Lee et al., 
2006) 
In-vitro incubation  
28 strains of pathogenic and prebiotic strains (5% 
inoculum) incubated in a broth with or without 1% 
polyphenol extracts of tea: epicatechin, catechin, 3-O-
methyl gallic acid, gallic acid and caffeic acid, 3-PPA,  4-
HPAA, 4-HPPA 
 
Monitoring 
growth of 
bacteria using 
spectrophoto
metry  
The growth of pathogenic bacteria such as Clostridium perfrigens, 
Clostridium difficile and Bacteroides spp was inhibited especially by the 
phenolic acid derivatives.  
 
Commensal anaerobes and probiotics such as Clostridium spp, 
Bifidobacterium spp and Lactobacillius not affected much. 
 
Caffeic acid had the strongest inhibition especially for E. coli, 
Salmonella, Pseudomonas, Clostridium and Bacteroides.  
 
(Tzounis et 
al., 2008a)  
In-vitro fermentation   (pH controlled stirred batch-culture) 
N=3 
(i)-[FS + (+)-catechin (150mg/L or 1000 mg/L)] ± 1% 
(w/v) sucrose or FOS  
(ii)-[FS + (-)-epicatechin (150mg/L or 1000 mg/L)]± 1% 
(w/v) sucrose or FOS  
 
FISH Impact of (-)-epicatechin 
↑ Eubacterium rectale-C at 150 mg/L only 
 
Impact of (+)-catechin: 
↓C. histolyticum group (1000 mg/L) 
↑C. coccoides-Eubacterium rectale (150 and 1000 mg/L) 
↑ Lactobacillus spp. And Bifidobacterium spp (150 mg/L) 
 
No difference in total number of bacteria. 
 
-volunteers 
were not put 
on low 
polyphenol 
diet 
(Parkar et 
al., 2008) 
In-vitro incubation of bacteria with polyphenols  
Representative of gut microbiota: Escherichia coli, 
Staphylococcus aureus , Salmonella typhimurium , 
Lactobacillus rhamnosus . bacterial suspension (50 µl, 
1 × 105 cfu/ml) 
Polyphenols : caffeic acid, chlorogenic acid, o-coumaric 
acid, p-coumaric acid, catechin ,  epicatechin, phloridzin, 
rutin, quercetin, naringenin, daidzein and genistein at a 
concentration ranging from 62.5-1000 ug/ml 
Bacterial 
viability 
tested using 
broth micro-
dilution 
method 
All polyohenols except rutin had an inhibitory impact on bacteria at 
different MIC. Phloridzin only inhibited Staphylococcus aureus at MIC 
125 ug/ml 
Quercetin and naringenin had the lowest MIC varying depending on 
bacterial strain. 
Required MIC (ug/ml):  
-Escherichia coli, catechin=1000, epicatechin=1000, rutin>1000, 
quercetin=125, Gentamicin=8 
-Staphylococcus aureus catechin=125, epicatechin=125, rutin>1000, 
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quercetin=62.5, Gentamicin=1 
-Salmonella typhimurium catechin=1000, epicatechin=1000, rutin>1000, 
quercetin=125, Gentamicin=8 
-Lactobacillus rhamnosus catechin ≤ 250, epicatechin=500, rutin>1000, 
quercetin=250, Gentamicin=32 
(Vaquero et 
al., 2007) 
In-vitro incubation  
Escherichia coli ATCC 35218 tested against  
50 or 100 ug/ml of Gallic, Protocatechuic, Vanillic, Caffeic 
acids, Rutin, Quercetin and Catechin in 99.8% ethanol 
(ethanol added to all media toobtain 5% (v/v) 
 
Control: media + 5% ethanol 
Bacterial 
growth 
measured in a 
microplate 
reader 
-Quercetin allowed the least growth at 50 and 100 ug/ml (0.44±0.05 and 
0.19±0.02) having the most growth reduction (1.91 and 2.16 
respectively) 
-Rutin allowed for growth at 50 and 100 ug/ml (1.12±0.07 and 0.7 ±0.05) 
having the growth reduction 1.23 and 1.65 respectively 
-catechin had the most growth of flavonoids at 50 and 100 ug/ml 
(1.4±0.09 and 1.31 ±1.04) having the growth reduction 0.95 and 1.04 
cfu/ml respectively) 
- Gallic acid: growth at 50 and 100 ug/ml : 1.77±0.08 and 1.4 ±0.09 
having the growth reduction 0.58 and 0.95 cfu/ml respectively 
- protocatechuic acid: growth at 50 and 100 ug/ml : 2.05±0.09 and 1.8 
±0.08 having the growth reduction 0.3 and 0.55 (cfu/ml) respectively 
- vanillic acid: growth at 50 and 100 ug/ml : 2.2±0.07 and 2.08 ±0.05 
having the growth reduction 0.15 and 0.27 cfu/ml respectively 
- caffeic acid: growth at 50 and 100 ug/ml : 0.85±0.05 and 0.2 ±0.03 
having the growth reduction 1.5 and 2.15 cfu/ml respectively 
 When rutin and quercetin were mixed their impact was synergistic, when 
rutin and catechin were mixed their impact was additive 
 
(Tzounis et 
al., 2011) 
N=22 healthy humans (12 men, 10 women, 30.2 ± 11yr, 
BMI 23.2 ± 2.5) 
Faecal samples collected before and after  
(i)-High cocoa flavanol diet (494 mg cocoa flavanols/d) or 
(ii)-Low cocoa flavanol diet (23 mg cocoa flavanols/d) for 
4 weeks + 4 weeks washout period 
FISH ↑ lactobacillus and Enteroccocus (p<0.01) 
↑ Bifidobacteia post intervention (p<0.01) only for HFC 
↓ C.Histolyticum counts (p<0.01)  
↓ TAG and CRP (p<0.05) 
↓ lactobacilli ≈ ↓CRP (p<0.05, R2= -0.33) 
No change in total bacterial count, bacteroides or Ecoli 
drinks 
matched for 
fibre 
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Batch culture fermentation was conducted with 10g Faeces 
(with 10ml phosphate buffer) 
Cocoa contained <1% overall fibre (10mg/ml) 
 
(Duda-
Chodak, 
2012) 
Bacterial culture of microbiota representatives were used in 
a bacterial suspension of 1.5×108 units/ml: Bacteroides 
galacturonics, Lactobacillus sp, Enterococcus caccae, 
Bifidibacterium catenulatum,  Ruminococcus gauvereauii, 
Escherichia coli were used in a bacterial suspension of 
1.5×108 units/ml 
 
Impact of 20, 200, 250 ug/ml of naringenin, naringin, 
hesperetin, hesperidin, rutin, catechin and 4,20, 50 ug/ml 
ug/ml quercetin on 1ml of bacterial suspension after 24 
hours of incubation at 37 C 
Measurement 
of turbidity 
Quercetin MIC ≥ 50 for all species except for Ruminococcus gauvereauii 
at 20 ug/ml 
 
Rutin, no inhibitory impact except for Enterococcus caccae and 
Ruminococcus gauvereauii at MIC > 250 ug/ml  
 
Catechin: inhibitory impact only for Bifidibacterium catenulatum at  
MIC > 250 ug/ml 
Naringenin inhibition of all species at  MIC ≥ 250 ug/ml 
Nringin: no inhibitory impact  
Hesperidin: no inhibitory impact  
Hesperetin minimum inhibitory impact at ≥ 250 ug/ml except for 
Lactobacillus sp. 
Aglycones 
had an impact 
but glycosides 
didn‘t 
 
 
(Massot-
Cladera et 
al., 2012) 
Female wistar rats (n= )  
Cocoa enriched diets [10% (w/w)] containing 10.62 mg/g 
polyphenols for 6 weeks 
Faecal samples collected before and after 6 weeks.  
 FISH - FCM Total bacterial count not affected but there was a reduction in 
Bacteroides, Clostridium and Staphylococcus(p<0.05) 
Body weight significantly lower (p<0.01) for cocoa diet 
(167.36 ± 0.40 g) compared to control group 193.84 ± 0.25 g 
 
 
(Kemperma
n et al., 
2013) 
In-vitro SHIME ( 2 weeks) 
Impact of black-tea extract (1000 mg/day)  
SHIME and 
qPCR / 
pyrosequencin
g.  
Reduction in Bifidobacteria, Blautia coccoides, Anaeroglobus and 
Victivallis 
Increase in: Klebsiella sp. Enterococci Akkermansia 
SCFA: Reduction of butyrate concentration, Initial increase in acetate 
concentration. Towards the end of the study a sharp decrease in total 
SCFA and acetate was demonstrated 
 
  
After careful consideration of the relevant literature, it was clear that the metabolism of fibre and 
polyphenolics by colonic bacteria will involve some element of interaction. It was therefore important 
to ask whether the interaction of these compounds and their metabolites result in synergistic, additive 
or modification of their metabolism and how this may impact on their potential health benefit. There is 
great need, given the increased awareness of the role of gut bacteria in health to have a better 
understanding of colonic bacterial release of bioactive molecules under real life conditions, and to the 
best of our knowledge there have been no previous studies investigating the impact of food matrix 
interaction between fermentable fibres and polyphenols.  
In this PhD we aimed to investigate the impact of the antimicrobial properties of polyphenols on the 
production of bioactive molecules essential for human health such as SCFA from fibre fermentation, as 
well as the impact of prebiotic food components such as soluble fibre on phenolic acid produced from 
polyphenol degradation by these colonic microbiota. Given that majority of polyphenols and fibre 
reach the colon intact, it is of great interest to evaluate their matrix interaction in the presence of the 
colonic microbiota and the final metabolites produced as the result of this microbial metabolism. Given 
the fact that very low concentrations of polyphenols are readily absorbed and that they are heavily 
metabolised in the colon, it can be said that their impact on health is largely dependant on these 
metabolites and thus any factor inhibiting the production of phenolic acids, prevents the health impacts 
induced by polyphenols by reducing their bioavailability. In a similar manner, most of the health 
impact exhibited by soluble fibres is dependent on the SCFAs produced through microbial 
fermentation, and thus any factor affecting the microbial population may in turn influence the 
composition and amount of SCFAs produced.  Understanding the food matrix interactions between 
fibres and polyphenol, particularly those related to the production and absorption of their colonic 
metabolites will help draw a clearer picture of the biological and health implications induced by each 
of these food components. 
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CHAPTER 2                                                                       
General Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
 
This chapter details the methods and materials common to many of the experiments making up this 
PhD, or variations of a protocol used in more than one study/experiment. As fermentation products are 
the primary outcomes in most of the studies, the methods relevant to production and analysis of these 
outcomes are detailed in this chapter as well as the ex-vivo fermentation model and preparation of 
samples for ex-vivo experiments. 
The methods described in this chapter are relevant to:  
 Chapter-3: Matrix interaction between the polyphenols rutin and quercetin and the soluble fibres 
raftiline, ispaghula and pectin, on their metabolism by colonic bacteria- ex-vivo 
 Chapter-4: Matrix interaction between cocoa polyphenols and the soluble fibres raftiline, 
ispaghula and pectin, on their metabolism by colonic bacteria- ex-vivo 
 Chapter-5: Impact of ispaghula on the phenolic acid production from cocoa in-vivo 
 
 
2.1 Faecal sample collection 
 
The colonic microbiota responsible for the fermentation of fibre and polyphenols are a complex 
community with approximately 1000 different species of bacteria (Slavin, 2013) many of which 
(>60%) are not able to be isolated and cultured. The process of fermentation in the gut is difficult to 
assess directly due to inaccessibility of the proximal colon where most bacteria activity occurs 
(Edwards and Rowland, 1992). Thus indirect measurements, in faeces, urine, plasma and breath have 
to suffice but these are limited in their usefulness. 
In-vivo models of colonic fermentation are expensive and often non-ethical. Human studies where 
colonic fermentation is measured directly include: intubation, which is invasive, expensive and 
requires medical supervision. This model provides accurate measurements of the metabolites but may 
not be suitable for assessing transit time (Florent et al., 1985). Animal models may allow assessing the 
impact of a restricted diet on the bacteria and metabolite production; however they are expensive, 
invasive and may not necessarily be translatable to human physiology (Martin et al., 1998).  
Indirect measures include the measurement of acetate in the peripheral blood and breath hydrogen. 
Peripheral acetate measurement, although convenient, may not only be reflective of bacterial action but 
also endogenous production of acetate (Rumessen et al., 1992). Breath hydrogen measurement 
provides an estimated rate of fermentation but no qualitative information on metabolite production 
(Rumessen, 1992). This method is often used for the estimation of mouth-caecum transit time (MCTT). 
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Hence, faecal samples are often used as a representation of the colonic bacteria population. However 
this representation of the complex microbial colony may not necessarily be accurate as they are found 
in larger numbers towards the end of the ileum and caecum which may be due to the optimum acidic 
environment for their growth; as the pH changes (more neautral) towards the distal colon, so might the 
composition of the bacteria. Little is known about the composition of caecal bacteria due to their 
inaccessibility and often it is relied upon the faecal sample to provide a representation of this colony 
for the mimicking of their metabolic action in the colon. Marteau et al. (2001a) have shown that the 
composition of caecal microbiota contains 25% anaerobes vs. 1% in faeces. Despite this limitation the 
faecal bacteria are still widely used in in-vitro fermentation models to understand their metabolic 
action and products of fermentation as direct metabolite measurement from the faeces does not take 
into consideration the absorption of the metabolites in the proximal colon.   
 Even though there have been doubts regarding the accuracy of this representation (Marteau et al., 
2001b), the use of faecal sample in the ex-vivo fermentation model for the measurement of metabolites 
was found to be the most feasible, ethical non-invasive method as well as being the most simple and 
effective way of obtaining these bacteria (Edwards and Rowland, 1992). We did not use faecal 
measurements for any in vivo study as these provide less useful information as most fermentation and 
other products have been absorbed before the faeces was passed. 
In this thesis, fresh faecal samples were obtained from healthy non-smoker male and female volunteers 
who had not experienced any gastrointestinal infection or received antibiotics and laxatives for at least 
3 months prior to start of the study. The volunteers were asked to follow a low polyphenol diet for 3 
days prior to study (Appendix-1). This was meant to reduce the concentrations of polyphenols and their 
metabolites at baseline and thus improve the comparison of outcomes. 
Volunteers were asked to pass the entire bowel movement into single use plastic tubs with the help of 
paper bedpans placed on the toilet seat. The sample was placed in a gas proof bag immediately after 
passage, along with a kit to induce anaerobic conditions (AnaeroGen-Anaerocult A, Merck, Germany) 
and an Anaerob indicator (Anaerotest- Merck, Germany) to check the anaerobic conditions. These 
were then placed in insulated bags with ice packs. Samples were either collected from the residence or 
work of the volunteer or transported to the reception of Yorkhill hospital by taxi service.  In all cases, 
samples were transported to the lab immediately and processed within 2 hours of passage.  
This method is relevant to chapters 3 and 4. 
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2.2 Ex-vivo Modelling of anaerobic colonic fermentation 
 
Due to difficulties mentioned in section 2.1 regarding the study of colonic fermentation in-vivo, an in 
vitro or it could be classed ex-vivo model of the gut was adopted to examine the fermentation of fibre 
and polyphenols by the microbiota.  There are three main models of ex-vivo anaerobic fermentation 
that use faeces as a source of the gut microbiota population, these are: batch (static), semi-continuous 
and continuous culture. 
Semi-continuous and continuous models are better representatives of the colonic environment. They 
model the influx of digestive substrates from the upper gastrointestinal tract, pH and dilution of media 
as well as addition of nutrients to the culture periodically; thus keeping the microbiota in a steady state. 
Hence it is a better representation of in-vivo conditions where the bacteria are mostly kept at a steady 
state. However, these methods are not feasible for the number of substrates investigated in this thesis as 
they are more time consuming and expensive than the batch culture models. Additionally this model 
does not allow the study of multiple samples at the same time, which was the objective of this PhD. 
A batch culture model therefore, was used in the studies conducted for this PhD. This feasible and 
easily reproducible model (Edwards and Parrett, 1999) allowed for the measurement of physiochemical 
changes, extent of fermentation and consequently SCFA and phenolic acids produced. Like most 
models, the batch model has limitations such as accumulation of fermentation products resulting in 
more drastic pH reduction which in turn can inhibit the microbiota population (Edwards and Rowland, 
1992).  Despite being suitable for the survival of anaerobic microbiota (Edwards et al., 1996).  
To replicate the model described by Edwards et al (1996), the fermentation medium was prepared by 
mixing 2.25g of tryptone in 450 ml of distilled water and 112.5 ul of micromineral solution (consisting 
of 13.2 g of CaCl2·2H2O, 10.0 g of MnCl2·4H2O, 1.0 g CoCl2·6H2O, FeCl3·6H2O, and distilled water 
up to 100 ml). This solution was agitated to dissolve the chemicals followed by the addition of 225 ml 
of buffer solution (2 g of NH3·CO3, 17.5 g of Na2·2CO3, and 500 ml of distilled water), 225 ml of 
macromineral solution (2.85 g of Na2HPO4·H2O, 3.1 g of KH2PO4·H2O, 0.3 g of MgSO4·7H2O, and 
500 ml of distilled water), and 1 ml of 0.1% (w/v) resazurin solution (a redox indicator). This medium 
was adjusted to pH 7 using 6M HCl, after which it was sterilised by being boiled for 5 minutes. This 
also allowed the removal of oxygen from the medium. Reducing solution prepared on the day of 
fermentation (312.5 mg of cysteine hydrochloride, 2 ml of 1 M NaOH, 312.5 mg of sodium sulfide, 
and 47.5 ml distilled water) was added at 0.5 ml per 10 ml of medium after the solution was cooled to 
37°C under oxygen-free nitrogen (OFN) until anaerobic conditions were achieved as indicated by a 
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colour change from pale indigo to colourless resulting from the reduction of resazurin (Jaganath et al., 
2009) 
A 32% faecal slurry was prepared for each subject in phosphate buffer (pH=7), homogenised in a 
household blender for 2 minutes and strained through a nylon stocking. 5ml of the slurry was added to 
44 ml of the pre-reduced fermentation medium in 100-ml autoclaved fermentation bottles. Each batch 
culture consisted of 50 ml of the above slurry mixture to which 1g of fibre and/or polyphenol was 
added (respective to the study). The small scale (50ml) and 32% slurry were used to provide higher 
amount of bacteria at the start of each culture and a better chance of survival (Jaganath et al., 2009). 
The fermentation bottles were then purged with OFN for 2 minutes/bottle and sealed air-tight using gas 
tight aluminium crimp tops with septum. A purging tube was designed, making it possible to purge 
multiple bottles with OFN simultaneously. They were then placed in a shaking water bath at 37°C and 
60 strokes/min. Incubate took place over 24 hours. Aliquots of the fermented faecal samples (6 ml) 
were collected after measuring gas production and pH at 0, 2, 4, 6 and 24 hours and stored immediately 
at −80°C. 
This method is relevant to chapters 3 and 4. 
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Figure 2-1 Ex-vivo fermentation method 
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2.2.1 Gas production 
 
One of the inevitable by-products of colonic fermentation is the production of gases such as carbon 
dioxide (CO2), hydrogen (H2) and Methane (CH4). Hence, production of gas can be an indication of 
rate and extent of fermentation. These gases are produced in different volumes depending on the CHO 
subjected to fermentation and the bacteria present in the faeces. Rapidly fermented gases can result in 
an initial high volume of gas, whereas slowly fermented fibres demonstrate a more steady production 
of gas over time (Cummings et al., 2001).  Some individuals are more likely to produce hydrogen, CH4 
or hydrogen sulfide (H2S). 
The gas produced through fermentation may be of importance when translating the fermentation of 
fibres in vitro to predicting in vivo gas.  Rapidly fermented fibres might cause discomfort to the 
consumer due to high volumes of gas produced in a short period of time. 
Gas was measured using 3 way valves ensuring the fermentation media was not exposed to oxygen. A 
needle was inserted into the 3-way valve and into the septa sealing the bottle tight. A 50 ml graduated 
syringe was then inserted into one opening of the valve while the other openings were tightly closed.  
After securing the syringe the valve was opened, allowing the gas produced in the bottle to escape into 
the syringe, pushing the plunger of the syringe out as a result of accumulated pressure (Kaur et al., 
2011). 
The amount of gas in the syringe was noted, the valve was tightly shut, the syringe was removed and 
the gas was emptied into a flask containing water. If the gas produced was over 50 ml, once the syringe 
was full the valve was shut, the syringe was emptied and the procedure was repeated to measure the 
remaining gas in the bottle. 
 
                                    
 
 
     
 
 
 
Figure 2-2 measurement of gas produced 
in fermentation bottles 
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2.2.2  Measurement of pH  
The accumulation of SCFA and phenolic acids produced through colonic fermentation can result in 
changes in pH levels. In the batch culture model, it is possible for the pH to be reduced to levels that 
can inhibit microbial activity (Clausen et al., 1991, Rumney and Rowland, 1992). In a batch culture 
model pH may also be used as an indication of rate and extent of fermentation.  
In our studies aliquots for SCFA measurement were placed in pre-weighed bijoux bottles containing 
1ml NaOH. As sodium hydroxide changes the pH of the faecal slurry these samples were not used for 
measuring pH. The quantity of sample suitable for pH measurement was relatively small thus pH was 
measured with a micro combination pH electrode (Shelfscientific- Lazer Research Laboratories, Inc - 
USA) suitable for measuring pH in small volumes.  
A comparison was also made for pH indicator paper ranging from a scale of 1-14 (Fisherbrand 33041) 
vs. the micro combination pH electrode. This resulted in similar values for both measurement methods.  
 
2.3 SCFA analysis 
 
Measurement of the production of SCFA in the ex-vivo studies was conducted according to the method 
by Laurentin & Edwards (2004), which is well established in the Department of Human Nutrition at 
the University of Glasgow. 
Aliquots for SCFA measurement were placed in pre-weighed bijoux bottles containing 1ml NaOH 
(ratio 2:1) immediately after sampling and storage at -20°C. This was done due to the volatile nature of 
SCFA (Martin et al., 2010). The strong alkaline environment reduced their volatility as well as 
inhibiting further metabolic activity by the microbiota. 
SCFA were estimated by gas liquid chromatography using a TRACE 2000 gas chromatogram 
equipped with a flame ionisation detector (250 °C) and an oven programmed at an initial temperature 
of 80 °C going up to 210 °C; using a Zebron ZB-Wax capillary column (15 m x 0.53 mm id x 1 μm 
film thickness). Nitrogen (flow rate: 30ml/min) was used as the carrier gas. 
0.1 ml of internal standard (2-ethylbutyrate 73.8 mmol/L) and 0.1 ml orthophosphoric acid were added 
to 0.8 ml of faecal slurry aliquots (homogenised by vortex for 15 seconds before sampling).  
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Extraction was done three consecutive times with 3ml of diethyl ether and vortexed for 1 minute each 
time. The diethyl ether layer was recovered and pooled into a clean tube. 1ul of the pooled extract was 
injected onto the column using an autosampler. Extractions were done in duplicate for each sample. 
The chromatograph and peak integrals were analysed by chrom-card 32-bit version 2.2 
(Thermofinnigan, Milan, Italy) using an averaged (n=5) response factor for each external standard 
(Table 2-2) for calibration. All standards were of analytical grade and purchased from Sigma-Aldrich 
Ltd (Dorset, UK), except for acetic acid (glacial), which was purchased from Fisher Scientific 
(Loughborough, UK). Calibrators were run in 6 different concentrations (10ul, 25 ul, 50 ul, 100 ul, 200 
ul, 300 ul) at the start and end of each run with concentration 100 being repeated every 24 samples as a 
measure of quality control.  This Method is relevant to chapter 3 and 4. 
 
 
Table 2-1 Preparation of external standard for SCFA analysis 
SCFA Acid name Conc. (mM) g / 200ml of NaOH 
C2 Acetic 183.2 2.2014 
C3 Propionic 133.2 1.9735 
iC4 Iso-butyric 104.2 1.8362 
C4 Butyric 86.3 1.7628 
iC5 Iso-pantanoic 74 1.7192 
C5 Pantanoic 64.7 1.6847 
iC6     Iso-hexanoic     57.5 1.6584 
C6 Hexanoic 102 1.7974 
C7 Heptanoic 86 1.7566 
C8 Octanoic 50 1.1616 
Internal std 2-ethylbutyrate 73.8 1.71452 
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Table 2-2 Reproducibility and repeatability of SCFA measurement 
Acid name Response     factor* 
reproducibility 
CV** 
Reproducibility 
Response   factor* 
repeatability 
CV** 
repeatability 
Acetic 0.16 ± 0.01 4.86 0.15 ± 0.0001 0.077 
Propionic 0.36 ± 0.02 4.94 0.35 ± 0.0004 0.13 
Iso-butyric 0.55 ± 0.03 5.05 0.54 ± 0.0003 0.07 
Butyric 0.54 ± 0.03 4.97 0.53 ± 0.0004 0.07 
Iso-pantanoic 0.72 ± 0.03 4.81 0.71 ± 0.0005 0.06 
Pantanoic 0.71 ± 0.03 4.88 0.71 ± 0.0003 0.04 
Iso-hexanic  0.88 ± 0.05 5.11 0.88 ± 0.001 0.11 
Hexanoic 0.90 ± 0.04 4.82 0.89 ± 0.0005 0.06 
Heptanoic 1.06 ± 0.05 5.17 1.06 ± 0.0008 0.07 
Octanoic 1.22 ± 0.06 5.31 1.23 ± 0.003 0.28 
Values are mean ± standard deviation (n=15 for reproducibility, n=5 repeatability) 
*The response factor (Rf) for each SCFA was calculated asRf=(AUCES/AUCIS)/(ConcES/ConcIS)  
Where AUC= area under the curve, Conc=concentration, ES=external standard, IS=Internal standard. 
** Coefficient of variance = (standard deviation/mean)*10 
Figure 2-3 SCFA external standard run using standard 300 (mg/ml) 
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2.4 Phenolic acid analysis 
 
Phenolic acids are not completely stable and are easily prone to oxidation. Hence, aliquots for phenolic 
acid analysis from both ex-vivo and in-vivo studies were stored at -80°C in 2ml eppendorf tubes to 
inhibit further metabolic activity of the microbiota and oxidation of phenolic acids.  
The protocol used for the analysis of phenolic acids in this thesis was adapted from Combet et al 
(2011). 1ml of faecal slurry, 30ul of internal standard (2,4,5-Trimethoxycinnamic acid) was added and 
samples were acidified by adding 60ul of 1M HCL. They were vortexed and placed at 4°C for 10 
minutes. They were partitioned twice against 1.5ml ethyl acetate. Each time, after addition of 1.5ml 
ethyl acetate, samples were centrifuged for 10 minutes at 1426 × g at 4°C.  Upper organic phases were 
combined and transferred into an amber glass and dried at 37°C under a gentle flow of nitrogen. 200ul 
of dichloromethane was added to rinse the wall of the vials and dried at 37°C under a gentle flow of 
nitrogen. 50ul N,O-Bistrifluoroacetamide (BSTFA) was added as a derivatisation reagent, vials were 
flushed with a gentle flow of nitrogen, sealed and placed on a hot block at 80 °C for 4 hours, during 
which they were vortexed every 30 minutes in order to achieve complete silanisation.  
Hexene (450 ul) was added to the derivatised samples. Samples were analysed by a Trace GC 
interfaced to a DSQ mass spectrometer equipped with a split/splitless injector and an AI3000 
autosampler (Thermo Fisher, Hemel Hampsted, UK). Samples (1ul) were injected in a split mode with 
a 25:1 ratio. A 220 °C inlet temperature was maintained while the oven was programmed with an 
initial temp of 45°C going up to 300°C (ramp: 45- 160- 200- 250- 300 °C). The helium carrier gas flow 
rate was at 1.2 ml/min. hexane was used as prewash solution and acetonitrile as post wash solution. 
Extraction was done in duplicate for each sample. 
 
Phenolic acids present in the external standard were also analysed individually to determine retention 
time and identifying ions (Table 2-3) This library was used to identify phenolic acids present in the 
urine and faecal slurry samples using the software Xcalibur for windows XP. Retention time, target ion 
and reference standard comparison were used for identification. 
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Table 2-3 Phenolic acid standards 
Phenolic acid name Retention 
time 
Target ion Other  
qualifying ions 
Molecular 
weight 
Benzoic  6.91 179 105, 135 122 
Phenyl acetic 7.45 164 73, 91, 164 136 
Mandelic 9.97 179 71, 147, 253 152 
3-Hydroxy benzoic 12.09 267 223,73.193,282 138 
3-Hydroxy phenyl acetic 13.22 164 73, 147, 75 152 
4-Hydroxy benzoic 13.82 267 73, 267, 193 138 
4-Hydroxyphenyl acetic 14.15 179 73, 164, 281, 252 152 
3-Hydroxy phenyl propionic 17.17 205 192, 177, 73, 310 166 
4-Hydroxy phenyl propionic 18.44 179 192, 73, 75, 177 166 
Vanillic 18.55 297 73, 267, 223, 126 166 
Homo vanillic 18.79 209 73, 179, 326, 267 168 
4-Hydroxy mandelic  19.08 267 73, 268, 147 182 
3,4-Dihydroxy benzoic 20.87 193 73, 370, 194 168 
3,4-Dihydroxy phenyl acetic 21.1 179 73, 179, 267. 384 154 
Hippuric  21.88 206 105, 73, 207 168 
m-coumaric 23.38 203 73, 293, 308, 249 164 
4-Hydroxy 3-methoxy phenyl propionic 24.16 209 73, 192, 340, 179 196 
p-coumaric 26.4 219 73, 293, 308, 249 164 
3,4-Dihydroxy phenyl propionic 26.51 179 73, 267, 398 182 
Gallic 27021 281 73, 458. 179 170 
Ferulic 33.79 338 73, 249, 323, 308 194 
Caffeic 35.16 219 73, 396, 191 180 
4-Hydroxy hipuric 37 193 73, 294 195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-42 phenolic acid external standards 
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For quantification the internal standard was referred back to an external standard, which was analysed 
in concentration of 4, 8, 15, 27, 32 ul/ml. Area ratio was calculated as area of standard or sample/ 
area of internal standard. A calibration curve was constructed for each phenolic acid using the 
external/internal standard ratios. The computer calculated gradient of the calibration curve was then 
used to quantify the concentration of phenolic acids. 
This method is relevant to chapter 3, 4 and 5.  The other methods used in chapter 5 are included within 
the chapter. 
Figure 2-5 2 5 phenolic acid peak identification 
 
3,4-Dihydroxy phenyl acetic acid 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 3                                                       
Matrix interaction between the 
polyphenols rutin and quercetin and 
the soluble fibres raftiline, ispaghula 
and pectin, on their metabolism by 
colonic bacteria- ex-vivo  
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Flavonoid containing foods also contain dietary fibre. As both types of compounds can affect the 
metabolism and growth of colonic bacteria it is important to consider how they affect each other‘s 
metabolism in the colon. The study described in this chapter investigated the impact of the flavonoids 
rutin and quercetin on the SCFA production from the fermentation of the soluble fibres ispaghula, 
pectin and raftiline, as well as the impact of the individual fibres on the colonic bacterial metabolism of 
rutin. The use of isolated components from their food matrix such as rutin and quercetin allows better 
understanding of mechanisms. 
 
3.1 Introduction 
 
Fibres and polyphenols are two major contenders of health benefits induced by fruits and vegetables. 
The majority of both components escape absorption in the small intestine and reach the colon intact 
where they are heavily metabolised by bacteria in the colon but so far their metabolism by these 
colonic bacteria has been studied separately. However these are most likely consumed together as part 
of the daily diet. Both components also have the potential to alter the growth and population of the gut 
microbiota by which they are both catabolised. The fibres may increase the growth of the bacterial 
population while there is evidence for both antibacterial effect and a prebiotic effect for several 
polyphenol compounds. Thus it is important to understand the interaction of these compounds on 
bacterial activity and the release of bioactive molecules. 
Rutin and quercetin are amongst the most abundant flavonoids found in fruits and vegetables. Studies 
have shown that when quercetin is ingested in its glycosidic form (rutin), 83-86% is recovered in the 
ileal fluid of ileostomy patients, as intact rutin (Hollman et al., 1995, Jaganath et al., 2006a). These 
compounds would be made available to the colonic microbiota of healthy individuals; here these 
compounds will be initially hydrolysed to yield quercetin, which is further degraded to produce lower 
molecular weight phenolic acids. Rutin is the least absorbed in the human small intestine compared to 
quercetin-glucosides or the aglycone quercetin. In fact, unlike the glycosidic moiety, the glucoside 
moiety has been found to increase the absorption of quercetin with only 24-44% of ingested quercetin-
glucosides reaching the colon which is less than that observed for quercetin aglycones (~77%) 
(Hollman et al., 1995, Walle et al., 2000). It was hypothesised that the absorption of quercetin is 
facilitated by its glucose moiety which is drawn into the enterocyte by the glucose carrier; the lack of 
the glucose moiety on the aglycone quercetin may be a factor contributing to lower absorption 
(Hollman et al., 1995).   
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Table 3-1 Type and amount of quercetin available to colonic microbiota in humans (Ileostomy studies) 
Author Feed Main component in 
feed 
Concentration 
of component 
in feed 
Recovery of 
component in 
ileal fluid 
% of ingested 
dose 
Hollman 
et al 
(1995) 
-Fried onion (=89mg 
aglycone) 
-quercetin-rutinoside 
(=100mg aglycone) 
-quercetin aglycone 
100mg 
Quercetin glucoside 
Rutin 
 
quercetin 
 
89mg 
 
100mg 
 
100mg 
44mg 
 
83mg 
 
66mg 
49% 
 
83% 
 
77% 
Walle et 
al (2000) 
-Fried onion 
(76-150 g) 
Quercetin-
monoglucosides 
Quercetin 
diglucosides 
4.7-29.7mg 
 
5.9-21.7mg 
    29±19mg 
Quercetin-
aglycones           
~24% 
Kahle et 
al (2005) 
-Apple juice (cloudy) Quercetin glycoside: 
-glucosides 
-rhamnosides 
-galactosides 
-xyloside 
-arabinoside 
(10.8 ug/ml) 
1.8 ug/ml 
2.7 ug/ml 
1.5 ug/ml 
3.9 ug/ml 
0.9 ug/ml 
 
- 
0.27 ug/ml 
- 
- 
0.05 ug/ml 
~3% 
Jaganath 
et al 
(2006) 
-Tomato juice 
supplemented with 
quercetin-rutinoside 
Quercetin-rutinoside 176umol 
(~107.45 
ug/ml) 
151±5umol 
(~92.18 
ug/ml) 
86% 
 
This is an indication that bioavailability of rutin and quercetin is greatly dependent on the action of the 
gut microbiota and its colonic metabolites, thus any factor with the potential to modify the gut 
microbiota can indirectly impact the bioavailability of rutin as well as its colonic metabolites, thus 
affecting its impact on health (Jaganath et al., 2009, Rechner et al., 2004).  
As the colon was found to be the main site of rutin degradation and absorption, the importance of its 
colonic metabolites were emphasised. The metabolites resulting from the colonic degradation of rutin 
and quercetin have been studied in urine, plasma and faecal incubations and summarised in chapter-1. 
However these studies do not take into consideration the presence of other food matrices with 
microbiota modifying potential in-vivo, such as carbohydrates, especially fibre. Evidence on the food 
matrix interaction between carbohydrates and rutin/quercetin is modest. A study that merits attention is 
the one conducted by Jaganath et al. (2009); investigating the bioavailability of rutin and quercetin 
with or without 0.5g of the simple carbohydrate glucose in an in-vitro fermentation model. The 
addition of glucose to incubation vessels increased the extent of rutin deglycosilation, subsequent 
phenolic acid production and the decomposition pathway. Simple carbohydrates such as glucose may 
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act as a direct source of energy for the colonic microbiota, promoting their growth and hence their 
ability to hydrolyse and degrade substrates, as is seen with vessels containing glucose having more de-
glycosylation of rutin. In addition, simple carbohydrates lack the physio-chemical properties of fibre 
such as viscosity. Moreover simple carbohydrates such as glucose are mostly absorbed in the small 
intestine, whereas fibre is most often present in the colon along with the polyphenols, where it is 
fermented and can induce changes in the microbiota composition. This modification may be induced 
by SCFA through the reduction of colonic pH (chapter-1). Additionally SCFA may have a direct 
impact on specific bacterial species, as seen that the growth of Bifidobacteria was enhanced in the 
presence of propionate (Arora et al., 2011). 
Despite the great potential for food matrix interaction between soluble fibres and the abundant 
polyphenolics such as rutin and quercetin and their metabolites, studies in this area are few. Most such 
studies are based on the impact of dietary fibre on antioxidant bioavailability and have conflicting 
results. An example of this is an increased absorption of quercetin metabolites in plasma after chronic 
ingestion of pectin as demonstrated in animal studies (Nishijima et al., 2009, Tamura et al., 2007) 
compared to reduced β-carotene bioavailability in the presence of pectin, guar gum or cellulose 
(Hoffmann et al., 1999). Studies on antioxidant interaction with dietary fibre suggest that apart from 
increasing luminal viscosity, dietary fibre may reduce the release of antioxidants by physically trapping 
them within the fibre matrix (Palafox‐Carlos et al., 2011). The chemical interaction between dietary 
fibre and polyphenols has been suggested as the formation of ordered junctions stabilised by arrays of 
non-covalent bonds between hydroxide groups from phenolic compounds and the polar groups from 
polysaccharide molecules (Eastwood and Morris, 1992). Unabsorbed low molecular weight phenolic 
and polyphenol compounds that are associated with dietary fibre constitute a major part of dietary 
polyphenols and are not absorbed in the human small intestine (Manach et al., 2005). 
The health benefits from rutin, depends not only on its concentration in the diet but also on its 
bioavailability and bioaccessibility from the matrix after ingestion. Considering that rutin is not 
absorbed in the small intestine, its bioavailability is directly related to its bioaccessibility. Hence it is of 
importance when discussing the health benefits of rutin, to understand the impact of dietary fibre, most 
often present in the matrix on the bioaccessibility of rutin. This was demonstrated in a study by 
Hollman et al. (1995), investigating the recovery of quercetin and its conjugates when consumed in 
different forms. Quercetin ingested in the form of onions had higher recovery rates (1.39 ± 0.49 % 
proportion of intake) as compared to quercetin ingested as apple, which contains the soluble fibre 
pectin (0.44 ± 0.22 % proportion of intake). The least amount of recovery was from the consumption of 
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rutinoside (0.35 ± 0.41% proportion of intake), which was only 25% of that seen for quercetiningested 
from onions and 79% of quercetin from apple. 
For better understanding of the impact of soluble fibres on the bioavailability of polyphenols and 
consequently their metabolites, three different soluble fibres; raftiline, ispaghula and pectin were 
chosen as they vary in viscosity and rates of fermentation. Rutin was used as a pure source of 
polyphenols to avoid any other matrix impact; allowing us to attribute any differences in rutin 
metabolite concentrations to the impact of soluble fibres. As suggested by Palafox-Carlos et al (2011) 
some of the inhibitory effect of fibre on polyphenol bioavailability can be attributed to their viscosity. 
This study design allowed us to investigate the impact of soluble fibres with low and high viscosity and 
fermentation rates on rutin degradation by colonic bacteria. This allowed for the better understanding 
of the role of viscosity or fermentability on the polyphenol metabolite bioavailability. 
As soluble fibres exhibit many of their health benefits through the production of short chain fatty acids 
in the colon, it is also of importance to understand the impact that polyphenols, can have on their 
production through the modification of the colonic microbiota. 
Many polyphenols have been shown to exhibit an inhibitory effect on the gut microbiota. However, 
there are very few studies investigating their impact on non-pathogenic bacteria in a complex 
ecosystem such as that in the human colon. Due to the large family of polyphenols and various 
methods used, there is a lack of consistency in the understanding of the inhibitory mechanism of action 
of polyphenols on gut microbiota (Chapter 1).  
Quercetin has demonstrated stronger antibacterial properties more than other polyphenolic compounds 
tested in the same studies (Arima et al., 2002, Parkar et al., 2008), however its glycosidic form rutin 
did not exhibit any antibacterial properties. The same was seen in the case of aglycone naringenin but 
not its glycoside naringin (Parka et al., 2008) These studies were carried out in-vitro, which may not 
translate well in-vivo conditions, as the glycosidic forms of these polyphenols will be hydrolysed by 
the bacteria, releasing the aglycones. It is possible that the glycosidic forms may be of more 
importance in this regard as some aglycones may be absorbed in the small intestine but majority of the 
glycosidic bacteria reach the colon intact where they will be deconjugated by the bacteria.  
For better understanding of the antibacterial properties of these polyphenolic compounds more studies 
are required, especially studies using in-vivo or in-vitro fermentation models, allowing the use of more 
than a few bacterial species and better investigation of glycosidic compounds. Even though rutin has 
not shown an antibacterial impact in-vitro it must not be ignored as an antibacterial agent as its role in-
vivo may be of great importance given that larger numbers of rutin than quercetin reach the colon, 
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where it is initially converted to quercetin by the colonic bacteria (Jaganath et al., 2009) before its 
further degradation to lower molecular weight phenolic acids. Moreover phenolic acids have 
demonstrated to have stronger antibacterial properties than their parent compounds in-vitro (Lee et al., 
2006). 
The above mentioned studies investigating the impact of rutin and quercetin on bacteria were carried 
out in-vitro on pure cultures, not taking into consideration factors such as pH and other food 
components in the food matrix that may act as prebiotics, thus ameliorating the antibacterial properties 
of these phenolic compounds. Moreover, these studies demonstrated a shift in bacterial species but no 
change in total bacterial counts. A shift in bacterial species may result in a difference in their 
fermentation metabolites, which has not been investigated so far. This was previously shown in a study 
using tea extracts as an antibacterial agent, demonstrating a reduction in butyrate production 
accompanied by an initial increase in acetate production, which was attributed to the reduction in 
butyrogenic bacteria. By the end of two weeks, a drastic fall in total SCFA and acetate concentration 
was observed (Kemperman et al., 2013). However it is important to note that 1000 mg of polyphenol 
extracts were fed into the Simulator of Human Intestinal Microbial Ecosystem (SHIME) model three 
times daily, which is relatively high considering total polyphenol intake has been estimated as 1g/day. 
Secondly this study model does not take into consideration the ingestion of other food components, 
which may inhibit the antibacterial effect seen from the high dose of polyphenols.  
 In this chapter we investigated the impact of rutin and quercetin as well as their colonic metabolites on 
SCFA production from soluble fibres which may act as enhancers of bacterial growth. Quercetin has 
demonstrated antimicrobial activity (Vaquero et al., 2007, Rodríguez Vaquero et al., 2010, Duda-
Chodak, 2012, Parkar et al., 2008), which in turn can affect the production of these SCFA and thus 
their impact on health. 
 
3.1.1 Hypothesis 
To test the hypothesis that soluble fibres change phenolic acid production from rutin in the colon by 
fermentation related mechanisms, and that the potential antibacterial properties of quercetin, rutin and 
their colonic metabolites inhibit the production of SCFA from the microbial fermentation of soluble 
fibres. 
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3.2 Materials and methods 
 
3.2.1 Study design 
The study used is an ex-vivo model of the gut using inoculated faeces from human volunteers (n=10) 
on 10 separate occasions. Volunteers followed a three day low polyphenol diet; avoiding fruits, 
vegetables and beverages high in polyphenols such as tea, coffee and cocoa milk. On the 4
th
 day faeces 
was collected from volunteers according to the method described in 2.1 Faecal sample collection. 
To investigate the impact of fermentable fibres on phenolic acid production from rutin, three different 
fibres with varying fermentability rates were chosen (raftiline, pectin and ispaghula), resulting in 11 
different combinations (detailed in 4.2.3).  
3.2.2 Participants 
For this ex-vivo batch fermentation, fresh faecal sample was collected from healthy volunteers (n=10) 
with a mean (± SD) BMI of 22.5 ± 3.0 (range, 18.4 to 27.4) and a mean (± SD) of 23 ± 3.8 years 
(range, 19 to 33). Volunteers were non-smokers who had not received antibiotics, constipation 
remedies or probiotics for at least 3 months prior to start of the study.  
 
Table 3-2 volunteer characteristics 
 Gender Age 
(years) 
Height   
(cm) 
Weight 
(kg) 
BMI 
(Kg/m2) 
Waist 
circumference (cm) 
Blood pressure 
(mmHg) 
1 M 22 175.5 84 19.7 96 125/60 
2 F 19 161 47.9 27.4 77 109/71 
3 F 21 158 63.9 18.4 73 129/67 
4 F 21 156 54 25.6 80 119/71 
5 F 26 174 57.2 22.2 78 107/59 
6 F 22 160 50.5 18.9 73.5 112/80 
7 F 25 161 54.3 20.9 83.5 112/80 
8 M 23 183 77.8 23.2 91 143/83 
9 M 33 175 76 24.8 93 165/63 
10 M 23 176 72.2 23.3 93 114/72 
Mean ± 
STDEV 
 23  
± 3.8 
152.5  
± 53.7 
63.8  
± 12.8 
22. 
± 2.9 
83.8  
± 8.7 
123.5 / 70.6 
 ± 18.2 / 8.5 
Values are means (± SD), M: male, F: female, BMI: body mass index  
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3.2.3 Ex-vivo fermentation 
The ex-vivo fermentation was carried out with faeces from each of ten volunteers on separate 
occasions, according to the method described in 2.2 Ex-vivo Modelling of anaerobic colonic 
fermentation. The incubation bottles contained faecal slurry alone with or without one of 11 possible 
combinations of fibre and/or polyphenols. Incubation was allowed for 24 hours and samples for 
phenolic acid analysis were collected at 0, 2, 4, 6 and 24 hours; and stored at -80 °C immediately.  
 
 
 
 
 
 
  
 
Figure 3-1 Substrate combinations for faecal fermentation. 
FS: Faecal slurry, ISP: Ispaghula, PEC: Pectin, RAF: Raftiline, R: Rutin, Q: Quercetin 
 
3.2.4 Materials  
Rutin and quercetin were purchased from sigma-Aldrich (Poole, UK), final concentration: 28 umol/L 
in distilled water and incubated along with the soluble fibres, Ispaghula husk (Whole ispaghula husk – 
myprotein.com) pectin (pectin apple- 250 grade, BDH laboratory supplies) and raftiline (Siber Hegner 
Ltd). The concentration of rutin used in the study was based on the recovery of 28 umol/L rutin in ileal 
fluid of patients consuming tomato juice supplemented with 176 umol/L of rutin (Jaganath et al., 
2006b). The amount of fibre used is based on 6g of fibre as moderate fibre consumption (Khossousi et 
al., 2008), present in 300ml of colonic content, resulting in 1g of fibre present in 50ml incubation 
bottles. 
3.2.5 Phenolic acid analysis 
Phenolic acid analysis was carried out for samples taken from the fermentation vessel at 0, 2, 6 and 24 
hour time points using 23 phenolic acids (Table 2-3) as standard references, according to the method 
described in 2.4Phenolic acid analysis. 
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Data for all identified phenolic acids were quantified and analysed separately and a sum of all 
identified phenolic acids was considered as the total sum of phenolic acid production. 
3.2.6 SCFA analysis 
SCFA were analysed in samples from the fermentation vessels at 0, 2, 4, 6 and 24 hours according to 
the method described in 2.3 SCFA analysis. Analysis of the results focused mainly on acetic, propionic 
and butyric acid and the total sum production as the sum of acetate, propionate, butyrate, iso-butyric, 
iso-pentanoic, pentanoic, iso-hexanoic, hexanoic, heptanoic, octanoic. 
3.2.7 pH measurement 
pH was measured for all samples at 0, 2, 4, 6 and 24 hours according to the method described in 2.2.2 
Measurement of pH. 
3.2.8 Gas volume  
Gas was measured for all samples at 0, 2, 4, 6 and 24 hours post incubation according to the method 
described in 2.2.1 Gas production 
3.2.9 Statistical analysis  
To determine the impact of the soluble fibres raftiline, ispaghula and pectin on phenolic acid 
production from rutin, and the impact of rutin and quercetin on SCFA production from the fibres, a 
general linear model Anova was performed using the software Minitab-15. This statistical model 
allowed for the analysis of paired data with repeated measures. In this analysis phenolic acid 
concentration was used as the response, with volunteer, time, substrate and time*substrate included in 
the model. Volunteer was included in the random factors. 
Further analysis was conducted for the data at 24 hours separately, using a paired t-test model or 1-way 
Wilcoxon test after assessing for normality. This analysis was conducted as the general linear model 
considers change over time and ignores differences at specific time points. Soluble fibres differ in their 
rate of fermentation, resulting in some slowly fermented fibres such as ispaghula to demonstrate an 
impact only at 24 hours. Hence, it was important to investigate the 24 hour time point separately. 
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3.3 Results 
 
The soluble fibres used in this study are plant extracts. Hence, some phenolic acid production from 
these soluble fibre sources was expected. The main outcome investigated in this chapter was the 
difference in phenolic acid production from rutin incubated with soluble fibre (represented as fibre+R, 
where R represents rutin) to rutin incubated alone. 
The phenolic acids identified in the rutin incubations are listed in Table 3-3. Phenolic acid production 
from soluble fibres is discussed in the relevant sections. 
Table 3-3 Phenolic acids identified from Rutin incubation with human faecal bacteria 
Phenolic acid Abbreviation Conc. at 24 hours (ug/ml) Number of volunteers 
producing 
4-Hydroxy benzoic acid 4-HBA 0.04 ± 0.03 2 
Phenyl acetic acid PAA 5.60 ± 3.35 10 
3-Hydroxy phenyl acetic acid 3-HPAA 1.26 ± 1.60 9 
4-hydroxy phenyl acetic acid 4-HPAA 0.79 ± 0.65 10 
3,4- Dihydroxy phenyl acetic acid 3,4-DHPAA              3.11 ± 4.2 10 
3-Hydroxy phenyl propionic acid 3-HPPA 0.43 ± 0.28 10 
4-Hydroxy phenyl propionic acids 4-HPPA 0.39 ± 0.6 10 
Total sum of phenolic acids  TP  11.98 ± 6.0 10 
Concentration of rutin added  - 17.08 10 
 
 
Figure 3-2 Phenolic acids identified in rutin only incubations with human faecal bacteria in comparison to total sum of 
phenolic acids produced.  
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Figure 3-3 Phenolic acids identified in rutin incubations with human faecal bacteria 
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Figure 3-4 Identified phenolic acids in rutin incubations 
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3.3.1 Impact of raftiline on phenolic acid production from rutin 
 
Raftiline fermentation resulted in the production of 3-HPAA in 1 volunteer and 4-HPAA in 8 out of 10 
volunteers. Raftiline had an inhibitory effect on the production of both of these phenolic acids from 
rutin fermentation (p< 0.01 (98.4%), Figure 3-5 and p < 0.01 (76%), Figure 3-6 respectively).  
 
 
Figure 3-5 Impact of raftiline on 3-HPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in faecal incubations having 28 umol/L rutin with 1g of RAF (n=10), 
FS: Faecal slurry, R: Rutin, RAF: Raftiline, Raf+R: Raftiline+Rutin *P < 0.01 
 
 
 
 
Figure 3-6 Impact of raftiline on 4-HPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of RAF 
(n=10), FS: Faecal slurry, R: Rutin, RAF: Raftiline, Raf+R: Raftiline+Rutin, *P < 0.01 
* 
* 
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Figure 3-7 Impact of raftiline on 3,4-DHPAA production from rutin incubation with human faecal bacteria             
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of RAF 
(n=10), FS: Faecal slurry, R: Rutin, RAF: Raftiline, Raf+R: Raftiline+Rutin, *P < 0.01 
 
 
A similar inhibitory impact (p < 0.01 (81.6%), Figure 3-7) was seen on the production of 3,4-DHPAA, 
which was not produced in any volunteers when raftiline was incubated separately. 
The inhibitory effect of raftiline on 4-HPAA and 3,4-DHPAA was seen as early as 2 hours post 
fermentation. Unlike the other 2 phenolic acids, 3-HPAA was produced only after 6 hours of 
fermentation, suggesting a later release from the intermediate 3,4-DHPAA. 
The total phenolic acid production from rutin was inhibited by 85.5% in the presence of raftiline (p 
<0.01, Figure 3-8), seen as early as 2 hours post fermentation. Raftiline also showed an inhibitory 
effect on the production of phenolic acids from polyphenolics present in the background diet of the 
volunteers, resulting in higher values for phenolic acids in the control than that of raftiline and rutin 
combined, or raftiline alone. The three-day dietary records of volunteers demonstrated compliance to 
the low polyphenol diet, hence the possible explanation for the phenolic acid production from faecal 
slurry alone incubation can be either due to inaccurate record of diets or the presence of insoluble 
phenolics bound to cereal cell-walls. 
 
* 
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Figure 3-8 Impact of raftiline on total phenolic acid production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of RAF 
(n=10), FS: Faecal slurry, R: Rutin, RAF: Raftiline, Raf+R: Raftiline+Rutin, *p < 0.01 
 
 
Raftiline inhibited the production of PAA, 3-HPAA, 4-H PAA, 3,4-DHPAA and total phenolic acids. 
This inhibitory effect was not seen for 3-HPPA and 4-HPPA. These two phenolic acids increased 
rapidly up to 6 hours post fermentation and plateaued thereafter. The analysis at 6 hours for both 
phenolic acids did not result in a statistical difference between raftiline and rutin to rutin alone. 4-HBA 
was produced in only 2 volunteers from rutin fermentation and was not affected by the presence of 
raftiline. 
Table 3-4 inhibitory effect of raftiline on phenolic acid production from rutin incubation with human faecal bacteria 
Substrate Raf+R 
Conc. at 24h (ug/ml) 
R 
Conc. at 24h (ug/ml) 
 
 P value 
P AA 0.49 ± 1.0 5.60 ± 3.35 P < 0.01(92.5%) 
3-HPPA 0.35 ± 0.15 0.43 ± 0.28 P > 0.05 
4-H PPA 0.15 ± 0.12 0.42 ± 0.59 P > 0.05 
4-HBA      0.05 ± 0.0 0.04 ± 0.02 P > 0.05 
Results are shown as mean values (± SD) at 24 hours in 50ml faecal incubations having 28 umol/L rutin with 1g of raf (n=10), 
R: Rutin, RAF: Raftiline 
 
 
3.3.2 Impact of ispaghula on phenolic acid production from rutin  
Ispaghula was slowly and incompletely fermented; hence it exhibited any impact through fermentation 
at 24 hours post fermentation. The results were compared across time and at 24 hours separately. 
* 
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When ispaghula was fermented alone, it resulted in the production of 3-HPAA in 1 volunteer, 4-HPAA 
in 9 volunteers and 3,4-DHPAA in none of the volunteers. This is similar to results seen from raftiline 
only fermentation.  
 
Figure 3-9 Impact of ispaghula on 3-HPAA production from rutin incubation with human faecal bacteria  
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of ISP 
(n=10), FS: Faecal slurry, R: Rutin, ISP: Ispaghula, ISP+R: Ispaghula+Rutin.  
 
 
 
Figure 3-10 Impact of ispaghula on 4-HPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of ISP 
(n=10), FS: Faecal slurry, R: Rutin, ISP: Ispaghula, ISP+R: Ispaghula+Rutin 
 
 
Ispaghula did not inhibit the production of 3-HPAA or 4-HPAA over the time period of the 
experiment. Further analysis at 24 hours did not indicate any inhibitory effect of ispaghula. 
Similar to these two phenolic acids, 3,4-DHPAA was not inhibited in the presence of ispaghula when 
all time points were considered together, however a further analysis showed an inhibitory effect of 
27.6% by ispaghula at 24 hours post fermentation (p= 0.04, Figure 3-11). 
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Figure 3-11 Impact of ispaghula on 3,4-DHPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of ISP 
(n=10). FS: Faecal slurry, R: Rutin, ISP: Ispaghula, ISP+R: Ispaghula+Rutin 
** at 24 h only p=0.04  
 
As seen in Figure 3-9 and Figure 3-10, 3-HPAA is produced only after 6 hours of fermentation, 4-
HPAA is produced up to 2 hours post fermentation and plateaus thereafter, whereas 3,4-DHPAA is 
rapidly produced only up to 6 hours post fermentation. As seen for 3,4-DHPAA, ispaghula inhibited 
the production of total phenolic acids only at 24 hours post fermentation (p= 0.03 (42.3%), Figure 3-
12) and not across the time period. 
The total phenolic acid production for rutin with or without ispaghula is the same up to 6 hours post 
fermentation, after which ispaghula exhibited an inhibitory impact. 
 
 
Figure 3-12 Impact of ispaghula on total phenolic acid production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of ISP 
(n=10), FS: Faecal slurry, R: Rutin, ISP: Ispaghula, ISP+R: Ispaghula+Rutin, ** at 24 h only p=0.03.  
 
** 
** 
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Ispaghula exhibited an inhibitory effect on PAA production across time (p= 0.0145), the same was not 
seen for 3-HPPA or 4-HPPA across time or at 24 hours post fermentation. In fact, an initial analysis 
demonstrated higher 3-HPPA production from rutin in the presence of ispaghula. This was due to the 
additive effect of high concentrations of 3-HPPA produced from both ispaghula and rutin. To 
determine the inhibitory impact of ispaghula on 3-HPPA production, a predicted value was calculated 
as the sum of 3-HPPA produced from ispaghula only fermentation and rutin only fermentation, this 
was then compared to the concentration obtained from when ispaghula and rutin were incubated 
together. The results did not show any difference between the two, hence we attributed the increased 
amount to the additive effect of 3-HPPA produced from both ispaghula and rutin. 
 
Table 3-5 inhibitory effect of ispaghula on phenolic acid production from rutin 
 
Substrate 
Isp+R 
Conc. at 24h  (ug/ml) 
R 
Conc. at 24h (ug/ml) 
P value 
PAA 2.94 ± 2.6 5.60 ± 3.35 P < 0.01 (47.2%) 
3-HPPA 0.69 ± 0.78 0.43 ± 0.28 P > 0.05 
4-HPPA 0.48 ± 0.69 0.42 ± 0.59 P > 0.05 
4-HBA      0 0.04 ± 0.02 P < 0.01 
Results are shown at 24 hours in 50ml faecal incubations having 28 umol/L rutin with 1g of ISP (n=10), R: Rutin, ISP+R: 
Ispaghula+Rutin 
 
3.3.3 Impact of pectin on phenolic acid production from rutin 
 
Pectin fermentation resulted in the production of 3-HPAA in one volunteer, 4-HPAA in 8 volunteers 
and 3,4-DHPAA in none of the volunteers. Pectin had an inhibitory effect on the production of both of 
these phenolic acids from rutin fermentation (p < 0.01 (89.6%), Figure 3-13 and (74.6%), Figure 3-
14). A similar inhibitory impact (p < 0.01 (66.8%), Figure 3-15) was seen on the production of 3,4-
DHPAA. 
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Figure 3-13 Impact of pectin on 3-HPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of PEC 
(n=10). FS: Faecal slurry, R: Rutin, PEC: Pectin, PEC+R: Pectin+Rutin, *p < 0.01 
 
 
 
Figure 3-14 Impact of pectin on 4-HPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of PEC 
(n=10), FS: Faecal slurry, R: Rutin, PEC: Pectin, PEC+R: Pectin+Rutin, *p < 0.01  
 
The inhibitory effect of pectin on 4-HPAA and 3,4-DHPAA was seen as early as 2 hours post 
fermentation. The total sum of phenolic acid production from rutin was greatly inhibited by 78.1% in 
the presence of pectin (p < 0.01, Figure 3-16). Pectin also showed an inhibitory effect on the 
production of phenolic acids from polyphenolics present in the background diet of the volunteers, 
resulting in higher values for phenolic acids in the control as compared to that of pectin and rutin 
combined, or pectin alone                                 .                                                                                                                                
Pectin inhibited the production of PAA, 3-HPAA, 4-HPAA, 3,4- DHPAA and total phenolic acids. 
This inhibitory effect was not seen for 3-HPPA and 4-HPPA.  
* 
* 
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The production of 4-HBA was not detected in the combination (pectin+rutin) fermentation. 
 
Figure 3-15 Impact of pectin on 3,4-DHPAA production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of PEC 
(n=10), FS: Faecal slurry, R: Rutin, PEC: Pectin, PEC+R: Pectin+Rutin, *p < 0.01 
 
 
 
Figure 3-16 Impact of pectin on total phenolic acid production from rutin incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile in 50ml faecal incubations having 28 umol/L rutin with 1g of PEC 
(n=10) FS: Faecal slurry, R: Rutin, PEC: Pectin, PEC+R: Pectin+Rutin, *p < 0.01 
 
 
Table 3-6 inhibitory effect of pectin on phenolic acid production from rutin incubation with human faecal bacteria 
Substrate Pec+R 
Conc. at 24h (ug/ml) 
R 
Conc. at 24h (ug/ml) 
 
 P value 
P AA 0.29 ± 0.54 5.60 ± 3.35 P < 0.01 (95%) 
3-HPPA 0.40 ± 0.18 0.43 ± 0.28 P > 0.05 
4-HPPA 0.10 ± 0.10 0.42 ± 0.59 P < 0.01  
4-HBA      0 0.04 ± 0.02 P < 0.01(n=1) 
Results are mean (± SD) shown at 24 hours in 50ml faecal incubations having 28 umol/L rutin with 1g of PEC (n=10), , R: 
Rutin, PEC+R: Pectin+Rutin 
* 
* 
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3.3.4 Concentration of rutin retrieved as phenolic acids 
To estimate the efficiency in the bacterial metabolism and subsequent breakdown of rutin into phenolic 
acids, a percentage of total sum of 
phenolic acids produced from rutin 
catabolism was calculated (Table 3-3). 
The total sum of phenolic acids 
retrieved was estimated as 11.98  ± 
6.0 ug/ml, accounting for 70% 
(Figure 3-17) of total rutin added to 
fermentation vessels (17.08 ug/ml).   
 
 
 
3.3.5 Impact of rutin and quercetin on fermentation of soluble fibres 
The bacterial metabolism of rutin and quercetin was not expected to produce significant amounts of 
SCFA; hence the SCFA produced from the combination of fibre + rutin/quercetin was compared to that 
of fibre alone to determine if rutin or quercetin had any impact on SCFA production from soluble fibre 
fermentation. Analysis of the results focused mainly on acetic, propionic and butyric acid and the total 
production as the sum of acetic, propionic, butyric, valeric, caproic, enanthic, caprylic, isobutyrate, 
isovalerate and isocaproic acid). 
Inter-individual variation in the gut microbiota of volunteers resulted in high standard deviations for 
SCFA production in these bacterial fermentations. Hence, a further analysis was conducted by 
separating high and low SCFA producers based on the average SCFA production of each fibre.  
The polyphenols rutin and quercetin and their resulting metabolites from bacterial fermentation had no 
impact on the production of acetate, propionate, butyrate or total SCFA from raftiline fermentation. 
The total sum of SCFA production demonstrated a rapid rate of increase up to 6 hours post 
fermentation for raftiline (64%) and pectin (65%) of total SCFA being produced between 0-6 hours; 
whereas majority of ispaghula fermentation took place between 6-24 hours (58%). The proportion of 
individual SCFA production from each fibre is displayed in table 3-7.  
 
Unknown 
30% 
Total sum of 
phenolic acids  
70% 
Figure 3-17 Concentration of 28 umol/ L of rutin retrieved as phenolic acid 
metabolites after faecal incubations with human colonic bacteria. 
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Table 3-7 Proportion of individual SCFA production from fibre fermentations with human faecal bacteria  
Substrate Acetate Propionate Butyrate 
Raftiline 68.3% 9.6% 7% 
Ispaghula 56.7% 27.7% 8.9% 
Pectin 71% 15% 10.5% 
 
The impact of rutin and quercetin on fermentation of fibres was further analysed by partitioning the 
volunteers into two categories of high and low producers of SCFA (Table 3-8) based on the average 
sum of all SCFA produced by the fermentation of fibres. The separate analysis of results for impact of 
rutin and quercetin on SCFA production of high producers and low producers did not demonstrate any 
impact of these polyphenols on the SCFA production from the fibres (Table 3-8).  
 
Table 3-8  Total SCFA concentration for high producers of SCFA from raftiline fermentation with faecal bacteria 
Substrate Total SCFA concentration 
at 6 hours (mmol/l) 
Total SCFA concentration 
at 24 hours (mmol/l) 
Raftiline 49.6 ± 8.4 80.3 ± 8.2 
Raftiline + Rutin 42.6 ± 11.3 76.6  ± 7 
Raftiline + Quercetin 41.9 ± 17.8 80.6 ± 7.4 
Ispaghula 28.5 ± 11.8 76.8 ± 7.8 
Ispaghula + Rutin 29.1 ± 9.5 66.2  ± 4.5 
Ispaghula + Quercetin 28.6 ± 9.7 63 ± 16.5 
Pectin 39.9 ± 15.3 68.7 ± 47.6 
Pectin + Rutin 38.8 ± 9.3 67.5  ± 21.8 
Pectin + Quercetin 38 ± 13.6 59.8 ± 29.2 
Values are mean (± SD) at 6 and 24 hours for 50ml faecal incubations having 28 umol/L rutin / quercetin with 1g of fibre 
(n=5). 
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Figure 3-18 Impact of rutin and quercetin on SCFA production from fibre incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin or quercetin with 
1g of RAF / ISP /PEC (n=10), RAF: Raftiline, RAF+R: Raftiline + Rutin, RAF+Q: Raftiline+Quercetin, ), ISP: Ispaghula, 
ISP+R: Ispaghula + Rutin, ISP+Q: Ispaghula+Quercetin, Pec: Pectin, Pec+R: Pectin + Rutin, Pec+Q: Pectin+Quercetin.
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Figure 3-19 Individual volunteer plots of total SCFA production from raftiline incubation with human faecal bacteria with or without quercetin and rutin 
Values are sum of total SCFA for each volunteer at 6 and 24 hours (n=10). RAF: Raftiline, RR: Raftiline+Rutin and RQ: Raftiline + Querceti
  
Figure 3-20 Individual volunteer plots of total SCFA production from ispaghula incubation with human faecal bacteria with and without quercetin and rutin 
Values are sum of total SCFA for each volunteer at 6 and 24 hours (n=10). ISP: Ispaghula, ISP+R: Ispaghula+Rutin and ISP+Q: Ispaghula + Querceti
  
Figure 3-21 Individual volunteer plots of total SCFA production from pectin incubation with human faecal bacteria with or without quercetin and rutin 
Values are sum of total SCFA for each volunteer at 6 and 24 hours (n=10). PEC: Pectin, PEC+R: Pectin+Rutin and PEC+Q: Pectin+ Quercetin
  
3.3.6 Impact of rutin and quercetin on pH within fermentation vessels 
Change in pH can be used as an indication of bacterial activity and fermentation rate in the batch 
culture model 
3.3.6.1 Measurement of pH in fermentation vessels  
The measurement of pH using the pH meter demonstrated the same results as mentioned above. Rutin 
and quercetin did not impact the pH of raftiline, ispaghula or pectin as seen for all time points for 5 
volunteers or for all volunteers at 6 and 24 hours.  
 
Figure 3-22 pH of control substrates 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin (n=10)  
FS: Faecal slurry, R: Rutin, Q: Quercetin 
 
 
 
Figure 3-23 Impact of rutin and quercetin on the pH of raftiline vessels  
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin with 
1g of RAF (n=10). RAF: Raftiline, RR: Raftiline+Rutin, RQ: Raftiline+Quercetin. 
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Figure 3-24 Impact of rutin and quercetin on the pH of ispaghula vessels 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin with 
1g of ISP (n=10), ISP: Ispaghula ISPR: Ispaghula+Rutin, ISPQ: Ispaghula+Quercetin 
 
 
 
 
Figure 3-25 Impact of rutin and quercetin on the pH of pectin vessels 
Values displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin with 1g of 
PEC (n=10). PEC: Pectin, PR: Pectin+Rutin, PQ: Pectin+Quercetin. 
 
3.3.7 Impact of rutin and quercetin on gas production 
Gas in the head space of fermentation chambers was measured as an indication of bacterial activity and 
rate of fermentation. Rutin and quercetin did not affect the gas volume produced from the fermentation 
of raftiline, ispaghula or pectin. The data presented in this section is the mean cumulative gas 
production ± standard deviation over 24 hours post fermentation. 
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Figure 3-26 Gas productions in fermentation vessels of control substances 
Values Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin 
(n=10)  FS: Faecal slurry, R: Rutin, Q: Quercetin 
 
 
 
 
Figure 3-27 Impact of rutin and quercetin on gas production from raftiline fermentation 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin with 
1g of RAF (n=10). RAF: Raftiline, RR: Raftiline+Rutin, RQ: Raftiline+Quercetin. 
 
 
A non-significant trend was seen over time for higher gas production from the incubation of rutin and 
quercetin as compared to faecal slurry. This would in turn contribute to the higher gas production from 
the combination of raftiline with rutin and quercetin as compared to raftiline alone. 
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Figure 3-28 Impact of rutin and quercetin on gas production from ispaghula fermentation 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin with 
1g of ISP (n=10), ISP: Ispaghula ISPR: Ispaghula+Rutin, ISPQ: Ispaghula+Quercetin 
 
 
 
 
Figure 3-29 Impact of rutin and quercetin on gas production from pectin fermentation 
Values displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin / quercetin with 1g of 
PEC (n=10). PEC: Pectin, PR: Pectin+Rutin, PQ: Pectin+Quercetin. 
 
The reverse trend was seen for ispaghula and pectin compared to raftiline; with rutin and quercetin 
decreasing gas production at 24 hours for ispaghula and across time for pectin when combined with 
quercetin. 
 
 
 141 
 
3.3.8 Summary of results 
The highest produced phenolic acid identified in rutin incubations was found to be PAA, followed by 
3,4-DHPAA and 3-HPAA, demonstrated in Figure 3-2.  
Table 3-9 Summary of soluble fibre inhibition of phenolic acids production from rutin incubation with human faecal 
bacteria 
Phenolic acids Inhibition by  raftiline  Inhibition by ispaghula Inhibition by pectin 
4-Hydroxy benzoic acid  ↓ ↓ 
Phenyl acetic acid ↓ ↓ ↓ 
3-Hydroxy phenyl acetic acid ↓  ↓ 
4-hydroxy phenyl acetic acid ↓  ↓ 
3,4- Dihydroxy phenyl acetic acid ↓ ↓ *at 24 h only ↓ 
3-Hydroxy phenyl propionic acid    
4-Hydroxy phenyl propionic acid    
Sum total of phenolic acids ↓ ↓ *at 24 h only ↓ 
Phenolic acids from background diet ↓ ↓ ↓ 
↓ Significant reduction in profuction of phenolic acid 
 
 
All incubation groups demonstrated a rapid production of 3,4-DHPAA up to 6 hours and a plateu 
thereafter, as well as no production of 3-HPAA up to 6 hours and a rapid production thereafter. 
Suggesting that this phenolic acid is produced as a result of further degradation of 3,4-DHPAA. 
 
 
Figure 3-30 production of 3-HPAA from degradation of 3,4-DHPAA by human colonic microbiota 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 28 umol/L rutin 
 
 142 
 
3.4 Discussion 
 
Seven phenolic acids produced in the incubation vessels using an ex-vivo batch fermentation model 
were identified and quantified:  PAA, 3-HPAA, 4-HPAA, 3,4-DHPAA, 3-HPPA, 4-HPPA and 4-HBA. 
A comparison between phenolic acids identified in this chapter and previous studies is given Table 3-10. 
3,4-DHPAA was a dominant phenolic acid produced in all seven studies from rutin/quercetin colonic 
degradation followed by 3-HPAA produced in six of the studies. The high standard deviations 
presented in the figures were expected due to varying inter-individual microbiota profile and metabolic 
potential. The high standard deviations in actual amounts of products are not relevant to the paired data 
presented in this chapter, where the change for each individual is the key outcome.  
Table 3-10 phenolic acids identified from in-vitro fermentation of rutin/quercetin by human faecal bacterie 
  FS: Faecal slurry, R: Rutin 
 
Majority of PAA was produced from the background diet. The production of this phenolic acid was 
almost completely inhibited from both rutin and the background diet. Previous studies did not detect 
PAA in faecal incubations. This could be due to their analysis methods using LCMS compared to 
GCMS analysis conducted in this chapter. Considering PAA has a low molecular weight, and is non-
polar in its non-conjugated form (Sandler et al., 1982), it is better suited for analysis by the GCMS as it 
may not ionise well in the LCMS. Previous studies have demonstrated low sensitivity of LCMS for 
Phenolic acids Current 
study   
 
Current 
study   
(GCMS) 
Justesen 
et al., 
2000 
(LCMS) 
Aura et 
al., 2002 
(HPLCMS) 
Rechner et 
al.,2004 
(LCMS and 
GCMS) 
Labib et 
al.,2004 
(HPLC-
DAD) 
Jaganath et 
al.,2009 
(HPLC-
PDA-MS2) 
 Main 
source  
rutin/ 
quercetin 
Rutin 
/quercetin 
Rutin/ 
quercetin 
rutin quercetin Rutin/ 
quercetin 
PAA FS, R x      
3-HPAA  FS(n=1,)R x x x x  x 
4-HPAA FS, R x x     
3,4-DHPAA R x x x x x x 
4-HBA R x     x 
3,4-DHBA       x 
3-HPPA FS, R x   x  x 
4-HPPA FS, R x      
3,4-DHPPA R x  x    
3,4-Dihydroxy 
tuluo 
  x   x  
3,4-Dihydroxy 
Benzaldehyde 
  x     
phloroglucinol 
 
     x  
 143 
 
PAA and PBA detection, compared to improved sensitivity of GCMS (Hommes, 1999, Brusilow, 
1991, Yu et al., 2001).  
The production of 3,4-DHPAA was rapid from the degradation of rutin, reaching a plateau concomitant 
with the production of 3-HPAA at 6 hours; suggesting that 3-HPAA was produced from further 
degradation of 3,4-DHPAA. This is in accordance with previous data by Aura et al (2002) obtained 
from an in-vitro batch culture fermentation. They determined 3,4-DHPAA as the primary metabolite 
from rutin degradation. Unlike our study, they detected the presence of these phenolic acids in the 
background diet of the volunteers. This could be attributed to the volunteers ingesting a normal diet 
prior to faecal sample collection in the Aura study as compared to our volunteers, consuming a low 
polyphenol diet for three days prior to faecal sample collection.  
In contrast to these two phenolic acids, majority of 4-HPAA was derived from the background diet. 
The production of 4-HPAA increased up to 2 hours post fermentation and remained steady up to 24 
hours post fermentation, whereas a transient production was seen in the control incubations. The 
production of 3-HPAA, 4-HPAA and 3,4-DHPAA was inhibited across time by pectin and raftiline. 
Ispaghula only inhibited the production of 3,4-DHPAA at 24 hours post fermentation. 
The production of 3-HPPA and 4-HPPA was not inhibited. In fact, an initial glance at the data 
suggested higher concentration of 3-HPPA in the presence of ispaghula. This was attributed to 
phenolic acid produced from ispaghula alone. To confirm this, a predicted value as the sum of 3-HPPA 
produced from ispaghula only and rutin only was compared to the combination incubation of ispaghula 
and rutin together for 3-HPPA and did not result in any difference between the two, confirming that 
ispaghula had no impact on increasing the production of this phenolic acid. Unlike the previous two 
phenolic acids, 4-HBA was inhibited by all the soluble fibres.  
The presence of 3,4-DHBA in the study by Jaganath et al. (2009) and 3,4-DHPPA in the study by Aura 
et al. (2002) was not detected in our study. We speculate that this may be due to the rapid conversion 
of 3,4-DHPPA to 4-HPPA (Jaganath et al., 2009), and 3,4-DHPPA to 3-HPPA. Both of which were 
identified in our samples.  
In the above mentioned study by Jaganath et al, It was proposed that quercetin was the first metabolite 
to be produced from degradation of rutin, followed by 3,4-DHPAA. They also found 3,4-DHPAA to be 
present in the highest concentration compared to other phenolic acids. These results were supportive of 
the observations made by Aura et al. (2002) demonstrating complete degradation of rutin within 60 
minutes of incubation and concomitant production of quercetin which was initiated at 20 minutes, 
however transiently before further degradation to the primary metabolite 3.4-DHPAA. The degradation 
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of quercetin-glucuronides in their study occurred very rapidly with complete degradation of the 
compounds within 20 minutes, this was attributed to the high activity of β-glucosidases and β-
glucuronidases, while the activity of α-rhamnosidases remained low, leading to the slower de-
conjugation of rutin.  
Unlike the above studies determining 3,4-DHPAA as the most produced phenolic acids, our study 
found PAA which was not detected in the above studies as the highest contributor to the total sum of 
phenolic acid production. Although we did not measure the release of quercetin from rutin our results 
are consistent with that of Jaganath et al. (2009) in terms of phenolic acids solely produced from rutin, 
showing 3,4-DHPAA being the highest produced phenolic acid. It is important to note the difference in 
analysis methods between the two studies, the GCMS analysis did not allow for the identification of 
smaller compounds such as PAA not detected in studies using LCMS analysis. The total phenolic acid 
production, calculated as the sum of all phenolic acids produced was greatly inhibited by pectin and 
raftiline across time and ispaghula at 24 hours.  
The detection of phenolic acids in FS alone from the background diet although undesirable, did not 
affect the observations made in this study due to the paired study model. The dietary record of 
volunteers, used as a reference in case of abnormal values, demonstrated compliance to the low 
polyphenol diet. Hence, we speculate the phenolic acids detected in FS alone can either be due to 
inaccurate recording of diet or the release of insoluble phenolics bound to the cell-wall of cereals. 
Studies have shown that phenolic acids bound to the cell-wall of cereals such as brown rice, wheat, rye, 
barley and oats can be released in-vivo and result in a modest and transient increase in plasma phenolic 
acid concentrations. This modest increase is not sufficient to induce health benefits through antioxidant 
properties (Belobrajdic and Bird, 2013). The phenolic acids most associated with the cell-wall of 
cereals belong to the hydroxycinnamic acid group with the most prominent of them identified bound to 
cereal cell-walls being ferulic acid followed by diferulic acids, sinapic acid, p-coumaric acid, caffeic 
acid and benzoic acid derivatives (Vitaglione et al., 2008). These phenolic acids are covalently bound 
to the cell-wall polysaccharides through ester bonds. Ferulic acid is found bound to arabinoxylans by 
the acetylating acid group. Phenolic acids may also be found bound to cell wall pectins (Saura-Calixto 
and Díaz-Rubio, 2007, Hatfield et al., 1999). The amount of these bound phenolics is highly variable; 
they are not absorbed in the small intestine and reach the colon along with the fibres. 
Figure 3-31 represents the speculated catabolic pathway of rutin. The compounds encircled in dashed 
red line were also identified in our study.  
 
 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31 Speculated catabolic pathway of rutin in relation to the findings in this chapter. Adapted from Jaganath et 
al. (2008). Encircled in red line: parent compound, encircled in dashed red line: phenolic acids also identified in the results of 
this chapter from in-vitro catabolism of rutin 
 
3,4-DHBA was encircled in blue even though it was not detected in our study, as the product of its 
degradation (4-HBA) was detected. It is possible that the presence of fermentable fibre in the 
fermentation vessels increased bacteria population, leading to increased activity and thus the early 
disappearance of the intermediate 3,4-DHBA. A similar observation was for the lack of quercetin 
intermediate when glucose was added to fermentation vessels in the Jaganath et al. (2008) study. In 
addition to the metabolites shown in Figure 4-20, we also detected 3,4-DHPPA, 4-HPPA, 4-HPAA and 
PAA. It can be speculated that PAA is derived from further dehydroxylation of some of the compounds 
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detected (eg: 3,4-DHPAA, 3-HPAA and 4-HPAA). 4-HPAA may also be produced from the 
dehydroxylation of 3,4-DHPAA at C-3. Most catabolic pathways of polyphenol compounds are 
speculative. This may be due to the complex family of microbiota with a range of metabolic capacity 
and the impact of other food components such as carbohydrates in the food matrix on the rate at which 
transitory phenolic are utilised. 
It is not known exactly which bacteria are responsible for the catabolism of rutin and quercetin in-vivo, 
however some that have been found to have the ability to do so in-vitro consist of: Eubacterium 
ramulus (for rutin, quercetin-3-glucoside and quercetin aglycone), Butyrivibrio sp (rutin), 
Enterococcus casseliflavus (quercetin 3-glucoside) and Flavonifractor plautii, Eubacterium 
oxidoreducens and Clostridium sp. (Blaut et al., 2003, Winter et al., 1989). The impact of these 
bacteria on rutin and quercetin and subsequent phenolic acid production in-vivo is affected by factors 
such as their interaction with other bacteria, bacterial metabolites and food components such as 
carbohydrates in the colon. 
Cheng et al. (1969), identified and extracted 15 anaerobic bacteria capable of degrading rutin from the 
bovine rumen contents. However the action of different bacteria resulted in different end products from 
rutin degradation. The bacterial species, Butyrivibrio fibrisolvens D1 and Selenomonas ruminantium 
GA192, cleaved the glycosidic bond of rutin and fermented the released sugar moiety but failed to 
degrade the released insoluble aglycone; Unlike these two bacteria, Peptostreptococcus sp. B178 
degraded the substrate to soluble products. This was further demonstrated in an in-vitro study 
(Schneider et al., 1999) investigating the degradation of quercetin-glucosides by the two bacteria 
Entero-coccus casseliflavus and Eubacterium ramulus. While Entero-coccus casseliflavus only utilised 
the glucose moiety of the compound, Eubacterium ramulus also cleaved the A and C ring. Interestingly 
this bacteria was only capable of degrading quercetin in the presence of 10-20 mM of glucose and not 
in its absence. A review by Selma et al (Selma et al., 2009) has demonstrated that Bacteroides 
uniformis and Bacteroides ovatus are responsible for the conversion of rutin to quercetin while the 
conversion of quercetin to 3,4-DHPAA involves Clostridium orbiscindens, Eubacterium 
oxidoreducens and Butyrivibrio spp. 
The impact of carbohydrates on colonic metabolism of rutin has not been investigated sufficiently. The 
study by Jaganath et al. (2009) demonstrated that the addition of 0.5g glucose to incubation vessels not 
only increases rate of rutin deconjugation leading to increased phenolic acids, but also alters the 
catabolic pathway possibly by causing a shift in microbiota composition. This was seen when the 
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conversion of 3,4-DHBA was directed toward the production of 4-HBA in the absence of glucose, and 
toward the production of HPAA derivatives in the presence of glucose.   
The above mentioned studies have all investigated the impact of glucose, readily available as a 
substrate for bacteria on the metabolite production from rutin in-vitro as a model for fermentable 
fibres. While the Eubacterium and Clostridium species seem to be involved in the degradation of rutin 
and quercetin, the fermentation of raftiline, ispaghula and pectin is more dependent on the bacterial 
species Bacteriodes, representing one of the major species in the colon (Discussed in Chapter-1).  
In our results we observed that the fibres having higher fermentability (raftiline) had more inhibitory 
impact on the phenolic acid production from rutin degradation than the fibre having higher viscosity 
and lower fermentability (ispaghula). We did not measure viscosity of fibres in this study and 
fermentability was estimated according to the concentration of SCFA production from fibre 
fermentation. It is possible that the fermentability of these fibres promotes the Bacteriodes species, thus 
reducing the activity of competing bacterial species responsible for rutin and quercetin degradation. 
This may also be induced through a reduction of pH due to SCFA accumulation. Additionally we did 
not detect an inhibitory impact on the higher molecular weight phenolic acids: 3-HPPA and 4-HPPA 
which were detected in incubation vessels in very low concentrations, possibly owing to their 
conversion to lower molecular weight phenolics. The low concentration of these two phenolic acids 
may have also resulted in a small effect size as a slight but non-significant trend for inhibition of these 
phenolic acids by raftiline and pectin was observed. 
As expected the fermentation of the three different soluble fibres resulted in different proportions of 
SCFA produced by each fibre (Paturi et al., 2012, Chen et al., 2010). The pattern of SCFA production 
differed between the three fibres with raftiline having the highest relative molar ratio of butyrate, 
ispaghula having the highest molar ratio of propionate and pectin having the highest molar ratio of 
acetate. This difference in pattern of SCFA production relative to these fibres has been previously 
demonstrated in various studies (Timm et al., 2010, Chen et al., 2010) and summarised in Table 1-1. 
The total sum of SCFA production was highest for raftiline compared to ispaghula and pectin. This 
sum total of SCFA was mostly made of acetate, propionate and butyrate, which represented 92.3%, 
93.6% and 96.7% of total SCFA production for raftiline, ispaghula and pectin respectively. Despite 
efforts to reduce inter-individual differences through diet and time of sample processed; there were 
factors beyond our control. Certain volunteers had a tendency to ferment pectin much more than the 
other fibres. An example of this was volunteer-4, exhibiting approximately double the concentration of 
all SCFA through the fermentation of pectin compared to the mean values obtained from the other nine 
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volunteers. Even though this does not affect the results of the study due to the samples being paired, it 
does result in very high standard deviations. 
In this study we did not detect any impact of the polyphenols rutin and quercetin or their colonic 
metabolites on the pH, gas production or SCFA production from raftiline, ispaghula or pectin. The 
individual plot of outcomes did not demonstrate any pattern for the impact of rutin or quercetin on total 
SCFA production. The lack of impact of rutin and its metabolites on the pH in fermentation vessels 
was also demonstrated in an in-vitro fermentation study by Aura et al. (2002) over 24 hours of 
incubation.  
There have been no previous studies on the interaction of rutin and quercetin with the fibres raftiline, 
ispaghula and pectin. Most studies have been developed to observe the antibacterial and antimicrobial 
properties of these polyphenols and not their impact on the colonic metabolite production of these 
bacteria. These studies can only provide an assumption that the possible antibacterial activity of these 
polyphenols will result in a different SCFA production from fibre. We did not detect this at a 
concentration of 28 umol/l for rutin and quercetin. 
 However in an in-vitro study, Rodriguez Vaquero et al. (2010) demonstrated antibacterial activity for 
both rutin and quercetin (summarised in table Table 1-9), they also demonstrated a synergistic impact 
when rutin and quercetin were mixed, whereas the addition of rutin to catechin resulted in an additive 
effect.  The results are contradictory to many other studies not demonstrating any impact of rutin on 
bacterial growth (Arima et al., 2002, Parkar et al., 2008, Duda-Chodak, 2012). A possible explanation 
for this could be the use of 99.8% ethanol to dissolve phenolics used in this study, as well as the 
addition of ethanol to incubation plates to reach a concentration of 5% (v/v). Ethanol is toxic to 
bacteria at concentrations > 3% especially to more sensitive gram-negative bacteria such as E.coli. The 
use of 5% ethanol as a negative control may have corrected for this toxic effect to an extent. In studies 
using more standardised methods such as broth micro-dilution method (Parker et al., 2008) and using 
DMSO as a solvent (Arima et al.,2002), rutin did not demonstrate any inhibition on bacterial growth 
even at concentrations of 1000 ug/ml, while quercetin inhibited the growth at the lowest MIC (62.5 
ug/ml and 250 ug/ml respectively). Interestingly even though rutin had no impact on its own, when it 
was mixed with quercetin, the MIC required for inhibition of bacteria reduced to 100 and 200 ug/ml 
respectively. The authors were not able to find an explanatory mechanism for this synergistic impact.  
Most studies, looking into the antibacterial activity of rutin or quercetin have focused on specific 
bacterial species in an in-vitro model. The study undertaken in this chapter is more complex. This 
study introduces the food matrix interaction between fibre and polyphenols in an ex-vivo condition. 
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Hence, it is important to consider the prebiotic potential of the soluble fibres in conjunction to the 
antibacterial properties of the polyphenols. While rutin and quercetin might have had some 
antibacterial activity this could have been ameliorated by the prebiotic activity of the fibres. 
Interestingly, the above studies have demonstrated that the lactic acid bacteria such as lactobacillus are 
more resistant to the antibacterial activity of polyphenols (Parkar et al., 2008, Duda-Chodak, 2012, Lee 
et al., 2006), this information coupled with the ability of the soluble fibres to enhance the growth of 
probiotic bacteria such as Bifidobacteria and Lactobacillus, especially in-vivo, as the partial hydrolysis 
of ispaghula and pectin has shown to increase their prebiotic potential (Olano‐Martin et al., 2002, 
Salyers et al., 1978, Kolida et al., 2002, Marteau et al., 1994). This may lead to a shift in bacterial 
composition, which may or may not reflect in their metabolite production. There are other factors that 
can play into the results obtained in this study, such as the reduction of the pH in the incubation bottles 
as a result of fermentation.  
Additionally, the studies discussed above have used high concentrations of polyphenols mainly for 
their application in the pharmacology and food industry. However intake of these polyphenols at such 
high concentrations may prove toxic (Scalbert et al., 2002). Additionally many of the above studies 
claimed antibacterial activity at MIC > 100 ug/ml whereas the application of these antimicrobial agents 
is possible and of relevance only at MIC <100 ug/ml and of great interest at MIC <10 ug/ml (Rios and 
Recio, 2005). The concentration of rutin and quercetin used in our study (17.0 ug/ml rutin and 8.46 
ug/ml quercetin) was much lower than the lowest MIC found for these compounds in-vitro. 
Additionally the in-vitro studies have not taken into consideration the bioavailability of these 
compounds, whereas the concentration of rutin and quercetin used in our study is based on their 
physiological bioavailability as recovered in the ileal fluid of patients 0-24 hours after consuming 
tomato juice supplemented with 17 5umol/L rutin (Jaganath et al., 2006a).  
The in-vitro studies investigating the antibacterial impact of polyphenols on bacteria have based their 
observations on prolonged periods of incubation of these bacteria along with the polyphenols. Previous 
studies have shown that quercetin is almost completely degraded by the colonic microbiota within 6 
hours (Jaganath et al., 2009), whereas in an in-vitro study the complete degradation of quercetin-
glucuronides took place within 20 minutes and 60 minutes for rutin (Aura et al., 2002) thus yielding 
lower weight phenolic acids. Despite in-vitro studies demonstrating strong antibacterial impacts of 
these phenolic acids, these outcomes are highly dependent on the accumulation and prolonged 
interaction of these phenolic acids with gut microbiota. However in-vivo these phenolic acids are 
absorbed and enter circulation where they are further metabolised and utilised by various tissues 
preventing their accumulation in concentrations as high as those used in in-vitro studies.  
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It is difficult to draw an accurate comparison and conclusion from current studies relevant to this 
chapter, due to the use of various different strains of bacteria, concentrations and medium of 
polyphenols investigated and methods of analysis; all of which have shown to have an impact on the 
extent of antibacterial potential. 
We have studied SCFA in this study as an indication of fibre fermentation and bacterial activity. 
However we cannot say with complete certainty that our results conclude that rutin and quercetin have 
had no antibacterial activity. These polyphenols might have had an inhibition effect on specific strains 
of bacteria as demonstrated and discussed above, which may have not reflected in the overall SCFA 
production. Our objective was to study the interaction of fibre and polyphenol and to observe the effect 
of polyphenols and soluble fibre on the metabolite production from the gut microbiota. Based on this 
we did not observe any impact of polyphenols on SCFA production from fibre, however there was a 
strong impact of soluble fibres on the phenolic acid production from the polyphenols. 
 
 
3.5 Conclusion 
 
Soluble fibres, especially highly fermented soluble fibres inhibit phenolic acid production from the 
degradation of rutin by human faecal bacteria. Whereas the polyphenols: rutin and quercetin have no 
impact on SCFA production from fibre fermentation.  
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CHAPTER 4                                          
Matrix interaction between cocoa 
polyphenols and the soluble fibres 
raftiline, ispaghula and pectin, on their 
metabolism by colonic bacteria- ex-
vivo  
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Cocoa is widely consumed worldwide. The health benefits associated with consumption of cocoa have 
been attributed to its high polyphenol content and their colonic metabolites. Thus it is important to 
determine the factors influencing the bioavailability of these polyphenols. Information on the impact of 
food matrix interaction between carbohydrates, especially fibre on the colonic phenolic acid production 
from cocoa is scarce. In this chapter we investigate the impact of cocoa polyphenols and phenolic acids 
on colonic metabolite production from soluble fibres, as well as the impact of soluble fibres, present in 
many cocoa products on the phenolic acid production from cocoa. 
 
4.1 Introduction 
 
Cocoa is widely consumed in the form of confectionary, chocolate products and beverages. It is a rich 
source of polyphenols (Detailed in Chapter -1), mainly the monomers (+)-catechin, (-)-epicatechin and 
their derived polymers known as procyanidins (Massot-Cladera et al., 2012). It is estimated that cocoa 
contributes towards 20% of total catechin consumption (Arts et al., 1999) also having a higher 
concentration of polyphenols per dose of consumption than tea or red wine (Lee et al., 2003) and 
higher procyanidin content than that of cranberries and blue berries on a dry weight basis (Gu et al., 
2002). Dark chocolate (100g) contains on average, 42 mg (-)-epicatechin and 12 mg (+)-catechin 
(Tzounis et al., 2008a). The total polyphenol concentration in chocolate is dependent on the type of 
chocolate, and varies depending on the method of analysis. The total phenol content in dark chocolate, 
milk chocolate and cocoa powder may vary from 8.4, 5 and 20 mg/g respectively when measured as 
gallic acid equivalent (Waterhouse et al., 1996) to 36.5, 15 and 65  mg/g respectively when measured 
as catechin equivalent (Vinson et al., 1999).  
Consumption of cocoa has been associated with increased levels of plasma antioxidants preventing 
LDL oxidation (Waterhouse et al., 1996, Salah et al., 1995, Pearson et al., 2001). Additionally cocoa 
flavanols have demonstrated the ability to increase nitric oxide synthesis, suppress platelet activation, 
positively modulate eicosanoid synthesis, inhibit the production of certain pro-inflammatory cytokines 
and stimulate the production of anti-inflammatory cytokines (Andújar et al., 2012, Zhu et al., 2002). 
All of these potent biological properties of cocoa polyphenols may contribute towards their health 
benefits; such as protective mechanism in heart disease and anti-carcinogenic properties. However, 
these beneficial properties exhibited by cocoa are largely dependent on its polyphenol content and their 
antioxidant properties. Hence, the bioavailability of these polyphenols is of great importance, as it 
would determine the extent of impact cocoa may exhibit on health.  
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However not all of these polyphenolic compounds are readily available for absorption. 20% of ingested 
epicatechin (Auger et al., 2008) as well as 90% of ingested procyanidins have been found in the 
ileostomy bags of patients (Kahle et al., 2007). The absorption of these compounds from the small 
intestine has been studied in ileostomy patients and summarised below (Table 4-1). 
 
Table 4-1Type and amount of cocoa polyphenols available for colonic microbiota degradation 
Author Feed Main component in feed Concentration 
of component 
in feed 
Recovery of 
component in 
ileal fluid 
% of 
ingested 
dose 
Kahle et 
al (2007) 
Cloudy apple 
juice  
(1 L) 
Catechin 
Epicatechin 
Oligomeric procyanidins 
10.3 umol 
51.7 umol 
97.9 umol 
    - 
8.8 umol 
88.4 umol 
0% 
17% 
90.2% 
Auger et 
al  (2008) 
Polyphenol E 
(200mg) 
Flavan-3-ol monomers: 
(–)-epicatechin 
(–)-Epigallocatechin-3-gallate 
(–)-epicatechin-3-gallate 
(−)-epigallocatechin 
(+)-Gallocatechin gallate 
452 umol: 
71 umol 
310 umol 
32 umol 
18 umol 
- 
194 umol 
15umol 
160umol 
11umol 
- 
7.8 umol 
43% 
21% 
52% 
34% 
- 
71% 
Stalmach 
et al  
(2010) 
Green tea 
(300ml) 
Total flavan-3-ols: 
(+)-catechin 
(-)-Epicatechin 
(+)-Gallocatechin 
(-)-Epigallocatechin 
(-)-epigallocatechin-3-O-gallate 
(+)-Gallocatechin-3-O-gallate 
(-)-Epicatechin-O-gallate 
634 umol: 
18 umol 
69 umol 
50 umol 
190 umol 
238 umol 
5.2 umol 
64 umol 
207 umol 
1.2 umol 
7.9 umol 
13 umol 
35 umol 
116 umol 
4.6 umol 
29 umol 
33% 
6.8% 
11% 
27% 
18% 
49% 
89% 
45% 
Hagl et al  
(2011) 
 
Apple 
smoothie  
(0.7 L) 
Catechin  
Epicatechin  
Procyanidins 
1.1 mg 
1.3 mg 
1136.3 mg 
0.4mg 
0.7mg 
705.6mg 
36.3% 
53.8% 
62% 
 
 
The least absorbed compounds are procyanidins followed by epicatechin and catechin. The recovered 
polyphenolic compounds in the ileal fluid would be available for colonic degradation by gut microbiota 
in healthy individuals. The colonic degradation products of cocoa or pure polyphenols present in cocoa 
have been summarised in table Table 4-2. 
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Table 4-2 Phenolic acid production from cocoa or cocoa polyphenols in in-vitro fermentation models 
Author  
( year) 
Study method   Phenolic acid production 
(Déprez et 
al., 2000) 
in-vitro fermentation (n=1) 
In-vitro fermentation (48h) with procyanidin or  150 
or 100 mmol/L expressed 
4-HPAA, , 3-HPAA, PPA, 4-HPPA, 3-HPPA, 3-
hydroxy phenyl valeric acid 
(Bazzocco 
et al., 2008) 
 Digestion followed by in-vitro fermentation 
apple – short PA chains and long PA chains 
 
3,4-DHPPA, 3-HPPA, 3-PPA, BA, 3,4-DHPAA, 3-
HPAA 
Tzounis et 
al  
(2008)  
In-vitro fermentation   (n=3) 
150mg/L or 1000 mg/L of catechin / epicatechin  
 
 
Phenolic acids from (-)-epicatechin: 
5-(3,4-DHP)—valerolactone,   PPA, 5-phenyl—
valerolactone 
Phenolic acids from (+)-catechin: 
(+)-epicatechin, 5-(3,4-DHP)—valerolactone, 5-
phenyl—valerolactone 
Appeldoorn 
et al (2009) 
In-vitro fermentation (N=4 pooled) 
Mixture of procyanidins dimmers (5umol)  
 
3,4-DHPAA, 3,4-DHPVA, 3-HPAA, 4-HPAA, 3-
HPPA, PVA,  Monohydroxylated 
phenylvalerolactone and 1-(3,4-dihydroxyphenyl)-
3-(2,4,6-trihydroxyphenyl) propan-2-ol 
Roowi et al  
2009 
In-vitro fermentation  N=3  
epicatechin   
 
4-HPAA, 3-HPAA, 3-HPPA (54%) , 5-(3,4-
dihydroxyphenyl)-γ-Valerolactone  (38%) , 5-(3,4-
dihydroxyphenyl)-valeric acid (32%). 
Stoupi et al 
(2010) 
In-vitro fermentation (N=1) 
5mM (-)-epicatechin/ 5mM Dimer B2 
1-(3,4-DHP)-3-(2,4,6-THP)- propan-2-ol,  1-(HP)-
3-(2,4,6-THP)-propan-2-ol,   5-(3,4-DHP)-γ-
valerolactone,  3-HPPA 
(Fogliano et 
al., 2011) 
In-vitro fermentation (N=1) 
Insoluble-fraction of cocoa  
20g of cocoa in 120ml of water digested, followed by 
dialysis and freeze drying 
A concentration of 1% w/v used.  
3-HPAA, 3-HPPA, 3,4-DHBA 
-and an unknown compound with MRM  
fragmentation peak of m/z 289245 
Dall‘Asta et 
al (2012) 
In-vitro fermentation (N=3) 
(i)- FS+ 9%  chocolate extract (90% chocolate) 
5-(3,4-DHP)- γ-valerolactone, 3,4-DHPAA, 
protocatechuic, HBA 
 
As shown in the above table, most research is based on degradation of pure polyphenolic compounds 
by the gut microbiota and very little information is available on the fate of these polyphenols as present 
in the cocoa matrix upon being subjected to the action of gut microbiota. Often these polyphenols are 
extracted from other food sources such as apple and green tea which may contain different length 
proanthocyanidin chains, which has shown to affect their colonic metabolites (Bazzocco et al., 2008). 
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As mentioned above, majority of cocoa polyphenols are not readily absorbed by the small intestine, 
thus reaching the colon where they are converted to phenolic acids. Hence it is possible that phenolic 
acids and not necessarily their parent compounds are responsible for the health benefits (Chapter-1) 
exhibited by cocoa. However information in this area is very limited, additionally these polyphenolic 
compounds are most often present in association with fibres, which are also subjected to colonic 
microbiota action. 
 Previously, the cocoa shell was considered to be a waste product of the bean. It was either used as fuel 
or garden mulch after being composted. However, recently the treated and ground cocoa shell is being 
sold as cocoa fibre. Depending on local regulations, these products can sometimes be incorporated into 
cocoa powder or chocolate to increase product fibre content. Similarly, some cocoa products such as 
cereal bars and breakfast cereals contain soluble fibre. The food matrix interaction between fibre and 
cocoa on the bioavailability of their metabolites is of importance, given that cocoa and fibre health 
benefits, associated with their metabolites, are increasingly being promoted. In this chapter we 
incubated the three soluble fibres ispaghula, raftiline and pectin having various physio-chemical 
properties such as fermentability and viscosity with cocoa in an ex-vivo faecal incubation model.  
In a similar study to that conducted in this chapter, Tzounis et al. (2008) conducted a continuous in-
vitro fermentation model (Summarised in Table 1-7) incubating 150 mg/L or 1000 mg/L of (+)-
catechin and (-)-epicatechin in the presence or absence of sucrose, and / or fructo-oligosaccharides. 
Both catechin and epicatechin displayed higher bacterial metabolism in the presence of both sucrose 
and fructo-oligosaccharides. Unfortunately the impact of sucrose and FOS on the amount and kind of 
phenolic acid production was not described. 
While simple sugars and prebiotics can enhance the deglycosilation of parent compounds reaching the 
colon and increase phenolic acid production, there is not enough evidence on the impact of more 
complex carbohydrates such as soluble fibres on phenolic acid production from polyphenols. In a study 
by Bazzocco et al. (2008) detailed in Table 1-7, briefly, long or short chain proanthocyanidn extract of 
apples were incubated with 100 mg of cell-wall preparation containing pectin. Cell-wall preparations 
delayed the maximal extent of conversion from 4 hours to 8 hours post incubation of proanthocyanidin, 
without affecting the total concentration of phenolic acid production. Additionally the maximum extent 
of conversion for apples was much later (6hours) than their proanthocyanidin extracts (2hours).  
To our best knowledge, there have been no previous food matrix studies investigating the impact of 
soluble fibre on the phenolic acid production from cocoa. Most food matrix interaction studies on the 
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impact of carbohydrates on cocoa polyphenol bioavailability are conducted in-vivo and investigate the 
impact of simple carbohydrates such as glucose and bread (Table 1-7). 
Carbohydrates such as fibre present in the colon are the preferred source of energy for the microbiota 
(Tzounis et al., 2008a), thus limiting the degradation of polyphenolic compounds and consequent 
phenolic acid production. Additionally the production and accumulation of SCFA through fibre 
fermentation may indirectly impact phenolic acid production by lowering the colonic pH, which has 
demonstrated an impact on colonic microbiota composition (summarised in chapter-1). Additionally 
SCFA may have a direct impact on specific bacterial species, as seen that the growth of Bifidobacteria 
was enhanced in the presence of propionate (Arora et al., 2011). Interestingly studies have 
demonstrated that cocoa polyphenols inhibit Bacteroides (Lee et al., 2006) growth and either increase 
or have no impact on the growth of Lactobacillus and Bifidobacteria. 
Indeed, there is some evidence of a prebiotic effect of cocoa polyphenols. The impact of a cocoa drink 
on faecal microbiota was investigated in a long-term study (summarised in Table 1-8) by Tzounis et al. 
(2011), where volunteers were supplemented with either a high cocoa flavonol drink (494mg total 
cocoa flavanols) or a low cocoa flavonol drink (29mg total cocoa flavanols). The cocoa drinks were 
matched for macro / micro mineral and fibre content. This study demonstrated modification in bacterial 
composition with changes in Bifidobacterium spp, C. histolyticum group, E. rectale–C. coccoides 
group, Lactobacillus and Enterococcus spp for both interventions. However the high cocoa flavanol 
drink demonstrated a greater increase in Lactobacillus and Enterococcus spp than the low flavonoid 
intervention (p < 0.01), as well as an in increase in Bifidobacterium spp not observed for the low 
flavonoid group. Additionally the high flavonoid intervention resulted in a decrease in C. histolyticum 
as opposed to its increase in the low flavonoid group (p <0.01). Interestingly the authors demonstrated 
a similar increase in Lactobacillus spp. (p <0.01) and Bifidobacterium spp (p <0.05) and decrease in C. 
histolyticum group (P <0.01) in an in-vitro faecal incubation model using a high-flavanol cocoa-
powder extract (1 mg extract/mL; amounting to ≈0.4 mg/mL flavanols) containing less than 1% 
(10mg) of fibre. 
 A comparison of the recent Tzounis et al. (2011) study to a previous study by the same authors 
(2008a), demonstrates that the matrix in which cocoa polyphenols are introduced in, plays an important 
role on their pre/antibiotic properties. Contradicting their previous study the cocoa matrix did not result 
in the modification of the coccoides–E. rectale group. It was suggested that the Lactobacillus spp. uses 
the oligomers preferentially by catabolising them, whereas the same may be said in the case of the 
coccoides–E. rectale group and the monomers. The authors attributed the lack of increase in 
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coccoides–E. rectale to the presence of more complex phenolic compounds such as the oligomers, as 
these observations were replicated in their in-vitro study using a cocoa extract. However it is possible 
that the presence of fibre in the most recent study contributed to the observations made (= 3-4g in the 
in-vivo study and 10 mg/ml in the in-vitro study compared to 25mg/ml in our study). It is also 
interesting to note that their 2008 study mostly demonstrated a prebiotic impact at lower concentrations 
(150 ug/ml), whereas higher concentrations (1000 ug/ml) resulted in an inhibitory impact on bacteria. 
Thus both matrix in which polyphenols are presented and their concentration is of importance in such 
studies. 
Similar observations were made by Massot- Cladera et al (2012) by enriching the diet of wistar rats 
with 10% (w/w) cocoa (10.6 mg/g polyphenols) compared to a standard diet (summarised in Table 1-
8). The diets were isoenergetic, with similar levels of insoluble fibre, however the cocoa diet was 
higher in soluble fibre and polyphenols. They detected a reduction in Bacteroides, Clostridium and 
Staphylococcus (p < 0.05). It is possible that this resulted in an increase in other bacterial species, as 
the total number of bacterial count was not affected (Massot et al., 2012).  
Although it is important to investigate the impact of cocoa as a whole matrix on the gut bacteria, it is 
also important to note that cocoa products especially cocoa powder contain dietary fibre which could 
be a contributing factor to the prebiotic effect observed in the Tzounis et al. (2011) study.  
Thus for the better understanding of the impact of polyphenols on the faecal bacteria it is essential to 
investigate the impact of these polyphenols outside the cocoa matrix, eliminating the impact of any 
other components present in the cocoa matrix.  
One such study was carried out by Smith and Mackie (2004) demonstrating that long term (3.5 weeks) 
consumption of 0.7% and 2% proanthocyanidins in rats significantly increased the number of tannin 
resistant bacteria (p<0.05), while gram-positive bacteria decreased in the presence of the 
proanthocyanidins. The post-proanthocyanidin diet analysis of faecal bacteria demonstrated a return of 
tannin resistant bacteria to pre-treatment numbers.  
Most other studies investigating the impact of extracted polyphenols on the microbiota have been 
carried out in-vitro and summarised in Table 1-8. Duda-Chodak (2012) did not find any impact of 
catechin on the probiotics nor the pathogenic bacteria. A similar in-vitro study was conducted by 
Parkar et al (2008) using the more standardised broth microdilution technique according to the CLSI 
guidelines for analytical methods. Different concentrations of catechin and epicatechin were required 
to induce growth inhibition on different species.  
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The above mentioned in-vitro studies are mostly conducted for the use of polyphenolics as 
antimicrobial agents in the pharmaceutical industry. With many of these studies investigating the 
antibacterial effect of cocoa polyphenols on specific pathogenic bacteria, especially those threatening 
oral health (Bakri and Douglas, 2005, Choi et al., 2012, Petti and Scully, 2009). The concentrations 
used in these studies once translated into cocoa consumption are not physiological. As previously 
mentioned, 100g of cocoa (= 1 chocolate slab or > 4 cups of cocoa beverage) contains12 mg catechin 
and 42 mg epicatechin, keeping in mind that only 20% of these epi/catechins will reach the colon (~4 
and 8.4 mg). The concentration of these polyphenols in the above studies vary from 20-1000 ug/ml 
(20, 100, 250, 500, 1000 ug/ml); in-vivo this translates to 6, 30, 75, 150 and 300 mg respectively in the 
colon (considering 300 ml of colonic content). These concentrations cannot be physiologically 
achieved through cocoa consumption. Moreover, these studies have not taken into consideration the 
fate of catechins in-vivo. The above results were obtained from continuous exposure of the bacteria to 
epi/catechin over 24 hours, whereas these compounds will be degraded to lower molecular weight 
phenolic acids by the microbiota. Hence, even though epi/catechins failed to have a strong antibacterial 
impact, it is possible that they may exhibit their antibacterial properties through their colonic 
metabolites.  
Lee et al (2006) conducted a study investigating the impact of phenolics from catechin degradation on 
the faecal bacteria. They incubated 28 pathogenic and prebiotic strains (5% inoculum) in a broth with 
or without 1% epicatechin, catechin, 3-O-methyl gallic acid, gallic acid and caffeic acid, 3-PPA, 4-
HPAA and 4-HPPA. The results of this study supported previous studies demonstrating a general 
inhibition of pathogenic bacteria (Clostridium perfrigens, Clostridium difficile and Bacteroides. spp) 
especially by the phenolic acid derivatives and a small to no impact on the prebiotic bacteria (such as 
Clostridium spp, Bifidobacterium spp and Lactobacillius). Thus demonstrating that epi/catechins and 
their metabolites and not only fibre can impart a prebiotic effect. However more research is required in 
this area.  
These studies investigated only the impact of polyphenols on bacterial populations but not the impact 
of this antimicrobial activity on metabolite production from the colonic bacteria. Bazzocco et al (2008) 
investigated the impact of apple proanthocyanidins on the SCFA production from apple cell wall 
preparations (containing pectin). They found an inhibitory effect of apple PA on SCFA production 
with a correlation between PA chain length and inhibitory impact. Extracts with longer PA chains 
displayed a greater inhibitory impact on SCFA production than shorter chain PA. Unfortunately the 
extent of inhibition was not discussed. However this impact was not seen for apples when the PA was 
 159 
 
present in the matrix (impact of apple). They found acetate to be the highest SCFA produced, followed 
by butyrate and propionate. 
In another study Kemperman et al. (2013) investigated the impact of 1000 mg/day of tea extract 
polyphenols on the growth of gut microbiota and their metabolite production for 2 weeks in a 
Simulator of Human Intestinal Microbial Ecosystem (SHIM). In addition to the antimicrobial activity 
seen by the tea extract, a reduction in butyrate concentration in the proximal colon was demonstrated 
(from ~15mM to ~10mM), which was attributed to the inhibition of butyrate producing bacteria. 
Towards the end of the study a drastic reduction in total SCFA (data not provided) and acetate (from 
~30mM to ~22mM) concentration was demonstrated. This reduction in SCFA production 
corresponded to reduction in bacterial numbers observed.  Even though this in-vitro model is ideal for 
studying the longer-term impact of polyphenols on gut bacteria in-vitro, there is still the lack of other 
factors such as host-bacteria inter-relationship and presence of other influencing food matrix 
interactions. 
To our knowledge there have been no previous studies investigating the matrix interaction of cocoa 
polyphenols and soluble fibres on their metabolites from gut microbiota 
 
4.2 Hypothesis 
 
To test the hypothesis that soluble fibres change phenolic acid production from cocoa polyphenols in 
the colon by fermentation related mechanisms, and that potential antibacterial properties of cocoa 
polyphenols and their colonic metabolites inhibit the production of SCFA from the microbial 
fermentation of soluble fibres. 
 
  
4.3 Materials and methods 
 
4.3.1 Study design 
The study was an ex-vivo model of the gut, using faeces from ten human volunteers as a sample 
representation of the gut microbiota. Volunteers followed a three day low polyphenol diet; avoiding 
fruits, vegetables and beverages high in polyphenols such as tea, coffee and cocoa milk (Appendix-1). 
On the 4
th
 day faeces was collected from volunteers according to the method described in 2.1 Faecal 
sample collection. 
4.3.2 Participants 
For this ex-vivo fermentation, fresh faecal sample was collected from For this ex-vivo batch 
fermentation, fresh faecal sample was collected from healthy volunteers (n=10) with a mean (± SD) 
BMI of 22.4 ± 2.9 (range, 18.9 to 27.4) and a mean (± SD) of 23.6 ± 4.0 years (range, 19 to 33) 
Volunteers were non-smokers who had not received antibiotics, constipation remedies or probiotics for 
at least three months prior to start of the study.  
Table 4-3 Participant characteristics 
 gender Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(Kg/m2) 
Waist 
circumference 
(cm) 
Blood     
pressure 
(mmHg) 
1 F 22 160 50.5 19.7 73.5 112/80 
2 M 22 175.8 84 27.4 96 125/60 
3 F 19 161 47.9 18.4 77 109/71 
4 F 21 158 63.9 25.6 73 129/67 
5 F 21 156 54 22.2 80 119/71 
6 F 26 174 57.2 18.9 78 107/59 
7 F 25 161 54.3 20.9 83.5 112/80 
8 M 23 183 77.8 23.2 91 143/83 
9 M 33 175 76 24.8 93 165/63 
10 M 23 176 72.2 23.3 93 114/72 
Mean ± 
STDEV 
 23.6 
±4.0 
168.8  
± 9.8 
65.3 
± 12.7 
22.4 
± 2.9 
84.9 
± 8.4 
124.7 / 69.5 
 ± 18.8 / 8.3 
 4.3.3 Ex-vivo fermentation 
Ten ex-vivo fermentations were carried out according to the method described in 2.2 Ex-vivo Modelling 
of anaerobic colonic fermentation. The incubation bottles contained faecal slurry alone, or with one of 
seven possible combinations of fibre and/or cocoa. Incubation was allowed for 24 hours and samples 
for phenolic acid analysis were taken at 0, 2, 6 and 24 hours.  
 
 
Figure 4-1 Substrate combinations for faecal fermentation. 
 
 
4.3.4 Materials  
1g of the soluble fibres: Ispaghula husk (Whole ispaghula husk – myprotein.com), pectin (pectin apple- 
250 grade, BDH laboratory supplies) and raftiline (Siber Hegner Ltd) were incubated along with 0.5g 
cocoa (extra brute Cocoa-Cacao Barry, Barry Callebaut, Hardricourt, France). Faecal samples were 
obtained from participating volunteers. The amount of fibre used was based on 6g of fibre consumed 
(moderate fibre supplementation) present in 300ml of colonic content, resulting in 1g of fibre present 
in 50ml incubation bottles. The amount of cocoa in the incubation bottles was based on an average of 
2.5g of cocoa powder used in a 250ml cocoa drink. This translates to 0.5g in 50ml incubation bottles. 
The cocoa used in this study was a high grade 100% cacao powder (extra brute Cocoa-Cacao Barry, 
Barry Callebaut, Hardricourt, France), used in the food industry, confectionary and patisserie, also 
available for purchase at specific outlets. The detailed composition of this cocoa is given in Appendix-
3. A brief comparison of the composition of this cocoa powder to the more well-known Green & Black 
cocoa powder-16.3% powder (Green and Black's Ltd, London, United Kingdom) is given below. 
 
 
Ispaghula 
Cocoa + 
raftiline 
Raftiline Cocoa + 
pectin 
Pectin 
Cocoa + 
Ispaghula 
Cocoa 
Faecal slurry 
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Table 4-4 cocoa powder composition comparison 
Nutritional data/100g Extra brute 
Barry callebaut 
Organic dark cocoa 
Green & Blacks 
   
Energy 339 Kcal 350 Kcal 
Available Carbohydrate 13.0g 13.6 
 Sugars 
(mono+Disaccharides) 
 0.4g    0.4 
 Starch 12.6g Not specified 
Dietary Fibre 27.7g 28.7 
Total Protein 18.0g 23.6 
Milk Protein 0.0g Not specified 
Total Fat 23.0g 22.3 
Saturated Fat 14.5g 13 
Vanilla extract       × ✓ 
Soya Lecithin-Emulsifier      × ✓ 
This information was kindly provided by the customer service and quality control administration unit of respective brands. 
 
4.3.5 Phenolic acid analysis 
Phenolic acid analysis was carried out on samples from the 0, 2, 6 and 24 hour time points using 23 
phenolic acids (Table 2-3) as standard reference, according to the method described in 2.4 Phenolic 
acid analysis 
Data for all identified phenolic acids were quantified and analysed separately and a sum of all 
identified phenolic acids was considered as total sum of phenolic acid production. 
4.3.6 SCFA analysis 
SCFA were analysed in samples from the fermentation vessels at 0, 2, 4, 6 and 24 hours according to 
the method described in 2.3 SCFA analysis. Analysis of the results focused mainly on acetic, propionic 
and butyric acid and the total sum production as the sum of acetate, propionate, butyrate, iso-butyric, 
iso-pentanoic, pentanoic, iso-hexanoic, hexanoic, heptanoic, octanoic). 
4.3.7 pH measurement 
pH was measured for all samples at 0, 2, 4, 6 and 24 hours according to the method described in 2.2.2 
Measurement of pH. 
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4.3.8 Gas volume  
Gas was measured for all samples at 0, 2, 4, 6 and 24 hours post incubation according to the method 
described in 2.2.1 Gas production 
4.3.9 Statistical analysis  
To determine the impact of the soluble fibres raftiline, ispaghula and pectin on phenolic acid 
production from cocoa, as well as the impact of cocoa polyophenols on SCFA production rom the 
fibres, a general linear model Anova was performed using the software Minitab-15. This statistical 
model allowed for the analysis of paired data across time. In this analysis Phenolic acid was used as 
the response, with volunteer, time, substrate and time*substrate included in the model. Volunteer was 
included in the random factors.  
Further analysis was conducted for the data at 24 hours separately, using a paired t-test model or 1-way 
Wilcoxon test after assessing for normality. This analysis was conducted as the general linear model 
considers change over time and ignores differences at specific time points.  
Soluble fibres differ in their rate of fermentation; some slowly fermented fibres such as ispaghula 
demonstrate impact only at 24 hours and not before. Hence, it was important to investigate the 24 hour 
time point separately. 
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4.4 Results 
 
The soluble fibres used in this study were plant extracts. Hence, some phenolic acid production from 
these soluble fibres was expected. The main outcome was the impact of fibre on the phenolic acid 
production from cocoa. Therefore we calculated a predicted value as the sum of phenolic acid 
produced from fibre only and phenolic acid produced from cocoa only. This is presented as Fibre-C 
and is compared to the true combination of fibre and cocoa incubated together, presented as Fibre+C. 
A higher value for Fibre-C as compared to Fibre+C would be an indication of the fibre having an 
inhibitory effect on the production of phenolic acids from cocoa. The phenolic acids identified in the 
cocoa incubations are listed in Table 4-5. Phenolic acid production from soluble fibres is discussed in 
the relevant sections. 
Table 4-5 Identified phenolic acids from Cocoa incubation with human faecal bacteria 
Phenolic acid Concentration at 
24h (ug/ml) 
Number of volunteers       
producing 
Phenyl acetic acid 7.38 ± 3.80 10 
3-Hydroxy phenyl acetic acid 0.64 ± 0.93 8 
4-hydroxy phenyl acetic acid 
3,4- Dihydroxy phenyl acetic acid 
3-Hydroxy phenyl propionic acid 
4-Hydroxy phenyl propionic acid 
4-Hydroxy benzoic acid 
0.38 ± 0.41 
0.27 ± 0.49 
8.73 ± 16.0 
1.74 ± 2.51 
0.02 ± 0.04 
10 
10 
10 
9 
4 
3,4-Dihydroxy benzoic acid 0.08 ± 0.09 10 
3,4-Dihydroxy phenyl propionic acid 0.08 ± 0.12 6 
Hippuric acid 0.01 ± 0.04 2 
Vanillic acid 0.009 ± 0.02 1 
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4.4.1 Impact of Raftiline on phenolic acid production from cocoa 
 
3-HPAA was detected in the fermentation vessels of raftiline in 1 volunteer; mainly derived from the 
background diet as there was no difference in the concentration of 3-HPAA between FS and raftiline 
fermentations. Whereas 3,4-DHPAA was detected in raftiline only fermentations. Raftiline did not 
have an inhibitory effect on the production of these phenolic acids over time. However the analysis at 
24 hours demonstrated an inhibition of 3-HPAA production (Figure 4-2, p < 0.01). 
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Figure 4-2 Impact of raftiline on 3-HPAA production rom cocoa incubations with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of RAF 
(n=10), FS: Faecal slurry, RAF: Raftiline, C: Cocoa, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted value for Raftiline 
and cocoa combination, *only at 24h p < 0.01 
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Figure 4-3 Impact of raftiline on 3,4- DHPAA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of RAF 
(n=10), FS: Faecal slurry, RAF: Raftiline, C: Cocoa, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted value for Raftiline 
and cocoa combination.  
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Similarly, 4-HPAA was not inhibited by raftiline. This phenolic acid was detected as part of the 
background diet in all 10 volunteers and the concentration present in FS alone was no different from 
that of cocoa incubations. However the comparison of predicted to true combination value 
demonstrated an inhibitory impact on the production of this phenolic acid by raftiline (p < 0.01). 
59% of PAA concentration detected in cocoa incubations was derived from the background diet and 
there was no difference in concentration over time between FS and cocoa incubations. However, the 
presence of raftiline in the cocoa incubations reduced the production of PAA from cocoa (p < 0.01, 
Figure 4-4), a comparison of predicted to true combination values demonstrated an even greater 
inhibition (p < 0.01, Figure 4-4). Whereas there was no impact on the PAA production from the 
background diet (p > 0.05). 
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Figure 4-4 Impact of raftiline on PAA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of RAF 
(n=10), FS: Faecal slurry, RAF: Raftiline, C: Cocoa, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted value for Raftiline 
and cocoa combination. *P < 0.01 for RAF+C vs. C and RAF+C vs. PRED RAF-C. 
 
4-HBA and 3,4-DHBA were produced in very low concentrations (0.03, 0.08 ug/ml respectively), 
neither of which were affected by the presence of raftiline. These two phenolic acids were not detected 
in the background diet or raftiline only incubations. 3,4-DHBA increased rapidly in cocoa incubations 
up to 6 hours post fermentation, after which a great decline was seen. However, in the Raf+C 
incubations, the production did not decline after 6 hours, but reached a plateau. 4-HBA concentration 
remained constant over time, suggesting that this phenolic acid was not produced but present in cocoa.  
3,4-DHPPA was detected in incubation bottles containing cocoa only; demonstrating rapid increase up 
to 6 hours post fermentation after which it reached a plateau. Concomitantly 3-HPPA was produced 
only after 6 hours of incubation in both control (n=1) and cocoa incubations, suggesting its production 
from 3,4-DHPPA degradation. 4-HPPA increased gradually over time in both control and cocoa 
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incubations. Neither of these phenolic acids were affected by the presence of raftiline in the 
fermentation bottles. This could be due to the low concentration of these phenolic acids resulting in a 
smaller effect size.  
 
Figure 4-5 Impact of raftiline on 3,4- DHPPA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of RAF 
(n=10), FS: Faecal slurry, RAF: Raftiline, C: Cocoa, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted value for Raftiline 
and cocoa combination. 
 
 
The production of hippuric acid (produced in 2 volunteers: volunteer-5 and 6) and vanillic acid 
(produced in 1 volunteer: volunteer-5) were not affected by the presence of Raftiline in the incubation 
bottles.  
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Figure 4-6 Impact of raftiline on 3- HPPA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of RAF 
(n=10), FS: Faecal slurry, RAF: Raftiline, C: Cocoa, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted value for Raftiline 
and cocoa combination. 
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The total sum of phenolic acid production was greatly inhibited by the presence of raftiline in the 
incubation bottles (p < 0.01, Figure 4-7). As seen for PAA, the total sum of phenolic acid 
concentration in Raf+C incubations was reduced to the same concentration seen from raftiline 
incubation alone.  
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Figure 4-7 Impact of raftiline on total sum of phenolic acid production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of RAF 
(n=10), FS: Faecal slurry, RAF: Raftiline, C: Cocoa, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted value for Raftiline 
and cocoa combination. *p < 0.01for RAF+C vs. C and RAF+C vs. PRED RAF-C. 
 
Table 4-6 Impact of raftiline on phenolic acid production from cocoa with human faecal bacteria 
Substrate Raf+C 
At 24h  (ug/ml) 
C 
At 24h  (ug/ml) 
 P value 
4-HBA 0.02 ± 0.03  0.02 ± 0.04 P > 0.05  
3,4-DHBA 0.14 ± 0.13 0.08 ± 0.09 P > 0.05 
3-HPPA 0.80 ± 0.62 8.73 ± 0.16 P > 0.05 
4-HPPA 0.41 ± 0.62 1.57 ± 2.55 P > 0.05 
3,4-DHPPA 0.01 ± 0.03 0.08 ± 0.11 P > 0.05 
Hippuric acid 0.02 ± 0.04 0.01 ± 0.04 P > 0.05 
Vanillic acid  0.009 ± 0.02 0.009 ± 0.02 P > 0.05 
Values are mean (± SD) at 24 hours (n=10) , C: Cocoa, RAF+C: Raftiline+Cocoa, p-value is presented for the comparison of 
Raftiline+Cocoa to cocoa alone.  
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4.4.2  Impact of ispaghula on phenolic acid production from cocoa  
 
Ispaghula is a slowly fermented fibre, thus any impact induced through fermentation products would 
be demonstrated at 24 hours post fermentation. 3-HPAA was produced in ispaghula fermentation 
vessels of only one volunteer (mainly derived from the background diet). 3,4-DHPAA was not detected 
in ispaghula only fermentations. Ispaghula did not have an inhibitory effect on the production of these 
phenolic acids from cocoa over time (p > 0.5, p > 0.05) or at 24 hours. 
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Figure 4-8 Impact of ispaghula on 3-HPAA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of ISP 
(n=10), FS: Faecal slurry, ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. PRED ISP-C: predicted value for Ispaghula 
and cocoa combination. 
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Figure 4-9 Impact of ispaghula on 3,4-DHPAA production from cocoa with human faecal bacteria 
Values are displayed as mean ± STDEV (n=10), FS: Faecal slurry, ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. 
PRED ISP-C: predicted value for Ispaghula and cocoa combination. 
 
 170 
 
Similarly, 4-HPAA production from cocoa was not inhibited by ispaghula (p > 0.05).  The presence of 
ispaghula in the cocoa incubations reduced the production of PAA at 24 hours post fermentation (p < 
0.01, Figure 4-10). Initial analysis did not demonstrate the same impact on PAA across time (p > 0.05). 
However, the concentration of PAA detected in ispaghula only incubations was higher than the other 
two soluble fibres (2.27 ug/ml) resulting in a statistically significant difference over time between 
predicted value and the true combination (p < 0.01), indicating an inhibitory impact of ispaghula on 
PAA production over time (p < 0.01). However, the higher concentration of PAA in ispaghula vessels 
may not necessarily be due to its production from ispaghula, as the concentration of this phenolic acid 
is much higher in FS (4.39 ug/ml) than raftiline (0.90 ug/ml), pectin (0.50 ug/ml) and ispaghula (2.27 
ug/ml). Thus it may be that raftiline and pectin inhibited the production of this phenolic acid from the 
background diet more successfully than ispaghula. 75% of PAA production was seen after 6 hours of 
incubation, indicating that some of this phenolic acid might be produced from further de-hydroxylation 
of other phenolic acids such as 4-HPAA.  
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Figure 4-10 Impact of ispaghula on PAA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of ISP 
(n=10), FS: Faecal slurry, ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. PRED ISP-C: predicted value for Ispaghula 
and cocoa combination. *p < 0.01 
 
4-HBA and 3,4-DHBA were not detected in ispaghula only incubations and neither of the two phenolic 
acids were affected by the presence of ispaghula in cocoa incubation bottles. The combination of cocoa 
and ispaghula followed the same trend in 3,4-DHBA production as cocoa only incubations; increasing 
rapidly up to 6 hours post fermentation and declining thereafter.  
3,4-DHPPA was not detected in ispaghula incubations; 3-HPPA and 4-HPPA were produced in both 
ispaghula and cocoa incubations. None of these three phenolic acids were affected by the presence of 
ispaghula in the fermentation bottles.  
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Similarly, hippuric acid and vanillic acid were not detected in ispaghula incubations and their 
production from cocoa was not affected in the presence of ispaghula. 
The results seen for PAA were reflected in the sum of phenolic acid results as PAA was one of the 
highest contributors to the makeup of the total phenolic acids. Therefore, ispaghula had the highest 
concentration of total sum of phenolic acids compared to raftiline and pectin. This led to a significant 
difference across time between the predicted value and the true combination (p < 0.01, Figure 4-11). 
The comparison of Isp+C to cocoa alone did not show an inhibitory impact of ispaghula on total 
phenolic acid production from cocoa across time (p > 0.05). However a separate analysis at 24 hours 
for the same comparison groups resulted in a lower concentration in the combination group than cocoa 
alone (p= 0.03, Figure 4-11).  
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Figure 4-11 Impact of ispaghula on total sum of phenolic acid production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of ISP 
(n=10), FS: Faecal slurry, ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. PRED ISP-C: predicted value for Ispaghula 
and cocoa combination. *P= 0.031 
 
Table 4-7 Impact of ispaghula on phenolic acid production from cocoa with human faecal bacteria 
Substrate ISP+C 
At 24h (ug/ml) 
C 
At 24h (ug/ml) 
 P value 
4-HBA 0.03 ± 0.08 0.02 ± 0.04 P > 0.05 
3,4-DHBA 0.11 ± 0.15 0.08 ± 0.09 P > 0.05 
3-HPPA 3.48 ± 6.64 8.73 ± 16.03 P > 0.05 
4-HPPA 1.31 ± 1.71 1.74 ± 2.51 P > > 0.05 
3,4-DHPPA 0.27 ± 0.44 0.08 ± 0.11 P > 0.05 
Hippuric acid 0.01 ± 0.03 0.01 ± 0.04 P > 0.05 
Vanillic acid  0.007 ± 0.02 0.009 ± 0.02 P > 0.05 
Values are mean (± SD) at 24 hours (n=10) at 24 hours, C: Cocoa, ISP+C: Ispaghula+Cocoa, p-value is presented for the 
comparison of Ispaghula+Cocoa to cocoa alone. 
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4.4.3 Impact of pectin on phenolic acid production from cocoa  
 
Pectin fermentation resulted in the production of 3-HPAA in 1 volunteer, however 3,4-DHPAA was 
not produced from pectin only incubations. Pectin did not have an inhibitory effect on the production 
of these phenolic acids over time. However, as seen for raftiline, the analysis at 24 hours demonstrates 
an inhibition of 3-HPAA production (p = 0.02, Figure 4-12). 
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Figure 4-12 Impact of pectin on 3-HPAA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of PEC 
(n=10), FS: Faecal slurry, PEC: Pectin, C: Cocoa, PEC+C: Pectin+Cocoa. PRED PEC-C: predicted value for pectin and cocoa 
combination. *at 24h only p=0.02. 
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Figure 4-13 Impact of pectin on 3,4-DHPAA production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of PEC 
(n=10), FS: Faecal slurry, PEC: Pectin, C: Cocoa, PEC+C: Pectin+Cocoa. PRED PEC-C: predicted value for pectin and cocoa 
combination 
 
4-HPAA was detected in pectin only incubations as well as cocoa incubations, initial analysis did not 
demonstrate an inhibited of 4-HPPA production by pectin, however the comparison of predicted to true 
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value did demonstrate an inhibitory impact (p < 0.01). The presence of Pectin in the cocoa incubations 
reduced the production of PAA (p=0.03, Figure 4-14), the comparison of predicted to true combination 
group demonstrated an even greater inhibition (p < 0.01, Figure 4-14). The impact of pectin on the 
PAA production from the background diet was investigated as the background diet contributed largely 
to total PAA concentration. There was no impact from pectin on the PAA production from the 
background diet. 
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Figure 4-14 Impact of pectin on PAA production from cocoa with human faecal bacteria 
 Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of PEC 
(n=10), FS: Faecal slurry, PEC: Pectin, C: Cocoa, PEC+C: Pectin+Cocoa. PRED PEC-C: predicted value for pectin and cocoa 
combination.*P= 0.03 (RAF+C vs. C) and p < 0.01 (RAF+C vs. PRED RAF-C). 
 
 
4-HBA and 3,4-DHBA were not detected in pectin only incubations. Interestingly the presence of 
pectin in cocoa incubations resulted in a significantly higher production of 4-HBA across time as 
compared to cocoa only incubations (p <0.01). This increase was seen prominently 2 hours post 
fermentation. The concentration of 3,4-DHBA for the combination group was seen to increase up to 2 
hours reaching a plateau thereafter, resulting in a significant difference between the PEC+C and C only 
at 6 hours post fermentation (p=0.01). This would suggest that pectin acts as a facilitating factor for the 
production of 4-HBA from 3,4-DHBA. 
3,4-DHPPA was not detected in pectin only incubation bottles. In cocoa fermentation vessels it 
demonstrated a rapid increase up to 6 hours post fermentation after which it reached a plateau. 3-HPPA 
was produced only after 6 hours of incubation in both pectin and cocoa incubations. 4-HPPA was 
produced gradually over time in both pectin and cocoa incubations. Neither of these phenolic acids was 
affected by the presence of pectin in the fermentation bottles.  Similarly the production of hippuric acid 
and vanillic acid were not affected by the presence of pectin. These phenolic acids were not detected in 
pectin only incubations. 
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The sum of total phenolic acid production was greatly inhibited by the presence of pectin in the 
incubation bottles across time (p = 0.01, Figure 4-15). A comparison of predicted to true combination 
values demonstrated an even greater inhibition (P < 0.01, Figure 4-15). 
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Figure 4-15 Impact of pectin on total sum of phenolic acid production from cocoa with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder with 1g of PEC 
(n=10), FS: Faecal slurry, PEC: Pectin, C: Cocoa, PEC+C: Pectin+Cocoa. PRED PEC-C: predicted value for pectin and cocoa 
combination*P= 0.01 (RAF+C vs. C) and p < 0.01 (RAF+C vs. PRED RAF-C). 
 
Table 4-8 Impact of pectin on phenolic acid production from cocoa with human faecal bacteria 
Substrate Pec+C 
     At 24h (ug/ml) 
C 
At 24h (ug/ml) 
 P value 
4-Hydroxy BA 0.07 ± 0.10 0.02 ± 0.04 P < 0.01* 
3,4-Dihydroxy BA 0.08 ± 0.15 0.08 ± 0.09 P > 0.05 
3-Hydroxy PPA 0.99 ± 0.95 8.73 ± 16.03 P > 0.05 
4-Hydroxy PPA 0.39 ± 0.53 1.74 ± 2.51 P > 0.05 
3,4-Dihydroxy PPA 0.00 ± 0.01 0.08 ± 0.11 P > 0.05 
Hippuric acid 0.02 ± 0.04 0.01 ± 0.04 P > 0.05 
Vanillic acid  0.01 ± 0.04 0.009 ± 0.02 P > 0.05 
Values are mean (± SD) at 24 hours (n=10), C: Cocoa, PEC+C: Pectin+Cocoa, p-value is presented for the comparison of 
Pectin+Cocoa to cocoa alone.  
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4.4.4 Concentration of cocoa monomers retrieved as phenolic acids 
 
To estimate the efficiency in the bacterial catabolism of cocoa polyphenols into phenolic acids, a 
percentage of total sum of phenolic acids 
produced was calculated as 3.1% of cocoa 
monomers added to fermentation vessels. 
This recovery is very low compared to that 
of rutin phenolic acids (70%- chapter 3); 
further indicating matrix interaction when 
polyphenols are present in carbohydrate 
containing foods 
 
 
4.4.5 SCFA production from cocoa 
 
The carbohydrate and fibre content of the cocoa is considerably high. As this is an ex-vivo fermentation 
model, the starch and carbohydrate present in the cocoa was not subjected to digestion and was 
available for fermentation by the gut bacteria. Substantial amounts of SCFA were produced through 
the fermentation of these carbohydrates in cocoa. Acetate was produced as the highest percentage (50.1 
%) to total sum of SCFA followed by propionate (18.3%) and butyrate (16.3%). However, this was 
lower than the SCFA production from the soluble fibre fermentation. The difference between SCFA 
production from fibre and cocoa was the most pronounced in the case of raftiline, followed by 
ispaghula and pectin.  
Based on the composition of the cocoa powder, 0.5g of cocoa powder added to the incubation bottles 
contains 0.138g dietary fibre and 0.065g carbohydrates made up of 0.063g starch and 0.002g sugars 
compared to 1g of soluble fibre added to the incubation vessels. To correct for the fermentation of 
carbohydrates in cocoa, a predicted SCFA production was calculated as the sum of SCFA produced in 
cocoa alone to SCFA produced in fibre alone. This was then compared to the actual SCFA production 
of the mixture incubation. This allowed for the investigation of impact of cocoa polyphenols on the 
SCFA production from fibre. A difference between predicted SCFA and true SCFA value was 
considered as the inhibitory effect of the polyphenols on SCFA production. 
 
Figure 4-16 Concentration of 28 umol/ L of rutin retrieved as  
phenolic acid metabolites after faecal incubations with human 
colonic bacteria  
 
Unknown 
96.9% 
Total phenolics 
96.9% 
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Figure 4-17 and Figure 4-18 present the contribution of each SCFA to total sum of SCFA production 
before and after deduction of FS values from samples. As seen in the figures, total sum of SCFA did 
not increase for cocoa after 6 hours of fermentation when FS values were deducted from the samples. 
 
Figure 4-17 SCFA production from cocoa incubation with human faecal bacteria 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder (n=10). 
 
Figure 4-18 SCFA production from cocoa incubation with human faecal bacteria after deduction of FS 
Values are displayed as mean (± SD) of 24 hour profile for faecal incubations having 0.5g cocoa powder (n=10). 
 
 
4.4.6 Impact of cocoa polyphenols on the SCFA production from raftiline 
 
An initial comparison of the predicted value to the true combination value for total SCFA 
concentration demonstrated an inhibitory effect from the cocoa polyphenols on the production of total 
SCFA (p < 0.01, Figure 4-19) However, this was due the additive effect of faecal slurry present in both 
cocoa and ispaghula, resulting in a higher value for the predicted value [(FS+C) + (FS+FIBRE)] as 
compared to the true combination value (FS+C+RAF).  
The concentration of total sum of SCFA produced in faecal slurry was deducted from all comparison 
groups to correct for the additive effect of faecal slurry in the predicted value. This analysis was carried 
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out for all following results described in this chapter. After deduction of total sum of SCFA produced 
in faecal slurry from comparison groups, there no longer was an inhibitory effect of cocoa polyphenols 
on the total sum of SCFA production from raftiline. 
The total sum of SCFA production demonstrated a rapid rate of increase up to 6 hours post 
fermentation for raftiline (68.5%) and pectin (62%); whereas majority of ispaghula fermentation took 
place between 6-24 hours (57%). The proportion of individual SCFA production from each fibre is 
displayed in Table 4-9.  
 
Table 4-9 Proportion of each SCFA produced to total SCFA production for different fibres 
Substrate Acetate Propionate Butyrate 
Raftiline 64.5% 18.1% 13.2% 
Ispaghula 64.7% 27.2% 12.3% 
Pectin 57.3% 15.6% 21.8% 
 
 
The impact of cocoa on fermentation of fibres was further analysed by partitioning the volunteers into 
two categories of high and low producers of SCFA (Table 4-10) based on the average sum of all SCFA 
produced by the fermentation of fibres. The separate analysis of results for impact of cocoa on SCFA 
production of high producers and low producers did not demonstrate any impact of these polyphenols 
on the SCFA production from the fibres (Table 4-10). 
 
Table 4-10  Total SCFA concentration for high producers of SCFA from raftiline fermentation with faecal bacteria 
Substrate Total SCFA concentration 
at 6 hours (mmol/l) 
Total SCFA concentration 
at 24 hours (mmol/l) 
Raftiline*  51.3 ± 17.4 77.7 ± 16.4 
Raftiline + Cocoa 59.3± 15.8 88.2  ± 16.9 
Predicted Raftiline + Cocoa 96.7 ± 14.6 70.1 ± 17.2 
Ispaghula** 14.0 ± 6.2 50.1 ± 8.9 
Ispaghula + Cocoa 24.3 ± 3.44 60.6  ± 21.6 
Predicted Ispaghula + Cocoa 27.7 ± 11.3 69.4 ± 9.9 
Pectin**  47.8 ± 8.6  84 ± 11.2 
Pectin+ Cocoa 57.03 ± 14.6 89.8  ± 37.17 
Predicted Pectin + Cocoa 70 ± 11.1 104.5 ± 10.7 
Values are displayed as mean (± SD), at 6 and 24 hours for 50ml faecal incubations having 0.5g cocoa powder with 1g of 
fibre *(n=3), ** (n=5) 
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Figure 4-19 Impact of cocoa on SCFA production from fibre incubation with human faecal bacteria after deduction of 
FS. Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 0.5g cocoa powder with 1g of 
RAF / ISP /PEC (n=10), FS: Faecal slurry, C: Cocoa, RAF: Raftiline, RAF+C: Raftiline+Cocoa. PRED RAF-C: predicted 
value for Raftiline and cocoa combination, ISP: Ispaghula, ISP+C: Ispaghula+Cocoa. PRED ISP-C: predicted value for 
ispaghula and cocoa combination, PEC: Pectin, PEC+C: Pectin+Cocoa. PRED PEC-C: predicted value for pectin and cocoa 
combination. 
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4.4.7 Impact of cocoa on pH within fermentation vessels 
Change in pH can be used as an indication of bacterial activity and fermentation rate in the batch 
culture model. 
The pH of fermentation vessels was measured for all volunteers at all time points using a pH 
measuring paper according to the method mentioned in 2.2.2 Measurement of pH. In addition to this, 
pH was measured using a pH meter according to the method in section 3.2.7 for all time points in 5 
volunteers and for all volunteers at 6 and 24 hours.  
 
4.4.7.1 Measurement of pH in fermentation vessels  
Cocoa did not affect the pH in the fermentation vessels of raftiline or pectin, however the combination 
of cocoa and ispaghula resulted in a lower pH than ispaghula alone (p < 0.01). Additionally cocoa 
incubations resulted in a lower pH than FS alone (p < 0.01) incubations. Raftiline and pectin resulted in 
a lower pH than cocoa (p < 0.01), however there was no difference in pH between ispaghula and cocoa 
incubations. 
 
Figure 4-20 pH in batch culture vessels at all time points using pH paper 
Values displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 0.5 g cocoa powder with 1g of RAF/ 
ISP / PEC (n=10). FS: Faecal slurry ISP: Ispaghula, PEC: Pectin, RAF: Raftiline, C: Cocoa, ISP+C: Ispaghula+Cococa, 
PEC+C: Pectin+Cocoa, RAF+C: Raftiline+Cocoa 
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The pH of cocoa is seen to reduce between 0-2 hours, whereas this is seen after 6 hours of fermentation 
for ispaghula. Both raftiline and pectin caused a rapid reduction of pH up to 6 hours after fermentation 
after which little change was seen. 
 
4.4.8 Impact cocoa on gas production 
Gas in the head space of fermentation vessels was measured as an indication of bacterial activity and 
rate of fermentation. Cocoa did not impact gas production over time, however the combination of 
cocoa and pectin resulted in significantly higher gas at 24 hours than pectin alone (p=0.03).  While 
pectin and raftiline resulted in higher gas production than cocoa (p=0.02 and p < 0.01respectively), 
there was no difference in gas production between cocoa and FS alone or ispaghula.  
The data presented in this section is the mean cumulative gas production ± standard deviation over 24 
hours post fermentation. 
 
 
Figure 4-21 Cumulative gas productions in fermentation vessels 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 0.5 g cocoa powder with 1g of 
RAF/ ISP / PEC (n=10), FS: Faecal slurry ISP: Ispaghula, PEC: Pectin, RAF: Raftiline, C: Cocoa, ISP+C: Ispaghula+Cococa, 
PEC+C: Pectin+Cocoa, RAF+C: Raftiline+Cocoa.  
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4.4.9 Summary of results 
 
The comparison of the predicted value to the true combination value, demonstrated lower 
concentrations of acetate and total SCFA across time for all fibres, before deducting FS values from 
the samples. This was attributed to the additive effect of FS present in both cocoa and fibre when 
calculating the predicted value: 
 Predicted value = [(FS + Cocoa) + (FS + Fibre)] 
 True combination = (FS + Cocoa + Ispaghula) 
Hence, FS values were deducted from the samples, allowing for the correct comparison of the 
combination group to the predicted value: 
 Predicted value = (Cocoa) + (Fibre) 
 True combination = (Cocoa + Ispaghula) 
Cocoa polyphenols did not inhibit the SCFA production from the soluble fibre incubations with faecal 
bacteria. 
3,4-DHPAA, 3,4-DHPPA and 3,4-DHBA were produced in cocoa only incubations and not in controls. 
They all increased up to 6 hours post fermentation, the former 2 reached a plateau thereafter, whereas 
3,4-DHBA declined greatly after 6h. Concomitantly, 3-HPAA and 3-HPPA were produced only after 6 
hours of incubation, suggesting that they were produced from further degradation of 3,4-DHPAA, 3,4-
DHPPA respectively. An example of this can be seen in Figure 4-22. 
 
Figure 4-22 production of 3-HPAA from degradation of 3,4-DHPAA by human colonic microbiota 
Values are displayed as mean (± SD) of 24 hour profile for 50ml faecal incubations having 0.5g cocoa powder. 
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Raftiline and pectin, both had an inhibitory impact on the production of 3-HPAA at 24 hours only and 
PAA and total phenolic acids across time.  Pectin displayed a possible role in the conversion of 3,4-
DHBA to 4-HBA. Ispaghula alone had the highest concentration of PAA and consequently the highest 
concentration of total phenolic acids, inhibiting the production of both when present in cocoa 
incubation bottles. 
Table 4-11 Summary of soluble fibre inhibition of phenolic acids production from cocoa incubation with human faecal 
bacteria 
Phenolic acids Inhibition by     
raftiline  
Inhibition by ispaghula Inhibition by pectin 
Phenyl acetic acid x x x 
3-Hydroxy phenyl acetic acid x * @24 hours - x * @24 hours 
4-hydroxy phenyl acetic acid x x x 
3,4- Dihydroxy phenyl acetic acid - - - 
3-Hydroxy phenyl propionic acid - - - 
4-Hydroxy phenyl propionic acid - - - 
3,4-Dihydroxy phenyl propionic acid - - - 
4-Hydroxy benzoic acid - - x 
3,4-Dihydroxy benzoic acid - -      - 
Hippuric acid - -      - 
Vanillic acid - -      - 
Sum total of phenolic acids x x  x 
Phenolic acids from background diet x x x 
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4.5 Discussion  
 
The in-vitro incubation of cocoa resulted in the production of PAA, 3-HPAA, 4-HPAA, 3,4-DHPAA, 
3-HPPA, 4-HPPA, 3,4-DHPPA, 4-HBA, 3,4-DHBA, Hippuric acid and vanillic acid. Due to inter-
individual variation in gut microbiota as previously presented by Gross et al (2010), the large standard 
deviations seen in metabolite production were expected. The paired model of the study design makes 
these large standard deviations irrelevant to the data presented in this chapter.  
The recovery of phenolic acids as a product of cocoa polyphenol catabolism was found to be very low 
(3.1%) when compared to the phenolic acids recovered from rutin catabolism (70%, chapter-3). This 
may be attributed to the presence of carbohydrates and fibre in the cocoa powder, further indicating a 
matrix interaction when carbohydrates, especially fibres are present along with polyphenols. 
To our best knowledge there have been no previous studies investigating the ex-vivo catabolism of 
cocoa polyphenols as present in the intact cocoa matrix. A study similar to that conducted in this 
chapter was the in-vitro fermentation of the insoluble fraction of cocoa by Fogliano et al. (2011). This 
study contained an additional digestion step following the centrifugation of cocoa powder along with 
water and subsequent disposal of the supernatant containing soluble fractions of the cocoa. All 
metabolites identified in this study (summarised in Table 4-2) were also detected in the current study. 
A more recent study (Dall'Asta et al., 2012) was conducted by adding  9% chocolate extract obtained 
from 90% dark chocolate to fermentation vessels. The two main metabolites identified in this study 
(3,4-DHPAA, 3,4-DHBA) were also detected in the current study. The above two mentioned studies 
used different analytical methods: LCMS and LC/MS/MS respectively compared to GCMS used in the 
current study. The three main metabolites present in at least two out of three above mentioned studies 
were found to be: 3,4-DHPAA, 3,4-DHBA (present in cocoa only incubations) and 3-HPPA (present in 
both control and cocoa incubations). In addition to these metabolites we identified eight more 
metabolites (Table 4-2).  
Similarly to the study by Fogliano et al. (2011), we did not detect HBA which was identified in the 
Dall‘Asta et al. (2012) study; likely produced from further dehydroxylation of 4-HBA (Fairley et al., 
2002). The current study and the Fogliano et al. (2011) study were conducted using cocoa powder 
containing more carbohydrates than the chocolate extract used in the latter study. We speculate that the 
absence of HBA in the former two studies may be due to the high amount of carbohydrates present in 
the cocoa matrix delaying the production of this phenolic acid. As shown in the matrix interaction 
study by Bazzocco et al, the addition of apple cell-wall (made up of pectin) delayed the maximal 
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conversion extent from 4h to 8h. The mechanism behind this delay in-vitro has not been clearly 
understood, however a putative explanation could be the preferential use of carbohydrates as a source 
of energy by the microbiota (Tzounis et al., 2008a).  It is possible that the fewer number of metabolites 
detected in the above two mentioned studies could be due to the loss of total flavan-3-ols and short 
chain flavan-3-ols through the process of digestion and water rinsing. Previous studies have 
demonstrated that shorter chain proanthocyanidins demonstrate significant loss of total and short chain 
flavan-3-ol content through water extraction and enzymatic digestions (Bazzocco et al., 2008).  
However, the presence of hippuric acid and vanillic acid in the fermentation vessels was not expected 
as they are both hepatic metabolites derived from 3-HBA and 3,4-DHBA respectively (Monagas et al., 
2010, Urpi-Sarda et al., 2010). Hippuric acid is mostly produced through the glycination of benzoic 
acid in the liver, whereas vanillic acid can be derived from the oxidation of vanillin often added to 
cocoa products by the aldehyde oxidase of the liver or arise from the methylation of protocatechuic 
acid (Urpi-Sarda et al., 2010). Some studies have demonstrated that specific bacteria, such as the 
Pseudomonas fluorescens AN1 03 may be able to oxidise vanillin to vanillic acid in-vitro (Narbad and 
Gasson, 1998). However, the cocoa powder used in our study did not contain any vanilla extract. In the 
current study, hippuric acid was seen at a higher level at 0 hours than at 24 hours and in very low 
concentrations. On the other hand vanillic acid was produced only after 2 hours of fermentation up to 6 
hours and remained constant thereafter. Hippuric acid (volunteer 5 and 6) and vanillic acid (volunteer 
5) were detected at a maximum concentration of 0.27 ug/ml 0.01 ug/ml respectively. These 
concentrations are extremely low compared to total sum of phenolic acids produced (19.84 ug/ml). 
Both phenolic acids were only detected in cocoa incubations. The lack of their presence in the FS alone 
and fibre alone incubations eliminates the background diet as the source. Unfortunately we do not have 
a concrete explanation for the presence of these metabolites in the cocoa faecal incubations.  
The production of 3,4-DHPAA increased rapidly reaching a plateau concomitant with the production 
of 3-HPAA at 6 hours; suggesting that 3-HPAA was produced from further degradation of 3,4-
DHPAA. As discussed in Chapter-3, this pattern was also observed in the in-vitro catabolism of rutin 
in both our study and a study conducted by (Aura et al., 2002).  
The concentration of 4-HBA was constant from 0-24 hours, indicating that 4-HBA was not produced 
but present in the cocoa product. The concentration of 3,4-DHBA was lower at 6 hours for pectin and 
cocoa combination than cocoa alone (p= 0.014) reaching a plateau thereafter. The same combination 
demonstrated a higher concentration of 4-HBA after 6 hours, suggesting that pectin plays a role in the 
conversion of 3,4-DHBA to 4-HBA. This was not seen for ispaghula or raftiline.   
 Table 4-12 Phenolic acid production from in-vitro fermentation of cocoa or cocoa polyphenols by faecal bacteria 
Phenolic acids Current 
study   
 
Current 
study   
(GCMS) 
 
(GCM
S) 
Fogliano 
et al., 
2011 
(LCMS-
MS) 
Dall’Asta 
et al., 
2012 
(LCMS) 
Deprez et al 
2000 
(GCMS) 
Bazzocco et al., 
2008 
(GCMS) 
Appeldoorn 
et al 2009  
(HPLC) 
Tzounis et 
al., 2008 
(HPLC) 
Roowi et 
al., 2009 
(GCMS) 
Stoupi et al.,2010 
(LCMS) 
 Main 
source of 
phenolic 
acid 
0.5 g 
cocoa 
powder 
20g 
insoluble 
cocoa 
fraction 
(pre-
digested) 
90% dark 
chocolate 
extract 
100-150 
mmol 
procyanidins 
Apple long/short 
proanthocyanidin  
chains 
1% / 5% 
(w/v)  
procyanidin 
150-1000 
ug/ml 
catechin / 
epicatechin 
50 umol  
epicatechin 
5 mmol/l 
Epicatechin  
PAA FS, C x         
3-HPAA  C x x  x x x  x  
4-HPAA FS x   x  x  x  
3,4-DHPAA C x  x  x x    
4-HBA C x         
3,4-DHBA C x x x       
BA    x (HBA)  x     
Vanillic  C x         
Hippuric C x         
3-PPA      x     
PPA     x   x   
3-HPPA FS, C x x  x x x  x x 
4-HPPA FS, C x   x      
3,4-DHPPA C x    x     
1-(3,4-DHPl)-3-(2,4,6-
THPl) propan-2-ol 
      x   x 
1-(HP)-3-(2,4,6-THP)-
propan-2-ol 
         x 
Monohydroxylated 
phenylvalerolactone 
      x    
PVA       x    
5-P-valerolactone        x   
5-(3,4-DHP)-valeric acid       x  x  
5-(3,4-DHP)-
valerolactone 
   x    x x x 
3-HPValericA     x      
 
 3-HPPA was only produced after 6 hours of incubation. As seen in the PAA derivatives, it can be 
postulated that the 3-HPPA is produced as a result of further degradation and de-hydroxylation of 3,4-
DHPPA reaching a plateau at this time point.  
PAA was the second highest phenolic acid detected in cocoa incubations. The absence of this phenolic 
acid in the incubations of Fogliano. (2011) or Dall‘Asta et al. (2012) has been discussed in Chapter-3. 
59% of total PAA quantified in the cocoa samples was derived from the background diet and there was 
no difference across time. While raftiline and pectin inhibited the production of PAA across time from 
cocoa, they had no impact on the PAA production from the background diet. Ispaghula demonstrated a 
lower inhibitory impact than the other two fibres. A similar trend was seen for 4-HPPA, which was 
detected mainly due to its presence in the background diet. The total phenolic acid production was 
greatly inhibited by raftiline, ispaghula and pectin across time.  
 
Our data demonstrated more colonic metabolite production than the previous studies. The lack of 5-
(3,4-DHP)- γ-valerolactone was in agreement with the Fogliano et al. (2011) study, using insoluble 
fractions of cocoa powder and the studies using procyanidins in faecal incubations (Bazzocco et al., 
2008, Déprez et al., 2000, Appeldoorn et al., 2009). Interestingly all three studies involving incubation 
of epi/catechins demonstrated 5-(3,4-DHP)- γ-valerolactone production. However it is important to 
note that compared to procyanidins, the percentage of ingested epi/catechins reaching the colon in-vivo 
is smaller. As suggested by Stoupi et al. (2010) and Fogliano et al. (2011), the longer incubation times 
used in their studies may have contributed to the consumption of 5-(3,4-DHP)- γ-valerolactone 
resulting in lower molecular weight phenolic acids. However this may not necessarily be valid as both 
studies have taken samples at different intervals from the baseline to the end point of incubation.  
 The difference in metabolite production between the different studies may be attributed to the various 
food matrices used: cocoa containing dietary fibre vs. cocoa extracts or pure polyphenolic compounds. 
The pre-treatments of cocoa such as digestion and water rinsing also contribute greatly to these 
observed differences. Despite the various in-vitro studies carried out, the exact catabolic pathway of 
proanthocyanidins and the monomers has not been well elucidated.   
Figure 6-17 elucidates a compilation of speculated catabolic pathways of cocoa polyphenols by colonic 
microbiota, derived from various in-vitro studies and reviewed/compiled by Monagas et al. (2010). The 
compounds encircled in a red dash are common with the phenolic acids identified from in-vitro faecal 
incubation of cocoa in this chapter. However we did detect other phenolic acids, which are not 
displayed in this figure but discussed above.  
 Figure 4-23 Speculated catabolic pathway of cocoa polyphenols (Adapted from Monagas et al. (2010) 
 
>Encircled in red circle: Parent compound 
>Encicled in dashed red circle: phenolic 
acids detected in the results of this chapter 
>Dashted arrow: Hepatic pathway 
 The limitation in understanding the catabolic pathway of these flavan-3-ol metabolites (summarised in 
1.3.6.6 Flavan-3-ols) may perhaps be due to the use of different analytical methods, the complexity of 
the colonic bacterial composition, and their interactions with colonic content including other species. 
Depending on the catabolic capacity of these microbiota it is possible that different pathways exist, 
with some more predominant than others. Unfortunately there is not sufficient information on the 
bacteria involved in the degradation of these flavan-3-ols. The understanding of this subject is limited 
by the antibacterial growth inhibitory properties of these phenolic compounds. The bacteria involved in 
the degradation of other flavonoid subclasses such as flavonols and flavones have been shown to 
belong to the Clostridium and Eubacterium groups (Monagas et al., 2010). However it has been 
demonstrated that the same bacterial groups may also be responsible for the degradation of epi/catechin 
compounds and the ring fission of flavan-3-ols (Selma et al., 2009, Vitaglione et al., 2007). 
Some in-vivo work has demonstrated that Eggerthella lenta and Flavonifractor plautii are able to 
catalyse the degradation of both catechin and epicatechin (Kutschera et al., 2011). Others have also 
reported Eubacterium sp. SDG-2 for the catabolism of (+) and (-)-catechins; Clostridium cocoides - 
Eubacterium rectale group for (-) and (+)-epicatechins and Bifidobacterium spp and Escherichia coli 
for (-)-epicatechin ring fission and catabolism of catechin and epicatechin (Wang et al., 2001, Tzounis 
et al., 2008b). 
As previously discussed the composition of the microbiota on the catabolic pathway and the type of 
metabolites produced is crucial. However there have been no previous studies investigating the 
presence of soluble fibres and cocoa polyphenols on their subsequent impact on gut microbiota 
metabolite production. The study most relevant to this food matrix interaction was conducted by 
(Bazzocco et al., 2008) in an in-vitro faecal fermentation model, summarised in Table 1-7 following 
enzymatic digestion of apple Proanthocyanidins with or without apple cell-walls (containing pectin). 
They demonstrated that when apple cell-wall was present in the incubation vessels the maximal extent 
of conversion was delayed from 4 hours to 8 hours. This delay did not result in an enhanced conversion 
efficiency of the proanthocyanidins compounds. Unlike the Bazzocco study (2008), we did not find 
any difference in time of maximal conversion for cocoa phenolics. However we did demonstrate an 
inhibitory impact of soluble fibres on phenolic acid production from cocoa.  
This impact was more prominent in raftiline, followed by pectin and ispaghula. We did not measure 
viscosity in the incubation vessels of this study, thus we cannot say with conviction that this may be 
related to the viscosity of the fibres. However it is well known that raftiline is not viscous and 
ispaghula has great viscosity forming a gel upon mixture with water, which is maintained throughout 
the fermentation. We did measure the fermentability of these soluble fibres by measuring SCFA 
production from their fermentation. In this regard, raftiline demonstrated the highest fermentability, 
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followed by pectin and ispaghula. Thus it can be speculated that the inhibitory impact of the soluble 
fibres on the phenolic acid production from cocoa may be dependent on fermentability rate. 
As discussed in Chapter-1 these soluble fibres and their fermentation products have demonstrated 
bacterial growth enhancing properties. It is possible that the preferential use of raftiline, followed by 
pectin and ispaghula as a carbon source, resulting in relative SCFA production may be a factor to be 
considered in their inhibitory impact. In this regard we measured the pH in the incubation vessels, as 
higher concentrations of SCFA and their accumulation is associated with lower pH in incubation 
vessels. However the lowest pH was found to be in pectin incubation vessels followed by raftiline and 
ispaghula. The difference in pH between pectin and raftiline was not significant and the lower pH in 
pectin incubation vessels may be due to the high concentrations of galacturonic acid present in the 
pectin structure. The change in pH from baseline was found to be greater for raftiline than pectin.  
Thus, the inhibitory impact of soluble fibres on the phenolic acid production from cocoa may be due to 
their SCFA production, which in turn may alter microbiota composition directly or indirectly through 
the reduction of pH. It is also possible that the higher fermentability may be related to the preferential 
use of the specific fibre as a source of energy resulting in a delay of phenolic acid production as seen in 
the Bazzocco study or inhibition of phenolic acid production in our study.  
However as demonstrated by Bazzocco et al. (2008) pure Proanthocyanidins reached maximal extent 
of conversion at 2 hours compared to 6-8 hours when present in the apple matrix. In our study the 
cocoa contained substantial amounts of carbohydrates and fibre possibly further delaying the 
degradation of the phenolic compounds. As seen by total phenolic acid production in our findings, the 
production of these phenolic acids is continuously increasing, thus it would be of interest in future 
studies to analyse later time points beyond 24 hours until maximal conversion is reached, in order to 
investigate if the production of these phenolic acids is truly inhibited or delayed. 
For the analysis of the impact of cocoa on SCFA production from fibres, we corrected for the 
carbohydrate content of cocoa and the additive effect of SCFA produced from FS (summarised in 4.4 
Results). The SCFA production from cocoa alone resulted in acetate as the highest SCFA followed by 
propionate and butyrate, produced almost in equal amounts. As expected, acetate was the dominating 
SCFA as a percentage of total SCFA production for all fibres, cocoa and FS. This is a contributing 
factor to the initial results seen for a higher acetate concentration in the predicted value as compared to 
the true combination value, also reflected in total SCFA concentration; which was not seen for 
propionate or butyrate.  
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These results are in line with the results seen in Chapter-3, demonstrating no impact of the polyphenols 
on SCFA production from the same soluble fibres. The majority of the volunteers (8 out of 10) in the 
cocoa fermentation study were common with that of the rutin fermentation study, resulting in the same 
faecal sample being used for both fermentation sets. 
The fermentation products are an indication of bacterial activity and viability. However, studies 
investigating the impact of cocoa polyphenols (Tzounis et al., 2011, Lee et al., 2006) have 
demonstrated that these polyphenols can impact certain species of bacteria more than others.  
As mentioned previously (4.1 Introduction), the cross-over study by (Tzounis et al., 2011)  
demonstrated a change in bacterial composition. However this modification appears to be transitory as 
there was no difference in bacterial composition between the baselines of the two arms in this 
crossover model. The return of bacterial composition to the baseline profile was also demonstrated in a 
long-term study by Smith and Mackie (2004). 
It is also possible that the impact of cocoa on inhibition of pathogenic bacteria is indirectly related to 
the increase of Lactobacillus spp. and Bifidobacterium, as the increase in both species have previously 
demonstrated to inhibit the growth of pathogenic bacteria (Saulnier et al., 2009, O‘Sullivan et al., 
2002). 
This change in bacterial composition may not necessarily be reflected in SCFA concentrations, as both 
Tzounis et al. (2011) and Massot- Cladera et al (2012) demonstrated that even though certain species 
of bacteria were promoted or inhibited, the total bacterial count was not affected by the cocoa 
polyphenols. Hence, it is not possible to derive from the results in this chapter that cocoa polyphenols 
did not exhibit any antibacterial activity.  
However an inhibitory impact of apple PA extracts on SCFA production from apple cell walls was 
demonstrated by Bazzocco et al. (2008). This impact was no longer seen when PAs were present in the 
food matrix (whole apple). Apples having shorter chain PAs, exhibited an inhibitory impact on SCFA 
production from the cell walls both in the form of PA extract and when present in the food matrix. It 
was also shown that the longer chain PA extract had a greater inhibitory impact on the production of 
SCFA from the cell wall than shorter chain PA extract. It is difficult to conclude the extent of impact 
on SCFA production due to the lack of statistics on the above mentioned data. As previously 
emphasised, the type of polyphenolic compound and its constituting matrix play a key role on the 
ability of polyphephenols to produce pre/antibiotic properties. 
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Apple cell wall has a high level of pectin. The fermentation of this cell wall resulted in the same 
proportions of SCFA seen in our study for pectin fermentation. Similarly to the long chain 
proanthocyanidins present in the apple matrix, we did not see any inhibitory impact of the polyphenols 
present in the cocoa matrix on SCFA production from the fibres. 
A more specific result of a similar study model (SHIM) was provided by Kemperman et al. (2013) 
investigating the impact of 1000 mg/day of tea extract polyphenols on the growth of gut microbiota. In 
addition to the antimicrobial activity seen by the tea extract, a reduction in butyrate concentration in 
the proximal colon was demonstrated (from ~15mM to ~10mM), which was attributed to the inhibition 
of butyrate producing bacteria. Towards the end of the study a drastic reduction in total SCFA (data not 
provided) and acetate (from ~30mM to ~22mM) concentration was demonstrated. This reduction in 
SCFA production corresponded to the reduction in bacterial numbers observed. Even though this in-
vitro model is ideal for studying the longer-term impact of polyphenols on gut bacteria in-vitro, there is 
still the lack of other factors such as host-bacteria inter-relationship and presence of other influencing 
food matrix interactions. 
Neither of the above studies investigating the impact of polyphenols on the colonic metabolite 
production have demonstrated the impact of these polyphenols while present in their constituting food 
matrix on the colonic metabolite production or taken into consideration the fate of the polyphenols 
such as their degradation to phenolic acids in-vivo. This is of great importance as previous studies have 
shown that phenolic acids produced from cocoa polyphenols may exert a stronger antibacterial impact 
than the parent compound itself (Lee et al., 2006). 
 
Conclusion 
 
Soluble fibres can inhibit phenolic acid production from polyphenols present in the cocoa matrix. This 
inhibitory impact may be related to their fermentability rate. However cocoa polyphenols and their 
metabolites have no impact on SCFA production from the soluble fibres. 
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CHAPTER 5                                                   
Food matrix interaction between 
ispaghula and cocoa                                  
in-vivo 
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In the previous chapter an inhibitory impact of soluble fibres on phenolic acid production from cocoa 
was demonstrated in-vitro. However the in-vitro study was designed to mimic the matrix interaction of 
soluble fibres on cocoa polyphenol bioavailability and metabolism only in the colon and did not 
provide any information on the impact of soluble fibres on the absorption of polyphenols in the small 
intestine. Such effects would alter the amount of polyphenolics absorbed intact but also the amount 
reaching the colon and available for bacterial catabolism. In this chapter, the impact of ispaghula on the 
appearance of phenolic acids in urine in-vivo was investigated to better understand the food matrix 
interaction of cocoa and fibre in both the upper and lower digestive tract. The phenolic acids in urine 
are influenced by the amount of polyphenolic compounds escaping the small intestine as well as the 
metabolic activity of the colonic bacteria both of which could be affected by the presence of a soluble 
dietary fibre. 
 
5.1 Introduction 
The polyphenolic content of cocoa and related possible health benefits were discussed in chapter-1 and 
6.  It was noted that 20% of monomers and 90% of the polyphenolic oligomers from cocoa and foods 
with similar polyphenol profiles, escape absorption in the small intestine and enter the colon. The main 
products of polyphenol metabolism by the colonic microbiota are phenolic acids. The phenolic acids 
produced in vitro from the Cocoa used in this human study were presented and discussed in chapter 4. 
The phenolic acids, produced in the colon in-vivo may be absorbed into the body, reaching tissues 
where they may exhibit beneficial effects (but there is very little data on any health effects of phenolic 
acids rather than their parent polyphenolic compound), be further metabolised by the liver and kidneys, 
through phase II metabolism, before being excreted in urine. Studies which have measured urinary 
phenolic acids from cocoa in-vivo are summarised in Table 5-1. Strong correlations have been reported 
between polyphenol consumption and urinary phenolic acid excretion (Mennen et al., 2006, Mennen et 
al., 2008). 
The potential biological activity of the flavan-3-ol compounds in cocoa depend on their bioavailability 
in the body. Most publications investigating the bioavailability of cocoa polyphenols have focused on 
catechin, epicatechin and procyanidins. However, it is becoming evident that the health benefits 
associated with polyphenol rich foods is not due to the native polyphenol compounds present in foods 
but their metabolites produced through the microbiota (Del Rio et al., 2010). 
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Table 5-1 Phenolic acid production from cocoa polyphenols in-vivo 
Author  
( year) 
Study method   Phenolic acid production 
(Rios et al., 
2003) 
N=11 healthy (7men, 4 women) cross over 
80g of chocolate (439 mg proanthocyanidins and 147 
mg catechin) 
3-HPAA,  3,4-DHPAA,  3-HPPA,  3-HBA,  Ferulic 
acid,  Vanillic acid  
 
(Mullen et., 
al 2009) 
N=9 (6 male and 3 female) cross over 
250ml of a cocoa [45 umol (-)epicatechin and (-) 
catechin ]drink with hot water  
3,4-DHPPA,  3,4-DHPAA,  3-Methoxy-4-hydroxy 
PAA,  3,HPAA,  PAA,   protocatechuic, 4-HBA,  
3-HBA,  4-HPA,  Hippuric,  Vanillic,  Caffeic, 
Ferulic,  p-coumaric,  m-coumaric 
(Sarda et 
al.,  2009)  
N=42 (19 male, 23 female) cross over Long term 
study 
20g cocoa *2 day +250ml skimmed milk for 4 weeks 
 
3,4-DHPAA,  3-HPAA,  5-(3,4-DDHP)-γ – 
valerolactone, 3,4-DHPPA,  3-HPPA,  PAA, 
Homo-vanillic acid, m-coumaric, p-coumaric, 
caffeic, ferulic, protocatechuic, Vanillic, 4-HBA, 3-
HBA, 4-HHA, 3-HHA 
(Llorach et 
al.,2009) 
Acute- in-vivo randomised control crossover  
N=10 (5male, 5 female) 
40g cocoa [0.71 ± 0.09 mg/g of (−)-epicatechin, 0.21 
± 0.01 mg/g (+)-catechin, 0.64 ± 0.06 mg/g of 
procyanidin B2] + 250ml water  
5-(3,4-dihydroxyphenyl)- γ-Valerolactone  
sulphate,  5-(3,4-dihydroxyphenyl)- γ-
Valerolactone  glucuronide, O-Methylepicatechin, 
Epicatechin-O-Sulphate, 3-Methoxy-4-
hydroxyphenylvalerolactone,  3-Methoxy-4-
hydroxyphenylvalerolactone glucuronide,  4-
hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid, 
Vanillic acid 
 
Production of phenolic acids from polyphenols increases their bioavailability as previously large 
molecular weight polyphenols not suitable for absorption can be absorbed as their lower molecular 
weight metabolites (Scalbert and Williamson, 2000). Thus it is important to consider factors 
influencing the gut microbiota such as antibiotics, prebiotics and other food components in the colon 
when assessing the bioavailability of polyphenols.   
Polyphenol metabolite production in-vivo can be measured by comparing urinary excretion of these 
metabolites when the parent compound is consumed alone or in combination with dietary ingredients 
that influence the microbiota, such as fibre. Fibre may alter the gastric emptying, mouth-caecum transit 
time and colonic transit time; subsequently changing time of phenolic acid appearance in urine. Fibre 
may also act as a preferential source of energy for the bacteria thus delaying or inhibiting the 
catabolism of the polyphenols. The fermentation of fibres also results in the production of SCFA and 
subsequent fall in pH, which as previously mentioned may impact bacterial composition and their 
metabolites. Additionally viscous fibres may entrap the polyphenols thus reducing their absorption in 
the small intestine, and ultimately making more of these polyphenols available to the distal colon and 
possibly increasing their excretion (Detailed in section 1.2.2 and section 1.2.4). In the in-vitro study in 
Chapter 4 ispaghula had the least effect on phenolic acid production from Cocoa. However, in-vivo 
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ispaghula, which may increase the viscosity of the intestinal contents, may have a significant impact on 
the amount of polyphenolics entering the colon and also a prolonged effect on colonic metabolism 
potentially over several days rather than the 24 hours of the in vitro study. 
Most studies investigating the food matrix interaction on the bioavailability of cocoa polyphenols have 
focused on milk, commonly consumed along with cocoa powder or present along with cocoa in the 
form of chocolate. One of the factors that can impact polyphenol bioavailability in-vivo is gastric 
emptying and mouth-caecum transit time which could be affected by the fat content of milk or cream, 
but there also may be some physic chemical interactions between the constituents of milk eg minerals 
or proteins and cocoa. 
The results of these studies are contradictory and largely dependent on the amount of cocoa ingested 
and the polyphenol concentration of the cocoa used. A detailed description of these studies is provided 
in section 1.4 Food matrix on page 74, Briefly:  
Mullen et al (2009) investigated the impact of milk on bioavailability of cocoa flavan-3-ols. They 
demonstrated an inhibitory effect of milk on the bioavailability of these flavan-3-ols using the 
commercially available Green and Blacks cocoa having 45 umol flavan-3-ol monomers. The previous 
studies by Roura et al. (2007) and Keogh et al. (2007) did not show any inhibitory impact of milk or 
milk proteins on the flavan-3-ol bioavailability of cocoa. These studies used cocoa containing 128 
umol and 2374 umol flavan-3-ol monomers respectively, 3 and 25 fold the flavan-3-ols used in the 
Mullen et al. (2009) study.   
The potential impact of changing gastric emptying and small bowel transit was seen in the study of 
Mullen et al. (2008b) who investigated the impact of cream on polyphenol bioavailability from 
strawberries.  The cream delayed gastric emptying and small bowel transit time resulting in more than 
a one hour delay in Tmax for pelargonidin-3-O-glucuronide without affecting total absorption of this 
compound and its urinary excretion. This was reflected in delay in urinary excretion of pelargonidin-3-
O-glucuronide when strawberry was consumed with cream. Interestingly yoghurt consumption with 
orange juice had little impact on polyphenolic absorption, with no impact in transit times; Mullen et al 
(2008), however severely reduced urinary phenolic acid excretion by some unknown mechanism 
(Roowi et al 2009). 
Although there are no published studies of the impact of fibre on urinary phenolic acid excretion it is 
well established that viscous fibres can influence upper gut transit times. Meal viscosity was related to 
delayed gastric emptying (Di Lorenzo et al., 1988, Marciani et al., 2000) and subsequent decrease in 
appetite (Di Lorenzo et al., 1988, Bergmann et al., 1992, Marciani et al., 2000). However there is great 
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inconsistency in the literature, which may be due to the use of different fibres and methods of fibre 
administration i.e. as a liquid, mixed with water or as solids such as fibre in cookies. Viscous fibres 
may slow gastric emptying when consumed along with a liquid meal but accelerate emptying when 
eaten with a solid meal (Mcrorie and Fahey, 2013). Of course fibres may influence phenolic acid 
production mostly by affecting colonic bacterial metabolisms as in our in vitro studies. 
Despite this important potential impact of fibres on polyphenol bioavailability, most studies have only 
investigated the impact of simple carbohydrates such as glucose on their bioavailability in-vivo. Such 
studies (Detailed in section 1.4.1 on page 81) have demonstrated that the presence of simple 
carbohydrates such as sucrose and bread can enhance the absorption of cocoa polyphenols from the 
small intestine and consequently increase the Cmax and AUC of these compounds in plasma (p<0.05), 
also resulting in a faster rate of their elimination (p<0.05) (Schramm et al., 2003). There are several 
hypotheses explaining the increased polyphenolic absorption aided by simple carbohydrates such as 
sugar in-vivo. Some of these include controlled cellular flavanol absorption by SGLT1 transporters and 
lactase phlorizin hydrolase enzymes (Gee et al., 2000).   
While simple sugars and prebiotics can enhance the deglycosylation of parent compounds reaching the 
colon and increase phenolic acid production, there is not enough evidence on the impact of more 
complex carbohydrates such as soluble fibres on phenolic acid production from polyphenols in the 
colon. These interactions have also been investigated in-vitro demonstrating enhanced catabolism of 
cocoa polyphenols and consequent increase in phenolic products by the gut microbiota in the presence 
of sucrose or fructo-oligosaccharides (Tzounis et al., 2008a).  
In a study by Bazzocco et al. (2008), previously described in detail (chapter-1), cell-wall preparation 
containing pectin delayed the maximal extent of conversion of proanthocyanidins from 4 to 8 hours 
post incubation without affecting the total concentration of phenolic acid production. Additionally the 
maximum extent of conversion for apples was much later (6hours) than their proanthocyanidin extracts 
(2hours) with maximum conversion of proanthocyanidins occurring in cider samples having the 
shortest proanthocyanidin chains. However this study is based on an in-vitro fermentation model and 
does not provide any information on the impact of the cell-walls on the absorption and excretion of 
polyphenols in-vivo. 
In this regard, the soluble fibre ispaghula, commercially available for purchase as a constipation 
remedy was desirable due to its high viscosity when mixed with water; maintained throughout the 
colon and the subsequent potential alteration of gastric emptying, mouth-caecum transit time, colonic 
transit time and other benefits in line with those seen from cocoa consumption. These properties can 
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potentially impact the absorption of polyphenols in the small intestine resulting in higher 
concentrations of the polyphenols reaching the colon and possibly higher amounts of polyphenols 
bound to the viscous mass being excreted through faeces.  
Similar to all fibres, the data on the impact of ispaghula on gastric emptying is inconsistent and in need 
of standardisation of analytical method and placebo used. As demonstrated in Table 5-2 ispaghula had 
no impact on gastric emptying or mouth-caecum transit time when consumed along with solid meals. 
When consumption of ispaghula added to a liquid lactulose meal was compared to lactulose only meal, 
a delay in gastric emptying attributed to ispaghula was demonstrated (p<0.05) with no impact on small 
bowel transit time.   
Table 5-2 Impact of ispaghula on gatsric emptying and mouth-caecum transit time in humans 
Author  
( year) 
Study design Analytical method Phenolic acid production 
(Bianchi and 
Capurso, 
2002) 
Standard meal (white bread,70 g 
egg the yolk of which was mixed 
with 100 mg of 13C octanoic acid 
and fried) with or without 5g of 
microcrystalline cellulose, guar 
gum or ispaghula 
Breath 13CO2 
measurements with IRMS 
Ispaghula, microcrystalline cellulose 
and guar gum did not impact gastric 
emptying time or mouth-caecum transit 
time 
 
(Rigaud et 
al., 1998) 
doubly labelled solid±liquid meal 
(omelet which contain two eggs, 70 
g white bread,10 g butter, 220 mL 
water) with 7.4g ispaghula or 6.9g 
placebo (gelatin) 
gamma scintigraphy Ispaghula had no impact on gastric 
emptying 
Ispaghula caused higher satiety and 
lower energy intake than placebo 
(Frost et al., 
2003) 
50g of pasta was consumed with or 
without 1.7g ispaghula 
Paracetamol absorption test  Ispaghula had no impact on gastric 
emptying  
(Washington 
et al., 1998) 
20ml radiolabeled lactulose (13.4g 
lactulose) x 3 times daily with or 
without 3.5g ispaghula  
Measurements were taken on the 5th 
day. 
gamma scintigraphy and 
Breath hydrogen 
measurement 
Ispaghula significantly delayed gastric 
emptying time (p<0.05) 
Ispaghula had no impact on mouth-
caecum transit time 
Ispaghula delayed the rise in breath 
hydrogen 
(McIntyre et 
al., 1997) 
Radio labelled rice pudding was 
consumed with either 15g wheat 
bran or 7g of Fybrogel containing 
3.5g of ispaghula or 15g plastic 
particles 
gamma scintigraphy Ispaghula, wheat bran and plastic 
particles had no impact on gastric 
emptying.  
Small bowel transit time was reduced by 
wheat bran and plastic particles but no 
impact from ispaghula. 
 
Unlike rapidly fermented soluble fibres, the benefits of slowly fermented fibres such as ispaghula can 
be extended to the distal colon. Rapidly fermented fibres are predominantly fermented in the proximal 
colon and the health benefits derived through their fermentation might not extend to the distal colon. It 
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is more likely for all of the colon epithelium to be exposed to fermentation products when a slowly 
fermented fibre is used. This was demonstrated in a study by Edwards et al. (1992) where rats were fed 
a basal diet supplemented with either 5% ispaghula or 10% wheat bran for 28 days. The measurement 
of SCFA concentration in different parts of the colon demonstrated a higher propionate production than 
wheat bran which was maintained throughout the colon, whereas wheat bran resulted in higher butyrate 
production in the caecum; however this concentration was lower in the distal colon and faeces 
compared to ispaghula, indicating that ispaghula pushes fermentation and production of SCFA towards 
the distal colon. Furthermore the presence of ispaghula can alter the fermentation rate of other 
carbohydrates, shifting their fermentation site in the direction of the distal colon. This was 
demonstrated when rats were fed a diet of low-amylose or high-amylose (50 g/kg) with or without 15 
g/kg of ispaghula. The high butyrate concentration seen from the high amylose diet reduced along the 
length of the colon reaching a third of its concentration in the caecum. When ispaghula was added to 
the diet butyrate concentrations were maintained along the large bowel with higher faecal butyrate 
excretions than the sum of low amylose + ispaghula and high amylose only diets (Morita et al., 1999). 
This is highly relevant as most disease occurs in the distal colon. In a similar manner ispaghula may 
lead to higher concentrations of polyphenolic compounds in the distal colon where they may have anti-
carcinogenic properties.  
Additionally the slower rate of fermentation of ispaghula results in less gas production and less 
discomfort in the abdomen as demonstrated by Bianchi and Capurso (2002) which may increase 
compliance in long-term interventions.  
Ispaghula can also increase satiety (Karhunen et al., 2010) which may reduce food consumption and 
thus polyphenol consumption in long-term interventions. To assess the impact of ispaghula on satiety 
we measured subjective appetite using VAS. In this human study, we did not investigate SCFA 
production as the in-vitro study (Chapter 4) did not show any impact of cocoa on SCFA production 
from ispaghula.   
 
5.1.1 Hypothesis 
This study aimed to test the hypothesis that the soluble fibre ispaghula delays or inhibits phenolic acid 
production from cocoa polyphenols through viscosity and fermentation related mechanisms.  
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5.2 Subjects and Methods 
 
5.2.1 Participants 
No previous studies have investigated the combination of ispaghula and cocoa, thus power calculations 
suitable for these specific outcomes cannot be performed, however based on a study by Mullen et al 
(2009a) investigating the food matrix interactions of milk and cocoa on polyphenol bioavailability; 
nine healthy volunteers were sufficient to observe a statistically significant reduction in 24h phenolic 
acid (flavan-3-ol) urinary excretion between the two food matrixes (3300 nmol/d) and SD (2000 
nmol/d).  
 
Healthy European male volunteers (n=12) with a mean (± SD) BMI of 23 ± 2.5 (range, 19.8 to 27.4) 
and a mean (± SD) of 23 ± 3.8 years (range, 21 to 31) were recruited through poster advertisements 
(Appendix-4) and word of mouth to allow for a 33% drop out rate. Volunteers with a BMI below 18 or 
over 29.9 and aged less than 20 years or above 40 years were excluded. Volunteers were given study 
information (Appendix-6), dietary record sheets (Appendix-2), appointment cards and urine collection 
kits at the first meeting. The study protocol was approved by the University of Glasgow, Faculty of 
Medicine Ethics Committee for Non Clinical Research Involving Human Subjects (Project 
No: FM08119). All subjects gave written informed consent. 
   
5.2.2 Study design  
The study design was adapted from Mullen et al (2009a). The study design was one that reduced the 
diversity in the study population and allowed for better comparison of outcomes. The cross-over model 
eliminated the impact of inter-individual variation in microbiota composition and subsequent 
metabolite production and a homogenous population was included to reduce inter-individual variations.  
The study was an acute randomised control cross over study using three meals: 
- 15g of ispaghula (whole ispaghula husk by MYProtein).  
- 20g of cocoa (extra brute Cocoa-Cacao Barry, Barry Callebaut, Hardricourt, France).  
- 15g of ispaghula and 20g of cocoa powder. 
The composition of the Barry Callebaut cocoa powder used in this study and a comparison to the more 
well-known Green and Blacks Cocoa powder (Green and Black's Ltd, London, United Kingdom) is 
given in Table 5-3. 
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Table 5-3 Composition of cocoa powder used with comparison to well-known Green and Blacks cocoa powder 
Nutritional data/100g Extra brute 
Barry callebaut 
Organic dark cocoa 
Green & Blacks 
Typical Composition 100% cocoa powder 16.3% 
Energy 339 Kcal 350 Kcal 
Available Carbohydrate 13.0g 13.6 
 Sugars 
(mono+Disaccharides) 
 0.4g    0.4 
 Starch 12.6g Not specified 
Dietary Fibre 27.7g 28.7 
Total Protein 18.0g 23.6 
Milk Protein 0.0g Not specified 
Total Fat 23.0g 22.3 
Saturated Fat 14.5g 13 
Vanilla extract       × ✓ 
Soya Lecithin-Emulsifier      × ✓ 
This information was kindly provided by the customer service and quality control administration unit of respective brands. 
 
volunteers were randomised to one of six randomisation patterns: 1- ispaghula+cocoa, ispaghula, 
cocoa. 2- ispaghula+cocoa, cocoa, ispaghula. 3-ispaghula, cocoa, ispaghula+cocoa. 4- ispaghula, 
ispaghula+cocoa, cocoa. 5- cocoa, ispaghula, ispaghula+cocoa. 6- cocoa , ispaghula+cocoa, ispaghula. 
 
 
 
 
All volunteers were asked to follow a low polyphenol diet, which excluded fruits, vegetable and 
polyphenol containing beverages such as fruit drinks, tea, coffee, cocoa drinks, and wine (Appendix-1) 
for 3 days prior to the study to reduce baseline urinary phenolic acid concentration. Volunteers 
maintained a food diary to determine compliance to the diet. They visited the Human Nutrition unit on 
 
 
Figure 5-1 Intervention substrates in cocoa in-vivo study 
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the 4th day after a 10 hour fast with no restrictions on water consumption.  
Upon arrival at the unit, anthropometric measurements were taken (height, weight, waist/ hip 
circumference and body composition) followed by fasting blood, urine and breath hydrogen samples. 
Volunteers completed a visual analogue scale (VAS) for the subjective assessment of appetite at 
baseline. They then consumed the supplement along with 240ml of water followed by 120ml of water 
to rinse any remaining supplement from the glass and 1g of paracetamol for estimation of gastric 
emptying rate. Urine (5.2.5), blood (5.2.4), breath hydrogen (5.2.13) and completed VAS 
questionnaires (5.2.12) were collected (Figure 5-2). Four hours after the test meal, volunteers were fed 
a low-polyphenol and low-fibre meal of chicken sandwich made of white bun, 2 layers of thin sliced 
chicken and 1 slice of low fat cheddar cheese. Collection of VAS questionnaires, blood and breath 
hydrogen ceased at 6 hours and volunteers left the unit with urine collection kits to collect to 24 hours. 
Volunteers remained on the low polyphenol diet until the completion of the 24-hour urine sample 
collection. 
 
There was a two week washout period between different arms of the study, and volunteers were asked 
to return to the unit and the study was carried out under identical circumstances for all arms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 In-vivo study design for the matrix interaction of cocoa polyphenols and ispaghula. 
 
Urine collection at 0, 0-2, 2-5, 5-8 and 8-24h 
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5.2.3 Anthropometric measurements:  
Anthropometric measurements were taken at every visit (total of 3 times) to ensure no significant 
change in weight. Volunteers were asked to remove shoes, socks and jewellery and to empty their 
pockets prior to measurements. Height was measured in centimetres using a stadiometer with 
volunteers standing straight having their back to the stadiometer, their head positioned to look straight 
forward and hands to their side. Body composition measurements were done using bioimpedance in 
duplicate for weight, body fat %, total fat mass, fat-free mass and total body water with the volunteers 
using a TBF-300, TANITA, Cranlea UK.  Water consumption was restricted (no more than 240ml of 
water) before body composition measurement. Waist circumference was measured midway between 
the lowest point of the costal margin and highest point of the iliac crest in the standing position and hip 
circumference was measured at the largest portion of the hip using a non-stretch tape measure 
(Waistwatcher, Kunzte Design, Germany). 
 
5.2.4 Blood samples collection:  
After completion of anthropometric measurement, volunteers were asked to rest on a bed. A venous 
cannula was inserted in the non-domimant arm. 12ml of blood was collected into EDTA tubes at 
baseline and every half hour for 4 hours and at the 6th hour. Saline was used to flush the cannula every 
half hour or more frequently when necessary to prevent any clots from forming. 
For the measurement of paracetamol, insulin, glucose and polyphenols; blood was centrifuged at 3000g 
at 4°C for 15 minutes, plasma was separated and aliquoted. For the analysis of CCK/PYY; Aprotonin 
(80 ul) was added to 1ml of blood, vortexed and centrifuged at 1400g for 4 minutes. All aliquots were 
stored at -80°C. 
 
5.2.5 Urine sample collection:  
Urine samples were collected at baseline and for 24 hours after test meal ingestion. The 24 hour urine 
sample was collected in 4 batches of 0-2h, 2-5h, 5-8h, 8-24h. Urine samples collection took place in 
the unit up to 6 hours post supplement ingestion, after which volunteers were issued with multiple ice 
packs in cool bags and spare collection containers to take home. 5-8h and 8-24h urine samples were 
returned to the unit by 9:30am the following morning. Collected urine samples were weighed 
immediately after collection, mixed well and aliquoted (2ml × 8) and stored at -80°C for later analysis 
of phenolic acids, total phenol and total antioxidant capacity.  
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5.2.6 Four day food records: 
Volunteers maintained a food diary to check for compliance and for better replication of the same diet 
for all arms of the study (Appendix-2). 
 
5.2.7 Phenolic acid measurement 
Phenolic acids were measured in duplicate in urine samples using the Phenolic acid analysis method 
detailed in CHAPTER 2.   
 
5.2.8 Total phenol 
The Folin & Ciocateau method (Singleton et al., 1999) was used to determine total phenols and other 
easily oxidised substances in the urine and plasma samples.  
For the preparation of the Folins reagent (1:10), 100 ml Folin & Ciocateau reagent was added to 900ml 
of distilled water. A standard calibration curve ranging from 50 – 500 ug/ml in methanol was prepared 
using 50ug/ ml gallic acid stock (0, 25, 50, 100, 200, 300, 400, 500 ug/ml). 100ul of the prepared Folin 
reagent was added to 20ul of sample or standard in a 96 well plate, followed by 70ul of distilled water 
using a multi-channel pipette. After 5 minutes of incubation 70ul of sodium carbonate solution 
prepared by dissolving 115g of sodium carbonate in 1L of distilled water was added to the plate. The 
plate was sealed with the Mylar plate sealer (Fisher scientific) and left to incubate for 2 hours. The 
plate was read at an absorbance of 765nm using a spectrometer (Thermo scientific multiskan spectrum) 
 
5.2.8.1 Total phenol analysis of free and bound phenolics (method1) 
This method was adapted from Holtekjølen et al (2008). Ten ml cold (4 °C) 60% acetone was added to 
200mg of cocoa or ispaghula. The mixture was shaken for 10 minutes at room temperature, followed 
by centrifugation (2800 rpm) for 10 minutes. The supernatant was used for measuring free phenolic 
acids. 2M NaOH (10ml) was added to the pellet and left overnight. This allowed the release of 
esterified (bound) compounds. The mixture was then acidified to pH 1.45-1.55 using 6M HCL. The 
released phenolic compounds were extracted with 10ml ethyl acetate ×4. The pooled extractions were 
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then concentrated to dryness and resolved in 10ml of DMSO. This was then analysed for bound 
phenolics quantification using the total phenol method. 
 
5.2.8.2 Total phenol analysis for free phenolics (method2) 
This method was adapted from Thondre et al. (2011) and is similar to the first step of method 1. Four 
ml of 70% acetone was added to 200mg of cocoa or ispaghula and shaken (2h) at room temperature. 
The extracts were centrifuged at 3000g for 10minutes. The supernatant was used in accordance to the 
method detailed in section 5.2.8 for the determination of free phenolic acids in cocoa and ispaghula. 
 
5.2.9 FRAP   
The ferric ion reducing antioxidant power assay was conducted for the measurement of total 
antioxidant capacity of both urine and plasma. This assay is based on the ability of the antioxidant to 
reduce the oxidant. in this context antioxidant are considered as reductants in a redox-linked 
colorimetric method. This assay measures the ferric reducing ability of plasma/ urine. The reduction of 
the ferric-tripyridyltriazine (Fe III-TPTZ) to ferrous (Fe II) at a low pH results in an intense blue colour 
with a maximum absorption at 593 nm (Benzie and Strain, 1996). 
For the preparation of the FRAP reagent, 10ml of 20mM Ferric chloride hexahydrate (0.54g ferrous 
chloride in 100ml distilled water) was added to 10ml of 10mM 2,4,6-tripyridyl-s-triazine (TPTZ) 
solution (0.03 TPTZ in 10ml 0f 40mM hydrochloric acid). This was then added to 100ml of acetate 
buffer, PH 3.6 (3.1g sodium acetate and 16ml acetic acid in 1 litre distilled water).  
The standard calibration curve was prepared by serial dilutions of Fe
2+
 (0.0278g ferrous sulphate 
heptahydrate, in 100ml distilled water). A range of 0.1mM – 1.0 mM Fe2+ was used for preparing the 
calibration curve (0, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mM Fe
2+
). 25ul of standard or sample was 
added to the 96 well plate in triplicate, Followed by the addition of 225ul FRAP reagent. Four minutes 
of incubation was allowed before reading the plate at 593nm using a spectrometer (Thermo scientific 
multiskan spectrum). This assay was repeated with different dilutions of urine in order to achieve more 
accurate results. This ensured that the concentrations obtained from urine samples were below that of 
the most concentrated standard. For the purpose of this assay, a 1:4 dilution (5ul urine, 15ul distilled 
water) was used for the urine samples. 
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5.2.10 Analysis of cocoa 
To quantify the concentration of catechin/epicatechin and procyanidins in the cocoa used in our study 
we adapted a method by Robbins et al (2009). Fat was extracted in triplicates, by adding 30ml n-
hexane to 1g of cocoa powder. This was vortexed for 1 minute and sonicated for 10 minutes at 38°C, 
followed by centrifugation at 3000 g. The supernatant was discarded and the pellet was dried with 
nitrogen and left overnight to ensure complete drying. 50mg of dried sample was extracted in triplicate 
with 2.5ml of acetone/water/acetic acid (70:28:2), vortexed for 1 minute, sonicated for 10 minutes at 
38°C and centrifuged at 3000 g. The supernatants were pooled, diluted in the following solvents (1:3) 
and filtered. Solvent A: acetonitrile/acetic acid (98:2) and solvent B: methanol/ water/ acetic acid 
(95:3:2). The linear gradient for the determination of compounds was [mobile phase B, time (min)]: 
(7%, 3), (37%, 3-57), (100%, 57-60), (100%, 60-67), (7%, 67-73), (7%, 73-83) in a Surveyor HPLC 
system comprising a HPLC pump, a PDA detector (Thermo Fisher Scientific). 
The extraction of fat with n-hexene resulted in a high loss of catechin/epicatechin giving very low 
concentrations recovered from cocoa. Hence, we repeated the extraction of cocoa catechin/epicatechin 
and procyanidins adapting the method by Mullen et al.,(2009b). For this method 5ml of methanol or 
water was added to 1g of cocoa. This was vortexed for 2 minutes and centrifuged at 3000g for 10 
minutes in triplicate. The supernatants were pooled. 1 ml of the supernatant was further centrifuged at 
3000g to ensure clean injection. Standards for calibration curve were prepared as 50, 25, 12.5, 2.5, 0.5 
ng/ul for catechin and 800, 400, 200, 40, 8 and 0 ng/ul for epicatechin. Dimers, trimers and tetramers 
were quantified as catechin equivalents.  
5ul of standards or cocoa extracts were analysed on a Surveyor HPLC system comprising a HPLC 
pump, a PDA detector, scanning from 250 to 600 nm, and an autosampler cooled to 6 °C (Thermo 
Fisher Scientific). Analysis were carried out at 40 °C using a 100 × 2.1 mm i.d., 4 μmm Hypersil Gold 
column (Thermo Scientific) eluted with a 20 min gradient of 5-90% acetonitrile (solvent A), in 0.1% 
aqueous formic acid (solvent B), at a flow rate of 300 μl/min. The linear gradient for the determination 
of compounds was [% mobile phase B, time (min)]:  (95%, 0-1), (70%, 1-7), (50%, 7-10), (10% 10-
10.10), (10%, 10.10-15.0), (95%, 15-15.10), (95% 15.10-20). After passing through the flow cell of the 
PDA detector, the column eluate was directed to an LCQ Advantage ion trap mass spectrometer fitted 
with an electrospray interface (Thermo Fisher Scientific). Analyses utilised the negative ion mode. 
Samples were analysed in the mass spectrometer using selected reaction monitoring (SRM) scanning 
for fragments of the m/z 289 parent ion from m/z 150 to m/z 449. Capillary temperature was 300 °C, 
sheath gas and auxiliary gas were 30 and 10 units, respectively, the source voltage was 3 kV, and SRM 
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maximum cycle time was 200 ms. Both HPLC-MS systems were controlled by Xcalibur software 
(Thermo Fisher Scientific). This analysis was carried out with thanks to Dr. William Mullen (Senior 
Research Fellow-Institute of Cardiovascular and Medical Sciences- University of Glasgow) for his 
guidance and allowing the use of his lab. 
5.2.11 Paracetamol measurement 
Paracetamol was measured as an estimation of gastric emptying.  Given that gastric emptying is the 
limiting factor in paracetamol reaching its site of absorption, the time of paracetamol appearance in 
plasma is reflective of time of gastric emptying. Additionally there is a good correlation between 
gastric emptying measured by scintigraphy and paracetamol absorption (Willems et al., 2001). 
Paracetamol levels were measured in plasma using an acetaminophen assay kit (Cambridge Life 
Sciences, Cambridge, United Kingdom). The standard calibration curve was prepared by serial 
dilutions of paracetamol standard in distilled water and ranged from 125-0.24 mmol/L (125, 62.5, 
31.25, 15.62, 7.8, 3.9, 1.95, 0.97, 0.48, 0.24, 0). The standard concentrations were determined during 
test-runs of the assay. 
After the preparation of the calibration curve, 50ul of either standard or sample was added to a 96 well 
plate in duplicate, followed by 0.5ml of reconstituted enzyme reagent. This was mixed well and 
incubated at room temperature for 5 minutes. Reagent A (1ml) and Reagent B (1ml) were added to all 
wells. The plate was left to incubate at room temperature for 30minutes after which it was read at 
615nm using a spectrometer (Thermo scientific multiskan spectrum). An index of gastric emptying 
time was obtained by applying curve fittings to the data from paraceramol concentrations calculated 
with subsequent calculation of T1/2 and paracetamol AUC. (Willems et al., 2001). The analysis of this 
data was carried out with thanks to Dr. Douglas Morrison (Senior Lecturer, Isotope Biochemistry, 
University of Glasgow). 
 
5.2.12 Subjective appetite assessment: 
Visual analogue questionnaires were used to assess subjective appetite and hunger levels after the test 
meals (Appendix-7). They were completed by the volunteers at baseline and every 30 minutes for 6 
hours. A validated VAS questionnaire (Flint et al., 2000) was used. Volunteers were asked to mark 
their sensation of hunger, fullness, satiety and prospective food consumption on a 100mm non-scaled 
VAS anchored at both sides with the most extreme response for each sensation, using the following 4 
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questions:  
- How hungry do you feel?  
- How satisfied do you feel? 
- How full do you feel? 
- How much do you think you can eat? 
A questionnaire was obtained before introduction of supplement and displayed as BL (baseline), and 
another immediately after introduction of supplement being the 0h time point. 
 
5.2.13 Breath hydrogen:  
Breath hydrogen (ppm) was measured as an estimation of oro-caecal transit time. Expiratory breath 
hydrogen concentrations were initially to be measured using a portable breath hydrogen monitor 
(Bedfont Scientific Ltd, Rochester, Kent, United Kingdom) allowing volunteers to measure breath 
hydrogen after leaving the unit for 9 hours post supplement ingestion. 
However due to a fault with equipment, we had to use a lab based machine and volunteers collected 
their breath very 30 mins for 6 hours into 20ml syringes and capped them immediately. Collected 
samples were injected into a breath hydrogen monitor (GMI, Medical Ltd, Renfrew) calibrated using 
Bedfont calibration gas (100ppm hydrogen, 100ppm methane and 20.9% air). The time of first 
sustained rise in breath hydrogen was taken as the mouth-to-cecum transit time (Mullen et al., 2009a).  
 
5.2.14 Statistical analysis  
To determine the impact of the ispaghula on phenolic acid production from cocoa, a general linear 
model Anova was performed using the software Minitab-15. This statistical model allowed for the 
analysis of paired data across time. In this analysis Phenolic acid was used as the response, with 
volunteer, time, substrate and time*substrate included in the model. Volunteer was included in the 
random factors.  Total phenol and FRAP results were analysed either by paired t-test model or 1-way 
Wilcoxon Test after assessing for Normality. AUC was calculated for plasma paracetamol, breath 
hydrogen and VAS questionnaires and analysed either by paired t-test model or Mann-Whitney Test 
after assessing for Normality. Correlations were determined using Minitab-15. 
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5.3 Results 
 
5.3.1 Anthropometric measurements  
Table 5-4 shows the anthropometric measurements for volunteers meeting the study criteria.  
 
Table 5-4 In-vivo cocoa study - participant information 
Volunteer 
no. 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
BMI Waist 
circumference 
(cm) 
Waist/Hip  
Ratio 
(cm) 
Body Fat% 
1 31 181 81 24.7 89.5 0.88 14.5 
2 23 182 68.8 20.8 80 0.88 11.5 
3 28 196 76.2 19.8 80 0.82 9.7 
4 21 200 88.6 22.2 86 0.88 11.9 
5 21 180 68.8 21.2 73 0.84 10.2 
6 21 189 74.6 20.9 90 0.98 15.3 
7 23 170 62.6 21.7 80.5 0.91 12.7 
8 24 176 86.2 27.8 98 0.91 21.7 
9 21 174 78.6 26 89.2 0.93 18.9 
10 23 176 78.4 25.3 80.5 0.89 15.4 
11 22 179 70.4 22 86 0.87 12.3 
12 21 186 79.6 23 88 0.84 14.4 
Mean ± 
STDEV 
23.3  
± 3.2 
182.4 
± 8.9 
76.2 
± 7.6 
23  
± 2.5 
85.1  
± 6.6 
0.89  
± 0.04 
14.0 
 ±3.5 
Values are means (± SD), BMI: body mass index  
 
5.3.2 Quantification of Cocoa Flavan-3-ols 
There have been no previous published studies quantifying the flavan-3-ol concentration of Barry 
Callebaut extra brute cocoa powder. This analysis of this cocoa powder was carried out with thanks to 
Dr. William Mullen for his guidance and allowing the use of his lab. 
The flavan-3-ol monomers were quantified using catechin/ epicatechin calibration curves. Dimmers, 
trimer and tetramers were quantified as epicatechin equivalents. Some traces of pentomers were also 
detected. A compound having a target ion of 305.0729 was putatively identified as gallocatechin 
having an extra hydroxyl group than catechin (accounting for the +16 mass of the identified 
compound). The chromatograph presented in  
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Figure 5-3 was obtained from a prior extraction. However, due to lack of mass-spec and standards at the 
given time, quantification was not possible. Hence, this analysis was used solely for the presentation of 
compound elution. 
Table 5-5 Flavan-3-ol quantification of extrabrute (Barry Callebaut) cocoa 
 MeOH extraction (ug/g) H2O extraction (ug/g) 
Catechin 1724.5 1757.7 
Epicatechin 9479.5 7390.5 
Gallocatechin 43992.7 238877.1 
Dimers 9225.86 10584.1 
Trimers 1798.76 1856.6 
Tetramers 187.8 7 109.16 
values are presented as mean concentration.  
 
 
 
The chromatograph was obtained with thanks to Dr. Gina Borges (Research Associate, Life-course 
Nutrition and Health, University of Glasgow) for her guidance and instructions. 
 
5.3.3 Phenolic acids 
Ispaghula husk is a plant based product and may contain polyphenolic compounds, which are released 
during fermentation. Hence, for better understanding of the impact of ispaghula on the phenolic acid 
production from cocoa we calculated a predicted value as the sum of phenolic acid produced from 
ispaghula only and phenolic acid produced from cocoa only. The predicted value is presented as ISP-C 
and is compared to the true combination of ISP+C ingested. A higher value for ISP-C as compared to 
 
 
 
 
 
 
 
Figure 5-3 Flavan-3-ol chromatograph of extra brute (Barry Callebaut) cocoa 
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ISP+C is an indication of food matrix interaction having an inhibitory effect on the production of 
phenolic acids from cocoa. 
Due to the high inter-individual variations observed in the results, volunteers were further divided into 
high producers and low producers of phenolic acids based on mean sum of total phenolic production. 
Volunteers producting total sum of phenolics above the mean were considered as high producers and 
those below the mean as low producer. Analysis of data was conducted for each group separately. 
The maximum concentration reached is defined as Cmax and the time in hours at which Cmax was 
reached is defined as (Tmax).The phenolic acids identified in the cocoa incubations are listed in table 
5-6. 
5-6 Identified phenolic acids from cocoa consumption 
Phenolic acid  (PA) Cumulative 
concentration at 24h 
 (mg/ time point) 
No. of volunteers 
producing PA  
from cocoa 
No. of volunteers 
producing  PA 
from Ispaghula 
No. of volunteers 
producing  PA 
from 
Ispaghula+Cocoa 
3-Hydroxy phenyl acetic acid 0.12 ± 0.07 12 10 11 
4-hydroxy phenyl acetic acid 1.21 ± 0.86 12 12 12 
3,4- Dihydroxy phenyl acetic acid 0.02 ± 0.02 9 5 6 
Hippuric acid 11.7 ± 7.1 12 12 12 
4-Hydroxy hippuric acid 0.09 ± 0.14 5 5 4 
4-Hydroxy benzoic acid 0.09 ± 0.04 12 7  11 
3,4-Dihydroxy benzoic acid 0.03 ± 0.05 9 3 6 
Vanillic acid 0.16 ± 0.07 12 8 11 
Homo-vanillic acid 0.17 ± 0.08 12 12 12 
Mandelic acid 0.02 ± 0.04 5 2 2 
4-Hydroxy mandelic acid 0.30 ± 0.15 12 11 11 
Total sum of phenolic acids 14.0 ± 7.26 12 12 12 
Values are presented as means (± SD) at 24 hours after 20g of cocoa in water (360ml) consumption (n=12). 
 
 
5.3.3.1 Impact of ispaghula on phenolic acid production from cocoa  
Ispaghula was slowly fermented and hence most of the phenolic acid production from this fibre was 
seen at 24 hours after ingestion. Data was analysed for time points over 24 hours and cumulative data 
(calculated as the sum of 0-2, 2-5, 5-8 and 8-24 hour samples) separately. 
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5.3.3.1.1 Phenolic acids present in higher concentration after cocoa 
consumption than ispaghula 
 
 3-HPAA: Ispaghula inhibited the production for the cumulative data (Figure 7-4, p < 0.01) but not 
for non-cumulative data. Cocoa produced 3-HPAA at 8 hours after ingestion compared with 5 hours 
after ingestion of ispaghula. The same observation was made for both high and low producers (p < 0.01 
and p = 0.01 respectively Figure 5-4). Ispaghula inhibited 3-HPAA for high producers (p < 0.01) but 
not low producers. 
 
 
Figure 5-4 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 3-HPAA in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p < 0.01.  a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value 
 
 
 
 
 
 3,4-DHPAA: Ispaghula did not inhibit the production when all volunteers were considered together  
(Figure 5-5). However it did inhibit production for high producers (p < 0.01). The higher concentration 
of 3,4-DHPAA for cocoa than ispaghula was only observed for high producers but not when all 
volunteers were considered together. 
Substrate High producers Low producers 
Cocoa 0.19 ± 0.05a 0.08 ± 0.04b 
Ispaghula 0.09  ± 0.06a 0.02 ± 0.03a 
Ispaghula+ Cocoa 0.13  ± 0.07d 0.08 ± 0.09 b 
Predicted value 0.28 ± 0.11a, b, c 0.11 ± 0.06b 
 * 
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Figure 5-5 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 3,4-DHPAA in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *ISP+C vs. cocoa, ispaghula and predicted (p= 0.01, p=0.01 & p=0.04).  a: p < 0.05 vs. cocoa, b: p < 0.05 vs. 
ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. predicted value 
 
 
 
 4-HBA: Ispaghula inhibited production for both cumulative (Figure 5-6) and non-cumulative data  
(p=0.02 and p=0.01 respectively). The production from cocoa began between 2-5 hours, followed by a 
decline at 5-8 hours and a rapid increase thereafter. The production began at 5 hours after ispaghula 
consumption. When ispaghula and cocoa were ingested together, the production was delayed to 8 hours 
after ingestion. Ispaghula inhibited the production of 4-HBA for high producers (p < 0.01) but not low 
producers.  
 
 3,4-DHBA: Ispaghula inhibited production for cumulative data only (p=0.01). Ispaghula also 
delayed the production (8 hours after ingestion) as compared with cocoa alone (5 hours after 
ingestion). Ispaghula inhibited production for high producers only (predicted vs. true value p < 0.01, 
true value vs. cocoa p=0.02). 
 
Substrate High producers Low producers 
  Cocoa 0.05 ± 0.008 b, c 0.005 ± 0.01 
Ispaghula 0.02  ± 0.02a 0.003 ± 0.007 
Ispaghula+ Cocoa 0.02  ± 0.03a 0.01 ± 0.02 
Predicted value 0.08 ± 0.02,b,c 0.008 ± 0.01 
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Figure 5-6 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 4-HBA in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p=0.02  a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 
 
 
Figure 5-7 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 3,4-DHBA in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p=0.01. a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 Mandelic acid: Ispaghula inhibited production for both cumulative and non-cumulative data 
(p=0.01 and p < 0.01 respectively). The production was seen after 2 hours of cocoa, 8 hours of 
Substrate High producers Low producers 
  Cocoa 0.11 ± 0.04d 0.07 ± 0.04b 
Ispaghula 0.09  ± 0.08d 0.01 ± 0.04a,c, d 
Ispaghula+ Cocoa 0.10  ± 0.05d 0.08 ± 0.08b 
Predicted value 0.20 ± 0.12a, b, c 0.09 ± 0.06b 
 
* 
Substrate High producers Low producers 
  Cocoa 0.05 ± 0.05b 0.02 ± 0.06 
Ispaghula 0.01  ± 0.03a, d 0.003 ± 0.009 
Ispaghula+ Cocoa 0.03  ± 0.04d 0.007 ± 0.01 
Predicted value 0.06 ± 0.07b, c 0.02 ± 0.06 
 * 
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ispaghula and 2 hours after the combination (reaching a plateau after 8 hours) ingestion. Similar results 
were observed for high producers; there was no inhibition in production for high producers.  
 
 
Figure 5-8 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of mandelic acid in 
urine. Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in 
water (n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p < 0.01. a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 
 Vanillic acid: The production was not inhibited by ispaghula. The production began between 0-2 
hours of cocoa ingestion, declining thereafter and increased again at 8 hours; this increase was only 
seen at 8 hours after ispaghula ingestion and 5-8 hours after combination ingestion The higher 
production of vanillic acid from cocoa than ispaghula was observed in both high and low producers (p 
< 0.01). Ispaghula inhibited vanillic acid production in high producers only (p=0.04). 
 
 Homo-vanillic acid: ispaghula inhibited production for both cumulative and non-cumulative data (p 
< 0.01). The higher production of homo-vanillic acid from cocoa than ispaghula was observed in both 
high and low producers (p < 0.01). The concentration of this phenolic acid increased 5 hours after 
cocoa and combination group ingestion, but 8 hours after ispaghula ingestion. 
Substrate High producers Low producers 
  Cocoa 0.04 ± 0.05b 0.007 ± 0.01 
Ispaghula 0.009  ± 0.01a,d 0.00 ± 0.00 
Ispaghula+ Cocoa 0.01  ± 0.01 0.00 ± 0.00 
Predicted value 0.05 ± 0.05b 0.007 ± 0.01 
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Figure 5-9 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of vanillic acid in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12),  ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination.  a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. predicted value. 
 
 
 
 
 
 
Figure 5-10 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of homo-vanillic acid 
in urine. Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula 
in water (n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and 
cocoa combination. *p < 0.01. a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 
 
 
 
 
 
 
 
Substrate High producers Low producers 
  Cocoa 0.17 ± 0.05b 0.15 ± 0.08b 
Ispaghula 0.05  ± 0.04a,c,d 0.02 ± 0.04a,c,d 
Ispaghula+ Cocoa 0.17  ± 0.06b,d 0.12 ± 0.08b 
Predicted value 0.22 ± 0.01b, c 0.17 ± 0.12b 
 
Substrate High producers Low producers 
  Cocoa 0.37 ± 0.18d 0.25 ± 0.11d 
Ispaghula 0.28  ± 0.13d 0.13 ± 0.08c,d 
Ispaghula+ Cocoa 0.34  ± 0.22d 0.25 ± 0.16b,d 
Predicted value 0.66 ± 0.31a,b,c 038 ± 0.17a,b,c 
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5.3.3.1.2 Phenolic acids present in high concentration after both cocoa and 
ispaghula consumption:  
 
 4-HPAA: The matrix interaction of ispaghula and cocoa inhibited production for cumulative data 
(Figure 5-11, p = 0.04) and non-cumulative data (p = 0.04). This inhibition was also seen for high 
producers low producers (p < 0.01). 
 
 
Figure 5-11 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 4-HPAA in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *ISP+C vs. cocoa, ispaghula and predicted (p= 0.01, p=0.01 & p=0.04).  a: p < 0.05 vs. cocoa, b: p < 0.05 vs. 
ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. predicted value 
 
 
 4-HMA: The matrix interaction of ispaghula and cocoa inhibited production for both cumulative 
and non-cumulative data (p < 0.01). This inhibitory impact was only observed for the high producer 
group (p < 0.01) and not low producers. 
 
 Hippuric acid was the highest produced phenolic acid from both cocoa and ispaghula. Hippuric acid 
is produced through various metabolic pathways in the body, which may explain its high concentration 
at baseline. The production of hippuric acid was seen between 8-24 hours after ingestion and was 
inhibited by the matrix interaction of cocoa and ispaghula for both cumulative and non-cumulative data 
(p < 0.01). This inhibitory impact was observed for both high and low producers as well (p < 0.01).  
Substrate High producers Low producers 
  Cocoa 1.88 ± 0.96 d 0.73 ± 0.31 c,  d 
Ispaghula 1.33  ± 0.66 d 1.00 ± 0.66 c, d 
Ispaghula+ Cocoa 1.31  ± 0.53 d 1.63 ± 1.51 a, b 
Predicted value 3.22 ± 1.36 a, b, c 1.73 ± 0.94 a, b 
 
* 
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Figure 5-12 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 4-HMA in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p < 0.01. a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p< 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 
 
 
 
Figure 5-13 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of hippuric acid in 
urine. Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in 
water (n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. predicted value 
 
 
 
 
 
Substrate High producers Low producers 
  Cocoa 0.23 ± 0.07d 0.12 ± 0.06d 
Ispaghula 0.21  ± 0.07d 0.07 ± 0.08c 
Ispaghula+ Cocoa 0.27  ± 0.10d 0.12 ± 0.09b 
Predicted value 0.44 ± 0.13a,b,c 0.20 ± 0.12a 
 
Substrate High producers Low producers 
  Cocoa 14.8 ± 2.29d 9.50 ± 8.68d 
Ispaghula 12.6  ± 3.26d 8.85 ± 4.44d 
Ispaghula+ Cocoa 13.8  ± 4.60d 10.7 ± 8.14d 
Predicted value 27.5 ± 4.78a,b,c 18.3 ± 12.2a,b,c 
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 4-HHA: The matrix interaction of cocoa and ispaghula inhibited the cumulative concentration of (p 
= 0.01). Contrary to the observations made for hippuric acid, this inhibition was only seen for low 
producers (p = 0.02). The production of 4-HPA was seen earlier for ispaghula and ispaghula+cocoa (5 
hours after ingestion) than cocoa *8 hours after ingestion).  
 
 
 
Figure 5-14 Impact of matrix interaction between ispaghula and cocoa on cumulative excretion of 4-HHA acid in 
urine. Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in 
water (n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p= 0.01. a: p < 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 
 
5.3.3.1.3 Impact of matrix interaction between ispaghula and cocoa on total sum 
of phenolic acid production:  
Hippuric acid was the highest contributor to the sum of total phenolic acids. The similar concentration 
of hippuric acid for both ispaghula and cocoa was reflected in sum of total phenolic acids; resulting in 
no difference between the two. However, the food matrix interaction between cocoa and ispaghula 
resulted in an inhibition of total phenolic acid production for both cumulative and non-cumulative 
concentrations (p < 0.01, Figure 5-15). 
Substrate High producers Low producers 
  Cocoa 0.19 ± 0.18d 0.02 ± 0.04d 
Ispaghula 0.19  ± 0.22d 0.02 ± 0.05d 
Ispaghula+ Cocoa 0.20  ± 0.20 0.01 ± 0.03d 
Predicted value 0.38 ± 0.39a,b 0.05 ± 0.09a,b,c 
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Figure 5-15 Impact of matrix interaction between ispaghula and cocoa on cumulative sum of total phenolis in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. *p < 0.01. a: p< 0.05 vs. cocoa, b: p < 0.05 vs. ispaghula, c: p < 0.05 vs. Ispaghula+cocoa, d: p < 0.05 vs. 
predicted value. 
 
 
 
This inhibition was also seen for high and low producer and low producers (p < 0.01, Table 5-7 and 
Figure 5-16) 
 
Substrate High producers Low producers 
  Cocoa 18.2 ± 1.6 11.0 ± 8.3 
Ispaghula 14.9  ± 3.6 10.1 ± 4.4 
Ispaghula+ Cocoa 16.4  ± 4.4 13.0 ± 8.5 
Predicted value 33.1 ± 4.7 21.1 ± 11.7 
Table 5-7 Impact of matrix interaction between ispaghula and  
cocoa on cumulative sum of total phenolics in urine for high and  
low producers.  
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Figure 5-16 cumulative sum of total phenolics in 
urine of high and low producers at 24 h  
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Hippuric acid was the highest contributor in the makeup of the total phenolic acids. Followed by 4-
HBA > Vanillic acid > 4-HMA > Homo-vanillic acid and 3-HPAA (Figure 5-17). 
 
 
 
                                                              
                                                 
Figure 5-17 contribution of individual phenolic acids to sum of phenolics from cocoa ingestion. 
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5.3.4 Total phenol 
5.3.4.1 Total phenol analysis (TP assay) of cocoa and ispaghula 
As phenolics can be found in both free and bound form, we conducted this analysis for both. The free 
phenolics are the highest in concentration; hence, we used two different methods of free phenolic 
measurements for comparison purposes. The free phenolics were measured with 3 levels of dilution 
(with distilled H2O), to control for any impact of acetone. Extraction of phenolics for Method-1 was 
conducted with 10ml of 60% acetone and allowed to shake for 10 minutes, followed by centrifugation. 
Method-2 extraction was conducted with 4ml of 70% acetone and was allowed to shake for 2 hours 
prior to centrifugation. 
 
 
As seen in Figure 5-18 the higher concentration of acetone could be interfering with absorbance 
reading, resulting in lower calculated concentration for cocoa and ispaghula in method-2. When diluted 
to 50% this interference is reduced, resulting in equal concentration of free phenolics from cocoa for 
both methods. Further dilution to 75% resulted in higher concentration from cocoa using method-2 
compared to method-1. Even though the concentration is higher when further diluted to 75% for 
method-2, higher volumes of acetone at lower concentration appears to better extract these free 
phenolics, resulting in constant higher values for free phenolics in ispaghula for method-1 despite the 
dilution factor. We also observed that the relative proportion of ispaghula to cocoa increases with 
further dilution for method-1 (5.39%, 8.03% and 21.2%). This was not seen for method-2 (4.69 %, 
Figure 5-18 Free phenolics present in cocoa and ispaghula as measured by the Holtekjølen et al (2008)- method 1 
and Thondre et al. (2011) – method 2. 
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4.60% and 6.04%). This demonstrates that the data on free phenolics obtained from method-2 are more 
reliable due to proportionate increase in concentration for both cocoa and ispaghula. 
Table 5-8 concentration of free phenolics from cocoa and ispaghula 
Substrate Cocoa Ispaghula Cocoa 1/2 Ispaghula 1/2 Cocoa 1/4 Ispaghula 1/4 
Method 1 371.0 ± 48.5 20.0 ± 0.31 416.8 ± 51.3 33.54 ± 0.34 470.66 ± 50.1 62.30 ± 3.6 
Method 2 283.5  ± 5.3 13.3 ± 0.78 417.0 ± 25.98 19.2 ± 0.53 524.8 ± 59.0 31.7 ± 2.8 
Values are presented as mean GA equivalent (ug/g) ± STDEV 
 
To better determine any impact of acetone on absorbance, a standard curve prepared with acetone was 
compared to the standard curve prepared with methanol. We did not identify any impact of acetone on 
the standard curve slope. 
 
 
 
 
 
 
 
 
 
The bound phenolics for cocoa and ispaghula were extracted using method-1 as described in 5.2.8.1. 
These results demonstrated relatively but not significantly higher proportions of bound phenolics for 
ispaghula to cocoa (Figure 5-21).  
 
Figure 5-20 Standard curve with methanol 
 
 
Figure 5-19 Standard curve with acetone 
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Figure 5-21 Bound phenolics concentration in cocoa and ispaghula as measured by the Holtekjølen et al (2008)- 
method 1 and Thondre et al. (2011) – method 2. 
 
 
The absorbance was read at 765nm rather than 450nm used to read the absorbance of brown solutions. 
To ascertain that the brown colour of the cocoa extract had no impact on the read absorbance, we used 
cocoa extract at different dilutions (50% and 75%) to spike the GA standards. The obtained standard 
curve from these spiked standards was compared to that of GA standards in methanol only. The cocoa 
extract was not used for spiking standards without dilution, as the combination of cocoa extract and 
GA would result in concentrations above that of 500 ug/ml standard. Any concentration above this 
level would result in a plateau of the standard curve (Figure 5-22, 5-23 and 5-24). 
 
 
 
                                                                                                       
 
 
 
 
 
 
 
Figure 5-22 GA/Methanol standard curve + 0% cocoa extract 
Values are displayed as the mean of triplicate measurements. GA: Gallic acid 
 
 224 
 
 
 
 
 
 
 
 
 
 
 
As seen in the above figures, the presence of cocoa extract at different concentrations had no impact on 
the standard curve slope, and hence, had no impact on the read absorbance. 
 
5.3.4.2 Total phenol concentration of urine samples 
Due to the high concentration of total phenols in urine, a 50% dilution in distilled water was used. 
Similar to the results shown for phenolic acids, ispaghula consumption resulted in high urine total 
phenol concentrations. This could be attributed to the high concentrations of hippuric acid present in 
urine samples. The total phenol concentration in urine was not different after cocoa was ingested alone 
to when ispaghula was ingested alone for cumulative or non-cumulative analysis. However, the 
concentration of total phenols for the true combination was significantly lower than the predicted value 
(p < 0.01); demonstrating that interaction of ispaghula and cocoa results in a lower total phenol 
concentration. The concentration of total phenols began to increase at 2 hours after cocoa ingestion, 
whereas this increase was seen after 8 hours of ispaghula ingestion (Figure 5-25).  
 
 
Figure 5-24 Standard curve + 50%cocoa extract 
Values are displayed as the mean of triplicate measurements. 
 GA: Gallic acid 
 
 
 
 
Figure 5-23 Standard curve+ 25% cocoa extract 
Values are displayed as the mean of triplicate measurements. 
 GA: Gallic acid 
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Figure 5-25 Non-cumulative concentration of total phenols in urine 
Values are displayed as non-cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in 
water (n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. 
 
 
 
Figure 5-26 Cumulative concentration of total phenols in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. 
 
 
 
TP concentration in urine increased significantly in 24 urine samples compared to baseline for both 
cocoa and ispaghula (p < 0.01) 
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5.3.4.3 Total phenol concentration in plasma 
 
Plasma samples for total phenol analysis did not require dilution. Plasma total phenols did not differ 
between cocoa alone and ispaghula alone consumption. When they were consumed together, the total 
phenol plasma concentration was lower than predicted (p < 0.01). 
 
 
Figure 5-27 Total phenol from cocoa and ispaghula in plasma 
Values are displayed as mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water (n=12), ISP: 
Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa combination. 
 
 
 
Despite similar overall plasma concentrations of total phenol for cocoa, ispaghula and 
cocoa+ispaghula, there was a difference in Tmax for the three groups. The earliest Tmax was seen for the 
combination group at 2.0 hours, followed by ispaghula at 2.5 hours and cocoa at 4.0 hours after 
ingestion. 6h plasma TP did not increase significantly after the consumption of cocoa or ispaghula 
(p=226 and p= 394 respectively). 
5.3.5 Antioxidant capacity in urine 
 
Urine samples were diluted 1:4 for the analysis of antioxidant capacity after the consumption of cocoa, 
ispaghula or the combination of both. Similar to the results seen for total phenol-urine, the ingestion of 
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cocoa and ispaghula did not result in different antioxidant capacity in urine, for cumulative or non-
cumulative analysis. However, both analyses demonstrated an inhibitory impact on antioxidant 
capacity of cocoa and ispaghula when ingested together, when predicted and true combination values 
were compared (p < 0.01). 
 
 
 
Figure 5-28 Cumulative antioxidant capacity in urine 
Values are displayed as cumulative mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water 
(n=12), ISP: Ispaghula, C: Cocoa, ISP+C: Ispaghula+Cocoa. Predicted ISP-C: predicted value for Ispaghula and cocoa 
combination. 
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5.3.6 Gastric emptying 
The cocoa meal had the highest t1/2 for gastric emptying compared to combination group and ispaghula 
alone (p=0.01 and p < 0.01 respectively, Figure 5-29). There was no difference between the 
combination group and ispaghula alone. Similar results were seen for Tmax. The combination group and 
ispaghula did not differ in their impact on paracetamol Tmax (p=0.679); however, they both had lower 
Tmax compared to cocoa (p=0.01 and p < 0.01 respectively). There was a correlation in the results by 
volunteer across trial arms (figures 7-32 to 7-35). 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5-29 Impact of food matrix interaction on gastric emptying  
Values are displayed as mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water (n=12) 
measured as plasma concentration of paracetamol (1g). T1/2 and Tmax: p= 0.01 (C vs. C+ISP), <0.01 (C vs. ISP). 
 
  
There were no significant differences in AUC for the different arms of the study. However, the area 
under the curve from highest to low would be in the following order cocoa > ispaghula+cocoa > 
ispaghula order. 
 
 
 
 
T 1/2 Tmax 
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Figure 5-35C vs. I+C AUC correlation 
 
Figure 5-35 C vs. I AUC correlation 
 
Figure 5-35 I vs. I+C t1/2 correlation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-36 Paracetamol AUC 
Values are displayed as mean (± SD) across 24 h after consumption of 20g cocoa and /or15g ispaghula in water (n=12) 
measured as plasma concentration of paracetamol (1g). AUC: area under the curve 
Figure 5-32 C vs. I+C t1/2 correlation 
 
Figure 5-32 C vs. I t1/2 correlation 
 
Figure 5-32 I vs. I+C t1/2 correlation 
 
  P= 0.014   P= 0.010   P= 0.010 
  P= 0.001   P= 0.003   P= 0.113 
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5.3.7 Mouth to caecum transit time 
Breath hydrogen was measured as an estimation of transit time and reported for each volunteer. >6 
hours was assigned when the head of meal did not reach the caecum before 6 hours of meal 
consumption. There was no difference in MCTT between the meals. 
Table 5-9 Mouth to caecum transit time measured as exhaled breath hydrogen  
         Time for head of meal reaching caecum (hours) 
volunteer Ispaghula Cocoa Ispaghula+Cocoa  
2 >6.0   >6. 0 4.5 
3 4.5 4.5 4.5 
4 4.5 5.0 4.5  
5 5.0 5.5 4.5  
6 2.5 4.5 3.5 
7 5.0 4.5 4.0 
8 >6.0    >6.0 >6.0 
9 5.5 >6.0 5.5 
10 5.5 4.5 4.5 
11 5.0 4.5 5.5 
12 4.5 4.0 4.5 
13 4.5    >6.0 5.5 
Mean  ± STDEV 4.0 ± 1.0 5.25 ± 0.9 4.7 ± 0.8 
 
 
Figure 5-37 mouth to caecum transit time 
Values are displayed as mean (± SD) across 6 h after consumption of 20g cocoa and /or15g ispaghula in water (n=12) 
measured as exhaled breath hydrogen.  
 
 
Breath hydrogen is also an indication of fermentation by the gut microbiota, ispaghula had the highest 
AUC for breath hydrogen (12.9) followed by ispaghula+cocoa (11.8) and cocoa (8.7).  
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5.3.8 Subjective assessment of appetite 
The results were analysed for first meal (feed-1: ispaghula, cocoa or ispaghula+cocoa) and second 
meal (feed-2: lunch) separately. The area under the curve was used as an indication of subjective 
assessment of appetite. 
5.3.8.1 Q1- How hungry do you feel? 
Hunger ratings for cocoa were higher than the combination group for feeding-1 (p=0.037), however 
there were no differences between cocoa/ispaghula and ispaghula/ ispaghula+cocoa (p=0.175 and 
p=0.06 respectively). There were no differences between groups for feeding-2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The change in hunger levels was the highest for the combination group from BL to 0h (21.7mm) 
followed by ispaghula (16.4mm) and cocoa (10 mm). Hence, the immediate satiating effect was most 
for the combination group and least for cocoa. This pattern was extended up to 270 minutes, after 
which lunch meal was introduced.  
 
 
 
Figure 5-38 VAS rating and AUC for Q1 
Q1: How hungry do you feel? Values are displayed as mean (± SD) across 6 h after consumption of 20g cocoa and /or15g 
ispaghula in water (n=12). C: cocoa, ISP: ispaghula, ISP+C: ispaghula+cocoa, BL: baseline, feeding-1 (pre-lunch) <4h, 
feeding-2 (post-lunch) >4h 
 
 
 
Ispaghula+Cocoa 
         Cocoa 
Ispaghula 
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5.3.8.2 Q2-How satisfied do you feel? 
The combination group had the highest rating compared to cocoa (p=0.03) but there were no 
differences for ispaghula with the combination group or cocoa for feeding-1. Similarly to Q1, there 
were no differences between groups for feeding-2. 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.8.3 Q3-How full do you feel?  
Similarly to Q2 the combination group had the highest rating compared to cocoa (p=0.02) but there 
were no differences for ispaghula with the combination group or cocoa for feeding-1. There were no 
differences between groups for feeding-2. 
 
5.3.8.4 Q4-How much more do you think you can eat? 
There were no differences in VAS ratings between groups for feeding-1 or feeding-2. A correlation 
was found between feeding-1 and feeding-2 for Ispaghula+cocoa (p=0.02), cocoa (p < 0.01) and 
ispaghula (p < 0.01). This could be an indication that the impact of the supplement on appetite is 
extended to after secondary meal consumption. 
 
 
 
 
Figure 5-39 VAS rating and AUC for Q2 
Q2: How satisfied do you feel? Values are displayed as mean (± SD) across 6 h after consumption of 20g cocoa and 
/or15g ispaghula in water (n=12). C: cocoa, ISP: ispaghula, ISP+C: ispaghula+cocoa, BL: baseline, feeding-1 (pre-lunch) 
<4h, feeding-2 (post-lunch) >4h 
 
 
 
Ispaghula+Cocoa 
Cocoa 
Ispaghula 
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Figure 5-41 VAS rating and AUC for Q4 
Q2: How much more do you think you can eat? Values are displayed as mean (± SD) across 6 h after consumption of 20g 
cocoa and /or15g ispaghula in water (n=12). C: cocoa, ISP: ispaghula, ISP+C: ispaghula+cocoa, BL: baseline, feeding-1 
(pre-lunch) <4h, feeding-2 (post-lunch) >4h. 
 
 
 
Ispaghula+Cocoa Ispaghula 
Cocoa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An expected high variation is seen in the subjective assessment of appetite among volunteers. Due to 
the paired natured of the study, the standard deviations presented in the above figures are not relevant 
to the statistical analysis of the results.  
 
 
 
Figure 5-40 VAS rating and AUC for Q3 
Q2: How full do you feel? Values are displayed as mean (± SD) across 6 h after consumption of 20g cocoa and /or15g 
ispaghula in water (n=12). C: cocoa, ISP: ispaghula, ISP+C: ispaghula+cocoa, BL: baseline, feeding-1 (pre-lunch) <4h, 
feeding-2 (post-lunch) >4h 
 
 
 
 
Ispaghula+Cocoa 
Cocoa 
Ispaghula 
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5.4 Discussion  
 
The ingestion of 20g cocoa increased the urinary excretion of eleven phenolic acids, nine of which 
were significantly reduced when cocoa was consumed along with ispaghula (Table 5-10). 
Consumption of 15g ispaghula also resulted in the increase in concentration of four phenolic acids in 
urine as well as an acceleration in gastric emptying rate. Total phenol and antioxidant capacity were 
not different between cocoa and ispaghula in urine or plasma, however the consumption of cocoa and 
ispaghula together significantly reduced the total phenol (TP assay) and antioxidant capacity. While 
free phenolics were found to be significantly higher in cocoa, the reverse was seen for bound 
phenolics. The overall sum of bound and free phenolics remained higher for cocoa than ispaghula.  
 The study model was optimised by administering ispaghula and cocoa with water rather than milk. 
This allowed for the better understanding of the impact of ispaghula on gastric emptying, eliminating 
fat and proteins present in milk as a co-founding factor. Additionally, studies investigating matrix 
interactions between cocoa consumed with milk, demonstrated a lower bioavailability of cocoa flavan-
3-ols when cocoa was consumed with milk (Mullen et al., 2009a). Epicatechin levels have been shown 
to return to baseline measurements within 6 hours after the consumption of cocoa in both chocolate and 
beverage form (Schramm et al., 2003, Serafini et al., 2003, Neilson et al., 2009). Based on this 
evidence we collected plasma samples over 6 hours. 
The phenolic acids produced from cocoa consumption in-vivo were 3-HPAA, 4-HPAA, 3,4-DHPAA, 
Hippuric, 4-HPA, 4-HBA, 3,4-DHBA, Vanillic, 4-HVA, Mandelic and 4-HMA. A summary of urinary 
phenolic acid excretion after cocoa consumption, comparison to previous in-vitro study (Chapter-4) 
and previously published studies has been summarised in Table 5-101.  
It is important to note that in the previously published papers, even though these phenolic acids were 
detected in urine, not all were significantly higher from baseline after the consumption of cocoa. An 
example of this is the identification of 17 colonic metabolites after long-term cocoa consumption in the 
study by Urpi-Sarda et al., (2009). Out of the 17 metabolites only DHPV, vanillic acid , 3-HPAA, 3,4-
DHPAA and 3-HHA increased significantly from baseline with DHPV being the highest produced and 
3-HPAA the lowest produced phenolic acid. As vanillic acid and 3-HPAA were produced in all four 
studies and at significantly higher concentration than baseline after cocoa consumption, they could be 
considered as good biomarkers of cocoa polyphenol bioavailability. Ispaghula, being a plant extract 
produced relatively high concentrations of phenolic acids. However, in our study vanillic acid and 3-
HPAA, along with 3,4-DHBA, mandelic acid and homo-vanillic acid were significantly higher after 
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cocoa consumption than ispaghula consumption. This further supports the use of these two phenolic 
acids as biomarkers of cocoa polyphenols. 
Table 5-10 Impact of ispaghula on phenolic acid production in-vitro and in-vivo 
Phenolic acids Current study  
(GCMS) 
 
(GCMS) 
Ex-vivo study 
(Chapter-4) 
GCMS 
 20g cocoa 
powder  
0.5g cocoa in 
50ml incubation 
vessel 
PAA         ↓ X 
3-HPAA ↓ X X 
4-HPAA ↓ X        ↓ X 
3,4-DHPAA    X X 
4-HBA ↓ X X 
3,4-DHBA ↓ X X 
Vanillic   X  X* 
Homo-vanillic 
acid 
↓ X  
Hippuric ↓ X  X** 
4-HHA ↓ X  
3-HPPA  X 
4-HPPA  X 
3,4-DHPPA  X 
Mandelic ↓ X  
4-HMA ↓ X  
Total sum of      
phenolic acids 
↓ ↓ 
↓ inhibition in production either by ispaghula (ex-vivo study) and/or matrix interaction between ispaghula and cocoa (in-vivo 
study), *produced only in one volunteer  **produced in only two volunteers. 
 
Incidentally the two phenolic acids (vanillic acid and 3,4-DHPAA) not inhibited by ispaghula were 
also found in significantly higher concentration after cocoa consumption than ispaghula. Despite there 
being no inhibitory impact of ispaghula on production of these two phenolic acids when all subjects 
were considered, an inhibitory impact of ispaghula on the production of these phenolic acids were 
demonstrated in the high producer group but not in the low producer group. The production of the 
remaining nine phenolic acids was inhibited which was determined by the comparison of the predicted 
value to the true combination value. Additionally 4-HPAA exhibited a lower concentration for the 
combination group than cocoa.  
An inhibitory impact of food matrix interaction was seen in high producers of phenolic acids for all 
phenolic acids except 4-HHA. Only three of the phenolic acids (HVA, Hippuric acid and 4-HHA) were 
inhibited in the low producers of phenolic acids.   It makes sense that if an individual does not produce 
much of a phenolic acid that it will be less easy to deomstrate an inhibitory effect of a fibre than if a 
larger amount is produced.  
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In addition to an inhibitory impact, the food matrix interaction resulted in a delay of phenolic acid 
appearance in excreted urine. Examples of this delay observed in this study were 3,4-DHBA detected 
in urine 5h after consumption of cocoa and 8h after consumption of cocoa+ispaghula, 4-HBA 2h for 
cocoa and 5h for cocoa+ispaghula, HVA acid was detected at 2h for cocoa, 8h for ispaghula and 5h for 
cocoa+ispaghula.  
We may have expected ispaghula to slow gastric emptying but it speeded up paracetamol accumulation 
in the plasma. Viscous have been shown to both slow and speed gastric emptying depending on 
whether the meal was liquid or solid. Amidon (1985) hypothesised that the relation between the 
movement of food particles and their suspending fluid is dependent on how fast these particles sink or 
float out of the fast moving central stream of water in the lumen. Thus based on this hypothesis 
increased viscosity can result in faster gastric emptying and small bowel transit of solid particles. 
Meyer et al. (1986) investigated the impact of 200-800ml of saline or saline+guar on the gastric 
emptying of the solid meal 75 g of steak plus 25 g of 99mTc-labeled chicken liver. They demonstrated 
that guar accelerated the gastric emptying of the solids and delayed the gastric emptying of the fluids. 
Thus it is important for studies interested on the impact of viscosity on gastric emptying and MMCT to 
consider both liquid and solid meals. 
The mean time required for the head of the meal to reach the caecum was not affected in previous 
studies regardless of physical state of food or analytical method i.e the gold standard scintigraphy or 
breath 
13
C measurement (Washington et al., 1998, Bianchi and Capurso, 2002, McIntyre et al., 1997) 
as summarised in Table 5-2. However ispaghula delayed the gastric emptying of a liquid meal in a 
study by Washington et al but had no impact on the gastric emptying of solid meals (McIntyre et al., 
1997, Bianchi and Capurso, 2002, Rigaud et al., 1998, Frost et al., 2003). 
In our study the MCTT was found to be the slightly but not significantly higher for ispaghula alone, 
followed by the combination of cocoa+ispaghula and cocoa alone. This could possibly explain the 
delay in phenolic acid excretion in urine from ispaghula and when ispaghula was combined with cocoa. 
The breath hydrogen method measures the transit time of the head of the meal only and it is possible 
that the transit of the rest of the meal was delayed.  Additionally, the AUC for breath hydrogen was 
found to be highest for ispaghula, followed by the combination group and cocoa alone; indicating that 
cocoa has a slight inhibiting impact on ispaghula fermentation in-vivo. However, this claim was not 
supported by statistical analysis.  
Another factor playing a key role in matrix interaction studies is the flavanol concentration of the 
cocoa used. Mullen et al (2009) investigated the impact of milk on bioavailability of cocoa flavan-3-
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ols. They demonstrated an inhibitory effect of milk on the bioavailability of these flavan-3-ols using a 
cocoa having 45 umol flavan-3-ol monomers. The previous studies by Roura et al (2007) and Keogh et 
al (2007) did not show any inhibitory impact of milk or milk proteins on the flavan-3-ol bioavailability 
of cocoa. These studies used cocoa containing 128 umol and 2374 umol flavan-3-ol monomers 
respectively, amounting to 3 and 25 fold of the flavan-3-ols used in the Mullen et al (2009) study. The 
flavanol monomer concentration of our study was 39 umol, which was similar to that of the Mullen et 
al (2009). Hence, it is possible that cocoa phenolic production could be inhibited in the presence of 
viscous fibre and other food components such as milk when commercially available cocoa is used in 
amounts feasible for daily consumption. 
There have been no previous studies investigating the impact of viscous fibre on cocoa flavanol 
bioavailability and there is certainly a need for more investigation of different kinds of carbohydrates 
and their matrix interaction on cocoa flavanols.  
Due to the high concentration of phenolic acids produced by ispaghula we conducted a total phenol 
assay investigating both free and bound phenolics in cocoa and ispaghula. There was not time for a full 
polyphenolics analysis.  While cocoa had significantly higher free phenolics, the reverse was seen for 
bound phenolics; with ispaghula having relatively high concentrations of bound phenolics. The 
consumption of both cocoa and ispaghula resulted in an increase in urine Total phenol and antioxidant 
capacity at 24 hours compared to baseline. This increase was not seen in plasma samples. 
We aimed to investigate the satiating effect of ispaghula on appetite using 3 questions after the test 
meal (meal 1) and after introducing lunch (meal 2). We observed the following pattern for the 
questions on hunger levels (Q1) and the ability to eat more (Q4) for meal 1: Cocoa > Ispaghula 
>Ispaghula+cocoa. The reverse order (Ispaghula+cocoa > Ispaghula> cocoa) was seen for level of 
satisfaction and fullness. There was a significant difference between the combination group and cocoa 
for Q1,Q2 and Q3. Even though there were no significant differences for the second meal, a correlation 
was found between meal 1 and meal 2 patterns, indicating that the satiating impact of the supplements 
can be extended to after secondary meal consumption. Understandably, the results of these subjective 
appetite assessments could have been influenced by the caloric content of the test meal. As the main 
outcome of this study was the impact of food matrix interaction on the bioavailability of cocoa 
phenolic acids, we did not introduce a further matrix interaction such as sugar/fat or protein, previously 
seen to influence cocoa flavan-3-ol bioavailability to produce 3 isocaloric supplements. Furthermore, 
most of the satiating effects seen in the study can be attributed to ispaghula as we did not find any 
differences between ispaghula+cocoa (having higher caloric content) and ispaghula alone. The only 
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differences observed were between ispaghula+cocoa and cocoa alone. The results observed for 
subjective assessment of appetite are in accordance with the observations made for mouth-caecum 
transit time.  
 
Table 5-11 Phenolic acid excretion in urine after cocoa consumption 
Phenolic acids Current study  
(GCMS) 
 
(GCMS) 
Mullen et al., 
2009    (LCMS) 
 
Rios et al., 
2003 (GCMS) 
Sarda et al., 2009              
( LCMS-MS) 
 20g cocoa 
powder  
10g cocoa powder  80g Chocolate (20g cocoa 
powder)* 2 /day 
for 4 weeks 
PAA  X  X 
3-HPAA ↓ X X X X 
4-HPAA ↓ X    
3,4-DHPAA    X  X X 
4-HBA ↓ X X  X 
3-HBA  X X X 
3,4-DHBA ↓ X    
Vanillic   X X X X 
Homo-vanillic 
acid 
↓ X X  X 
Hippuric ↓ X X X  
4-HHA ↓ X X  X 
3-HHA    X 
3-HPPA   X X 
3,4-DHPPA  X  X 
Mandelic ↓ X    
4-HMA ↓ X    
Ferulic  X X X 
Caffeic  X  X 
P-coumaric  X  X 
m-coumaric  X  X 
protocatechuic  X  X 
DHPV    X 
Total sum of      
phenolic acids 
↓    
↓ inhibition in production either by ispaghula (ex-vivo study) and/or matrix interaction between ispaghula and cocoa (in-vivo 
study), 
 
The exact nature of the mechanism resulting in the reduction of urinary phenolic acids after ispaghula 
is unclear as it may be due to the viscosity inhibiting mixing of the bacteria and substrates and this 
could push more of the phenolics to the distal colon.  However, it may be that the bacteria are diverted 
to other metabolic activities such as ispaghula degradation or that the bacterial composition has been 
altered by the fibre although there is not much time for this in the acute study. The viscosity of the 
ispaghula may also have brought more of other compounds such as lipids to the colon and these may 
have some impact too. There was less inhibition in the in vitro model for ispaghula than the in-vivo 
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study but this may have been due to the impact of viscosity in the upper gut  and the impact of gut 
motility and other in-vivo factors not present in the in-vitro model. It wsa not possible to explore these 
further. 
 
5.5 Conclusion  
 
The consumption of both ispaghula and cocoa resulted in increased urinary Total phenol, antioxidant 
capacity and phenolic acid concentration. The food matrix interaction between the two, inhibited and 
delayed the production of phenolic acids from cocoa, reduced total phenol and antioxidant capacity. 
The consumption of ispaghula and cocoa separately could induce beneficial health effects by 
increasing total phenol and phenolic acid production, however the consumption of both simultaneously 
does not correspond to the sum of individual (cocoa / ispaghula) total phenol and phenolic acid 
production. More studies are required to better understand the impact of different kind of 
carbohydrates on phenolic acid production from cocoa in-vivo. 
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CHAPTER 6                                      
Discussion 
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6.1 Research questions: 
 
The research questions addressed in this PhD build on previously established evidence on the role of 
the colonic microbiota in the fermentation of fibre, and degradation of polyphenols and, prebiotic and 
antibiotic impact as well as the low absorption of both of these compounds in the small intestine, 
making the colon their main site of metabolism.  
 
After consideration of the relevant literature, it was clear that the metabolism of fibre and 
polyphenolics by colonic bacteria will involve some element of interaction.  It was therefore important 
to ask whether the interaction of these compounds and their metabolites results in synergistic, additive 
or modification of their metabolism and how this may impact on their potential health benefits.  This 
led to two main research questions:  
 
Q1- Do fermentable fibres affect phenolic acid production from polyphenols?  
Q2- Do polyphenols affect the SCFA production from fermentable fibres?  
 
By using the model demonstrated in Figure 6-1, we addressed the research questions and demonstrated 
that there is indeed an impact of the matrix interaction between fibres and polyphenols.  
 
A series of studies were conducted to achieve the aims and objectives of this PhD. The studies were 
designed to feed into a final long-term intervention study (Figure 6-1). However due to limitations 
discussed below, the long-term study was omitted, thus changing the direction of the PhD yet 
maintaining the same research questions.  
  
 
 
 
 
 
 
 
 
 
 242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 Overview of the studies in this PhD.  
 
 
Q1- Impact of soluble fibres 
on phenolic acid production 
from polyphenols 
 
 
Q2-Impact of polyphenols 
on SCFA production from 
soluble fibres 
 
 
Impact of ispaghula, 
raftiline and pectin 
on phenolic acid 
production from 
rutin and quercetin 
 
 
Impact of rutin and 
quercetin on SCFA 
production from 
ispaghula, raftiline 
and pectin 
 
 
Impact of ispaghula, 
raftiline and pectin 
on phenolic acid 
production from 
cocoa polyphenols 
 
 
Impact of cocoa 
polyphenols on 
SCFA production 
from ispaghula, 
raftiline and pectin 
 
 
In-vivo: Pilot study – 
feasibility and 
practicality of long 
term 
supplementation of 
ispaghula & 
cocoa 
 
 
 
In-vivo: Acute 
bioavailability 
study: impact of 
ispaghula on 
phenolic acid 
production from 
cocoa, gastric 
emptying, transit 
time and satiety 
 
 
Screening for 
long-term 
intervention 
study  
Urinary SCFA & 
fermentable fibre 
correlation study 
In-vivo: Long-term intervention study: 
impact of ispaghula on phenolic acid 
production from cocoa, risk of CVD, satiety 
and weight loss 
 
Rutin, Quercetin 
& Fibres 
 
In-vitro 
Cocoa  
 & Fibres 
In-vitro 
Cocoa  
 & Fibres 
 
In-vivo 
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6.2 Do fermentable fibres affect phenolic acid production from 
polyphenols? 
 
The impact of soluble fibres on the production of phenolic acids was investigated both in-vitro and in-
vivo. The soluble fibres ispaghula, raftiline and pectin were chosen based on their different physio-
chemical properties such as fermentability and viscosity.  
We began by exploring the impact of these soluble fibres on the colonic metabolism of the pure 
polyphenolic compounds; rutin and quercetin, which are present in abundance in the diet. This allowed 
the potential observed impact to be directly attributed to the action of the soluble fibres. In previous 
studies, the addition of glucose to fermentation vessels containing rutin by (Jaganath et al., 2006b) to 
simulate the presence of fibres such as cellulose, beta glucan and other such fibres with glucose as their 
common constituent, resulted in an increased deglycosilation of rutin and subsequent increase in 
phenolic acid production. Given that ~77-86% of ingested rutin and quercetin escape absorption in the 
small intestine (Hollman et al., 1995, Walle et al., 2000, Kahle et al., 2005, Jaganath et al., 2006); their 
bioavailability is greatly dependent on their colonic metabolite production.  
The studies in this thesis provided evidence that fermentable carbohydrates inhibit the phenolic acid 
production from polyphenols like rutin in-vitro, thus reducing their bioavailability. 
However, polyphenols are usually consumed as part of the diet integrated in plant based foods. Thus 
we further explored the impact of soluble fibres on polyphenols present within their food matrix. 
Cocoa is a rich source of polyphenols (Total polyphenols: 512 mg/100g, phenolic acids: 37.06 
mg/100g), especially compared with commonly consumed foods containing rutin or quercetin (Onion: 
167 mg/100g total polyphenols, 2.0 mg/100g phenolic acids, Tomato: 3.87 mg/100g total polyphenols, 
0.29 mg/100 g phenolic acids). However, the bioavailability of cocoa polyphenols may be affected by 
its food matrix, such as its reduction when consumed with milk (Mullen et al., 2009a). Most 
importantly cocoa is a popular food choice and commonly consumed, making it a suitable meal rich in 
polyphenols for long-term interventions. This is of importance as one of the limitations of long-term 
interventions is the compliance of volunteers to the food/diet. Cocoa is also incorporated in commonly 
consumed foods along with soluble fibres such as the Kellogg‘s-All Bran-Bran Buds Cereal containing 
ispaghula husk, wheat bran and oat bran in the USA.  
Using this information we conducted another in-vitro study incubating cocoa with or without 
ispaghula, raftiline or pectin. Similar to the results seen for rutin and quercetin, phenolic acid 
production from cocoa was inhibited by the soluble fibres.   
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Such in-vitro studies provide information on the potential interaction of fibres with polyphenols in the 
colon but are limited by the accumulation of fermentation products in the vessels due to the lack of 
absorptive mechanisms; not providing any information on the potential impact of these fibres on 
polyphenol absorption in the small intestine. Thus we followed up the above study with an in-vivo 
study model. 
In this regard the high viscosity of ispaghula was ideal for investigating the impact of gastric emptying 
and transit time modification on the subsequent reduction or delay of the cocoa phenolic acid excretion 
in the urine. 
Initially I planned to do a long-term feeding trial in over-weight individuals with increased risk of 
CVD. The plan of studies comprised of three parts: Pilot study, acute in-vivo cross-over study, 
followed by long-term intervention (4 weeks/arm, Appendix-5) cross-over study. I obtained the ethics 
and began with the pilot study and screening individuals for the CVD risk factors including 
hyperlidemia > 2.6 mmol/l LDL-C. 
The pilot study was conducted to assess the feasibility and practicality of long-term supplementation/ 
consumption of ispaghula and cocoa.  Thus we tried to find a good dietary vehicle for the cocoa and 
ispaghula. 30 volunteers received ispaghula alone or in combination with cocoa in three different 
supplementation forms for two days each: biscuits, milk or water based beverage. An estimated food 
diary was kept to monitor changes in energy intake (Ei). VAS questionnaires were used for appetite 
ratings as well as taste and convenience of supplement form. The biscuit meal was the most preferred 
whereas the water beverage was hardly tolerable. VAS questionnaires were not easy to be completed in 
everyday life. It was concluded that acceptability of the cocoa/ispaghula supplement was good in the 
correct administration form such as biscuits.  
Upon completion of the pilot study we began the screening of volunteers for the long-term study. 
Inclusion criteria included over the age of 30, having a waist circumference over 94 cm for men, and 
over 80 cm for women and LDL levels > 2.6 mmol/L. Participants were excluded for one of the 
following reasons: participants younger than 30 years of age, smoking, females on menopause, 
medication e.g. statins. Over 40 individuals who met all criteria were screened for plasma LDL levels. 
None of the individuals displayed LDL > 2.6 mmol/L. Additionally there was no association between 
BMI (over weight vs. obese) and plasma cholesterol levels. Thus the long-term intervention was 
deemed non-feasible in the time frame of this PHD. 
We then proceeded with the acute bioavailability study, which has been described in Chapter-5. Given 
that the long-term study was omitted, the risk of CVD was no longer relevant. Hence the inclusion 
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criteria of the bioavailability study were modified to represent a homogenous healthy population, more 
suitable for assessing the impact of ispaghula on cocoa polyphenol bioavailability and minimising 
inter-individual variation.  
Our initial observation was the high urinary phenolic acid excretion for four of eleven phenolic acids 
after ispaghula ingestion. This was not surprising as ispaghula is a plant extract and some phenolic acid 
production may be expected. The test meals in this study were ispaghula, ispaghula+cocoa and cocoa, 
thus there was no point of reference for the urinary excretion in the absence of these compounds and 
we could not determine if these phenolic acids were produced from ispaghula or through other 
metabolic pathways in the body. We addressed this limitation in the analysis for the impact of 
ispaghula on the phenolic acid production of cocoa by comparing the data obtained from simultaneous 
ingestion of cocoa and ispaghula to the expected/ predicted value for the urinary excretion of phenolics 
after consumption of cocoa+ispaghula (sum of urinary phenolic acid excretion after ispaghula 
consumption to after cocoa consumption). 
The results obtained from this study were supportive of the in-vitro study results, providing further 
evidence of the inhibitory impact of soluble fibres on phenolic acid production from polyphenols. 
However it may be that the phenolic acid production from cocoa is delayed rather than completely 
inhibited as the total sum of phenolic acid demonstrated a linear increase in concentration of total 
phenolics up to 24 hours. This can be determined in future studies by measuring phenolic acids until 
maximal conversion of polyphenols is achieved. The comparison of the in-vitro study and in-vivo study 
clearly demonstrated a stronger inhibitory impact of ispaghula in-vivo than in-vitro. It would be 
important to explore the impact of pectin and raftiline on cocoa phenolic acids in-vivo to determine if 
their impact is magnified as in with ispaghula or reduced. 
Some of the impact of ispaghula in-vivo may be due to its viscosity and the potential modification of 
gastric emptying rate and MCTT. The high viscosity of ispaghula may entrap the polyphenols, 
preventing their absorption in the small intestine, thus delivering higher amounts of the polyphenols to 
the colon. Within the colon the high viscosity of ispaghula may reduce the accessibility of the 
polyphenols to the bacteria and it may also deliver higher amounts of the polyphenols to the distal 
colon and subsequent result in higher amounts of the polyphenol being excreted through faeces (Figure 
6-2).  
Additionally fermentable fibres may be used as a preferential source of energy for the bacteria thus the 
hydrolysis of the polyphenols may be delayed in the presence of fermentable fibres. The fermentation 
of the fibre by the colonic bacteria results in SCFA production and the accumulation of these 
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metabolites decrease the colonic pH, which may affect the composition of the bacteria. Very little is 
known on how this change in colonic pH may affect the metabolism of polyphenols. Next Generation 
DNA sequencing would provide information on bacterial diversity and the mechanism behind the 
impact of fermentable fibres on phenolic acid production from polyphenols, especially for in-vitro 
models. It would be difficult to get meaningful information in vivo as the only samples available would 
be faecal and the metabolism of phenolics mainly happens in the proximal colon. We did not have 
sufficient funds to carry out this analysis but it should be included in future studies, especially now the 
costs have substantially reduced. 
Another measurement which would be key to the understanding interactions with fibre, especially in-
vivo is the measurement of parent polyphenolic compounds, their appearance in plasma and urine and 
their disappearance in in vitro models. However due to limited funding, access to equipment and the 
time available, this analysis was not possible during the period of this PhD.  
  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 6-2 Impact of dietary fibre on bioavailability of polyphenols 
The figure illustrates the impact of fibre on bioavailability of polyphenols using flavan-3-ols as an example. Adapted from Monagas et al. (2010) 
 
 6.3 Do polyphenols affect the SCFA production from soluble fibres?  
 
The impact of polyphenols on soluble fibres was investigated based on previous evidence 
demonstrating the potential antibiotic and prebiotic impact of some polyphenolic compounds and that 
this possible modification of colonic microbiota may impact their fermentation action on fibre and 
subsequent SCFA production. The review of literature on the antibiotic impact of polyphenols clearly 
demonstrated great inconsistency in findings and poor understanding of the impact of these 
polyphenols in relation to their physiological concentration in the diet; as majority of the methods have 
used non-physiological concentrations of polyphenols applicable to the pharmaceutical industry but not 
achievable through the diet. Additionally the majority of studies were conducted using in-vitro pure 
batch cultures of selected bacterial species, which is not representative of the complex microbiota 
colony.  
An overview of these studies may suggest a stronger impact of phenolic acids and aglycones than 
glycosidic compounds on the inhibition of bacterial growth, with little to no change in total bacterial 
count (Arima et al., 2002, Lee et al., 2008, Parker et al.,2008). Many studies have also demonstrated 
that the beneficial bacteria Lactobacilli are more resistant to this antimicrobial action (Parker et 
al.,2008, Tzounis et al.,2008). Although there is some evidence on the antibacterial properties of 
polyphenols, there is no information available on how this may impact the production of metabolites 
such as SCFA from the fermentation of fibre, which is one of the mechanisms through which the 
microbiota benefit the host. 
Quercetin has been demonstrated to have one of the strongest antibiotic effects compared to other 
tested polyphenolic compounds (Vaquero et al., 2007, Parker et al., 2008). Its glycosidic form rutin has 
however shown little if no impact on the colonic microbiota population in-vitro (pure culture growth), 
which may not necessarily relate to in-vivo conditions; where rutin is degraded by the colonic 
microbiota to quercetin and smaller molecular weight phenolics which may in turn exhibit 
antimicrobial properties (Lee et al., 2008). Thus we investigated the impact of both rutin and quercetin 
on the metabolite production from fibres using the highly fermented non-viscous raftiline, highly 
fermented viscous pectin and incompletely fermented, highly viscous ispaghula. There was no 
evidence on the impact of these polyphenols on metabolic action of the microbiota. The polyphenols 
did not affect the pH or gas production from fermentations. It may be that the promotion of growth by 
the fibres overcomes any antibiotic action but also as we did not measure directly any bacterial 
populations there may be some inhibition of bacteria but no impact on metabolism.  
We then continued to investigate the impact of the polyphenols present in the cocoa matrix on the 
SCFA production from the same fermentable fibres. Unlike the pure polyphenolic compounds, cocoa 
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contains high carbohydrate and fibre content, which resulted in substantial SCFA production. The 
digestion of cocoa before it is added to fermentation vessels in future studies may reduce SCFA 
production from the simple carbohydrates, which would normally be absorbed in the small intestine.  
However some starch may escape digestion in-vivo and be fermented in the colon. We applied the 
same analytical method for the correction of SCFA production from cocoa as that described for the 
impact of ispaghula on cocoa phenolic acids in-vivo (expected/predicted value vs. true combination 
value). The outcomes of this study were in line with the results of rutin/quercetin impact on SCFA 
production; not demonstrating any impact of cocoa polyphenols on SCFA production from the soluble 
fibres. 
Rutin, quercetin and cocoa polyphenols did not affect the pH or gas production from the fermentation 
vessels, In fact there was no difference in pH of rutin or quercetin to that of faecal slurry alone. Due to 
the lack of evidence on the impact of the polyphenols on SCFA production from soluble fibres in-vitro 
and the relatively low concentration of urinary SCFAs, we did not proceed with the investigation of 
this interaction in-vivo. The use of faecal sample for measurement of SCFAs is not a good measure due 
to the continuous absorption of SCFAs throughout the colon, thus faecal SCFAs may not be 
representative of metabolism in the proximal colon. 
There was a high level of biological variation in the bioactive molecules produced in the models used 
in this PhD supporting previous statements on high inter-individual variation of colonic microbiota 
profile and their metabolic products. The overall design of the PhD was meant to facilitate the 
reduction in this inter-individual variation. The faecal samples used for both rutin and cocoa in-vitro 
studies were common with the exception of two volunteers. The age, BMI and ethnicity of participants 
did not differ between the two studies. Additionally the high standard deviations were not relevant to 
the statistical analysis of the paired model of the in-vitro studies or the cross-over model used for the 
in-vivo studies. 
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6.4 Relevance and applications of findings:  
 
To our best knowledge there have been no previous studies investigating the matrix interaction of the 
fermentable fibres and polyphenols.  
The microbiota and their role in health and disease is currently a subject of much interest (Turnbaugh 
et al., 2007, Greenhill, 2014). Fibre and polyphenols have demonstrated potential to modify these 
microbiota and they are both largely dependent on the colonic microbiota for their metabolism in the 
gut. The health benefits of fibres and polyphenols are to a great extent dependent on this colonic 
metabolism.   
Previous evidence reporting health benefits from polyphenols or fibre consumption have not 
considered the interaction of these two components, most often than not present in the colon together; 
where their potential interaction with the microbiota may impact the production of their bio-active 
metabolites. We have demonstrated that fibre inhibits or delays the phenolic acid production from 
polyphenols, this must be considered in future studies assessing bioavailability and health impact of 
polyphenols both in-vitro and in-vivo.  
The health claims for fibre has led the food industry to incorporate fibre in many products which are 
naturally high in polyphenols. Cocoa bean shell which was previously discarded as waste, used as fuel 
or garden mulch is now being incorporated into cocoa products, which may lead to the reduced 
bioavailability of their polyphenols, and phenolic acids and subsequent benefits on health.  
The considerable phenolic acid production detected in our in-vivo study from ispaghula adds to 
previous findings which showed polyphenols are found in association with dietary fibre in plant based 
foods and may be considered as an important constituent of dietary fibre (Goñi et al., 2009). Thus 
when considering the health benefits and the bioavailability of polyphenols the impact of fibre both as 
a delivery vehicle of the bound phenolics and inhibition of their metabolism in the colon must be 
considered.  
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6.5 Research questions arising from the findings of this PhD and future 
work:  
 
  Is the impact of soluble fibre on phenolic acid production inhibitory or retardation? 
 (Assessed by measuring phenolic acids until maximal extent of conversion has been 
achieved) 
Our findings demonstrated a reduction in urinary excretion of phenolic acids and their 
concentration in fermentation vessels. However the total sum of phenolic acids demonstrated 
a linear increase suggesting that is more time were available the final total amount could 
have been much higher. To confirm if the effect of fermentable fibre on polyphenols is 
inhibitory or retardation, a longer period of incubation and urine collection is required; until 
all parent compounds have been degraded to their maximum extent. 
 
 Do viscous fibres have a stronger impact on phenolic acid production from polyphenols in-vivo 
than in-vitro? 
(Replication of the acute in-vivo study and substituting ispaghula with pectin and raftiline) 
Ispaghula demonstrated a much stronger impact on reducing cocoa phenolic acid production 
in-vivo (Chapter-5) than in-vitro (Chapter-4). This may possibly be due to the viscosity of 
ispaghula, which is maintained in the colon and the reduction in bio-accessibility of the 
polyphenolic compounds, modification of transit time and increased excretion of the 
compound (Figure 6-2). Using fibres with different viscosities, which may be lost or 
maintained throughout the digestive system in a similar model to the acute bioavailability 
study (Chpater-5) will aid the understanding of impact of viscosity on phenolic acid 
production from the polyphenols. 
 
 How does the composition of the bacteria change when they are subjected to both prebiotic 
fibre and antibacterial polyphenols and how may this impact the metabolite production? 
(Analysis of bacterial profile in an in-vitro setting or direct faecal sample after a long-term 
intervention). 
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In both in-vitro studies (Chpater-3 and Chapter-4), the fermentable fibres having the highest 
fermentability and the lowest pH had a stronger impact on reducing phenolic acid 
production. However the mechanism behind this impact is not clear. Two mechanisms may 
be postulated. The first being that the highly fermentable fibres were a preferential source of 
energy for the bacteria and the uptake of these compounds delayed the hydrolysis of the 
polyphenols. It is also possible that high fermentability and subsequent high amounts of 
SCFA resulted in lower colonic pH, which may have altered bacterial composition involving 
the bacteria responsible for the degradation of polyphenols. In this regard next generation 
DNA sequencing and metabolomics may provide information on the change in bacterial 
composition when they are exposed to fermentable fibre and polyphenols at the same time 
and possible association between this change and the profile of metabolites produced. Due to 
limitation of funding, resources and time this measurement was not possible during the time 
of this PhD. 
 
 Correlation between fermentability, viscosity and inhibitory impact of phenolic acid 
production observed?   
(Viscosity of fibres to be measured)  
In all in-vitro studies conducted in this PhD, fibres with different physio-chemical properties 
were used. Even though we observed that the fibres with higher fermentability had more 
impact in reducing phenolic acid production than fibres with high viscosity, an association 
could not be made. However using fibres with different known viscosity may allow the 
understanding of the association between fermentability, viscosity and inhibition of phenolic 
acid production.  
 
 How do the soluble fibres impact the polyphenol absorption and subsequent excretion? 
(Measurement of parent compounds in urine/plasma to determine the extent of their 
absorption and measurement of the polyphenols in faecal sample to determine the 
percentage of ingested concentration being excreted). 
Due to limitation of funding, resources and time this measurement was not possible during 
the time of this PhD. The measurement of the parent compounds may demonstrate the 
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impact of fibre on the delay or reduction in absorption of these compounds, which may then 
be associated with the concomitant phenolic acid production.  
 
 What is the catabolic pathway of the parent compounds and what is the role of the phenolic 
acid produced on health? 
 (Use of radio or stable isotope labelled parent compounds to determine the catabolic 
pathway and site of accumulation and action of metabolites).  
It is becoming more evident that very small amounts of the polyphenols are absorbed with 
the majority reaching the colon where they are subjected to the bacterial action, resulting in 
the production of phenolic acids. However, the catabolic pathway responsible for phenolic 
acid production is not very well understood and many of the pathways given are speculative. 
In the same manner, the fate of these phenolic acids and their bioavailability is not 
understood. The use of isotopically labelled polyphenol compounds may aid the 
understanding of the catabolic pathways and target tissues of phenolic acids in human and 
animal models in vivo. Additionally there is a big gap in the literature on the health benefits 
of these phenolic acids.  Given that they contribute greatly to the bioavailability of the 
polyphenols, it is essential to understand their role in health. 
 
 
 
6.6 Conclusion 
 
Fermentable fibres inhibit or delay the phenolic acid production of polyphenols in-vitro and in-vivo, 
reduce gastric emptying time and do not affect small bowel transit time. Polyphenols present as 
isolated compounds or within their food matrix have no impact on the fermentability and SCFA 
production from fermentable fibres. It is essential for studies investigating the bioavailability of 
polyphenols and their impact on health to take into consideration such matrix interactions between 
fermentable fibres and polyphenols, which may impact the bioavailability of the polyphenols. 
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Appendix-1: Dietary guidelines for low polyphenol diet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 303 
 
 
Appendix-2: Dietary record forms 
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Appendix-3: Barry Callebaut cocoa specification 
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Appendix-4: Recruitment poster for long-term cocoa study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix-5: Long-term intervention study plan 
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Appendix-5: Long-term human intervention trial design 
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